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ABSTRACT -
Schizophrenia is a severe and debilitating mental disorder that affects 1% of the 
population. Clinical symptoms usually show at late adolescence or early adulthood 
and include a constellation of delusions, hallucinations, decreased motivation and 
impaired executive functions. The aetiology of schizophrenia remains unclear but 
like most psychiatric disorders it is classified as complex in origin, resulting from an 
interplay of genetic, developmental and environmental factors.
Recent intensive research has enabled the identification of susceptibility genes for 
schizophrenia, giving interesting insights into its pathophysiology. However, 
schizophrenia is such an heterogeneous and polygenic disease that more genes will 
have to be discovered, not only to help further towards a better understanding of the 
molecular mechanisms associated with schizophrenia but also to lead to the 
identification of novel pharmacological targets.
A global transcriptome screen to identify differentially expressed novel psychosis- 
related genes was performed utilising a phencyclidine (PCP) model of schizophrenia 
and rat oligonucleotide GeneChips from Affymetrix. The chronic PCP model of 
schizophrenia has been shown to produce a pattern of metabolic hypofunction and 
neurochemical changes in the rodent brain that closely mirror those observed in the 
brains of schizophrenic patients (Cochran et a l  2003). This microarray study allowed 
the screening of rat genes and expressed sequence tags (ESTs) that have the potential 
to represent novel and uncharacterised genes.
Bioinformatic analyses of the 209 significantly differentially expressed ESTs 
revealed 66 cDNAs. Three (Edg2, EST AI072720 and Tm4sfl2) were selected as 
candidate genes for which to validate and characterise. Two of them, Edg2 and EST 
AI072720, were confii-med as differentially expressed in the rat chronic PCP model 
by quantitative real-time PCR. The differential expression of Tm4sfl2 was not 
confirmed and therefore was not characterised further.
Edg2 (LPAl) is a G-protein-coupled receptor for lysophosphatidic acid (LPA), a 
mediator of diverse cellular activities. Is is widely expressed but predominantly in
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the brain, where it was suggested to be involved in the control of myelination. Edg2 
distribution in the rat brain (as revealed by in situ hybridisation) was consistent with 
this hypothesis. However, its increased expression in the prefrontal cortex of rats 
after chronic treatment with PCP, consistently with increased expression in the 
dorso-lateral prefrontal cortex of schizophrenic patients, suggested that Edg2 may 
also have a role in cortical regions which may be related to schizophrenia. 
Microarray data from the rat chronic PCP model and from human post-mortem tissue 
led to hypothesise a novel pathway involved in schizophrenia that was termed the 
“Pyk/Nck” pathway. This signalling cascade leading from Ptk2b to activation of 
Jnk2 (Mapk9) is activated by HMDA receptor stimulation, therefore its suggested 
dysfunction is consistent with the antagonism properties of PCP at NMDA receptors. 
Edg2 activation was proposed to constitute another route to activating the “Pyk/Nck” 
pathway thus restoring NMDA receptor function in schizophrenia. Using a stable cell 
line overexpressing EDG2 receptors, EDG2 activation was shown to induce gene 
expression changes within this pathway leading to an increased phosphorylation -  
hence activation- of Jnk2, its final output. These results provided in vitro evidence 
suggesting that compounds acting at the EDG2 receptor, via their ability to enhance 
activity within the “Pyk-Nck” cascade, may be promising for the treatment of 
schizophrenia. To enable screening of EDG2 agonists in vitro, a f^S]-GTPyS 
binding assay was developed using the EDG2-overexpressing stable cell line. This 
assay was shown to be sensitive enough for being used as a high throughput 
screening assay.
Using techniques that enable the analysis of transcripts (RACE and RT-PCR), the 
EST AI072720 was confirmed as a genuine rat transcript, which had been 
hypothesised from bioinformatics analyses. “Similar to KIAA1189 protein” 
{RGDI308367), is an uncharacterised rat gene predicted to have a C-terminal ezrin- 
radixin-moesin (ERM) actin-binding domain which suggests it may have a role in 
cytoskeletal architecture.
Differential expression of R G D l308367 was confirmed in the rat chronic PCP model 
by quantitative real-time PCR, while its human orthologue KIAA1I89 also showed a 
significant increase in post-mortem tissue from schizophrenic patients. As expected, 
in situ hybridisation on EST AI072720 and RGD1308367 revealed the same 
expression pattern in the rat brain, with very high expression within all major white
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matter tracts and much lower expression within all cortical and sub-cortical areas. 
FLAG immunofluorescence was performed using C6 rat glioma cells overexpressing 
a FLAG-KIAA1189 fusion protein, to determine the sub-cellular localisation of the 
protein. KIAA1189 was found to be expressed in the plasma membrane and in 
neuronal-like processes and colocalisation with actin (suggested from the predicted 
C-terminal ERM domain) was confirmed by double labelling with phalloidin, a toxin 
that specifically binds F-actin. Because actin filaments are known to play a crucial 
role in neurite extension, a potential role for KIAA1189 in neurite outgrowth was 
investigated in vitro using PC12 cells overexpressing KIAA1189 and undergoing 
NGF-induced differentiation. Using a semi-quantitative assay, overexpression of a 
FLAG-KIAA1189 protein was found to prevent neurite outgrowth by comparison 
with the empty FLAG expression vector. Although this role will have to be further 
characterised, such a function of KIAA1189 may be consistent with the major 
theories of schizophrenia, the overexpression of KIAA1189 at critical times of 
development potentially affecting neuronal connectivity while its overexpression 
following chronic PCP treatment may be related to altered synaptic plasticity by 
modulating cytoskeletal changes of dendritic spines in response to learning and 
experience.
Finally, genotyping of three single nucleotide polymorphisms (SNPs) within the 
human KIAA1189 gene did not reveal any significant genetic association with 
schizophrenia in a population of 600 schizophrenic patients and controls. However, 
this transcript maps to chromosome 2q, a key schizophrenia locus pointed out in 
several linkage studies and recently associated with visual working memory. This 
genetic evidence adds to our functional evidence suggesting that KIAA1189 may be 
an intriguing novel candidate gene for schizophrenia.
All together, this work has identified and characterised two interesting candidate 
genes for schizophrenia. One of them, EDG2, may represent a promising drug target 
for schizophrenia while the other one, KIAAl 189, may provide novel insights into 
the pathophysiology of schizophrenia and further evidence supporting its 
neurodevelopmental hypothesis.
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CHAPTER 1: INTRODUCTION
1.1- Schizophrenia
Schizophrenia is a chronic, severe and debilitating mental disorder characterised by 
profound disturbances of cognition, emotion and social functioning. The lifetime risk 
of developing schizophrenia is approximately 1% in the general population, with a 
typical onset during adolescence or early adulthood (Andreasen 2000; Sawa and 
Snyder 2002).
Schizophrenia is one of the most important public health concerns for society, not 
only because of its costs but also because it damages some of the most advanced 
functions of the brain that we regard as specifically human (Wong and Van Toi 
2003).
Although extensive research over the past half century has allowed us to improve our 
knowledge of schizophrenia, it still only provides an incomplete understanding of 
this complex and multifactorial disorder which results from an inteiplay of genetic 
and environmental factors (Sawa and Snyder 2002). Similarly, despite improvements 
in the tolerability and, to some extent, in the efficacy of schizophrenia 
pharmacotherapy, new treatments still follow approximately the same paradigm as 
older antipsychotics, which may explain their failure to treat effectively many 
refractory patients (Miyamoto et al. 2005). Therefore it remains of major importance 
to improve both the understanding of schizophrenia pathophysiology and its 
pharmacotherapy.
In this context, novel insights may come in particular from translational approaches 
aiming at establishing a link between mechanistic hypotheses of the disease in 
animals and the complex disorder of cognition and behaviour that schizophrenia 
represents in human.
1.1.1- Diagnosis, symptoms and treatment of schizophrenia
1.1,1.1- Diagnosis and symptoms o f schizophrenia
In addition to having a complex multifactorial aetiology, schizophrenia is also 
complex in that it affects nearly all domains of mental functions, with diverse and 
variably expressed symptoms including disorganised thought patterns, delusional 
beliefs, hallucinations, blunted or incongruous mood, apathy and social withdrawal. 
Nevertheless, since not any molecular abnormality seems to be common to all 
patients with schizophrenia, its diagnosis is based entirely on clinical symptoms, and 
operational explicit criteria associated with structured interviews have been defined 
to achieve a high degree of diagnostic reliability (Bray and Owen 2001).
The criteria for the diagnosis of schizophrenia are currently defined in the 4th edition 
of the Diagnostic and Statistical Manual of the American Psychiatric Association 
(DSM-IV, (American Psychiatric Association 1994) and the 10th edition of the 
International Classification of Diagnosis (ICD-10, (WHO 1992). Both classifications 
establish the diagnosis of schizophrenia on the prominent presence of particular 
symptoms from specified sets of symptoms for defined periods of time. Thus, while 
the ICD-10 demands that symptoms from a set of characteristic symptoms are clearly 
present for the majority of time for at least 1 month, the DSM-IV requires that 
characteristic symptoms are present for 1 month but also that one of these symptoms 
persists for more than 6 months.
The characteristics of schizophrenia are frequently classified into positive and 
negative symptoms and cognitive dysfunction (Bassett et a l 1993; Andreasen et a l  
1994).
Positive symptoms include hallucinations (sensory experiences in the absence of 
external stimulation), delusions (irrational beliefs that are unresponsive to logical 
argument) and thought disorder:
- Hallucinations may be visual, or even, occasionally, olfactory or tactile, but they 
are most often auditory hallucinations of human speech, “voices” which may
comment on the patient’s actions or thoughts or more dramatically command the 
patient to action.
- Delusions typical to schizophrenia are commonly referred to as paranoid, and 
include delusions of persecution, grandiosity, external control, having thoughts 
inserted or withdrawn from one’s head, ideas of reference and mind reading.
- Thought disorder may be described along a spectrum of severity ranging from 
tangential and circumstantial thinking to loosening of associations and disorganised 
speech.
Negative symptoms may be described as a loss of capabilities that most well people 
have. They include severe disturbances in social interaction, motivation, expression 
of affect (flattened or blunted affect and impaired emotions), spontaneous speech 
(alogia), ability to seek out and experience pleasure (anhedonia) and a fall in self­
esteem leading to personal neglect (avolition-apathy) (Hales 1994). In extreme cases, 
people with schizophrenia may become almost totally unresponsive and will not 
move, speak or respond (a condition known as catatonia).
Negative symptoms may coexist with positive symptoms from the outset (primary 
negative symptoms) or appear later in the illness (secondary negative symptoms), 
sometimes as a side effect of drug treatment (Andreasen et a l  1994). Moreover, 
unlike positive symptoms, negative symptoms typically do not respond well to 
current antipsychotic medication.
Cognitive symptoms are probably the most important symptoms of schizophrenia as 
they relate to disturbances of logical thought processes that are required for a number 
of mental activities and are exhibited by the large majority of schizophrenic patients 
(even those regarded as “almost well”) (Kelly et a l 2000). They include deficits in 
attention and memory (both verbal and non-verbal) and executive function, including 
the ability to plan, weigh-up situations, form abstract concepts and take appropriate 
courses of action. In particular, working memory may be affected, which is important 
because it helps to keep information in the mind and use it in complex decisions. 
Many patients demonstrate cognitive impairment prior to clinical symptoms (Jones et 
al. 1994) and some deficits may also be detected in an attenuated form in non­
schizophrenic relatives (Cannon et a l 1994) suggesting that these deficits are an 
inherent biological phenomenon rather than a correlate of chronic antipsychotic
medication. Cognitive deficits have a major impact on many aspects of daily life of 
schizophrenic patients, compromising social function, education and employment 
(Weickert et a l  2000) and have the most substantial impact upon illness outcome in 
schizophrenia, more than positive or negative symptoms (Green 1996).
Although schizophrenia has a typical onset during adolescence or early adulthood 
(Andreasen 1995; Sawa and Snyder 2002), the disease can follow different courses 
which again reflect its complexity and its heterogeneity. Thus, it may start with an 
acute psychotic episode expressed most commonly by hallucinations, delusions and 
formal thought disorder, or develop gradually through progressive changes in 
behaviour. Acute schizophrenia may disappear and never come back; in fact, almost 
25% of people diagnosed with schizophrenia recover completely within 5 years. 
However, the first episode is usually followed by a series of intermittent episodes of 
psychotic symptoms on top of a persistent disability with pronounced negative 
symptoms and cognitive deficits (Watt et a l 1983). In chronic-onset schizophrenia, 
symptoms are usually hardly visible at first but develop gradually and are less often 
followed by acute episodes. The long term is variable. About 10% of schizophrenic 
patients suffer from persistent, severe disability throughout life, while among 
patients who suffer from severe illness in the early phase of the disease over 50% 
function quite well in later life. It has also been shown that patients receiving 
treatment soon after the beginning of the disease usually have a better outcome 
(Johnstone ï^/. 1986).
Overall, although symptoms of schizophrenia vary in intensity over time, the 
negative and cognitive dysfunction are quite persistent whereas chronic psychotic 
symptoms have an episodic pattern (Andreasen 1995). Therefore it really makes 
sense that none of these symptoms alone are diagnostic for schizophrenia and in fact, 
the criteria defined by the ICD-10 and the DSM-IV have been structured to allow for 
the possibility that two patients with schizophrenia may not overlap in their 
symptomatology (Wong and Van Toi 2003). Thus, the question of what clinical 
deficit is central to the disease remains unanswered and clinically, three major types 
of schizophrenia have been proposed; among them, paranoid schizophrenia 
(including hallucinations and delusions) is by far the most common followed by 
hebephrenic (characterised by unpredictable behaviour and incoherent speech) and
catatonie (with stupor and unresponsiveness alternating with states of high 
excitement) schizophrenia (ABPI 2003; Wong and Van Toi 2003). However, there 
are no correlations between these sub-classes and response to treatment or other 
outcomes (Marneros e ta l  1995).
Therefore, the diversity of schizophrenia, together with its unknown molecular 
aetiology, makes it difficult -if not impossible- to find a treatment which may 
improve all the different features of the disease.
L L L 2 - Schizophrenia medication
It was only about 50 years after the word “schizophrenia” was introduced by 
E. Bleuler (1911), replacing the “dementia praecox” described by E. Kraepelin, that 
the first effective treatment for schizophrenia, chlorpromazine, was made available. 
Since then, development of medicines and understanding of the functions of the brain 
and of the neurochemical basis of schizophrenia have progressed side by side, 
characterisation of the pharmacological profile of some compounds yielding insights 
into the involvement of neurotransmitters in schizophrenia while such findings 
stimulated the search for and the synthesis of further compounds with specific 
properties. A number of medicines were thus developed and antispychotics of 
various chemical classes have been used in the treatment of schizophrenia for over 
40 years.
“Typical” (or “conventional”) antipsychotic drugs such as haloperidol, perphenazine, 
trifluoperazine and fluphenazine have been the first line of schizophrenia therapy 
since the introduction of chlorpromazine in 1954. The main therapeutic mechanism 
of these drugs lies in their ability to block dopamine D2 receptors, which probably 
mediates their effectiveness in controlling positive symptoms such as hallucinations 
and delusions (van Rossum 1966). However, these drugs do not improve the negative 
symptoms and the cognitive deficits associated with schizophrenia. Moreover, 
blockade of dopamine receptors in the striatum appears to be responsible for motor 
side effects termed extrapyramidal symptoms (EPS) which resemble motor 
abnormalities (tremors, akinesia, i.e. slowing of voluntary movements, rigidity and 
akathisia, i.e. discomfort in the legs and inability to sit for long periods of time) 
observed in Parkinson’s disease (Meltzer and Stahl 1976; Carlsson 1978; Peacock et
a l  1996). Tardive dyskinesia, a choreathetotic movement disorder causing 
uncontrollable movements, initially of the face, lips and tongue but eventually 
affecting other parts of the body, is the most serious extrapyramidal symptom since it 
develops, generally after several years of treatment, in about 20% of patients treated 
with typical antipsychotics and is most often irreversible (Gardos et a l 1994). 
Moreover, a significant proportion of schizophrenic patients do not respond or 
become resistant to typical antipsychotic drugs during their illness (Mayerhoff et a l
1994). However, the most important drawback of these drugs is their inability to treat 
the negative symptoms and improve cognitive dysfunction, resulting in chronic 
morbidity and poor long-term outcome.
A second generation of antipsychotic drugs termed “atypical” antipsychotics was 
thus developed following on from the synthesis of clozapine and the realisation of 
the potential of this drug many years later in clinical trials. Clozapine, which was 
notably almost devoid of extrapyramidal (EPS) side effects, proved indeed to display 
an improved efficacy against the negative symptoms and, most importantly, against 
the cognitive dysfunction of schizophrenia and was interestingly effective in a 
proportion of patients resistant to older antipsychotic treatments (Brunello et a l
1995). Unfortunately, it was soon realised that clozapine caused a very severe 
agranulocytosis in a small number of patients and clozapine was immediately 
withdrawn from the market in 1975. Finally, after more rigorous clinical trials, it was 
reintroduced and is now used in refractory patients with regular blood monitoring 
under the control of a specialist. Clozapine’s atypical pharmacological properties 
have been attributed to its unique pharmacological profile, which includes a lower 
affinity for dopamine D2 receptors but a notable affinity for serotonin, adrenergic, 
dopamine, histamine and muscarinic receptors (Tamminga 1997). Therefore, 
attempting to resemble the profile of clozapine, a number of other “atypical” 
antipsychotics were developed in which blockade of dopamine D2 receptors was no 
longer the sole therapeutic mechanism (Meltzer 1989). Thus, these second- 
generation antipsychotics, including risperidone, olanzapine, quetiapine and 
ziprasidone share the dopamine-serotonin antagonism of clozapine (Freedman 2003) 
but also display unique phannacological profiles with diverse affinities for other 
neuroreceptors including muscarinic cholinergic and histamine receptors and 
potential interactions with the glutamate system (Miyamoto et a l  2005).
With regards to efficacy, most second-generation antipsychotics have been shown to 
offer some advantages over the “typical” antipsychotics particularly through their 
ability to improve the negative symptoms (Moller 2003) and the cognitive 
impairment of schizophrenia to some extent (Meltzer and McGurk 1999; Harvey and 
Keefe 2001) and prevent potential relapse (Miyamoto et al. 2005). However, 
concerns about extrapyramidal (EPS) side effects of first-generation anti psychotics 
have been replaced by other distressing effects including weight gain, hyperglycemia 
and dyslipidemia (Volavka e ta l  2002; Baptista e ta l  2004; Newcomer 2005).
The therapeutic benefit of “atypical” antipsychotics is therefore controversial and 
their advantages are most often regarded as not necessarily substantial (Miyamoto et 
a l 2005) especially since the extent to which they improve cognition in 
schizophrenic patients may not translate into an improved quality of life (Cramer et 
a l 2001).
These limitations of existing antipsychotic drugs have made people aware that no 
single treatment may be sufficient, paving the way to the search for compounds to be 
used in adjunction to antipsychotic drugs. Various adjunctive treatments including 
benzodiazepines, lithium, anticonvulsants, antidepressants, beta-blockers and 
dopamine agonists, have thus been used to treat residual symptoms of schizophrenia 
or to enhance the response to antipsychotic medications (Miyamoto 2002). However, 
theoretical and regulatory rationale to support this practice only came recently with 
the recognition of cognitive impairment as a critical and independent feature of 
schizophrenia that needs to be targeted independently (Friedman et a l 1999; Gold
2004). This is reflected by two recent initiatives of the American National Institute of 
Mental Health (NIMH): Measurement and Treatment Research in Cognition in 
Schizophrenia (MATRICS, (Marder and Fenton 2004) and Treatment Units for 
Research on Neurocognition in Schizophrenia (TURNS). In addition, as a 
consequence of the development of a battery of neurocognitive tests by the 
MATRICS consortium, the Food and Drug Administration (FDA) has now made it 
clear that it is reasonable for industry to seek approval for medications that enhance 
cognition in schizophrenia, which marks an important turning point in schizophrenia 
therapeutics (Gold 2004).
The development of novel additional strategies to obtain potentially new 
antipsychotic compounds and adjuncts possessing unique pharmacological profiles 
with fewer side effects is still a major challenge, both scientifically and financially 
(Miyamoto et a l  2005). However, this challenge is actively being pursued by the 
pharmaceutical industry based on specific hypotheses, and a number of agents with 
antipsychotic efficacy are currently being developed. In addition, novel approaches 
aiming at tailoring treatments or treatment regimes based on particular genotypes, 
SNP profiles or any other technique defining subgroups of patients are also pursued 
that have the potential to maximise the efficacy of the drug and to minimise the risk 
of developing side effects.
1.1.2- Genetic and environmental basis of schizophrenia
Although the prevalence of schizophrenia in the general population is about 1%, the 
results of numerous family, twin and association studies have conclusively shown 
that the risk of developing this illness is increased among the relatives of affected 
individuals, suggesting that genetic factors are largely involved (Gottesman 1991; 
McGuffm 1994; Riley 2004). The five most recent twin studies report a concordance 
rate among monozygotic twins of 41-65% compared to 0-28% for heterozygotic 
twins, estimating the broad heritability {le. the proportion of the total variance of the 
phenotype “schizophrenia” that is accounted for by genetic effects) of schizophrenia 
of about 85% (Cardno and Gottesman 2000). Thus, the approximate 10-fold increase 
in risk of developing schizophrenia in children and siblings of individuals with 
schizophrenia may be explained by a reduction in the reproductive opportunities, 
drive and possibly the fertility of affected individuals (Kirov et a l  2005). 
Nevertheless, while twin and adoption studies clearly show that genetic factors are 
essential, they also point out the importance of environmental factors since the 
concordance for schizophrenia in monozygotic twins is typically around 50% and 
heritability is less than 100% (Owen et a l  2005a). Thus, it appears that what is 
inherited is probably the predisposition to develop the disorder, rather than the 
certainty of disease accompanying a genotype (Jurewicz et a l  2001). In other words, 
schizophrenia appears largely genetically “mediated” but not genetically 
“determined” (Riley and Kendler 2006). Moreover, there are recent studies
suggesting that gene-environment interactions may also be important components in 
the overall risk (Tienari et a l 2004).
Studies of the relative risk in various relatives have excluded the possibility that 
schizophrenia is a single-gene disorder or collection of single-gene disorders even if 
these genes had an incomplete penetrance (Jurewicz et a l  2001). Rather, they 
strongly suggest that, similar to other common disorders, schizophrenia has a 
complex and non-Mendelian mode of transmission (Gottesman and Shields 1967; 
McGue and Gottesman 1989). However, the number of susceptibility genes 
(oligogenic and polygenic modes of transmission may be possible), the disease risk 
conferred by each locus and the degree of interaction between loci remain unknown 
(Kirov et a l 2005). Risch (1990) has calculated that the data for recurrence risks in 
the relatives of probands with schizophrenia are incompatible with the existence of a 
single locus conferring a relative risk in siblings {i.e. a risk in siblings relative to the 
risk in the general population) of more than 3 and that, unless there is extreme 
interaction between genes (a phenomenon called epistasis), models with two or three 
loci of relative risks less than or equal to 2 are more plausible (Risch 1990). 
However, this does not exclude that genes of larger effects may exist in some 
subpopulations of patients or in families with a high density of illness since such 
families are normally expected under a model of polygenic inheritance (McGue and 
Gottesman 1989).
In summary, studies of the inheritance of schizophrenia have thus revealed that 
schizophrenia is a multifactorial disease characterised by the contribution of multiple 
susceptibility genes that probably act in conjunction with epigenetic processes and 
environmental factors.
1.1.3- Neurocheinical basis of schizophrenia
Attempts to elucidate the biological correlates of schizophrenia have traditionally 
focused on several levels of explanation, including the neuropsychological, the 
neuropathological and the neurochemical evidence. The theory according to which 
schizophrenia is caused by disturbances in particular neurotransmitter systems arose 
during the 1950s and 1960s, based on the lack of obvious structural abnormalities in
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the schizophrenic brain and motivated by the observed antipsychotic or 
psychomimetic effects of certain chemical compounds. Thus, the dopamine 
hypothesis (van Rossum 1966; Carlsson 1978), which suggests that schizophrenia is 
associated with a hyperdopaminergic state, was proposed based on the proportional 
correlation observed between the potency of the first generation of antipsychotic 
drugs and their ability to block dopamine receptors (Seeman and Lee 1975) 
(section 1.1.1.2). This theory has long prevailed as the dominant neurochemical 
theory of schizophrenia before a more complex picture was suggested whereby the 
increased dopaminergic transmission in the basal ganglia is associated with acute 
psychosis (Abi-Dargham et a l 2000) and the chronic prefrontal cortical deficit is 
responsible for cognitive impairments (Weinberger et a l 2001) resistant to first- 
generation antipsychotic drugs. According to this refined hypothesis, which was 
notably suggested by the understanding of the pharmacological profile of clozapine 
(section 1.1.1.2), the clinical efficacy of recent antipsychotics was proposed to be 
partly mediated by actions on other neurotransmitter systems in addition to 
dopamine, which is consistent with evidence showing alterations in serotoninergic 
(Woolley and Shaw 1954), glutamatergic (Kim e ta l  1980) and GABAergic (Roberts 
1972) neurotransmission in schizophrenia.
Evidence suggesting that a dysfunction in glutamatergic neurotransmission might be 
involved in the pathophysiology of schizophrenia has been accumulating in the last 
two decades mainly based on the observation that NMDA (N-methyl-D-aspartic 
acid) glutamate receptor antagonists such as phencyclidine (PCP) and ketamine can 
cause psychotic symptoms in normal humans (Malhotra et a l  1996) and exacerbate 
these symptoms in schizophrenic patients (Javitt and Zukin 1991; Malhotra et a l 
1997b). Moreover, adjunctive treatment with NMDA agonists such as glycine has 
been shown to provide a modest improvement of negative symptoms in 
schizophrenia (Javitt et a l 1994; Heresco-Levy et a l 1999). Interestingly, extensive 
interactions of the glutamatergic system with other neurotransmitter systems suggest 
that alterations in glutamate may affect other systems that may be implicated in 
schizophrenia so that the glutamate hypothesis of schizophrenia cannot be considered 
separately. Thus, schizophrenia may result from an alteration of the delicate balance 
between dopaminergic and glutamatergic neurotransmission within critical regions of 
the brain (Holcomb et a l  2004). Evidence supporting this theory includes data
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showing that glutamate neurons regulate the function of GABA (Gamma- 
aminobutyric acid) interneurons (whose morphology has been shown to be altered in 
schizophrenia; Lewis et a l  2005) and dopamine neurons (which are the target of 
antipsychotic drugs). In addition, NMDA receptor function appears to be strongly 
related with serotoninergic activity (Breese et a l 2002) while glutamatergic 
neurotransmission can be affected by neuropeptide modulators such as 
cholecystokinin (CCK) and N-acetylaspartylglutamate (NAAG), that have been 
shown to be altered in schizophrenia (Meador-Woodruff and Kleinman 2002).
Whether alterations in glutamatergic neurotransmission, like any other 
neurochemical findings, reflect primary rather than secondary, downstream 
pathology, compensatory mechanism or environmental influences remains unclear 
(Bray and Owen 2001). However, the fact that reciprocal connections between key 
cortical areas are exclusively glutamatergic suggests that glutamatergic neurons may 
represent the means by which aberrant information is transferred within and between 
different regions of the brain (Moghaddam 2003). Moreover, there is accumulating 
evidence that NMDA glumatate receptors may be critical in triggering the alteration, 
in the schizophrenic brain, of limbic thalamocortical circuits that integrate the roles 
of glutamate, dopamine and GABA and therefore are consistent with current 
hyperdopamine and hypoglutamate theories of schizophrenia (Tamminga 1999; 
Carlsson e ta l  2000; Sharp e ta l  2001; Coyle 2004).
1,1.4- Neuropathology of schizophrenia
A number of neuropathological abnormalities have been reported in the brains of 
schizophrenic patients, including reduced cortical volume, smaller glutamatergic 
somatic or neuropil size, reduced synaptic protein expression, disarray of neuronal 
orientation and area- and lamina-specific reductions in dendritic field size and 
dendritic spines. These abnormalities, which concern a number of regions (including 
the prefrontal cortex, the hippocampus and adjacent entorhinal cortex, the thalamus) 
rather than a few specific brain regions, are thought to represent the basis for at least 
a proportion of the aberrant connectivity (Harrison 1999). Besides, some of these 
post-mortem findings have interestingly been paralleled by in vivo structural
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neuroimaging findings indicating reduced cortical volumes, magnetic resonance 
spectroscopy studies consistent with reduced neuropil volume or viability and 
diffusion tensor imaging studies suggesting disturbances in cortical connectivity 
(Krystal et a l  2003).
A novel approach to understanding the pathophysiology of schizophrenia has thus 
emerged over the last decade based on the understanding that the complex brain 
functions disturbed in schizophrenia are dependent on the coordinated activity of 
distributed ensembles of neurons (Lewis 2002).
LL4,1-The dorso-lateral prefrontal cortical (DLPFC) circuit in 
schizophrenia
Studies examining potential alterations in neural circuits rather than specific brain 
regions were performed, and the dysfunction of the corticolimbothalamic circuit 
emerged as having the potential to correlate alterations in multiple neurotransmitter 
systems and observed brain abnormalities with the clinical symptoms, especially the 
cognitive dysfunction, of schizophrenia (Bunney and Bunney 2000; Lewis 2002; 
Morris et a l 2005). Within this circuit, the Dorso-Lateral Prefrontal Cortex 
(DLPFC), because of its integrative role, was suggested to represent the essential 
region. The DLPFC circuit then runs from the prefrontal cortex to the ventral 
striatum on to the ventral pallidum then to the mediodorsal thalamic nucleus before 
returning to the prefrontal cortex.
Evidence suggesting that this circuit was compromised was found at the level of 
anatomical, neuropathological and transmitter-related molecules and defects in any 
of the structures that it connects were shown to produce alterations potentially related 
to schizophrenic symptoms (Bunney and Bunney 2000). Moreover, imaging of 
regional cerebral blood flow and metabolic activity in schizophrenic patients 
interestingly revealed disturbances in the activity of the DLPFC circuit, with lower 
activity in the prefrontal, cingulate and temporal (including the hippocampus) 
cortical areas, the striatum/accumbens region and the thalamus (Hazlett et a l  2004; 
Morris et a l  2005). In particular, robust and specific deficits were shown in the 
prefrontal cortex, which is probably the nodal point of the circuit, in the thalamus 
and in the hippocampus of schizophrenic patients (Lewis 2002).
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The human dorso-lateral prefrontal cortex is a key structure of the cortex that 
mediates the temporal organisation of behaviour via mechanisms such as attention 
and working memory (Fuster 2000) so that its dysfunction appears to be a central 
feature in the pathophysiology of schizophrenia (Weinberger et a l  1986), 
particularly with reference to critical deficits on cognitive functions (Bunney and 
Bunney 2000). Thus, evidence showing reduced metabolic activity 
(“hypofrontality”) in the prefrontal cortex of schizophrenic patients during 
performance of a cognitive task (Hazlett et a l 2004) proved a particularly robust 
finding. Moreover, the magnitude of the deficits in the prefrontal cortex was 
interestingly found to correlate with the presence and the severity of negative 
symptoms and cognitive deficits while the reduced metabolic activity within the 
thalamic mediodorsal nucleus and the temporal lobe correlated with negative and 
positive symptomatology, respectively (Hazlett et a l 2004). Such alterations in 
metabolic activity may explain poor performance of schizophrenic patients in 
working memoiy tasks requiring intact prefrontal functioning, such as the 
oculomotor delayed response task and the Wisconsin Card Sort and Tower of 
London Tests (Weinberger et a l  1986; Green et a l  1992; Park et a l  1999; Glahn et 
a l  2000).
In addition, further evidence of the implication of the prefrontal cortex in 
schizophrenia pathology is provided by neuropathological studies showing 
alterations in synaptic function in the prefrontal cortex (Lewis 1997; Selemon and 
Goldman-Rakic 1999; Mimics et a l 2001). In relation to these findings, the 
diminished volume of prefrontal cortex grey matter observed in schizophrenic brain 
(McCarley et a l 1999) was suggested to be due to a decrease in the amount of axon 
terminals, distal dendrites and dendritic spines that represent the principal 
components of cortical synapses. Consistent with the interpretation that the 
dysfunction of the prefrontal cortex in schizophrenia involves a loss of synapses 
(Lewis et a l  1999; Selemon and Goldman-Rakic 1999; Woo and Crowell 2005), the 
expression of the synaptic vesicle protein synaptophysin was found to be reduced in 
the prefrontal cortex of schizophrenic patients (Glantz and Lewis 1997; Karson et a l 
1999), similar to the expression of many genes encoding for proteins that regulate 
synaptic structure and function (Mimics e ta l  2000; Hakak et a l 2001; Mimics e ta l  
2001; Vawter et a l  2001; Pongrac et a l  2002). Also consistent with this hypothesis
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are in vivo proton spectroscopy studies showing reduced levels of N-acetyl aspartate 
(NAA), a putative marker of neuronal and/or axonal integrity, in the prefrontal 
cortex. Interestingly, the correlation observed between these changes and the degree 
of impaired activation in other brain regions during working memory tasks may 
suggest that neuronal abnormality within the prefrontal cortex could be involved in 
functional disturbances in the working memory network (Bertolino et al. 2000). 
Finally, anatomical studies of post-mortem prefrontal cortex from schizophrenic 
patients revealed a maldistribution of neurons originating from the cortical subplate 
which may result in altered connectivity of thalamocortical neurons (Bunney and 
Bunney 2000) and may interestingly be consistent with the neurodevelopmental 
hypothesis of schizophrenia (section 1.1.5.2).
Alterations in GABA transmission within the dorso-lateral prefrontal cortex strongly 
supported the implication of this brain region in schizophrenia, especially with 
regards to its cognitive disturbances. This long-suggested hypothesis, based on post­
mortem observations of alterations in presynaptic cortical GABA markers, decreased 
activity of the glutamic acid decarboxylase (GAD) GAB A-synthesis enzyme and 
decreases in GABA release and uptake within the DLPFC (Benes et a l  1991; 
Sherman et a l  1991; Benes et a l 1996; Simpson et a l  1998; Lewis et a l  1999; 
Blum and Mann 2002), was recently refined upon evidence of specific alterations of 
the chandelier subclass of GABA neurons and especially those located in the middle 
layer of the schizophrenic DLPFC (Lewis et a l  1999; Lewis et a l  2004).
Dysfunction of these cells, reflected by reductions in their parvalbumin (a neuronal 
calcium-binding protein commonly used to define this subclass of GABAergic 
interneurons specifically affected in the prefrontal cortex of schizophrenic patients) 
levels and in the number of axon terminals (Beasley and Reynolds 1997; Pierri et a l  
1999; Lewis 2000), was found to impact on pyramidal neurons to which they project, 
leading to an upregulation of some GABA receptors at the pyramidal axon initial 
segment (Selemon et a l  1995; Volk et a l  2002). In fact, this reduction of GABA 
activity in the prefrontal cortex, which may result In a compensatory increase in 
GABA receptors at the axon initial segment of pyramidal neurons (Volk and Lewis
2002), was suggested to constitute the primary process impaired in the dorso-lateral 
prefrontal cortical circuit contributing to cognitive dysfunction in schizophrenia. The
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pyramidal neuron axon initial segment, where chandelier neurons synapse, is indeed 
the site of generation of action potential whereby chandelier neurons exert powerful 
regulatory inhibitory control over pyramidal cell output (Lewis et a l  2004). Thus, 
the increase of GABA receptors at the axon initial segment may induce a major 
disruption in inhibitory neurotransmission on pyramidal neurons leading to elevated 
uncoordinated firing throughout the corticolimbothalamic circuit (Fuchs et a l  2001; 
Cunningham et a l 2004) and thereby compromising the synchrony of cortical 
activity that is required for working memory (Lewis et a l  2004).
Finally, evidence suggesting that disruption of the corticolimbothalamic circuit 
including the dorso-lateral prefrontal cortex may constitute a core feature of the 
pathophysiology of schizophrenia was further reinforced by the potential of this 
hypothesis to fit most major current theories of schizophrenia including the 
neurodevel opmental and dysconnectivity hypotheses.
1.1.5- Aetiological and pathophysiological hypotheses of schizophrenia
L 1 .5J- Synaptic plasticity and altered connectivity in schizophrenia
The hypothesis that schizophrenia does not result from focal brain abnormalities but 
from pathological connectivity within the brain is probably the oldest theoiy of 
schizophrenia. In fact, the term “schizophrenia” itself proposed by Bleuler in 1911 to 
reword the psychopathological concepts of psychosis postulated by Wernicke (1906), 
already suggested the “splitting” of different mental domains. This theme re-emerged 
recently in neurophysiologic and neuroimaging studies showing abnormal distributed 
activity and functional connectivity in schizophrenia (Volkow et a l  1988; 
Weinberger et a l 1992), leading to the hypothesis that schizophrenia may be 
regarded as a “disease of neuronal connectivity” (Andreasen 2000). Interestingly, 
this hypothesis may be consistent with evidence of alterations in neural circuitry, 
particularly in the cortex (section 1.1.4).
While the evidence suggesting brain disconnection in schizophrenia is thus 
accumulating, the underlying causes remain elusive (Stephan et a l 2006). Abnormal
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functional coupling between brain areas may indeed be due to alterations of their 
anatomical connections or result from an impaired control of synaptic plasticity 
resulting in abnormal functional integration of neural systems (Friston and Frith
1995). Whichever is the primary impairment is still unknown (Krystal et a i  2003) 
and each of these mechanisms (which may not be exclusive but have a common 
cause) has in fact been supported by a number of observations.
The hypothesis, first proposed by Friston and Frith (1995), that dysconnectivity may 
result from an impaired “microconnectivity”, i.e. the connectivity between adjacent 
cells and cortical microcircuits (Walterfang et al. 2006), leading to alterations in 
experience-dependent synaptic plasticity, is consistent with the NMDA receptor 
hypofunction hypothesis of schizophrenia (section 1.1.3) since NMDA receptors 
have long been shown to play a central role in the modulation of excitatory synaptic 
transmission and plasticity (Malenka and Nicoll 1993; Krystal et al. 2003). 
Following on this hypothesis, the mechanisms by which NMDA antagonists can 
induce schizophrenia-like psychotic symptoms and cognitive deficits may be 
mediated by alterations in the activity-dependent synaptic plasticity that underlies 
learning and memory.
In addition, further support for abnormal plasticity in schizophrenia has been 
provided by recent genome-wide linkage and allelic association studies which 
identified a number of NMDA receptor-dependent signalling and/or 
neurotransmitter-related genes (Stefansson et al. 2002; Martucci et al. 2003; 
Goldberg et al. 2006).
An alternative to this hypothesis may be the accumulating evidence of white matter 
changes and myelin-related dysfunction in schizophrenia, supporting the theory that 
schizophrenia may result from an anatomical impairment in “macroconnectivity”, 
i.e. the connectivity between functionally related but anatomically disparate regions, 
in the schizophrenic brain (Davis et a l 2003; Walterfang et a l  2006). Myelination 
and factors that affects myelination, such as the function of oligodendroglia, are 
indeed critical processes that can profoundly affect neuronal connectivity, especially 
given the diffuse distribution of oligodendrocytes and the widespread distribution of 
brain regions implicated in schizophrenia (Davis et a l 2003).
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Thus, the coincidence between the peak age of onset of schizophrenia (during 
adolescence or early adulthood) and the time when prefrontal and hippocampal 
connections achieve full myelination (Rapoport et al. 2005) strongly supports the 
hypothesis that altered myelination may play an important role in the disruption of 
brain connectivity in schizophrenia.
The range of evidence for white matter abnormalities in schizophrenia includes 
neuropathological studies showing a reduction in size and density of 
oligodendrocytes, gene expression studies showing the downregulation of a number 
of oligodendrocyte and myelination genes (potentially responsible for the reductions 
in oligodendrocyte density) and both volumetric and non-volumetric neuroimaging 
techniques identifying contradicting but accumulating white matter abnormalities 
(Walterfang et al. 2006). In particular, white matter volume was found to be reduced 
in the prefrontal cortex of schizophrenic patients correlating with the negative 
symptoms suggesting that white matter abnormalities may be involved in the 
disturbance in connectivity within and between the prefrontal cortex and other brain 
regions (Davis et al. 2003) and thereby may have a role in the dismption of the 
corticolimbothamic circuit in schizophrenia (section 1.1.4).
In conclusion, there is converging evidence suggesting alterations in connectivity in 
schizophrenia, and several hypotheses have been proposed to explain the putative 
basis of this dysconnectivity. These hypotheses may not be exclusive; for example, 
since glial cells are known to play an important role in neuronal migration and 
synaptic function (including NMDA regulation), abnormalities in white matter 
oligodendrocytes may be related to NMDA receptor function and altered synaptic 
plasticity in schizophrenia. Thus, oligodendrocyte dysfunction may lead to 
abnormalities such as reduced neuronal size, reduced levels of synaptic proteins and 
abnormalities in neurotransmission representing the basis of impaired synaptic 
plasticity and functional dysconnectivity in schizophrenia (Kubicki e ta l  2005).
Ll.5.2-Neurodevelopmental hypothesis o f schizophrenia
In recent years, schizophrenia has increasingly been regarded as a 
neurodevelopmental disorder (Murray and Lewis 1987; Weinberger 1987). Indeed, 
although different hypotheses have been proposed as to the timing and nature of
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potential developmental disturbances, there is accumulating evidence suggesting that 
schizophrenia is the behavioural outcome of aberrations in neurodevelopmental 
processes beginning long before the onset of clinical symptoms and caused by a 
combination of environmental and genetic factors (Cardno et al. 1999; Singh et al.
2004). This theory is supported by epidemiological evidence showing increased 
obstetrical complications and childhood neuropsychological and motor deficits in 
individuals who subsequently develop schizophrenia, and neuroimaging studies 
showing ventricular enlargement and reductions in cortical volume at illness onset 
(Pantelis et al. 2003) and in people at higher genetic risk of the disorder (Lawrie et 
a l  1999). In addition, histological studies, though prone to methodological problems, 
have provided evidence for subtle cytoarchitectural abnormalities of putative 
developmental origin within the frontal lobes and temporo-limbic structures such as 
the hippocampus (Harrison 1999; Benitez-King et a l 2004).
Attempts to conceptualise the neurodevelopmental hypothesis of schizophrenia have 
mainly led to two models, one favouring an early “static” brain lesion model 
(Weinberger 1987; Gilmore et a l 1998) and one supporting a late disturbance in 
brain maturation (Feinberg 1982; Mathalon et a l 2003). The first model, supported 
by post-mortem studies showing abnormal patterns of neuronal migration, 
particularly during the development of the cerebral cortex (such as the disruption of 
cortical subplate activity; Bunney and Bunney 2000), suggests that the primary 
pathological event occurs during the pre- or peri-natal periods but does not become 
clearly evident until after puberty, when the affected networks become fully mature. 
Its functional consequences result then in disturbances in cortical connectivity and 
associative function (Weinberger 1987; Bunney and Bunney 2000). In contrast, the 
model favouring late developmental changes focuses on maturational events 
occurring during adolescence, such as the maturation of certain complex brain 
regions that are critical to meeting the challenges of adult life. This model is 
particularly supported by reproducible observations of reduced neuronal size and 
arborisation (Selemon and Goldman-Rakic 1999) suggesting that the 
pathophysiological processes involved in schizophrenia cannot be restricted to the 
pre- or peri-natal period (Rapoport et a l  2005). Therefore, although both models 
differ as to the supposed primary disturbances involved, they converge on a common 
view according to which late or ongoing developmental processes are critical to the
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pathogenesis of schizophrenia (Lewis 1997). Interestingly, this is consistent with 
brain imaging studies showing a pattern of progressive changes both for early onset 
and chronic adult patients (Lewis and Levitt 2002; Rapoport et a l 2005).
In addition, evidence showing that the connectivity of the prefrontal cortex is 
substantially refined during adolescence suggests that these developmental changes 
are critical for the appearance of the clinical symptoms of schizophrenia (Lewis 
1997). In the absence of classical degenerative changes, synaptic pruning, activity- 
dependent changes and myelination have been proposed as mechanisms whose 
alterations may underlie the development of schizophrenia during adolescence by 
leading to an abnormal reorganization or strengthening of cortical connections and 
therefore to alterations in connectivity and synaptic plasticity within critical cortical 
regions (Lewis and Levitt 2002; Benitez-King et a l  2004). Interestingly, this theory 
may not only provide further support to the dysconnectivity hypothesis of 
schizophrenia but a basis for the critical dysfunction of the dorso-lateral prefrontal 
cortex circuitry in schizophrenia (section 1.1.4).
The neurodevelopmental hypothesis of schizophrenia may therefore be consistent 
with most major theories of schizophrenia (sections 1.1.5) which explains why this 
model is probably the most largely accepted explanatory hypothesis about 
schizophrenia pathophysiology. Although the precise biological mechanisms 
underlying these putative changes remain unknown, the development of mature 
synaptic networks, which involves a dynamic interplay between genetic, 
environmental and stochastic factors, is likely to be the only process whose 
complexity may integrate the heterogeneity of schizophrenia and the complexity of 
its aetiology.
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1.2“ Approaches to gene identification in schizophrenia
Although epidemiological, pharmacological and neurobiological studies have 
definitely allowed considerable advances in the understanding of schizophrenia, they 
still only provide an incomplete picture of this highly complex disorder (Kirov et a l
2005). Moreover, because schizophrenia is a highly heritable but also multi factorial 
disorder, these studies cannot be considered exclusively and the most important 
advances in the comprehension of schizophrenia pathophysiology and aetiology will 
probably arise from their integration with genetic and genomic approaches to 
studying schizophrenia.
The identification of genes involved in the susceptibility and or in the pathology of 
schizophrenia is therefore of major importance. Nevertheless, in the context of the 
limited understanding of the aetiology and pathophysiology of schizophrenia, 
molecular genetic approaches have proven very difficult, especially because they not 
only share many of the problems encountered by other forms of schizophrenia 
research (including tissue availability, confounding factors such as medication) but 
also the problems inherent to complex disorders (including difficulties to reach 
statistical significance and/or to replicate findings). In addition, schizophrenia is such 
a heterogeneous disease in its presentation that it is very difficult to define a 
phenotype for human schizophrenia research, and to model it in any animal model.
Despite these issues, the more recent gene discovery studies have allowed the 
identification of a few well-supported candidate genes for schizophrenia whose 
interpretation may hold promising clues to understanding its neuropathology, giving 
insights into its causes and helping in the development of novel antipsychotic drug 
treatments.
1.2.1- The phenotype of schizophrenia
Besides being faced with the difficulty of the lack of a simple one-to-one relationship 
between genotype and phenotype (Owen et a l 2004), the identification of
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susceptibility genes for schizophrenia is complicated by the limitations of the 
“phenotype” concept in psychiatric research in general (Sanders et a l  2004). Similar 
to most major psychiatric disorders, schizophrenia displays indeed an extensive 
heterogeneity of symptoms, course and outcome, and although aetiological 
subgroups have not been defined yet, it is likely that the disorder includes several 
different disease processes (Owen et a l 2005a). Moreover, although the use of 
explicit operational criteria based on structured and semi-structured interviews 
allows excellent diagnostic reliability, the inherited genetic vulnerabilities may not 
be specific to schizophrenia but result in a range of clinical phenotypes including a 
spectrum of disorders such as schizoaffective disorders and schizotypical personality 
disorder (Farmer et a l  1987; Kendler et a l 1995). In addition, independently of the 
extensive co-morbidity of psychiatric disorders, it is plausible that in a number of 
instances different psychiatric syndromes may share common aetiological genetic 
factors. In particular, the limits of the schizophrenia spectrum and its relationship to 
other psychiatric disorders, especially bipolar disorder (Kendler et a l  1998; Tienari 
et a l  2000) remain uncertain.
Nevertheless, the high heritability of the schizophrenia syndrome as defined by 
current diagnostic criteria was shown to make it theoretically suitable for molecular 
genetic analyses. Therefore in the absence of validated ways of defining sub-groups, 
most groups have chosen to search for genes using “schizophrenia” as a phenotype 
(Owen et a l 2004).
In parallel, as an attempt to “decompose” or “deconstruct” the syndrome of 
schizophrenia, endophenotypes, i.e. measurable variables which are intermediate 
between the genotype and the phenotype, have emerged as an important concept in 
the study of complex neuropsychiatrie diseases (Gottesman and Gould 2003). These 
traits, which are not readily observable but require the use of special processes or 
instruments for their detection, are indeed assumed to have a closer relationship to 
the underlying disease genotype and thereby be less complex genetically (Cannon
2005). Several potential endophenotypes have been suggested for schizophrenia, 
including sensory-motor gating deficits such as deficits in pre-pulse inhibition (PPI), 
various event-related potentials (including the P50 event-related suppression) 
measured by electroencephalography (EEG), eye-tracking dysfunction and 
impairments in working memory. However, none of these has yet allowed the
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identification of replicated susceptibility genes for schizophrenia (Owen et a l 
2005a). In fact, the search for endophenotypes is not straightforward either because 
no a priori criterion can be used to decide if a particular element of schizophrenia 
reflects the effect of a single gene. Moreover, the assumption that the genetic 
architecture of endophenotypes is substantially simpler than that of schizophrenia 
itself is still under debate. Nevertheless, despite the lack of evidence of the relevance 
of endophenotypes as genetic “vulnerability markers”, the current consensus is that 
endophenotype-based strategies may play an important and informative role to 
understand schizophrenia by revealing the genetically-mediated vulnerability factors 
that interact with non-genetic factors to produce this complex psychiatric disorder 
(Freedman e ta l  1999; Braff 2002; Owen e ta l  2005a).
1.2.2- Animal models of schizophrenia
The difficulty and the complexity of working with human schizophrenic samples 
have long stimulated the development of animal models of schizophrenia, despite the 
concern about the fact that less cognitively developed animals such as rodents may 
not faithfully reproduce what is perceived to be a disorder of the highest human brain 
functions (Marcotte et a l  2001). Nevertheless, in psychiatry like in any other area of 
medicine, the use of animal models is indeed a valuable tool for helping to 
understand the pathophysiological mechanisms because of the inherent greater 
simplicity of working and manipulating animals as opposed to human subjects; this 
includes the availability of tissue, the freedom in designing experiments and the 
possibility of controlling many more variables, of testing particular hypotheses etc 
(Wong and Van Toi 2003). Nevertheless, schizophrenia is such a complex disease, 
both in its aetiology and in its clinical heterogeneity and putative pathophysiology, 
that developing a valid model represents a major challenge.
Therefore, in order to avoid misunderstandings or potential excessive extrapolations, 
it is very important to specify first what the model is intended for and therefore what 
criteria it should meet when developing and evaluating an animal model (Geyer 
2002b). Thus, at two extremes, “animal models” of schizophrenia may well refer to 
attempts to mimic the schizophrenia syndrome in its entirety or to develop a model 
for the study of antipsychotic drug treatments. Development of the former is
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necessarily confronted with the impossibility to reproduce the heterogeneity of 
schizophrenia and the complexity of its clinical course while the latter, being 
validated by reference to the effects of known antipsychotics, may be limited in its 
potential to identify drugs with novel mechanisms of actions or that might better treat 
the symptoms not improved by current medications (Geyer 2002a).
In this context, the most common approach used to develop an animal model of 
schizophrenia has been to focus on specific signs, symptoms or aspects of 
schizophrenia that can be mimicked and observed reliably in animals, most often 
rodents (Gainetdinov et al. 2001). A number of models have thus been developed 
that mimic biological phenomena potentially associated with schizophrenia 
symptoms, including developmental changes, abnormalities in neurotransmission and 
genetic characteristics (Lipska and Weinberger 2000; van den Buuse et al. 2005). 
Interestingly, the combination of these animal models may further help to understand 
the neurobiology of schizophrenia, for example by providing insights into different 
mechanisms giving similar symptoms and thereby help to draw a more complete 
picture of the complex aetiology and pathophysiology of schizophrenia (Lipska and 
Weinberger 2000; Wong and Van Toi 2003).
Different types of animal models of schizophrenia include the lesion models and 
environmental models, which are based on various aetiological theories, 
pharmacological models based on abnormalities in neurotransmission and the more 
recent genetic models that directly investigate the role of particular genes in 
schizophrenia pathophysiology.
The PCP model, despite being a pharmacological model of schizophrenia, will be 
presented separately as it has emerged as one of the most promising models that may 
have the potential to bridge a number of hypotheses of schizophrenia.
1.2.2.1- Neurodevelopmental models o f  schizophrenia
A number of animal models have been developed to explore the neurodevelopmental 
theories of schizophrenia by testing different aspects of this hypothesis, including 
several aetiological hypotheses (lesion models), the impact of disrupted neurogenesis 
and the relevance of early stressful experience (environmental models).
24
In lesion models of schizophrenia, disruption of the neurodevelopment or the correct 
functioning of specific brain regions at presumably critical times of the development 
constitutes a highly controlled approach to explore the neurodevelopmental 
hypotheses of schizophrenia (Marcotte et a l 2001) and such models have been 
invaluable in helping to understand the pathophysiology and neurodevelopmental 
functions of various brain regions in relation with schizophrenia (Wong and Van Toi
2003).
Thus, a number of brain regions potentially involved in schizophrenia, including the 
prefrontal cortex, the thalamus and the hippocampus, have been the object of 
targeted lesions, typically involving excitotoxic agents which destroy neuronal tissue 
by stimulating excitatory glutamate release or acting as direct glutamate receptor 
agonists (Marcotte et a l 2001).
Adult lesion models were found to exhibit some neurochemical and behavioural 
deficits similar to schizophrenic patients, such as preattentional sensorimotor gating 
deficits (reflected by altered prepulse inhibition of startle (PPI) after apomorphine 
injection in adult rats with prefrontal cortex (PFC) lesions (Swerdlow et a l  1995)). 
However their validity as animal models of schizophrenia appears limited by the size 
and the nature of lesions realised in adult mature brain regions (Marcotte et a l  2001). 
Conversely, neonatal lesion models, which have the ability to demonstrate a delayed 
onset of symptoms corresponding to the clinical presentation of schizophrenia in 
humans, appear much more valid to test neurodevelopmental theories of 
schizophrenia. The neonatal ventral hippoeampal (VH) lesion model may be of 
particular interest since it incorporates many features of schizophrenia, including 
enhanced dopaminergic neurotransmission, hyperactivity, altered prepulse inhibition 
of startle (PPI) and persisting deficits in spatial learning and memory (Lipska et a l 
1992; Lipska et a l  1995; Chambers et a l 1996; Wong and Van Toi 2003), promising 
insights into dissecting and understanding the molecular circuitry involved in the 
pathophysiology of schizophrenia.
The development of models based on disrupted neurogenesis has been stimulated by 
evidence showing alterations in cortical cytoarchitecture potentially of 
developmental nature (Lipska and Weinberger 2000). One example of these models 
is in iitero exposure to a mitotic toxin, methylazoxymethanol acetate (MAM) which 
destroys populations of rapidly dividing neurons. Very interestingly, animals having
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undergone MAM manipulations exhibit morphological changes in a number of brain 
regions implicated in schizophrenia, demonstrate a variety of behavioural alterations 
such as locomotor hyperactivity, stereotypies, cognitive impairments and alterations 
in prepulse inhibition of startle (PPI), and show electrophysiological abnormalities 
that may underlie psychomotor disturbances in schizophrenia (Johnston et a l  1988; 
Lipska and Weinberger 2000). This model therefore demonstrates that perturbation 
in cortical development can produce some of the behavioural characteristics 
associated with schizophrenia.
Finally, environmental models have been developed to explore the long-lasting 
consequences of stressful experience for brain development and for shaping adult 
behavioural responses (Lipska and Weinberger 2000). Thus, environmental factors 
that have been proposed as aetiological factors for schizophrenia, including pre­
weaning non-handling (Shalev et a l 1998), hypoxia (Schwarzkopf et a l 1992), 
isolation-rearing (Valzelli et a l  1977) or prenatal malnutrition (Morgane et a l 1993) 
were found to induce behaviours in rodents that may be compared to some features 
of schizophrenia in humans (Wong and Van Toi 2003). Finally, these models, which 
have also been used to provide evidence that there is an interaction between genetic 
predisposition and early life environmental factors, may also represent an interesting 
approach to study these interactions in the development of schizophrenia.
1.2.2.2- Pharmacological models
The development and use of pharmacological models based on the understanding or 
on hypotheses of neurotransmission alterations has been the major approach in 
preclinical schizophrenia research for many years (Marcotte et a l 2001). As an 
attempt to reproduce these alterations and particularly to explore the dopamine, 
serotonin (or serotonin-dopamine) and glutamate hypotheses of schizophrenia, a 
range of drugs were used, including dopamine agonists such as apomorphine and 
amphetamine (Hantraye 1998; Castner and Goldman-Rakic 1999), NMDA receptor 
antagonists such as phencyclidine (PCP), dizolcipine (MK-801) and ketamine (Noda 
et a l  1995; Reijmers et a l  1995; Sams-Dodd 1997; Sams-Dodd 1998), serotonin (5- 
hydroxytryptamine or 5-HT) 5-HT2a agonists such as lysergic acid (LSD) and 
mescaline (Geyer 1998; Yamada et a l  1999) and neurotoxins (MAM, 6-
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hydroxydopamine (6-OHDA), p-chlorophenylalanine; Johnston et a l  1988; Lillrank 
et a l 1995), the drugs being administered either to adult animals or targeted to 
specific periods of development (Marcotte et a l 2001). These models are limited by 
the current understanding of the fundamental basis of thought and cognition 
(Marcotte et a l 2001); however since most of them involve the administration of 
drugs that induce or exacerbate schizophrenic symptoms in humans, they generally 
have fairly good construct and predictive validities (Costall 1995).
The most studied pharmacological models of schizophrenia have long been based on 
the behavioural effects of psychostimulant drugs such as amphetamine (Lipska and 
Weinberger 2000). However, these dopamine-agonist models now appear to have 
limited validity since typical dopamine-induced stereotypies and locomotor 
hyperactivity are not thought to reflect the human condition of people with 
schizophrenia any more (Geyer 2002b). Nevertheless, dopamine agonists such as 
amphetamine and cocaine dismpt PPI in rodents, thereby mimicking one of the most 
robust behavioural deficits observed in schizophrenic patients, and their effects are 
interestingly reversed by antipsychotic drug treatment (Swerdlow and Geyer 1998). 
Thus, because of their very good predictive validity, dopamine-induced models are 
still largely used to test the efficacy of dopamine-antagonist treatments for 
schizophrenia (Geyer 2002b).
Interest in the serotonin-agonist models of schizophrenia was first driven by reports 
of the behavioural effects (namely hallucinations) induced by LSD, which appear to 
be mediated by its agonism properties at 5-HT2a receptors (Glennon et a l 1984), 
These models were then proved to exhibit deficits in habituation, PPI and latent 
inhibition that may interestingly be relevant to both specific abnormalities exhibited 
by patients in the early stages of schizophrenia and to the effects of antipsychotics 
(Geyer 1998).
Development of glutamatergic models of schizophrenia, similar to the NMDA 
receptor hypofunction hypothesis of schizophrenia (section 1.1.3), was primarily 
based on the observation that non-competitive antagonists of NMDA glutamate 
receptors such as phencyclidine (PCP) and ketamine exacerbate symptoms in chronic 
stabilised schizophrenic patients and produce a behavioural syndrome in healthy 
humans that so closely resembles symptoms of schizophrenia that it is frequently 
misdiagnosed as acute schizophrenia (Fauman et a l 1976; Javitt and Zukin 1991;
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Ktystal et al. 1994). Thus, the remarkable similarity of PCP-induced behaviours with 
the diverse array of schizophrenia symptoms, including cognitive deficits such as 
impaired attention and working memory, has prompted the use of PCP in 
pharmacological models of schizophrenia in both basic and clinical studies. The PCP 
model, which was shown to exhibit excellent construct, face and predictive validity 
as a model of schizophrenia, is further detailed in section 1.2.2.4.
1.2.2.3- Genetic models
Neurodevelopmental and pharmacological models of schizophrenia have recently 
been complemented by the development of genetic models (Smithies 1993). Beside 
studies investigating strain differences -thereby the contribution of genetic factors- in 
schizophrenia-relevant behavioural traits such as PPI (Paylor and Crawley 1997; 
Swerdlow et al. 2000), genetically modified (transgenic and knock-out) animal 
models of schizophrenia were developed following two different approaches (Geyer 
2002b).
In the initial approach, genetically modified mice were used to test specific 
hypotheses of relevance to schizophrenia, particularly hypotheses of alterations in 
neurotransmission. Thus, evidence of altered dopaminergic and glutamatergic 
transmission in the pathophysiology of schizophrenia led to the development of a 
number of mice models including dopamine D%-, D3- and D4- (Ralph et al. 1999), 
glutamate GRINi- and GRIN2- (Mohn et a l  1999; Miyamoto et a l 2001) and 
NMDA NRi-receptor knock-out mice (Mohn et a l  1999).
In the second approach, genetically modified mice were used to investigate the 
individual role of candidate genes involved in schizophrenia pathophysiology and 
evaluate their potential contribution to the development of schizophrenia-associated 
behaviours or symptoms (Geyer 2002b). Among all generated mice, calcineurin, 
neuregulin, NRi and STOP (Stable Tubule Only Polypeptide) knock-out mice were 
found to exhibit a range of alterations or deficits that may be relevant to 
schizophrenia, confirming the potential involvement of these genes in schizophrenia 
aetiology or pathophysiology (Geyer 2002b).
All these models have their own advantages and limitations. Lesion and 
environmental models appear interesting tools to test new theories of the origin of
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schizophrenia and its potential mechanisms; they have been particularly useful to 
confirm that dismption of neurodevelopment affects dopaminergic neurotransmission 
leading to schizophrenia-related behaviours. Pharmacological models are very 
valuable in preclinical research, particularly to screen novel potential antipsychotic 
treatments. Finally, genetic models of schizophrenia appear very promising since 
they may allow us not only to test the potential role of particular genes in the 
development of schizophrenia but also to investigate the interactions between genetic 
and environmental factors that are thought to be critical in schizophrenia 
pathogenesis.
1.2.2.4- The chronic PCP model o f schizophrenia
Accumulating evidence over the last decades has suggested the PCP model as one of 
the more valid models of schizophrenia, both in its ability to mirror schizophrenia 
pathophysiology with impressive precision and also as a very valuable tool to screen 
for novel antipsychotic medications.
The synthetic drug phencyclidine (PCP) was first developed as a surgical anaesthetic 
but rapidly withdrawn because of its secondary effects including hallucinations, 
disordered speech, delirium, agitation and disoriented behaviour. However, 
observations of the ability of PCP to trigger such experiences exactly prompted its 
illicit use as a hallucinogen and at the same time attracted interest of neuroscientists, 
intrigued by the similarity between PCP-induced behaviours and the symptoms of 
people with schizophrenia (Murray 2002).
PCP is a non-competitive antagonist of NMDA glutamate receptors that, similar to 
dizolcipine (MK-801), acts by binding to a site within the pore of the open NMDA 
channel (hence the term “open channel” blocker). However, PCP also exerts 
inhibitory effects on other receptors such as nicotinic acetylcholine and voltage- 
dependent sodium and potassium ion channels (Vincent et al. 1983; Oswald et al. 
1984; Ffrench-Mullen and Rogawski 1989) and sigma, dopamine Di and serotonin 
5 -HT2 receptors (Kapur and Seeman 2002). Nevertheless, since these actions are 
much less potent than its action on NMDA receptors, the effects of PCP in the
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central nervous system appear to be mostly mediated by its antagonism at NMDA 
receptors (Morris et al. 2005).
Initial obseiwations of the effects of PCP in humans prompted the use of PCP to 
model schizophrenia. However, although chronic exposure to PCP appears more 
relevant to model psychosis, it is only recently that efforts have been made to find 
the treatment regimes in rodents that may be equivalent to those inducing 
psychogenic effects in humans (Monis et a l  2005). A number of studies thus used 
single acute administration of PCP. In rodents and monkeys, acute sub-anaesthetic 
doses of PCP were shown to induce an array of symptoms relevant to schizophrenia 
symptomatology, including amphetamine-like increased locomotor activity and 
enhanced stereotyped behaviours (Javitt and Zukin 1991) but also cognitive and 
sensorimotor gating deficits (disruption of PPI) and impaired social interactions 
(Steinpreis et a l  1994; Sams-Dodd 1995; Swerdlow and Geyer 1998; Yamada et al. 
1999). Moreover, PCP and other NMDA receptor antagonists acutely increase 
extracellular levels of dopamine and glutamate in the prefrontal cortex and alter 
firing of dopaminergic and nucleus accumbens neurons (Verma and Moghaddam 
1996; ODonnell and Grace 1998).
In contrast, repeated exposure to PCP was reported to produce different 
electrophysiological and neuro chemical effects from single injections (Matsuzaki 
and Dowling 1985; Jentsch et a l 1997a; Hori et a l  2000), inducing a sustained 
decrease in dopamine turnover within the prefrontal cortex accompanied by deficits 
in working memory and prefrontal cortex-dependent tasks in both rats and monkeys 
(Jentsch et a l  1997a; Jentsch et a l  1997b). However, even if this treatment regime 
of PCP was proposed to be a useful model for some aspects of schizophrenia 
(Jentsch et a l 1997a), the relatively high doses of PCP that it employs may not be 
appropriate, since they are known to produce a pattern of degeneration (Olney et a l 
1989) which is not observed in post-mortem tissue from schizophrenic patients 
(Morris et a l 2005).
As a consequence, chronic low-dose regimes of PCP administration have recently 
emerged. Interestingly, these models have proved not only extremely valid in their 
ability to mimic the symptoms of schizophrenia in humans and to predict the effects 
of novel antipsychotic drug treatments, but also extremely valuable in their capacity
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to fit with a number of hypotheses of schizophrenia and explain a range of evidence 
of schizophrenia pathophysiology.
Thus, chronic low-dose PCP administration in rats was found to induce decreases in 
metabolic activity within the prefrontal cortex, reticular nucleus of thalamus and 
auditory structures, key structures displaying similar changes in schizophrenia 
(Cochran et a l 2003). Interestingly, the altered metabolic activity in the prefrontal 
cortex (“hypofrontality”) in the schizophrenic brain was shown to correlate with the 
presence and severity of negative symptoms and cognitive deficits while altered 
metabolic activities within the temporal lobe and thalamus correlate with positive 
symptomatology, suggesting that this dose regimen may have the ability to induce an 
array of symptoms that may excellently match the condition of people with 
schizophrenia (Cochran e ta l  2003).
In addition, chronic administration of PCP using this treatment regime was found to 
produce a selective reduction in prefrontal cortex parvalbumin mRNA expression 
indicating selective alterations in the activity of the basket and chandelier population 
of GABAergic interneurons (Cochran et a l 2003), consistent with alterations 
observed in post-mortem brains from schizophrenic patients (Lewis et a l 1999; 
Ohnuma et a l  1999; Pierri et a l 1999). This effect of PCP was also similar to data 
showing reduced parvalbumin mRNA expression in hippocampal interneurons after 
ketamine administration to rats for five days (Keilhoff et a l  2004). Interestingly, 
evidence showing that paiwalbumin-containing interneurons are fundamental in local 
circuits within the prefrontal cortex recruited in working memory (Rao et a l  1999) 
and that blockade of GABAa receptors also disrupts working memory (Sawaguchi et 
a l  1988) strongly suggests that the decrease in parvalbumin observed in both 
schizophrenia and after chronic intermittent PCP treatment may be important in 
mediating the cognitive deficits and negative symptoms associated with 
schizophrenia (Cochran et a l 2003).
Finally, chronic intermittent administration of low-dose PCP was shown to induce a 
significant decrease in N-acetylaspartate (NAA) and N-acetylaspartylglutamate 
(NAAG) concentrations in the rodent temporal cortex which closely reflects post­
mortem findings reported in schizophrenia and indicative of neuronal dysfunction 
(Reynolds et a l 2005).
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Thus, chronic administration of low-dose PCP in rats was found to produce a pattern 
of neurochemical and metabolic changes that mirror those observed in the brains of 
schizophrenic patients with impressive precision (Morris et a l 2005). Nevertheless, 
in addition to this excellent face validity as a model of schizophrenia, this model also 
appears a very valuable tool for screening novel antipsychotic drug treatments. The 
metabolic changes induced by chronic low-dose PCP in the temporal cortex and 
thalamus, but not in the prefrontal cortex, were indeed shown to be reversed by 
chronic antipsychotic treatment, which mirrors the clinical observations of the ability 
of existing anti-psychotic drugs to restore altered metabolic activity in the thalamus 
and temporal cortex, but not the prefrontal cortex, in schizophrenic patients (Cochran 
et al. 2003). In the light of the correlation between prefrontal metabolic hypofunction 
and negative symptoms and cognitive deficits of schizophrenia, these observations 
may therefore reflect the efficacy of current anti-psychotic drugs against the positive 
symptoms but not negative symptoms and cognitive deficits of schizophrenia 
(Cochran et a l 2003). Hence this model may represent an unprecedented tool to 
evaluate the atypicality of antipsychotic drugs. Consistent with this hypothesis, there 
is evidence that in normal human controls the psychomimetic effects of ketamine are 
not blocked by typical antipsychotics whereas they are significantly reduced by the 
prototypical atypical antipsychotic clozapine (Malhotra et a l  1997a). The differential 
effects of typical and atypical antipsychotic drugs in reversing PCP-induced deficits 
are probably due to the fact that PCP and related compounds do not mostly exert 
their effects by increasing dopamine neurotransmission, which distinguishes the PCP 
model from monoamine-based models (Geyer 2002b). In fact, although these models 
involved single administrations of PCP, the first non-monoaminergic ligands 
(including a glycine-site agonist and a metabotropic glutamate-receptor agonist) 
which entered clinical trials had interestingly been based on preclinical studies using 
PCP models (Moghaddam and Adams 1998; Javitt a/. 1999).
The chronic PCP model described by Cochran et al. (2003) appears to mirror the 
pattern of neurochemical and metabolic changes observed in schizophrenic patients 
remarkably (Cochran et al. 2003). Moreover, there is preliminary evidence that the 
low-dose treatment regime used in this study produces a selective deficit in the 
ability to shift attentional set from one perceptual dimension to another, which is in 
complete accordance with the executive deficits revealed in patients by the
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Wisconsin Card Sorting Test and characteristic of schizophrenic pathology (Joyce et 
a l 2002). Thus, although this regime does not cause any overt behavioural effects, it 
appears to induce the types of cognitive deficits seen in schizophrenic patients 
(Morris et a l 2005) and may therefore, unlike the dopamine-based models, show 
very strong construct validity for studying the cognitive and attentional deficits in 
schizophrenia (Geyer 2002b). In addition, the capacity of this model to predict and 
test the effectiveness of atypical antipsychotic drugs makes it an invaluable tool in 
preclinical research and for screening of potential antipsychotic or cognitive- 
enhancing drugs.
The ability of the chronic low-dose PCP model to mirror particularly well the 
cognitive and attentional deficits of schizophrenia (Morris et a l  2005) also makes it 
a very valuable tool to study some of the less elucidated aspects of schizophrenia 
pathophysiology. In this work, this model was thus used to identify genes associated 
with schizophrenia and particularly with the negative and cognitive deficits, which 
are also the most poorly improved by current antipsychotic medications.
1.2.3- Methods of gene identification in schizophrenia
Despite the difficulty of defining a phenotype for schizophrenia research and that of 
modelling it in an animal model, a number of strategies have been employed to 
identify susceptibility genes for schizophrenia. These approaches include in 
particular the traditional genetic approaches such as cytogenetic studies, linkage and 
association studies using genetic polymorphisms, as well as the more recent genomic 
or “transcriptomic” approaches investigating gene expression profiles in animal 
models or in schizophrenic patients by comparison with non-affected people.
1.2.3.1- Cytogenetic abnormalities
The identification of chromosomal abnormalities in affected individuals has been 
widely used to locate susceptibility genes for schizophrenia (Blair et a l  2005). 
Cytogenetic abnormalities such as translocations and deletions can indeed be 
valuable to point out a gene or a region somehow affecting the susceptibility to
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develop schizophrenia (by directly disrupting the function of a gene, by having a 
positional gene effect on gene expression or by showing linkage with another 
susceptibility variant (Bray and Owen 2001)). However, because of the high 
prevalence of schizophrenia and because of its complex genetic aetiology, one single 
report of a cytogenetic abnormality is not sufficient to conclude a causal relationship 
with schizophrenia; such a contribution needs to be “validated” somehow in a larger 
population or in another context. Thus, chromosomal abnormalities may only be 
considered of possible significance if they are found in greater frequencies in 
affected individuals (or, if the abnormality is rare, if there are multiple independent 
reports showing its coexistence with schizophrenia), if they colocalise with a region 
showing positive linkage or association or if  they co-segregate with schizophrenia in 
affected families (MacIntyre et a l 2003). Nevertheless, this approach has yielded 
some intriguing findings. In particular, the identification of a t ( l ; l l )  balanced 
reciprocal translocation segregating with schizophrenia in a large Scottish family (St 
Clair et a l 1990) has allowed the identification of two genes, of which one 
{Disrupted in Schizophrenia 1, DISCI) may have a critical role in the development 
of psychosis (Porteous et a l 2006). Valuable insights were also provided by 
evidence showing higher rates of schizophrenia with people with Vel o-cardi al -facial 
syndrome (Murphy et a l 1999), a condition associated with deletions of 
chromosome 2 2 q ll, within which two genes, catechoUO-methyltransferase {COMT) 
and mitochondrial enzyme praline deshydrogenase (PRODH) are now well- 
supported candidate genes for schizophrenia (Bray and Owen 2001; Owen 2005).
1.2.3.2- Linkage studies and positional cloning
For most patients, the susceptibility genetic variations cannot be found using classic 
or molecular cytogenetic methods. Genetic linkage approaches are thus used to 
examine the segregation of schizophrenia with alleles of polymorphic genetic 
markers in families with several affected individuals (Bourgeron and Giros 2003). 
The principle of this approach is that markers that are close to a gene tend to be 
inherited with it, therefore co-segregation of the disorder with a particular marker 
allele is suggestive of genetic linkage to a pathogenic locus.
The availability of well-characterised markers spaced across all chromosomes has 
enabled genome-wide linkage studies that may have the potential to locate disease
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genes without any prior knowledge of disease aetiology (Owen et a l  2004). 
However, because this approach is ideally suited to detect genes of large effect in 
genetically simple disorders, the results of linkage studies in schizophrenia have been 
disappointing. In particular, a number of linkage studies did not reach genome-wide 
significance, and attempts at replicating findings were often unsuccessful. This may 
be explained by the fact that small genetic effects probably act in combination 
therefore their stringent identification may require very large sample sizes, and by 
the use of marker maps of insufficient density to extract fully any genetic 
information (Suarez 1994).
Nevertheless, more than 20 genome-wide studies have now been reported and 
sample sizes have been increased, allowing some patterns to emerge, with some 
linkages reaching genome-wide significance on their own (according to the criteria 
set forth by Lander and Kruglyak, (Lander and Kruglyak 1995) and some others 
being supported by more than one study (Kirov et a l  2005; Owen et a l  2005a). 
Moreover, two meta-analyses of schizophrenia linkage data have been recently 
reported (Badner and Gershon 2002; Lewis et a l 2003) which, unsurprisingly owing 
to the different methods they employed, obtained overlapping but somewhat different 
results. Thus, the study of Badner and Gershon (2002) supported the existence of 
susceptibility genes on chromosomes 8p, 13q and 22q whereas that of Lewis et a l 
(Lewis et a l  2003) most strongly favoured 2q. All together, the 8p and 22q regions 
were the only regions that were supported by both meta-analyses whereas nine 
regions were only supported by one.
These linkage data therefore support the predictions made by Risch (1990), who was 
suggesting, on the basis of genetic epidemiological studies, that it is highly unlikely 
that there is a locus of major effect on schizophrenia susceptibility. Conversely, there 
is evidence implicating a number of regions, which is consistent with the existence of 
multiple susceptibility alleles of small or moderate effect rather than one single locus 
of major effect (Kirov et a l  2005). One way of removing any doubt would be to 
study larger samples (for example 800-1,000 families), however given the cost of 
sample collection, another approach may be to use existing samples but to extract as 
much information as possible, for example by using diagnostic information when it is 
sufficiently characterised (Evans and Cardon 2004). Such an approach may be 
particularly advantageous since this information may in fact correspond to
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intermediate phenotypes, which, despite lacking evidence of simple “genetic 
architecture”, have already proven very valuable to confirm and extend linkage 
findings in schizophrenia (Paunio et al. 2004).
1.2.3.3- Association studies
The limited power of linkage analysis to detect genes of moderate to small effect has 
stimulated the interest in the association design, which is a more powerful method of 
identifying such genes, especially in feasible sample sizes (Risch and Merikangas
1996). In this approach, the aim is to detect gene variants showing a different relative 
distribution in unrelated groups of affected and non-affected individuals (Bray and 
Owen 2001). Association studies can be used to evaluate the contribution of specific 
genetic polymorphisms within candidate genes, most often bi-allelic single 
nucleotide polymorphisms (SNPs) that may influence the functioning or the 
expression of the molecule. Thus, the choice of candidate genes gives an important 
flexibility to this approach by directly addressing the association of specific 
candidate genes, whether they are functional (i.e. genes encoding proteins 
implicated by an aetiological hypothesis) or positional candidates (i.e. genes 
mapping to regions implicated by previous linkage studies) (Owen et al. 2004). 
Because the robustness of linkage findings in schizophrenia is questioned, most 
studies have focused upon functional candidate genes.
However, despite the potential of the genetic association approach to identify genetic 
variants affecting susceptibility to schizophrenia, these studies are associated with a 
number of potential problems (Owen et al. 1997), making it necessary to be fairly 
cautious when considering their findings -at least until a consistent pattern of 
replication has emerged (Bray and Owen 2001). Most studies performed to date do 
not have sufficient power to detect reliably or confirm the presence of alleles of 
small effect and the combination of low power and low prior probability implies that 
a number of reported positive findings are more likely to be due to chance rather than 
reflect a genuine association (Owen et al. 2004). In addition, even in the best- 
designed studies (with larger samples etc), potential differences in the genetic 
structure of different populations (population stratification) may cast doubt on 
positive association findings, which also suggests that findings on samples collected
36
from different groups cannot probably be considered true replication experiments 
(Jurewicz et a l 2001).
Nevertheless, association studies have benefited greatly from the emergence of more 
systematic genomic approaches. Thus, it is now possible to screen a region (such as a 
linked region) for potential association and even to investigate simultaneously many 
thousands of markers (hence genes) using high-throughput microarray platforms. 
Moreover, the recent revelation of the first haplotype map of the human genome 
based on extensive SNP genotyping (2005) constitutes a major progress in genetic 
analysis of complex phenotypes such as schizophrenia. It should enable the 
consideration of both haplotypes {i.e. particular patterns of sequential SNPs on a 
single chromosome that are inherited as a block from a common ancestor) rather than 
individual SNPs and the selection of SNPs that capture the most information for a 
genomic region, two approaches that may be especially relevant to schizophrenia. 
Thus, haplotype-based analysis was shown to reduce the dimension of statistical tests 
for association and potentially improve their statistical power (Clark 2004). 
Moreover, defining allelic variants of genes associated with schizophrenia may 
constitute a useful tool in characterising the extent of allelic diversity of potential 
susceptibility genes (Hennah et a l 2004). In addition, selecting a reduced number of 
markers representing large genomic regions may not only reduce the cost of 
association studies but may also make it possible to optimise whole-genome 
association screens in particular (Kruglyak 2005). Although this approach is still 
controversial, mostly because of the lack of evidence of the relevance of haplotype- 
based SNP selection in populations outside those used for the HapMap project 
(Montpetit et a l  2006; Tenesa and Dunlop 2006), it has already proven highly 
valuable in increasing efficiency and power to detect rare causal alleles (at the cost of 
reduced power to detect common causal alleles) which is particularly relevant to the 
likeliest hypotheses on the genetic susceptibility to schizophrenia (de Bakker et a l
2005),
L2.S.4- Gene expression studies
Another approach for identifying schizophrenia susceptibility genes has been 
provided by the development of expression studies that, as a complementaiy
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approach to linkage and association studies, have the potential to identify not only 
the genetic component of the illness but any environmental or other causative factor 
and to reveal novel molecular mechanisms that contribute to disease. In particular, 
genome-wide expression studies can enable the identification of novel candidate 
genes that may not have been previously implicated in schizophrenia, on the basis of 
their dysregulation in tissues from people with the disorder.
Molecular differences between patients and controls have been reported in many 
post-mortem studies and a range of methods have been used to identify genes 
potentially over- or under-expressed in individuals with schizophrenia. Thus, 
methods such as in situ hybridisation, quantitative polymerase chain reaction (qPCR) 
or northern blotting have been used to examine the expression of individual genes 
(usually one at a time) with a high specificity and sensitivity that in a way 
counterbalances the disadvantage of these techniques of being time- and tissue­
consuming. In addition, functional genomic methods such as subtraction by 
hybridisation (SBH), serial analysis of gene expression (SAGE), total gene 
expression analysis (TOGA), massively parallel signature sequencing (MPSS) have 
emerged for high-throughput screening of differentially expressed genes in diseased 
versus control tissues. Nevertheless, although each of these techniques offer certain 
advantages, they are usually more time-consuming and less reliable in detecting 
differences in gene expression than microarrays (Vawter et a l 2001).
1.2.3.4.1- Microarray studies
Microaixays have become standard exploratory tools in drug discovery as well as 
drug development and clinical trials (Brazeau 2004). The opportunity they provide to 
analyse thousands of genes at a time is particularly relevant and offers huge potential 
to psychiatric disorders presumably of oligogenic or polygenetic susceptibility such 
as schizophrenia. Two widely accepted types of microarrays are currently used for 
gene expression analysis: cDNA and oligonucleotide microarrays, whose major 
manufacturer is Affymetrix. Although both types of microarrays have strengths and 
weaknesses, the Affymetrix GeneChip® technology offers several advantages, 
including the presence of multiple oligonucleotide probes on the chip that interrogate 
different regions of the same gene, quantitative results, good nominal sensitivity and
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the possibility of post-hoc comparison of data across many microarrays 
simultaneously.
Nevertheless, in addition to the complexities surrounding the phenotype issue in 
schizophrenia studies (section 1.2.1), these methods have a number of limitations 
including variations in expression as a result of polymorphism in genes unrelated to 
the disease, variation in expression due to the environment or other factors such as 
nutrition, variation in mRNA quality and variation in tissue preparation (Owen et a l 
2004). Whereas most of these issues, except the complexity of analysing gene 
expression in the brain, may be overcome when investigating gene expression 
changes in animal tissue, they are particularly apparent and potentially important 
when microarray studies are applied to the analysis of human post-mortem tissue. 
Indeed, the limited availability of post-mortem brain material makes it unavoidable 
to include brains of high diversity with respect to age, race, post-mortem interval 
(critical for mRNA quality), medication history and other factors that greatly affect 
the results of gene expression studies (Mimics and Pevsner 2004).
Whatever the species, the complexity of brain tissue must be considered when 
analysing and interpretating the outcome of microarray experiments. Thus, the 
immense phenotypic diversity of the brain may dilute out transcriptome changes in 
specific populations of brain cells, potentially pushing them back below microarray 
detection (Pongrac et a l 2002). Another issue that may explain the small magnitude 
of changes commonly detected in microarray studies on brain tissue is the limited 
plasticity of the mature brain and nervous system in terms of mRNA de novo 
expression, induction and repression (Mimics and Pevsner 2004). Because of these 
issues, gene expression changes found with microarrays on brain tissue are often 
only modest and hard to separate from experimental noise, which has a major 
influence on the analysis of their results. Finally, the interpretation of microarray 
data is further complicated by the predominant abundance of mRNA transcripts in 
the cell soma while the proteins are most often localised to axonal projections or 
nerve terminals, so that it is possible for the levels of the expression of a transcript to 
be up- or down-regulated while the protein is significantly regulated in the opposite 
direction. Overall, the number of factors influencing gene expression changes in such 
microarrays makes it necessary to be extremely cautious when interpretating detected
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fold changes that may not reflect functionally significant structural or chemical 
changes (Mimics e ta l  2001; Mimics and Pevsner 2004).
Therefore, statistical analysis of microarray experiments appears essential to ensure 
the validity of the final data. A variety of methods have been used in the three main 
phases of microarray data analysis: background adjustment and data normalisation 
(data pre-processing), statistical analysis to determine the significance of the changes 
in expression levels of individual genes, and identification of gene expression 
patterns such as clustering, multidimensional scaling or pattern identification 
(Chuaqui et a l  2002). In particular, among the various algorithms which have been 
developed to improve the one provided by Affymetrix, Robust Multichip Average 
(RMA) (Irizarry et a l  2003) has emerged as a very rigorous method of data pre­
processing (Bolstad et a l 2003). Significance Analysis of Microarrays (SAM) 
(Tusher et a l  2001) is considered as a very rigorous method of identifying 
differentially expressed genes by using an inferential statistical analysis. In 
particular, SAM software analysis tool may provide a reasonable balance between 
conservatism and tolerance by calculating a false discovery rate (FDR, Le. the 
probability that a given gene identified as differentially expressed is a false positive) 
that can reduce false-negative (type II) error rates compared to multiple 
measurements corrections (Mimics and Pevsner 2004). This approach may especially 
be useful for hypothesis testing in samples of reduced size (Jeffery et a l  2006).
1.2.3.4.2- Confirmation of microarray results
As there is currently no consensus about data analysis, confirmation of microarray 
results by an independent method appears essential to ensure their validity, 
particularly in brain disease microarray research where gene expression 
measurements can be affected by a large number of factors. There are two 
approaches to independent confirmation of microarray data: in silico analysis and 
laboratory-based analysis (Chuaqui et a l  2002). However, although the in silico 
method provides a great opportunity to validate data without further experimentation, 
this approach is inherently limited to the information available for comparison in the 
literature and in public or private expression databases, both in terms of quantity and 
quality. This approach is therefore not widely used at present but it is likely that it
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will become more useful when standardised methods for reporting array data, such as 
the MIAME format (Minimal Information About a Microarray Experiment, (Brazma 
et a l  2001), are commonly applied (Chuaqui e ta l  2002).
By providing an independent experimental verification of gene expression levels, 
laboratory-based validation of microarray data has become a standard in microarray 
research that has now become an official editorial policy in several journals (Rockett 
and Hellmann 2004). Although the methodology used may be different depending on 
the scientific question, two techniques have recently emerged as particularly relevant 
to confirm gene expression changes in brain tissue: quantitative real-time PCR (qRT- 
PCR) and in situ hybridisation.
Because once established, quantitative real-time PCR (qRT-PCR) is a rapid, 
relatively inexpensive and highly sensitive method for accurate quantification of 
specific mRNAs (Chuaqui et a l 2002), it is considered by many to be the technique 
of choice for validating gene expression changes identified in microarray 
experiments (Mimmack et a l 2004). Several investigators have thus shown a good 
qualitative correlation between microarray and qRT-PCR results (Rajeevan et a l 
2001; Yuen et al. 2002a), but this correlation seems to be poorer for genes exhibiting 
fold changes less than 1.5 {i.e. <±50%  expression) compared to those with fold 
changes greater than 1.5 {i.e. > ±50% expression) (Dallas et a l  2005). In quantitative 
terms, since fold changes are related to many parameters (including probe length and 
properties, absolute abundance of transcript, data standardisation) it would be 
inappropriate to directly compare microarray and qRT-PCR fold changes. In all 
cases, statistical significance has therefore to be the parameter considered when 
analysing gene expression data.
As an anatomical verification strategy, in situ hybridisation provides another 
important method of confirmation of gene expression that is particularly valuable in 
the brain since it can be used at multiple levels of resolution to confirm the presence 
of relevant mRNAs in brain regions, their localisation to subnuclei or layers and 
potentially the classes of cells in which they are expressed (Bunney et a l  2003). 
Nevertheless, the limited sensitivity of this technique suggests that in situ 
hybridisation should be considered more a qualitative than a semi-quantitative 
method of measuring mRNA expression. Therefore its value lies more in its potential
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to extend microarray results anatomically rather than to provide an infallible 
confirmation of detected gene expression changes.
In conclusion, although gene expression, particularly microarray studies, have to face 
challenges with studies of brain tissue, these approaches have proven very powerful 
for the analysis of human brain disorders, allowing the identification of dysregulated 
individual genes and the implication of abnormal patterns of gene expression in 
schizophrenia (Mimics and Pevsner 2004). Because microarray technology can 
provide such valuable insight into schizophrenia, it has become a mainstream 
technology for analysing gene expression as a complementary approach to molecular 
genetic studies of schizophrenia.
Although the genes whose expression changes are deemed of importance from 
microarrays are not necessarily the same as the ones classified as of importance from 
clinical, in situ, molecular, SNP association, knock out and drug perturbation data, 
the combination of these different approaches has allowed the identification of a few 
strong candidate susceptibility genes for schizophrenia and the emergence of 
converging hypotheses about its pathophysiology.
1.2.4- Current gene expression studies in schizophrenia
Because of the central role that has been attributed to the human dorso-lateral 
prefrontal cortex in schizophrenia pathophysiology, particularly as part of the 
corticolimbothalamic circuit (section 1.1.4), a number of microarray studies have 
been performed to investigate the expression of genes within this region following 
the hypothesis that such differentially expressed genes may be implicated in 
particular in the cognitive and attentional deficits of schizophrenia. Despite the 
limited availability of post-mortem tissue from schizophrenic patients, data are thus 
accumulating that report abnormal patterns of gene expression in the schizophrenic 
dorso-lateral prefrontal cortex compared with the same brain region of control 
individuals. In addition, as a complementary approach to avoid the complexities of 
working with human post-mortem brain tissue, a number of groups have chosen to 
use animal models of schizophrenia, particularly pharmacological models (including
42
the PCP model, section 1.2.2.4), to explore differences in gene expression as a 
reflection of gene expression changes in human schizophrenic patients.
Results of these studies are various and difficult to compare because of the diversity 
of microarray platforms and statistical analysis methods used, and because of the 
lack of general consensus on their validation.
Nevertheless, microarray studies on post-mortem dorso-lateral prefrontal cortex from 
schizophrenic patients have identified a number of genes and pathways potentially 
involved in schizophrenia, including genes related to synaptic function and plasticity, 
GABAergic and glutamatergic transmission, myelination, lipid metabolism and 
genes encoding metabolic or mitochondrial functions, which most often provided 
further support to existing hypotheses of schizophrenia pathophysiology 
(section 1.1.5).
Middleton et a l (2002) identified a decrease in the prefrontal cortical expression of 
several genes involved in the regulation of brain metabolism (Middleton et a l  2002) 
which is consistent with the highly specific pattern of metabolic alterations found in 
the prefrontal cortex of schizophrenic patients (section 1.1.4). Moreover, the 
abnormality in presynaptic or synaptic function that has largely been suggested from 
microarray studies (Mimics et a l  2000; Mimics et a l 2001; Vawter et a l  2002) 
based on the downregulation of a number of transcripts in the schizophrenic 
prefrontal cortex has been suggested to represent the molecular basis of the clinically 
observed hypofrontality of schizophrenic patients (section 1.1.4)
In addition, a number of microarray studies of the dorso-lateral prefrontal cortex of 
people with schizophrenia have provided further support to the dopamine and 
glutamate hypotheses of schizophrenia (section 1.1.3). Microarray analysis of an 
elderly cohort of schizophrenic patients (Hakak et a l 2001) thus revealed the 
upregulation of several postsynaptic transduction pathways known to be regulated by 
dopamine while the observed downregulation of genes involved in glutamate 
neurotransmission (Mimics et a l  2000) and of markers of inhibitory G ABA 
neurotransmission may contribute to the cognitive deficits characteristic of 
schizophrenia (Hashimoto et a l 2003). Interestingly, the study by Hakak et a l  
(2001), similar to that perfonued by Tkachev et a l  (Tkachev et a l  2003) also 
revealed the downregulation of several key oligodendrocyte-related and myelin-
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related genes, providing further support to the altered myelination and hence 
potential dysconnectivity hypothesis of schizophrenia (section 1.1.5.1).
In addition, cluster analysis of transcriptional alterations in the dorso-lateral 
prefrontal cortex of schizophrenic patients showed alterations in the expression of 
genes related to energy metabolism and oxidative stress, suggesting that oxidative 
stress and the resulting cellular adaptations are linked to the schizophrenia disease 
process (Prabakaran et a l  2004).
Finally, as a sort of bridge between the different hypotheses of schizophrenia 
pathophysiology, Middleton et a l (2005) recently reported consistent alterations in 
the expression of 14-3-3 genes in the schizophrenic dorso-lateral prefrontal cortex 
(Middleton et a l  2005). Although it is difficult to define precisely the appropriate 
context in which to view 14-3-3 gene alterations in schizophrenia, the integral role of 
the 14-3-3 family of proteins in regulating many aspects of cellular function in the 
brain, including signal transduction, synaptic neurotransmission (by interaction with 
markers of GAB A neurotransmission and/or RGS4), neurotransmitter metabolism 
and mitochondrial function, may indeed interestingly be consistent with most 
hypotheses of schizophrenia so that these proteins may be central in the 
pathophysiology of schizophrenia (Middleton et a l 2005).
As a complementary approach to microarray studies on post-mortem tissue from 
schizophrenic patients, a number of groups have chosen to evaluate the effects of 
experimental manipulations on gene expression levels in relevant animal models of 
schizophrenia (Marcotte et a l 2003). Thus, a few studies have been performed which 
explore gene expression changes induced by PCP treatment in rats and mice (Ito 
2002; Toyooka et a l  2002; Kaiser et a l 2004; Ouchi et a l  2005). Among these 
studies, that of Ito (2002), which was performed on the rat cortex using SAGE and a 
DNA array approach, reported that phencyclidine induced changes in gene 
expression related to neuroplasticity, including alterations in transcription factors, 
cell proliferation, apoptosis, cell adhesion and synaptic events other than 
neurotransmission (Ito 2002). In a similar approach but using the more reliable 
GeneChip® microarray technology, Kaiser et a l (2004) identified and independently 
confirmed the differential expression in the rat prefrontal cortex of a number of genes 
related to diverse biological processes including stress, inflammatory response, 
growth and development, neural plasticity and signal transduction (Kaiser et a l
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2004). Moreover, further analysis of these results in the context of schizophrenia 
revealed that the dysregulation of a number of these genes may be related to 
hypotheses of schizophrenia pathophysiology such as those suggesting disruption of 
thalamocortical circuitry, alterations in neurotransmission and neuromodulation, 
abnormal myelination and altered brain lipid metabolism in schizophrenia 
(section 1.1.5),
In conclusion, the recent advances in molecular genetics and functional genomics 
(gene expression) approaches have allowed the emergence of a few strong candidate 
susceptibility genes for schizophrenia including catechol-O-methyl ti^ansferase 
(COMT), proline dehydrogenase (PRODH), dysPobrevin-binding protein 1 
(DTNBPl), neuregulin 1 (NRGl), D-amino acid oxydase (DAAO), Disrupted in 
Schizophrenia 1 (DISCI) (first identified by cytogenetics) and regulator o f  G protein 
signalling 4 (RGS4), whose roles have been found to be consistent with different 
hypotheses of schizophrenia pathophysiology. Although the discrepancies between 
the results obtained using different approaches or using similar approaches but 
different statistical analysis methods may be enormous because of the inherent issues 
of investigating the aetiology and pathophysiology of a complex and heterogeneous 
brain disorder such as schizophrenia, their combination has recently proven to be 
very valuable in identifying novel candidate genes for schizophrenia (Vawter et a l
2006) and forming novel hypotheses of schizophrenia disease mechanisms. 
Nevertheless, these approaches will further benefit from the standardisation of 
statistical analysis and the way of reporting of microarray data (MIAME initiative) 
but also from improved phenotype definition, probably through the use of validated 
endophenotypes relevant to schizophrenia.
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1.3- Genomics and bioinformatics
The availability of the human genome sequence and the completion of the draft 
sequence of other species including the rat have provided a fantastic opportunity for 
scientists to explore the molecular mechanisms of human diseases and to reveal all 
possible human drug targets (Duckworth and Sanseau 2002). The analysis of these 
very large data sources containing the complete genomic DNA sequence of many 
species will indeed improve our understanding of biological systems, but it also 
requires sophisticated bioinformatics tools, in keeping with bioinformatics playing a 
more and more significant role in modem biological research (Yu et a l 2004).
Since “bioinformatics” is a general term which refers to the application of 
computational and analytical methods to biological problems, it includes both a 
number of methods to search for genes, patterns and inherent structure in biological 
data, and the development of new methods for database access and queries (NCBI). 
The term “computational biology” is more frequently used to refer to the physical 
and mathematical simulation of biological processes.
1.3.1- The human and the rat genome projects and their implication in 
genomic research
After ten years of international effort to unravel the human genome sequence and 
with a first draft announced in 2000, the official completion of the Human Genome 
Project was announced in spring 2003 (Collins et a l 2003), allowing free access to 
an extremely high quality genome sequence deposited in public databases. One year 
later, another large collaborative effort, the Rat Genome Sequencing Project 
Consortium (RGSPC) succeeded in decoding the genome sequence of the rat (Gibbs 
et a l 2004), the most widely used animal for studying physiology, nutrition and 
metabolism and a very useful animal for modelling human psychiatric diseases 
(Abbott 2004).
From then on, with sequencing of the rat genome complete (the third one being the 
mouse genome sequence, released in December 2002; Waterston et a l 2002), three
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mammalian genomes were available for parallel analysis, opening up new 
perspectives for comparative evolution surveys, biomedical research and drug 
discovery and development (Kola 2004). In particular, comparison of genome 
sequences of the species is particularly valuable to identify unpredicted exons and 
other regulatory elements (Yu et a l  2004), especially in species whose genome 
sequencing has not and will not receive labour-intensive annotation efforts (Wu et a l 
2004). This may be the case for the rat, since it is very unlikely that the first draft of 
the rat genome sequence, which covered about 90% of the genome (Gibbs et a l 
2004), will be followed and complemented by further sequencing effort. Alternative 
approaches may therefore be necessary to reveal the remainder of the rat sequence 
and more importantly yet unidentified genes.
In order to make access to human and other species genomes as easy as possible for 
ordinary biologists, and following the lead of the group at the University of 
California, Santa Cruz (Kent et a l  2002), the National Center for Biotechnology 
Information (NCBI), the European Bioinformatics Institute (EBI) and others released 
their own genome browsers and analysis tools, each having its own design concept 
which may be useful to answer specific questions. Nevertheless, the Ensembl project 
(Hubbard et a l 2002), a joint operation of the European Bioinformatics Institute 
(EBI) and Sanger Institute, represents one of the most interesting developments in 
the analysis of human genome sequence since it provides high quality annotation of 
genes based on evidence from known protein, cDNA and EST sequences (Curwen et 
a l  2004). Moreover, the Ensembl Project offers a particularly user-friendly browser 
that has unique capabilities such as protein-based queries.
1.3.2“ Approaches to gene prediction
Among the number of approaches which have been used to decode and understand 
the language of biological sequences, two distinct analytical themes have emerged: 
similarity-based and ah initio techniques. In the first approach, pattern recognition 
techniques are used to detect similarity between sequences and thus infer related 
structures and flmctions; in the second, ab initio prediction methods are used to 
deduce either novel genes or 3-dimensional (3D) structure of proteins from DNA
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sequences by applying statistical patterns (Mathe et a l  2002). However, both 
approaches are not exclusive but additional, and the most effective gene prediction 
results to date have been obtained by the simultaneous analysis of large DNA 
sequences using both exon prediction software and similarity searches (Jones et a l 
2002). The question of validity still remains if the putative gene is only predicted by 
one of the two methods.
1.3.2.1- InPoduction to pattern recognition methods
The underlying principle inherent to the majority of sequence-similarity-based gene 
or protein prediction methods is the combination of similarity information with 
signal sensors (i.e. short motifs such as splice sites, promoters, poly (A) sites or 
translation initiation codon sites). This information can be acquired by a variety of 
sequence comparisons including genomic DNA/protein, cDNA/protein, genomic 
DNA/cDNA and genomic DNA/genomic DNA. In all cases, the concepts of 
sequence identity, sequence similarity, homology and orthology apply to the 
comparison so that their definition is fundamental to the accuracy of the description 
of alignment results. Pairwise sequence identity is thus defined by the extent 
(percentage) to which two (nucleotide or amino acid) sequences are invariant while 
pairwise sequence similarity refers to the extent to which nucleotide or protein 
sequences are related. The extent of similarity between two sequences can be based 
on percent sequence identity and/or conseiwation.
Homology refers to similarity attributed to descent from a common ancestor while 
orthology refers to homology between sequences in different species that arose from 
a common ancestral gene during spéciation but may or may not be responsible for a 
similar function (NCBI). Identification of orthologues is critical for reliable 
prediction of gene function in newly sequenced genomes.
Pairwise comparison is based on database search algorithms that align sequences by 
inserting gap characters to bring them into vertical register and give alignment scores 
by counting the matched character positions. Scoring penalties are employed to 
minimise the number and length of gaps and matrices are used to score both identical 
and similar residues.
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Two general models are currently used that view alignments in rather different ways: 
the first considers similarity across the full extent of sequences (global alignment), 
the second focuses on regions of similarity on parts of the sequences only (local 
alignment). Neither model is more correct than the other, they simply reflect 
different biological perspectives. The rationale for local similarity searching is that 
functional sites are localised to relatively short regions, which are conserved 
irrespective of deletions or mutations in intervening parts of the sequence. Thus, a 
search for local similarity may produce more biologically meaningful and sensitive 
results than a search attempting to optimise alignment over the entire sequence 
lengths.
There are many publicly available pairwise comparison programs; much faster are 
those that look for local alignments such as FASTA and BLAST (Basic Local 
Alignment Search Tool). These programs concentrate on finding short identical 
marches, which may contribute to a total match. They use implementations which 
address the issues of execution speed, making them usable with any basic computer 
hardware.
13.2.2- Sequence-similarity-based gene finders
After the pioneered Procrustes (Gelfand et a l  1996), a number of software packages 
based on similarity searches have emerged. The principle of most of these programs 
is to combine similarity information with signal information obtained by signal 
sensors, which may predict the presence of a functional site such as a splice site, a 
promoter, a poly(A) tail, a start or a stop codon. Programs aligning the genomic 
DNA sequence against a cDNA database have proven quite reliable with regard to 
the identification of exons independently of their coding status, particularly when the 
genomic sequence is aligned against cDNA from the same or a closely related 
organism (Fukunishi et a l  1999). The comparison of homologous genomic 
sequences also helps in the identification of conserved exons and allows for the 
simultaneous prediction of genes on both sequences (Do and Choi 2006). Programs 
such as TWINSCAN (Flicek et a l 2003) have also been developed which exploit the 
sequence conservation between two genomes in order to predict genes. In 
TWINSCAN, the initial alignments conducted using standard tools such as BLASTN 
(nucleotide-nucleotide BLAST) or TBLASTX (translated query v>s translated
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database) are used to inform the prediction algorithm, which predicts which regions 
of a genome are transcribed into pre-messenger RNA, how they are spliced, and 
which portions of the spliced transcript are translated into protein (Korf et al. 2001; 
Flicek et a l 2003).
1.3.2.3-Ah initio gene-finders
The majority of ah initio gene prediction programs are based on a range of 
underlying statistical properties of the coding regions, and use a variety of different 
mathematical techniques to locate all the gene elements that occur in a genomic 
sequence, including possible partial gene structures at the border of a sequence 
(Mathe et a l 2002). They rely on two types of sequence information: content sensors 
and signal sensors, which refer to short sequence motifs (such as splice sites, branch 
points, polypyrimidine tracts, start and stop codons) present in almost all eukaryotic 
genes. A variety of algorithms can be applied to the modelling of gene structure, 
including Dynamic Programming (DP), Hidden Markov Models (HMM) and Neural 
Networks (NN). For example, among the number of programs available, GRAIL and 
GeneED both use a Dynamic Programming approach but combined with Neural 
Network and Markov Model methods respectively (Do and Choi 2006). HMM-based 
gene finders, which represent a DNA sequence as the output of an abstract process 
that progresses through a series of discrete states, have proven the most successful, 
GENSCAN (which uses a generalised HMM model) being probably one of the most 
popular gene prediction programs (Guigo et a l 2000).
Overall, similarity-based prediction programs appear to be able to detect only a 
limited number of genes (low sensitivity) due to the lack of known mRNAs, whereas 
ah initio gene finders which rely on intrinsic gene measures (including coding 
potentials and splice signals) may predict a number of false positive exons and genes. 
Therefore, programs have been developed that combine two or more gene prediction 
programs, of different or similar types to predict genes from genomic structures (Do 
and Choi 2006). These include the Exon Union-Intersection and Gene Intersection 
algorithms, which perform exon and gene structure prediction by taking the 
intersection of overlapping HMMGene and GENSCAN predictions (Rogic et a l
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2002), and programs such as GenomeScan, an extension of GENSCAN that 
incorporates similarity with a protein retrieved by BLAST (Yeh etal. 2001). 
Combinations of similarity-based and ah initio approaches have been determined to 
perform efficiently in terms of gene annotation in large-scale genomic projects 
(Fleischmann et a l  1995) so that the integration of different gene prediction methods 
is a very promising approach that will undoubtedly be much further developed in the 
future (Mathe et a l  2002). In addition, attempts to integrate gene prediction 
programs with some protein structure prediction (such as the ORNL Genome 
Analysis Pipeline that uses predicted gene structure as an input to perform motif and 
protein predictions) also appear very promising and are likely to benefit from further 
development as well.
1.3.3-Expressed Sequence Tags (ESTs), a powerful tool for gene 
discovery
In addition to genomic sequences, expressed sequence tags (ESTs) provide a very 
robust sequence resource that can be exploited for gene discovery, genome 
annotation and comparative genomics (Rudd 2003).
ESTs are small pieces of transcribed DNA sequence (usually 200 to 500 nucleotides 
long) that are produced by typically unedited, automatically processed, single-read 
sequencing of random gene transcripts that have been converted into cDNA and 
cloned. Libraries of cDNAs are routinely prepared that contain tens of thousands of 
clones, represent a variety of specific tissues types and a snapshot of gene expression 
at defined developmental stages and/or following various challenges (Zweiger and 
Scott 1997).
The concept of using cDNAs to discover new genes was first established in the early 
1980s (Putney et a l 1983) but it was only in 1991 that the term EST was first used in 
relation to gene discovery and the human genome project (Adams et a l  1991). Since 
these first publications, >16 million ESTs have been sequenced from more than 500 
distinctly annotated species, representing a wide taxonomic variety of fungi, plants 
and animals. These ESTs are listed in dbEST, the EST database developed by 
GenBank (Boguski e ta l  1993).
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EST sequencing initially favoured the 5’ end of directionally cloned cDNAs because 
the 5’ sequences are likely to contain more protein coding sequence than the 3’ ends, 
which often contain significant untranslated regions (UTRs). It is cuirently the 
converse, the 3’ end being most often preferred because it is likely to offer more 
unique sequence (in many cases, the UTR) and can be used to distinguish between 
gene paralogues, i.e, genes related by duplication within a genome that have evolved 
new functions (Rudd 2003). Because of their nature, ESTs are thus not the complete 
representation of the parental cDNA but rather constitute tags that may be used for 
fishing genes within databases. Moreover, the EST sequence collections are only as 
good as the libraries from which they were generated and a number of 
contaminations have been reported, including xenocontaminations from foreign 
genomes or contamination from structural or regulatory sequences. Nevertheless, 
because ESTs represent a copy of the expressed part of a genome that may contain at 
least partial representations of genes not otherwise available in other resources, they 
have proven a very powerful tool in the search for novel genes and novel drug targets 
(Duckworth and Sanseau 2002). Thus, some companies have based their drug 
discovery efforts on identifying potential new targets from EST collections; for 
example, Human Genome Sciences (Rockville, MD, USA) have been very active in 
this field (Haseltine 2001).
Different approaches are used to mine EST databases for the presence of genes and 
proteins of potential biological interest. These include EST clustering, EST contig 
assembly and the use of a range of tools to search the EST databases and find coding 
regions (Jongeneel 2000).
1.3.3.1- EST clustering
Because of the way EST sequences are generated, large-scale EST sequencing 
projects have unsurprisingly generated many more EST sequences than there are 
expressed genes. Thus, much of the information found in EST databases is 
redundant, with many genes being represented by more than one EST. Therefore, in 
order to establish a non-redundant catalogue of the transcripts expressed in any 
specific tissue at any specific time or in any specific condition, it is necessary to
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cluster EST sequences into groups that are likely to derive from the same mRNA 
species (Jongeneel 2000).
The most enduring effort at EST clustering is the Unigene project of the National 
Center for Biotechnology Information (NCBI) (Schuler 1997). In addition to EST 
data, it includes mRNA derived from known genes and “virtual” mRNAs deduced 
from the annotation of genomic sequences selected from Genbank. These elements, 
which are each given an accession number, are classified into clusters, each cluster 
putting together ESTs, known RNAs and gene transcripts that are thought to 
represent the same (and a unique) gene. In addition, many useful annotations are 
added to each cluster, including similarities to known genes, chromosomal
localisation, libraries of origin of the ESTs represented in the cluster and tissue 
specificity of expression. Therefore the identification of an EST as a member of a 
Unigene cluster greatly enhances the amount of information that can be gathered 
about the corresponding gene.
Among the attempts to identify unique genes represented by EST data (Bouck et a l 
1999), another important resource has been provided by the Institute of Genome 
Research (TIGR) through the creation of unique gene indices of clustered and 
assembled ESTs (Adams et a l 1995). Unlike the Unigene approach, the TIGR Gene 
Indices use assembly logarithms, rather than clustering, to produce tentative
consensus sequences that represent the underlying mRNA transcripts. This approach 
has resulted in the production of larger numbers of high-quality contigs, where one 
gene may be represented in multiple entries (Quackenbush et a l 2000).
L 3.3.2- EST contig assembly
Assembling of ESTs potentially derived from the same transcripts such as the 
members of Unigene clusters has become a highly valuable tool to identify new 
genes and a number of attempts have been performed to develop methods
specifically suitable for dealing with the particularities of EST sequences. In a
problem similar to the generation of contigs from shotgun sequences (as is performed 
in large-scale sequencing projects), these approaches all aim at deriving a 
“consensus” sequence from the clustered ESTs by eliminating redundancy and 
reducing the error rate while increasing the length of the deduced mRNA sequence 
(Jongeneel 2000). Thus, a number of sequence assemblers can be used to generate
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consensus sequence of ESTs, the most popular being Phrap (Green 1999), the TIGR 
Assembler (Sutton et a t 1995) and CAP3 (Huang and Madan 1999). However, since 
all of these are primarily designed to assemble genomic sequences, they do not 
necessarily take into account the specificities of EST assembly, generating a number 
of incorrect results (Maide et al. 2005). For example, ESTs, which represent gene 
transcripts, do not contain the repetitive sequences that are found in large amounts in 
the intragenic parts of genomic sequences. In addition, EST assembly is complicated 
by features like alternative splicing, single-nucleotide polymorphisms (SNPs) and 
post-transcriptional modifications. All these differences between genome and EST 
assembly make assemblers designed for genome assembly less applicable to ESTs 
(Pertea et a l  2003). Nevertheless, despite the need for specific tools to assemble 
ESTs and reconstruct gene transcripts, recent effort to improve the state of the art in 
sequence assembly tend to concentrate more on the issues of genomic than of EST 
assembly (Maide et a l  2005).
Therefore, although most of these programs are quite convenient, they are also quite 
error-prone in assembling ESTs therefore manual assembly remains a method of 
choice in the analysis of clustered ESTs (Jongeneel 2000). Thus, although the 
method requires extensive input from the user, it provides a much more flexible 
approach that allows not only all the specificities of ESTs but also some features 
such as the overlap of genes in the genome (sense-antisense transcription) to be dealt 
with. Nevertheless, because most alignment editor tools have been designed for 
contig assembly, manual EST assembly requires the use of alignment algorithms that 
are not intended to generate consensus sequences, such as the general purpose 
multiple sequence alignment program ClustalW. This method of EST assembly 
therefore necessitates a thorough manual inspection of the alignments generated to 
find the best fit and deduce a consensus sequence from aligned EST sequences 
(Jongeneel 2000).
1.3.3.3- EST-based similarity searches
Despite their incomplete and inaccurate nature, ESTs represent a highly valuable 
resource to speed up gene discovery and characterise genes expressed in normal and 
diseased tissues. Thus, the number of databases recently created to bring together 
ESTs (such as the dbEST created by GenBank) provide a resource for rapid
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identification of novel genes, including novel gene transcripts and novel gene 
orthologues and homologues. The most commonly used method to perform sequence 
similarities searches using ESTs is BLAST (Altschul et a l  1990), a very fast 
algorithm that has been popularised by the availability of a powerful cluster of 
servers at the NCBI database (Jongeneel 2000). Nevertheless, in addition to these 
nucleotide versus nucleotide similarity searches providing a starting point as to the 
potential similarity between an EST or a cluster of ESTs and cDNA or genomic 
databases, another important application in drug discovery is to find new coding 
sequences more distantly related to the query sequence. In this case, comparisons are 
based on amino acid sequences rather than nucleotides, the simplest method for 
searching EST databases being a tool called TBLASTN, which essentially performs 
a six-frame translation of the database and does a standard BLAST against this 
virtual protein database. Alternatively, coding sequences may be extracted from the 
ESTs first (as long as the sequences are long enough) and then searched against this 
database using a tool called TBLASTP (Jongeneel 2000).
Overall, even though ESTs are a precious tool for genome annotation, the overall 
quality of any individual sequence within all collections of ESTs remains one of the 
major problems that affects homology screening with genomic sequences and 
therefore complicates gene identification (Rudd 2003). Assigning ESTs to genes 
based on DNA sequence homology screens is very subjective since no perfect 
alignment can be obtained, making a manual guess often necessary to evaluate the 
potential relatedness between an EST and a particular gene or transcript.
Despite these limitations, ESTs are at the forefront of technological change by 
providing a high throughput means not only to identify gene transcripts but also to 
monitor complex gene expression patterns. This potential has soon been realised by 
microarray manufacturers, the first one, Affymetrix, having released EST-based 
GeneChip® arrays (such as the rat genome U34 B and C chips) for several years. 
EST-based technologies have been used to understand disease processes and may 
enable biology to move from single gene to multigene, or even more complex 
epigenetic, explanations of diseases (Zweiger and Scott 1997).
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1.4- Aims of this work
Schizophrenia is such a complex disease that trying to elucidate its neuropathological 
mechanisms is a real challenge. Using a range of different approaches, researchers 
have been trying for decades to tackle the issues associated with such a multifactorial 
disorder, whose clinical heterogeneity is likely to be the reflection of different 
pathological mechanisms. Although despite this complexity, neurochemical, 
neuropathological and more recently genetic and genomic approaches have yielded 
very valuable insights into the pathophysiology of schizophrenia and seem to 
converge on a few hypotheses as to its aetiology and neuropathology. However, the 
question as to whether schizophrenia is a single disorder or a “spectrum” of disorders 
still remains unanswered, especially since its criteria-based diagnosis, despite being 
quite reliable, enables two people with very different and sometimes almost non 
overlapping symptoms to be diagnosed with the same disease. Unless people had 
chosen to develop and use animal models of schizophrenia to overcome this issue, 
this heterogeneity of schizophrenia thus largely explains the lack of consistence 
between studies, failures to replicate findings and difficulty to interpretate results, 
which have characterised most studies for decades, It also explains why it is so 
difficult to develop novel antipsychotics, and why it is now commonly admitted that 
no single compound will be able to capture and improve all the features of 
schizophrenia.
In this context, several approaches have emerged, some of them prioritising the use 
of more specific phenotypes or even the development of diagnostic tools (similar to 
genetic tests already available for some cancer treatments) to identify subgroups of 
patients and develop or select more appropriate treatments, some others focusing on 
the most critical needs to guide the development of novel compounds with regard to 
currently available antipsychotics. Importantly, this approach was recently 
recognised by the American Food and Drug Administration (FDA) (as part of an 
initiative with the National Institute of Mental Health, NIMH) as essential through 
the identification of cognitive symptoms as critically unmet targets against which to 
specifically develop neurocognitive drugs.
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By enabling to specifically model specific aspects of schizophrenia, animal models 
may be particularly valuable to this aim, and in this context, the chronic intermittent 
PCP model developed in our laboratory (Cochran et a l  2003) following on the 
NMDA receptor hypofunction hypothesis of schizophrenia, appeared of very high 
potential. This model was indeed shown to mirror the negative and the cognitive 
symptoms of schizophrenia with impressive precision, so that it may be a very 
valuable tool for investigating the pathophysiological mechanisms specifically 
involved in these symptoms and potentially identifying novel drug targets with this 
regard. Likewise, the chronic PCP model may be very useful to identify novel genes 
which may be involved in the pathophysiology of schizophrenia and more 
specifically in the negative and cognitive symptoms of this disease.
In order to fully exploit the potential of the chronic PCP model to identify novel and 
uncharacterised genes associated with the cognitive deficits of schizophrenia, 
microarrays allowing the screening of not only genes but Expressed Sequenced Tags 
(ESTs), represent a very suitable method for measuring gene expression. In the 
context of a large program aiming at identifying such genes, a transcriptome analysis 
of prefrontal cortex {le. one of the regions most often pointed out as being altered in 
schizophrenia and a critical region for the integration of attentional and working 
memory processes) dissected from rats treated with PCP according to the regime of 
Cochran et a l  (2003), was thus performed using the rat oligonucleotide RG-U34 
GeneChips from Affymetrix, After a very rigorous statistical analysis, a few hundred 
probe sets representing genes and ESTs were identified as differentially expressed in 
the rat prefrontal cortex following chronic PCP treatment (Catherine Winchester). 
Because ESTs, due to their incomplete and inaccurate nature, required more 
extensive bioinformatics analyses to potentially be converted into genes first, the 
analysis of probe sets representing ESTs (corresponding to RG-U34B and C probe 
sets) was conducted separately from probe sets representing genes (RG-U34 A probe 
sets).
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The specific aims of this work were to:
1) analyse the ESTs represented by probe sets differentially expressed in the 
microarray analysis of the rat prefrontal cortex following chronic PCP treatment, in 
terms of correspondence to known or predicted rat, mouse and human genes.
2) select from the list of genes identified from the conversion of ESTs, a few 
candidates for further characterisation, and confirm independently their differential 
expression in the rat prefrontal cortex after chronic PCP treatment.
3) investigate the mechanisms by which each of the two candidate genes whose 
differential expression was confirmed, may be involved in the pathophysiology of 
schizophrenia and, depending on the gene, characterise them further as potential drug 
targets or investigate their potential association with schizophrenia in humans.
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CHAPTER 2: MATERIALS AND METHODS
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2.1- Materials
2.1.1- General chemicals
All chemicals were obtained from Sigma-Aldrich and were AnalaR grade with the 
exceptions of the items listed in table 2.1.
Supplier Chemicals
Antec International Zircon
Cambrex Biosciences Gelstar® nucleic acid gel stain
National Diagnostics EcoScint scintillation solution
Fisher scientific Glycine, Sodium hydroxide and Tris 
base
Invitrogen Agarose
Promega G418
Upstate Rat tail collagen I
Table 2.1. Chemicals
2.1.2- Plasticware
RNase- and DNase-free microcentrifuge and PCR tubes were obtained from Thermo 
Electron.
Tissue culture flasks, plates, petri dishes, falcon tubes and cell scrapers were all from 
Corning Incorporated. Sterile fine tip pastettes were from Alpha laboratories.
Filter tips (Rainin instruments) were used on Pipetman® P air-displacement pipettes 
(Gilson).
Oakridge centrifuge tubes were from Nalgene.
Syringes were from BD Biosciences and Minisart 0.2pM syringe filters were from 
Sartorius.
Scintillation vials were from Gordon Keeble Ltd.
2.1.3- Glassware
Glass tubes were from Fisher scientific and coverslips were from VWR.
6 0
2.1.4- Enzymes
Restriction enzymes as well as terminal deoxynucleotide transferase were obtained 
from Roche. T4 DNA ligase was from Promega, Superscript III™ reverse 
transcriptase was from Invitrogen, KOD Hot Start DNA polymerase was from 
Novagen and Advantage™ 2 polymerase mix was from BD Biosciences.
2.1.5- Immunochemicals
Immunochemicals were obtained from a variety of suppliers (table 2.2).
Supplier Immunochemicals
Abeam Anti-EDG2 antibody
Abgent Anti-EDG2 antibody
Cell Signalling Mouse anti-phospho SAPK/JNK 
antibody
HRP-linked anti-mouse and anti-rabbit 
antibodies
Cytoskeleton Inc. Anti-(pan)-actin antibody
Exalpha Biologicals Inc. Anti-EDG2 antibody
Invitrogen Alexa Fluor® 488 phalloidin 
Polyclonal anti-rabbit immunoglobulins 
(IgGs) conjugated with Alexa Fluor® 
488
Polyclonal anti-mouse immunoglobulins 
(IgGs) conjugated with Alexa Fluor® 
596
Santa Cruz Biotechnology HRP-linked anti-actin antibody
Sigma-Aldrich Anti-EDG2 antibody
Monoclonal anti-FLAG® M2 antibody
HRP-linked anti-FLAG® M2 antibody
Upstate Anti-EDG2 antibody
Table 2.2. Immunochemicals
2.1.6- Radioisotopes
Adenosine 5'-(a-thio)triphosphate, [35S] [a-^^S]-d-ATP (specific activity 1250Ci 
(46.2TBq)/mmol) was obtained from Perkin-Elmer, formerly NEN Life Sciences.
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Guanosine 5'-['y-35S]thiotriphosphate, triethylammonium salt (specific activity 
>1000Ci (37TBq)/mmol) was obtained from GE Healthcare, formerly Amersham 
Biosciences.
2.1.7“ Oligonucleotides
Oligo-dT and random hexamers primers for cDNA synthesis were from Invitrogen.
Desalted oligonucleotides for PCR, RT-PCR and qRT-PCR were obtained from 
Sigma-Genosys. The oligonucleotides, their sequences and use are listed in table 2.3. 
5’FAM/3’TAMRA-labelled oligonucleotide probes were obtained from MW G 
Biotech.
HPLC-pure oligonucleotides for in situ hybridisation were obtained from Thermo 
Electron.
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Oligo­
nucleotide
Nucleotide sequence 5’-3’ Purity Modifi­
cation
Use
B2m - F CGTGATCTTTCTGGTGCTTG
TO
Desalted Primer for rat B2m qRT- 
PCR
B2m - R GGCGAGAGTACACTTGAAT
TTGG
Desalted Primer for rat B2m qRT- 
PCR
B2m - p CCGTCGTGCTTGCCATTCA
GAAAAC
high purity 
salt free
5’FAM-
3’TAMRA
Probe for rat B2ni qRT- 
PCR
EST-F TCATGAAGATTTAGCTGAG
ATTTTGTG
Desalted Primer for rat EST 
AI072720 qRT-PCR + 
RT-PCRs on EST + 
RACE PCR
EST-R CAATCCCCATCAGGTATCA
GGTA
Desalted Primer for rat EST 
AI072720 qRT-PCR + 
RT-PCRs on EST + 
RACE PCR
EST-p CAGAATCCTTCCCACTCCT
GAACCTTGAA
high purity 
salt free
5'FAM-
3’TAMRA
Probe for rat EST 
AI072720 qRT-PCR
Edg2 -  F GGTCAGGAGGATGTCTGTG
AGAA
Desalted Primer for rat Edg2 qRT- 
PCR
E dg2-R CACGTCACATGCCTACCCT
OTA
Desalted Primer for rat Edg2 qRT- 
PCR
Edg2 - P CCCAGAATGCCACTCTCTG
CAGGACTT
high purity 
salt free
5 TAM -  
3’TAMRA
Probe for rat Edg2 qRT- 
PCR
hGAPDH - F CCCATGTTCGTCATGGGTG
T
Desalted Primer for human 
GAPDH qRT-PCR
liGAPDH - R TGGTCATGAGTCCTTCCAC
GATA
Desalted Primer for human 
GAPDH qRT-PCR
hGAPDI-I - p CTGCACCACCAACTGCTTA
GCACCC
high purity 
salt free
5 TAM -  
3TAMRA
Probe for human GAPDH 
qRT-PCR
hEST-F CATGGATGACACAATGTTT
TTGG
Desalted Primer for human EST 
qRT-PCR
hEST-R CTTTCGTGTAAGATGGCGG
TATAG
Desalted Primer for human EST 
qRT-PCR
liEST - p ACCCTGAAACTATTCTTTG
GCATTGGTGTCC
5 TAM -  
3TAMRA
Probe for human EST 
qRT-PCR
I1EDG2 - F GGATGTCAGTGCACGGTTA
GTG
Desalted Primer for human EDG2 
qRT-PCR
1tED G 2-R CTAATCGGGTCCCCACATT
CT
Desalted Primer for human EDG2 
qRT-PCR
I1EDG2 — p ACTACAGGTACTTTACAAG
TCTGCCCTCTGCTCAA
high purity 
salt free
5 TAM -  
3’TAMRA
Probe for human EDG2 
qRT-PCR
EST -  RACE - 
R
AATCCCCATCAGGTATCAG
GTACCAGAA
Desalted Primer for 5’RACE on rat 
EST AI072750
Q9ULN1~F*'F ACCTGAGAATGGCCAACAG
C
Desalted Primer for rat 
RGDl308367 exon 1
Q9ULN -  2"'‘ - 
F
CTTTGTTGTTCACCAGGCC
AT
Desalted Primer for rat 
RGD1308367 exon 2
Q9ULN1 -  
-F
GAGAAGATGAGAGCGCAG
CC
Desalted Primer for rat 
RGDl308367 exon 3
EST -  2as GACAAGGAGGTTCTTTATT
TAACAGCAGGTAGGTAGGT
TGATAAT
HPLC Probe for EST AI072720 
in situ hybridisation
Edg2 -  3 as GACACAAGCCACACCCTGC
CTTTCCTCCTCCCCAGAATG
CCACTC
HPLC Probe for Edg2 in situ 
hybridisation
Q9ULN1 -2as TCAGTTGTCTTCCTGGTTTG
ACTGCTAGGCTGTTGGCCA
TTCTCA
HPLC Probe for RGD1308367 
in situ hybridisation
Table 2.3. Oligonucleotides (F = forward primer and R= reverse primer)
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2.1.8“ Gene expression and SNP genotyping assays
Taqman®gene expression assays were obtained from Applied Biosystems.
Each gene expression assay consists of a FAJVF^* dye-labelled TaqMan®MGB probe 
and two PCR primers formulated into a single tube. Every assay is optimised to run 
under universal thermal cycling conditions and all assays have the same 
amplification efficiency.
Rat RGDJ308367 assay was a custom assay while human K1AA1189 and EDG2 
assays were pre-designed assays.
SNP genotyping (Allelic Discrimination) assays were also obtained from Applied 
Biosystems. Each of these assays consists of a set of two PCR primers and two 5’- 
labeled Taqman® MGB probes (one labelled with FAJVF^ dye, the other one labelled 
with VIC™ dye) which selectively anneal to each of the alleles. 5’ nuclease activity 
of Taq DNA polymerase allows discrimination between alleles by cleaving the 5’ 
allele-specific dye label.
The three SNPs tested for association with schizophrenia were all pre-designed 
assays.
2.1.9“ Drugs and solutions
Solutions and media were sterilised by autoclaving at 121°C for 15 minutes or by 
filtration through a sterile 0.2pm pore filter (Sartorius).
Lysophosphatidic acid (LPA):
Stock solution: ImM in PBS/0.1% BSA (stored at -20°C)
Working solution: O.lnMto lOOpM
1 kb+ ladder:
O.lpg/pl lKb+ DNA ladder (Invitrogen) in 2X Blue Juice™ (gel loading buffer, 
Invitrogen)
lOX TBE:
0.9M Tris, 0.6M H3BO3, 20mM EDTA (pH 8.0)
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DL-Dithiothreitol (DTT):
Stock solution IM in H2O (stored at -20°C)
Guanosine diphosphate (GDP):
Stock solution 10 pM (stored at -20°C)
RIP A buffer:
50 mM Tris-HCl (pH 7.4), 1% (v/v) NP-40, 150 mM NaCl, 1 mM EDTA, 1 mM 
NasVOq, 1% (v/v) protease inhibitor cocktail (final concentrations 1.04mM AEBSF, 
0.8pM aprotinin, 40pM bestatin hydrochloride, 140M E-64, 20pM leupeptin 
hemi sulfate and 15pM pep statin A)
Buffer I for membrane preparation:
20mM Hepes, ImM EDTA, 50mM NaCl (pH 7.5)
Buffer n  for membrane preparation:
50mM Hepes, 2mM EDTA, lOOmM NaCl, ImM MgCE
GTP-binding buffer:
50mM Hepes, lOOmMNaCl, lOmM MgCb (pH 7.5)
3X SDS loading buffer:
187.5 mM Tris-HCl (pH 6.8), 6% (w/v) SDS, 30% (v/v) glycerol, 150 mM DTT, 
0.03% (w/v) bromophenol blue
5X SDS loading buffer:
312.5 mM Tris-HCl (pH 6.8), 10% (w/v) SDS, 50% (v/v) glycerol, 250 mM DTT, 
0.05% (w/v) bromophenol blue
lOX Running buffer:
0.25 M Tris, 1.9 M glycine, 1% (w/v) SDS
IX TBS:
0.2M Tris, 1.4M NaCl (pH 7.6)
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lOX Transfer buffer:
0.2MTris, 1.5M glycine
Working solution: lOOmL 1 OX transfer buffer, 200ml methanol and 700ml H2O 
Stripping buffer:
62.5mM Tris-HCl (pH 6.7), 2% (w/v) SDS, lOOmM beta-mercaptoethanol
2.1.10- Media and antibiotics
2.1.10.1- Bacterial culture
Luria-Bertani (LB) medium and agar were made from Luria-Bertani broth and agar 
tablets (Sigma-Aldrich).
Ampicillin: stock solution lOOmg/ml in H2O, working solution: lOOpg/ml
2.1.10.2- Mammalian cell culture
Foetal bovine serum, penicillin-streptomycin solution (10000 units/ml penicillin and 
10000 pg/ml of streptomycin). Ham F 12 medium, Dulbecco’s Modified Eagle 
Medium (D-MEM) with L-glutamine, 4500mg/L D-glucose and llOmg/L sodium 
pyruvate and Dulbecco’s Modified Eagle Medium (D-MEM) with GlutaMAX™, 
4500mg/L D-glucose and without sodium pyruvate were all from Invitrogen.
2.1.11- Kits
A number of kits were used for many different purposes. They are listed in table 2.4:
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Supplier Kit
Qiagen RNeasy Mini kit
Qiagen QIAquick Gel extraction kit
Qiagen QIAquick PCR purification kit
Qiagen Plasmid DNA mini and midi kits
Qiagen QIAquick PCR purification kit
Qiagen QIAquick Nucleotide removal kit
FLAG® tagged protein immuno­ Sigma-Aldrich
précipitation kit
Pierce Biotechnology SuperSignal West Femto Maximum
Sensitivity Substrate
Amersham Biosciences ECL+ (enhanced chemiluminescence)
western blotting analysis system
Neurite outgrowth quantification kit Chemicon
Table 2.4. Kits
2.1.12- Membranes and paper
PVDF membranes and filter paper for western blotting were obtained from 
Invitrogen. Saran was from Fischer Scientific.
2.1.13- Photography and autoradiography
Biomax™ MR X-ray films for in situ hybridisation (Kodak) and Hyperfilm™ 
ECL™ films for western blottings (GE Healthcare, formerly Amersham Life 
science) were developed using an automatic developer (Hyperprocessor, GE 
Healthcare, formerly Amersham Life science).
Agarose gels, western blotting and in situ films were analysed and photographed 
using a computer-based system (MCID5) either connected to a UV transilluminator 
(for agarose gels) or to a CCD camera (for films).
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2.2- Experimental materials
2.2.1- RNA and DNA sources
Rat brain total RNA was obtained from Ambion.
Total RNA or first strand cDNA used for the rat qRT-PCRs were provided 
by Catherine Winchester (Strathclyde University, Glasgow). Total RNA had been 
extracted using the RNeasy Mini Kit (Qiagen) from the prefrontal cortex of rats 
treated with PCP or vehicle (n=6) according to YRING chronic PCP model treatment 
{i.p. injections of 2.58 mg.kg“^ PCP once daily on days 1-5, 8, 10, 12, 15, 17, 19, 22, 
24, 26 (Cochran et a l 2003), There were two collections of total RNA, one used 
primarily for a microarray study investigating gene expression changes in the 
YRING chronic PCP model (Catherine Winchester), the other one used of qRT-PCR. 
The quality of all samples had been confirmed by checking the electrophoretic 
pattern of the RNA using the Agilent 2100 Bioanalyzer (Sir Henry Wellcome 
Functional Genomics Facility, University of Glasgow).
First strand cDNA was synthesised from these total RNA samples (section 2.4.3).
The cDNAs used for the human qRT-PCR analysis were provided by Hiromitsu 
Ozeki (Mitsubishi Pharmaceuticals, Japan). They originated from brain tissue 
obtained from the Scottish Biomedical Foundation from different collections of 
schizophrenic patients and controls (namely Harvard, Brain-Net and UCLA). The 
purpose of this acquisition had been the realisation of a microarray to investigate 
gene expression in the human dorso-lateral prefrontal cortex of schizophrenic 
patients and this is what the tissue was used for first (Hiromitsu Ozeki).
Total RNA was extracted from post-mortem prefrontal cortex (Brodmann area 10) of 
schizophrenic patients and controls using the Qiagen lipid Midi kit (Hiromitsu 
Ozeki). Sample quality was confirmed using the Agilent 2100 Bioanalyzer (Sir 
Henry Wellcome Functional Genomics Facility, University of Glasgow). To enable a 
more detailed analysis, the samples were matched by pairs in order to take into 
account gender, approximate correlation of age and post-mortem delay, and if 
possible, cause of death (Hiromitsu Ozeki).
Table 2.5 shows known details of the samples.
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First strand cDNA was synthesised using the protocol described in section 2.4.3 
(Hiromitsu Ozeki).
source Donor source ID gender pmdelay Age cause of death
brain collection control or schizophrenic hours Years
Harvard control B4810 F 17 62 not given
control B5245 M 16 58 not given
control B5270 M 23 52 not given
control B5287 M 25 66 not given
schizophrenic B4942 F 14 61 not given
schizophrenic B5047 M 23 63 not given
schizophrenic B5103 F 11 61 not given
schizophrenic B5115 M 25 49 not given
Brain-Net schizophrenic BN007/01 M 16 32 suicide
control HH008/01 M 10 61 heart attack
UCLA control 482 M 26 24 homicide
control 2546 M 20.5 57 non-hodgkin’s
lymphoma
control 2556 M 27 74 myocardial infarction
control 3236 M 16.5 68 laryngeal cancer
schizophrenic 707 M 41 28 suicide
schizophrenic 2211 M 17.5 73 coronary artery 
disease
schizophrenic 2258 M 15.5 72 myocardial infarction
schizophrenic 2586 M 19.5 58 adenocarcinoma
Table 2.5. Information on human post-mortem prefrontal cortex samples 
F=female, M=male
2.2.2- Genomic DNA
Genomic DNA (gDNA) samples were obtained from Professor H.M. Gurling 
(Academic Department of Psychiatry, University College London Medical School, 
UK). These samples consisted of 300 control and 300 schizophrenic gDNA samples, 
distributed at a concentration of 20ng gDNA/pl (150pl per well in four duplicate 96- 
well microtitre plates). Blood had been collected from individuals of Anglo-Saxon 
parentage residing within the Greater London (UK) area.
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Original samples were diluted 10-fold in stock dilution plates mixing controls and 
schizophrenic samples and including negative water controls to obtain a 
concentration of 2ng/pl for the allelic discrimination assays (section 2.4.8).
2.2.3- EDG2 and KIAA1189 cDNAs
pBluescript-A0G2 and pBluescript-X7Æ4/75P cDNAs clones were obtained from 
OpenBiosystems. Human verified full-length cDNAs were isolated from bacterial 
cultures of E. coli in LB broth with growth indicator, 8% (v/v) glycerol and selective 
antibiotic.
2.2.4- Bacteria and mammalian cells
Sub cloning efficiency™ DH5a™ competent cells and one shot TOP 10 competent 
Escherichia coli were obtained from Invitrogen.
The strains and their genotypes are detailed in Table 2.6.
Bacterial strain Genotype
Subcloning efficiency F-(})80/acZAM15 A(/acZYA-
DH5 argT)\5169 deoK recK 1 endk 1 hsdRl 1 (rf
, mk^ ) phoK supEAA thi-\ gyrh96 relKl X 
One shot® TOPIC V-mcrK Eimrr-hsdBM.^-
competent cells mcrBC) (j)80/acZAM15 A/acX74 recAl ardD\39 ts{ara-
leu)1691 gaK5 galK rpsE (Sti^) endAl nupG
Table 2.6. Bacterial strains
Human SK-N-SH and rat C6 glioma and PC 12 cells were obtained from the 
European Collection of Cell Cultures (ECACC).
2.2.5- Vectors
Vectors were used for sub cloning and cloning EDG2 and K1AA1189\ pcDNA3.1(+) 
(Invitrogen), pcDNA3.1 -FLAG and pMSFl (gifts from Mitsubishi Pharma 
Corporation, Japan) and pcDNA3.1/NT-GFP (Invitrogen) was used to visualise 
transfected cells. Their structures are shown in figures 2.1-4.
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Ampicillin
pUC origin
pcDNA3.1 (+)
5428 bp
T7 promoter
NheI(896)
Hind 111(912) 
y  Asp718l(918)
/-K pn 1(922)
BamH I (930)
EcoR I (935)
EcoR V (965)
Not I (980)
Xho I (986)
Xba I (992)
'--A pa 1(1002)
BGH polyadenylation sequence
F1 intergenic region
Neomycin
Figure 2.1. Structure ofpcDNA3.1(+) expression vector
Ampicillin
pUC origin
pcDNA3.1-FLAG-N
5464 bp
- T7 promoter
Kpn 1(981) 
EcoR I (988) 
EcoRV(IOOI) 
Not! (1016) 
Xho I (1022) 
-  Xba I (1028) 
Apa I (1038)
BGH polyadenylation sequence 
F1 intergenic region
Neomycin
Figure 2.2. Structure o f pcDNA3.1 -FLAG expression vector
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Ampicillin
pUC origin
prsprotrypsin leader sequence 
FLAG
pMSFI.NUC
5474 bp
T7 promoter
- EcoR I (971) 
Pst I (979)
- EcoR V (982) 
Not I (997)
. Xho I (1003)
- Xba 1(1015) 
-  Apa I (1026)
BGH polyadenylation seq u en ce
F1 intergenic region
Neomycin
Figure 2.3. Structure o f pMSFl expression vector
Ampicillin
pUC origin
GFP ORF
fe ’U - oinnîi»!
T7 prom oter
PCDNA3.1/NT-GFP
6160 bp
BGH polyadenylation site
Neomycin
Nhe I (1640) 
A sp718l(1646) 
Kpnl(165Q) 
EcoR I (1681) 
EcoR V (1693) 
X ba 1(1720) 
Apa I (1730) 
P m el(1735)
FI intergenic region 
Sv4t- ar* pi
Figure 2.4. Structure o f pcDNA3.1/NT-GFP vector
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2.3- Bioinformatics methods
2.3.1- Resources 
NetAffx^^ Analysis Center^:
This website supported by Affymetrix, integrates array contents and available 
functional annotations. Its flexible query capabilities allow retrieval of biological 
information for specific probe sets. The resource provides probe sequence 
information, gene annotations and gene orthologue and functional information.
N C Bf:
The National Center for Biotechnology Information (NCBI) supports and distributes 
a variety of databases including GenBank, Online Mendelian Inheritance in Man 
(OMIM), the Molecular Modeling Database (MMDB) of 3D protein structures, the 
Unique Human Gene Sequence Collection (UniGene), a Gene Map of the Human 
Genome and the Taxonomy Browser. Its website provides many tools for searching 
and retrieving information from these databases. Among these tools are Entrez, a 
retrieval system designed for searching several linked databases, PubMed, a Web 
search interface that provides access to over 11 million journal citations and 
sequence analysis tools such as Basic Local Alignment Search Tool (BLAST), Open 
Reading Frame Finder (ORF Finder) and Electronic PCR. In addition, the NCBI 
website gives access to genetic and physical maps, among them integrated views of 
chromosome maps for 17 organisms (MapViewer),
European Bioinformatics Institute^ (EBI):
The European Bioinformatics Institute (EBI) is a non-profit academic organisation 
that forms part of the European Molecular Biology Laboratory (EMBL). It manages 
databases of biological data including nucleic acid, protein sequences and 
macromolecular structures. Its website provides freely available data together with a 
large number of bioinformatics tools for similarity and homology searching (BLAST, 
Fasta), protein functional analysis (InterProScan), sequence (ClustalW) and 
stmctural analysis (MSDfold, Dali).
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ENSEMBL'*:
ENSEMBL is a joint project between EMBL-EBI (European Molecular Biology 
Laboratory-European Bioinformatics Institute) and the Wellcome Tmst Sanger 
Institute (WTSI) to develop a software system which produces and maintains 
automatic annotation on selected eukaryotic genomes. Its website presents these 
analyses in the form of a database that allows different types of queries.
GeneCards®^:
GeneCards® is an integrated database of human genes that includes automatically- 
mined genomic, proteomic and transcriptomic information, as well as orthologies, 
disease relationships, SNPs, gene expression and gene function information.
Harvester^:
The Harvester is an open source software tool created at EMBL-Heidelberg. It 
caches and cross-links public bioinformatic databases and prediction servers to 
provide fast access to protein specific bioinformatic information. Implemented 
databases and servers include: Uniprot/SWISSprot, ENSEMBL, BLAST (NCBI), 
SOURCE, SMART, STRING, PSORT2, CD ART, UniGene and SOSUI.
Different gene prediction programs were used, including Genscan^, GRAIL^, 
HMMGene^, GeneID^°, and Integrated System for exon finding^^ (Zhang’s MZEF + 
Thanaraj’s Splice Proximal Check). In addition two “integrated” programs 
(GeneComber and NIX) were tried. GeneComber^^ is a graphical interface to the 
output of several gene prediction algorithms, EUI, GI and EUI-Frame that perform 
exon and gene structure prediction by taking the intersection of overlapping 
HMMGene and Genscan predictions. NIX^^ is a tool to view the results of running 
many DNA analysis programs on a DNA sequence: analysis programs include 
GRAIL, F ex, Hexon, MZEF, Genemark, Genefinder, F Gene, BLAST against many 
databases, Polyah, RepeatMasker, and tRNAscan.
The ORNL Genome Analysis Pipeline^"^ is a pipeline that predicts gene structure 
from the input sequence and uses this information to then perform motifs and protein 
predictions.
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Uniform Resource Locators (URLs) of all these software or tools can be found in the 
bibliography.
2.3.2- Homology screening
Comparisons of the rat EST sequences with mouse, rat and human cDNA and 
genomic DNA databases were performed to identify homologous genes for the ESTs. 
For each differentially expressed probe set, the exemplar sequence was retrieved 
using NetAffx™. Exemplar sequences refer to the longest member of an Affymetrix 
sub-cluster; i.e. the longest member of a group of sequences all representing the same 
transcript; sub-cluster sequences are the building blocks of probe selection.
The principle of the homology screening strategy is that exemplar sequences were 
individually aligned against different databases. BLAST at ENSEMBL rat database 
(cDNA and genomic databases) was used to confirm the identity and the 
chromosomal localisation of the differentially expressed rat genes and the exemplar 
sequences were then compared to the mouse and human databases (cDNA and 
genomic) to identify the human and mouse orthologues. Sequences of presumed rat 
and mouse/human genes were finally aligned at ENSEMBL to check they were 
genuine orthologues. Appendix A shows screenshots of NetAffx™ and ENSEMBL 
websites representing each step of this process for a given differentially expressed 
probe set.
However, because of the nature of the ESTs (which are uncharacterised sequences) 
and of the lack of rat transcriptome information, the homology screening process 
often proved to be more complex and involved repeated replicated sequence 
comparisons, as shown in the flow diagram (figure 2.5).
In most cases, the ESTs remained anonymous rat transcripts, with no rat gene and no 
mouse/human gene identified by aligning the exemplar sequence against appropriate 
databases. Identification of the rat gene was sometimes achieved by comparing the 
rat genomic locus with the rat homologous locus of presumed mouse/human genes 
and analysing neighbouring known or predicted genes. This process allowed the 
prediction of novel rat genes or novel exons {e.g. novel splice variants).
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Retrieve Affymetrix consensus sequences (NetAffx)
Align (BLAST at ENSEMBL) VMth rat cONA database Align (BLAST at ENSEMBL) with rat genomic database
Align (BLAST at ENSEMBL) with human/mouse cDNA databases
No human/mouse cDNAPredicted rat Human/mouse cDNANo rat cONARatcDNAcDNA
Human/mouse genePredicted rat gene Rat gene
Homologous rat genomic locusRat genomic locus
Anonymous rat transcrlpt/EST
Human/mouse genomic locus
Check that rat and mouse/human genes are orthologs (sequence alignment at ENSEMBL/ÉMBOSS)
Rat gene
Compare loci
■ predict rat gene ^■ predict novel exon —  e.g. novel splice variant
cloning
gene prediction programmes
Figure 2.5. Bioinformatic strategy for homology screening to identify rat genes
After retrieval of the consensus sequence of each probe set from the Affymetrix 
website (NetAffx), this sequence was aligned (BLAST at ENSEMBL) first with rat 
cDNA (i), then with rat genomic (2 ) and finally with mouse and human cDNA (3 ) 
databases, and processed for further analysis in each case.
Although absence of identification of rat cDNA from the rat alignment directly 
(from 1 ) prompted rat genomic (2 ) and mouse/human cDNA (») alignments, all four 
alignments were performed for each probe set anyway to check orthology between 
the genes identified and thereby increase confidence in the rat gene identified by the 
whole process.
When no rat gene but a rat genomic locus was identified from (2 ), this locus was 
compared with that of the rat orthologous gene of potentially identified human and 
mouse genes (from 3 ). This information was then used to potentially predict novel rat 
genes or novel exons of known or predicted rat genes, following what cloning and 
gene prediction programs were used for further in vitro and in silico analysis, 
respectively.
In case not any rat, mouse and human gene was identified after performing all four 
alignments, the EST represented by the probe set was considered an anonymous rat 
transcript.
2.3.3- Data mining and selection of candidate genes
GeneCards® and Harvester were used for doing data mining on all differentially 
expressed ESTs or genes and identify expression patterns, functions and any 
associations with schizophrenia. Mapping of the genes/ESTs loci with well-
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supported regions linked to schizophrenia (reported in many papers, section 1.2.3.2) 
was also considered.
In addition, the fold changes of the differentially expressed ESTs/genes were 
investigated and all information was combined and used as criteria for selecting 
genes that might be worth validating. These candidate genes were then classified into 
different categories.
2.3.4- Extended bioinformatic analyses on a selected EST
More thorough analyses were perfonned on a selected EST that had been confirmed 
as differentially expressed in the rat chronic PCP model.
The facilities BLAST, Entrez, Unigene and dbESTs (NCBI) were used to obtain 
information about the sequence of this EST and identify other ESTs belonging to the 
same cluster. ClustalW (EBI) was then used to obtain a multiple alignment of the 
DNA sequences of these ESTs.
To try to predict a potential novel gene the EST could be part of or identify a novel 
splice variant of a known gene, integrated programs such as GeneComber and NIX 
were used as well as several gene prediction programs, including Genscan, GRAIL, 
HMMGene, GenelD, and Integrated System for exon finding (Zhang’s MZEF + 
Thanaraj’s Splice Proximal Check).
2.3.5“ Protein prediction software
Position specific iterative BLAST (PSI-Blast) was used for searching protein 
sequence for similarities with database protein sequences. PSI-BLAST is similar to 
BLAST except that it uses position-specific scoring matrices derived during the 
search and may therefore be more sensitive than BLAST (meaning that it might be 
able to find distantly related sequences that are missed in a BLAST search).
Protein prediction tools were used to extract biologically important information from 
protein sequence and specifically search for sequence motifs or patterns that might 
surrender the function of the protein. Many software were used, including ProtFun 
(Jensen et a l 2002; Jensen et a l 2003), Blocks (Henikoff and Henikoff 1994), Jpred
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(Cuff et a l  1998; Cuff and Barton 1999; Cuff and Barton 2000), Pfam (Finn et a l  
2006), PredictProtein (Rost and Liu 2003), Prosite (Gattiker et a l 2002; Sigrist et a l  
2002), TopPred (von Heijne 1992; Claros and von Heijne 1994).
2.4- Molecular Biology
2.4.1- Preparation and purification of DNA
2.4.1.1-Preparation of plasmid DNA
Preparations of plasmid DNA were performed using Plasmid Mini and Midi kits 
(Qiagen). DNA was purified from 10ml and 100ml bacterial cultures by alkaline 
lysis followed by anion-exchange columns, according to the manufacturer’s manual.
2.4.1.2- Phenol/chloroform extraction of DNA
Phenol/chloroform extraction was used to further purify DNA (such as plasmid DNA 
extracted from bacterial cultures).
Briefly, 50% (v/v) phenol 50% (v/v) chloroform was added to the DNA and mixed 
gently by inversion. The two phases were separated by centrifugation at 12,500 g for 
5 minutes and the nucleic acids were precipitated from the upper phase by adding 0.1 
volume of 3M sodium acetate and 2 volumes of 100% (v/v) ethanol. After mixing, 
the tube was incubated on ice for 5 minutes. The nucleic acid pellet were collected 
by centrifugation at 13,000 g for 15 minutes and washed in 70% (v/v) ethanol. The 
pellet was air dried and resuspended in TE buffer.
2.4.1.3-Purification of DNA fragments from agarose gels
Gel star stained-DNA fragments (section 2.4.7) were excised from agarose gels after 
visualisation with UV light. Extraction of DNA was performed using the QIAquick 
Gel extraction kit (Qiagen) according to the manufacturer’s manual. Briefly, gel
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fragments were dissolved in a high-salt buffer, the mixture was applied to a silica-gel 
membrane column and pure DNA was eluted with low-salt buffer or water.
2.4.1.4- Purification o f DNA from PCR reaction mixture
In some cases, the PCR product was directly purified from the PCR reaction mixture. 
This was only possible when the PCR reaction was determined to have given a single 
amplicon as checked by loading some of the PCR reaction mixture on an agarose gel 
and visualising it with UV light. Cleaning up of the PCR mixture was performed 
using the QIAquick PCR Purification Kit (Qiagen) according to the manufacturer’s 
manual. As with the QIAquick Gel extraction kit (described previously), this method 
is based on the adsorbance of nucleic acids to a silica-gel membrane in high-salt 
conditions and their elution in low-salt conditions.
2.4.1.5-Determination o f DNA concentration
DNA concentration was determined by spectrophotometry after appropriate dilution 
(usually a 1/10 dilution in H2O).
2.4.2- RNA isolation
Qiagen RNeasy Mini kit was used to isolate total RNA from mammalian cell 
cultures. RNA was isolated by guanidine-isothiocyanate lysis and purified using a 
silica-gel-membrane according to the manufacturer’s manual. Within this protocol, 
the optional DNase digestion was performed to ensure complete DNA removal 
(which can be critical in DNA-sensitive applications such as qRT-PCR with a low 
abundant target).
The quality of the RNA was analysed at the Sir Henry Wellcome Functional 
Genomics Facility (University of Glasgow) using the Nano LabChip kit on an 
Agilent 2100 Bioanalyzer.
RNA concentration was determined by spectrophotometry.
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2.4.3- cDNA synthesis
First strand cDNA was synthesised from rat brain total RNA using oligo-dT primers. 
Briefly, lOnmol dNTP and 0.25 pg oligo-dT (both from Invitrogen) were added to 
Ipg total RNA in a RNase-free PCR tube and the volume was adjusted to 12pl with 
nuclease-free H2O (Invitrogen). After gentle mixing and a pulse spin the tubes were 
heated at 65°C for 5 min in a ThermoHybaid PCR thermocycler. IX buffer, 0.2pmol 
DTT and 40u RNase out (all from Invitrogen) were then added to each tube and the 
tubes were heated at 42°C for 2 min. Eventually, 200u Superscript III RT 
(Invitrogen) was added to each tube and the tubes were heated at 42°C for 50 
minutes, followed by 70°C for 15 minutes. First strand cDNA was stored at -20°C.
Human first strand cDNA was synthesised from human brain total RNA following 
the same protocol as for the rat cDNA except that 6pg random hexamers (Invitrogen) 
were used for priming the RT reaction and an additional heating step of 10 minutes at 
25°C was introduced before the final heatings at 50°C and 70°C. First strand cDNA 
was stored at -20°C.
2.4.4- PCR
PCR was performed using plasmid DNA to amplify gene fragments for subcloning 
or cloning. For this purpose, 5’ and 3’-specific primers were designed to contain 
recognition sites for restriction enzymes of the multiple cloning site of the target 
sub cloning or cloning vector so that digestion of the amplified product and of the 
target vector with the same enzymes followed by ligation will insert the gene of 
interest in its target vector, in frame if necessary.
PCR was also performed for confirming gene expression in premade cDNA library 
and for relating an EST sequence to its upstream predicted gene.
In all cases, PCR was performed following a standard protocol using 2-200ng DNA. 
Reactions were performed in 50pl final volume using IX Advantage® 2 polymerase, 
IX  Advantage® 2 PCR buffer, IX  dNTP mix and 0.025nmol of each primer or lu  
KOD Hot start polymerase, IX PCR buffer, lOnmol dNTPs, 50nmol MgS0 4  and 
0.015nmol of each primer. Annealing and extension temperatures were determined
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depending on the melting temperature (Tm) of the primers. 40 cycles were usually 
performed on a ThermoHybaid PCR thermocycler and a portion of the reaction was 
loaded on an agarose gel for checking for a single amplicon of the correct molecular 
weight.
2.4.5- qRT-PCR
Taqman® real-time quantitative PCR (qRT-PCR) was used for validating the 
differential expression of candidate genes. The first assays were designed manually 
while the others were purchased as ready-to-use mixes containing specific primers 
and probe in optimal concentrations (Applied Biosystems). In both cases, the assays 
were selected as close as possible to the location of Affymetrix probe sets within the 
ESTs (rat assays) and as close as possible to their human orthologous region (human 
assays).
For the manually-designed assays, optimal results were obtained through a careful 
experimental design, including selecting the appropriate enzymes, designing optimal 
primers, using different buffers and additives, establishing cycling parameters and 
preparing high quality templates.
Primer Express^'^ software package (Applied Biosystems) was used for designing 
specific PCR primers and fluorescently labelled probe).
Primers specificity was checked by performing a RT-PCR using qRT-PCR primers 
and rat/human brain first strand cDNA. Single amplicons of the right molecular 
weight were then sequenced to confirm gene identity using the forward and reverse 
qRT-PCR primers as sequencing primers.
Primers and probe concentrations were optimised by trying different dilutions of 
each component and the conditions giving the most efficient reaction were chosen. 
The optimised qRT-PCR assay was then performed using dilutions of rat/human 
brain first strand cDNA to check for efficient amplification with different amounts of 
first strand cDNA.
Real-time PCR was eventually performed on target gene and endogenous control 
gene with rat or human brain samples.
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For both types of assays (manually-designed or Assays-on-Demand®), qRT-PCR was 
performed using an ABIPrism 7000 (Applied Biosystems) in the Absolute 
quantitation mode following the manufacturer’s protocol and using the recommended 
PCR programme consisting of 10 min initial dénaturation at 95°C followed by 40 
cycles for 15 sec at 95°C and 1 min at 60°C.
Beta-2-microglobulin (B2m) and glyceraldehyde-2-phosphate dehydrogenase 
(GAPDH), which had previously been determined as the most appropriate 
housekeeping genes to use in these conditions (they were shown to exhibit reliably 
unchanged expression in the chronic PCP model of schizophrenia and in post­
mortem prefrontal cortex from schizophrenic patients, Hiromitsu Ozeki) were used 
for the rat and human qRT-PCR assays respectively. A standard curve consisting of 
accurate first strand cDNA dilutions was performed in some cases. H^O negative 
controls were added to each reaction plate to ensure the absence of contamination.
Analysis of covariance (ANCOVA) was used to determine the effect of chronic PCP 
treatment on the expression level of candidate genes. This approach allows 
parti ailing out any effects of PCP treatment on the expression levels of housekeeping 
genes from those specific to the candidate gene of interest and harbours the potential 
to increase the statistical power of qRT-PCR analyses (Bond et a l  2002). For the 
analysis, four cycles were chosen for each gene from the linear phase of 
amplification and the model incorporated ‘treatment group’ (PCP or vehicle), ‘cycle 
number’ (n=4), and ‘subject’ (n=5 or 6 samples) as the independent variables with 
‘subject’ included as a random factor nested within the treatment group variable. 
Expression levels of the housekeeping gene were incorporated as the covariate. As 
the ANCOVA analysis relies on the assumption that regression slopes are 
homogeneous, interaction between the dependent variable and the covariate was 
investigated and proper ANCOVA analysis of the data was only performed when 
having established that the regression slopes assumption had not been violated.
2.4.6- RACE PCR
Rapid Amplification of cDNA Ends (RACE) PCR was used for extending an EST 
sequence in the 5’ direction. Rat brain Marathon-Ready cDNA (Clontech) was used 
as a template for cDNA amplification. It consists of a premade “library” of adaptor-
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ligated double-stranded cDNA ready for use as template in both 5'- and 3 -RACE 
PCRs.
RACE PCR was performed as recommended by Clontech. An EST-specific reverse 
primer was designed to be the starting point for DNA elongation in the 5’ direction. 
This primer was similar to the reverse primer used for qRT-PCR but it was 
redesigned to comply with the criteria for RACE PCR and for use with Clontech 
adapter specific Primer. It was used together with an Adaptor Specific primer 
(provided by Clontech).
As recommended by the manufacturer, several controls were run alongside the 
experimental sample; two negative controls with only one primer each (either the 
Adaptor-specific primer or the EST-specific primer), one positive control for 
amplifying GAPDH using the Adaptor-specific primer and a control GAPDH 
5’RACE primer (Clontech) and one positive control for amplifying the EST using 
the EST-specific primer and the forward primer used in qRT-PCR. Negative controls 
without any template were also run to check there was no contamination.
Reactions were performed in 50pl total volume using 0.5ng Marathon-Ready cDNA, 
0.2pM of each primer, IX cDNA PCR reaction buffer, 0.2mM dNTP mix and IX  
Advantage 2 Polymerase Mix (in water).
Thermal cycling was performed using the following programme (optimised for the 
EST-specific primer): 1 min initial dénaturation at 94°C followed by 30 cycles for 
30 sec at 94°C and 4 min at 68°C.
5pi (out of 50pl PCR reaction) of each reaction were analysed in a 1.2% (w/v) 
agarose gel stained with Gel star nucleic acid along with 0.1 pg lKb+ DNA ladder.
2.4.7- Agarose gel electrophoresis
DNA molecules were separated according to size by agarose gel electrophoresis. 
Solutions of 1-2.5% (w/v) agarose in IX  TBE were prepared in a microwave. When 
the solution had cooled to approximately 50°C, 1/10,000 dilution Gel star nucleic acid 
stain was added and the gel cast in a horizontal tray with a 1.5mm comb. DNA 
samples were mixed with IX BlueJuice gel loading buffer and subjected to 
electrophoresis in IX TBE for 2 to 4 hours at 80-100 volts/cm. 0.1 pg 1Kb Plus DNA 
ladder (Invitrogen) was also run as a DNA size marker.
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Separated DNA samples were visualised using a UV transilluminator (wavelength 
254nm) and photographed.
2.4.8- SNP genotyping
For SNP genotyping, 2ng genomic DNA were used per allelic discrimination assay 
in a total volume of lOpl which had been determined to give as accurate results as the 
25 pi final volume recommended by Applied Biosystems.
Ipl DNA (at 2ng/pl concentration) was delivered per reaction to the bottom surface 
of an optical reaction plate and 9pi SNP reaction mix (1.25pl SNP genotyping assay 
mix, 5pi 2X TaqMan Universal PCR Master Mix, and 2.75pl DNase-free water per 
reaction) were added to each well. Plates were covered and sealed with an optical 
adhesive cover and centrifuged briefly to collect all reagents at the bottom of the 
wells and eliminate all eventual air bubbles.
SNPs genotyping was performed on an ABIPrism 7000 in real-time (absolute 
quantitation) and end-point reading (allelic discrimination) modes following the 
manufacturer’s protocol and using the recommended PCR programme. Real-time 
mode was run first to allow troubleshooting if needed and end-point reading mode 
allowed calling of the alleles for genotyping. Every single sample’s genotype was 
checked manually to ensure accurate results.
2.4.9“ DNA cloning technique
2.4.9.1- Restiiction endonuclease digestion o f PCR-amplified DNA 
fragments
Restriction digests were carried out to generate gene fragments for subcloning and 
for checking the inserts of recombinant plasmids containing foreign DNA.
250ng-lpg of Qiagen-prepared plasmid DNA or PCR-amplified DNA, 1-2 units of 
restriction endonuclease, IX recommended restriction endonuclease buffer in a total 
volume of 20 or 50pl with H2O were incubated at 37°C overnight.
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2.4.9.2- DNA ligation
Bacteriophage T4 DNA ligase was used to catalyse the formation of phosphodiester 
bonds between the 3’ hydroxyl groups and the 5’ phosphate groups of the restriction- 
digested DNA inserts and vectors. Ligation of vector and insert DNA were incubated 
at 4°C overnight with 1 unit of bacteriophage T4 DNA ligase and IX T4 DNA ligase 
buffer in a total volume of lOpl. DNA molecules were ligated at a vector:insert molar 
ratio of 1:3. Control ligations, with one component missing, were also incubated at 
4°C overnight.
2.5- Cellular biology
2.5.1- Transformation of competent bacterial cells
200pi of DH5a or TOP 10 competent cells were thawed on ice for 10 minutes. Ipl of 
the ligation mixture (section 2.4.9.2) or lOng of control plasmid DNA was added to 
the competent cells and the tube was gently mixed. After 10 minutes incubation on 
ice, the cells were heat-shocked at 42“C for 1 minute and immediately placed on ice 
for 2 minutes.
800pl of chilled SOC medium (a specialised microbiological medium which is a 
derivative of SOB -Super Optimal Broth- medium differing in that it contains 
glucose therefore gives rise to Catabolite repression) was added to the cells and 
incubated at 37°C for 1 hour.
Cells were centrifuged for 3 minutes at 10,000g, resuspended in 200pi LB and spread 
on an LB agar plate containing lOOg/ml ampicillin (to positively select transformed 
bacteria). The plates were incubated at 37°C overnight.
2.5.2- Generation of plasmid stocks
Stocks of bacterial host cells and bacteria transformed with recombinant plasmid 
were prepared for long term storage.
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A colony from an agar plate was used to inoculate 10ml (Mini Prep) or 100 ml (Midi 
Prep) of LB containing lOOpg/ml ampicillin (for transformed bacteria) and shaken at 
37°C overnight. 800pi of the overnight culture were mixed with 200pi of 50% (v/v) 
glycerol 50% (v/v) LB, mixed and stored at -70 °C.
2.5.3- Mammalian cell culture
Human SK-N-SH cells were cultured in D-MEM with L-glutamine, 4500mg/L D- 
glucose and 1 lOmg/L sodium pyruvate supplemented with 10% (v/v) FBS.
Rat PC 12 cells were cultured in D-MEM with GlutaMAX™, 4500mg/L D-glucose 
and without sodium pyruvate supplemented with 10% (v/v) FBS. Differentiation was 
initiated by the addition of 50ng/ml nerve growth factor (murine NGF 2.5S, 
Invitrogen).
Rat C6 glioma cells were cultured in Ham F 12 medium supplemented with 10% 
(v/v) FBS and ImM glutamine.
All cells were maintained at 37°C with 5% CO2 .
In all cases, confluent cells were washed with PBS at room temperature and detached 
with 0.05% (w/v) trypsin-EDTA (2mls for 75cm^ flasks and 400pl for 25cm^ flasks) 
at 37°C in the incubator.
The reaction was stopped by the addition of an excess of medium with FBS and cells 
were centrifuged for 5min at lOOOg. Pelleted cells were resuspended in their 
appropriate medium and split into sterile flasks using a ratio to total volume of cell 
suspension of 1:6 for SK-N-SH and PC12 cells and 1:5 for C6 cells. Volume was 
adjusted to 10ml for 25cm^ flasks and 25ml for 75cm^ flasks.
Trypan blue was used for counting cells when they had to be seeded at a certain 
density (before transfection for example). Haemocytometer chambers were filled 
with the cell sample diluted in trypan blue exclusion solution. Live cells present in 
each of 10 squares (Imm^, delimited by double lines, 9 small squares) were counted 
after a few minutes (to allow their deposition on the counting plane) using a 
microscope with lOX objective. The number of cells per ml was calculated by 
multiplying the average count per square by 10  ^ and by the dilution factor used for 
diluting cells in trypan blue.
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For making stocks of early passage cells, pelleted cells obtained after trypsinisatlon 
and centrifugation were resuspended in FBS with 1% (v/v) DMSO and frozen at - 
80°C as gently as possible (cryotubes were wrapped with cotton and placed inside 
polystyrene boxes to slow down the freezing process).
2.5.4- Transfection of cells
2.5.4.1- Transfection of SK-N-SH and C6 cells
TransIT®-LTl transfection reagent (Mirrus Bio Reagents) was used for transfecting 
SK-N-SH and C6 cells with plasmid DNA.
Approximately 24h prior to transfection, the cells were plated at a cell density of 
1-2 X 10  ^ cells in complete growth medium per well of a 6-well plate, to obtain 50- 
70% confluence the following day, and were incubated overnight at 37°C in 5% CO2. 
24h later, 6pi TransIT®-LTl transfection reagent were added into 250pl of serum- 
free medium in a sterile plastic tube. After 20 minutes incubation at room 
temperature, 2pg plasmid DNA were added to the diluted transfection reagent and 
incubated for 20 minutes at room temperature. In the meantime, medium was 
removed from the cells and replaced with fresh complete growth medium. The 
transfection reagent/plasmid DNA complex was then added dropwise to the cells in 
complete growth medium.
The plate was rocked gently back and forth and from side to side to distribute the 
complexes evenly. Cells were incubated for 24-48h depending on the application.
2.5.4.2- Transfection o f PC 12 cells
Lipofectamine™ 2000 reagent (Invitrogen) was used for transfecting PC I2 cells. 
Approximately 24h prior to transfection, PC 12 cells were plated at a cell density of 
4*10^ cells in complete growth medium per well of a 12-well plate so that they are 
90% confluent on the day of transfection.
For each well of cells to be transfected, 1.5pg DNA was diluted in lOOpl of Opti- 
MEM® medium. 4pl of Lipofectamine® 2000 reagent was diluted in another lOOpl of 
Opti-MEM® and incubated for 5 minutes at room temperature. The diluted reagent 
was then combined with the diluted DNA and incubated for 20 minutes at room
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temperature. DNA-Lipofectamine® 2000 complexes (200pl per well) were added 
directly to each well and the plate was rocked gently back and forth and from side to 
side to distribute the complexes evenly. After 24h incubation at 37°C, normal 
proliferation medium was replaced by differentiation medium (D-MEM 
supplemented with 50-100nm/ml NGF) and the cells were cultured for 1 to 6 days.
2.5.5- LPA treatment
For assessing the effects of LPA treatment on biochemical pathways, cells were 
treated with LPA prior to total protein extraction. Briefly, cells were washed with 
PBS and cultured for 30 minutes in serum-free medium containing LPA (at the 
desired final concentration, usually IpM) or vehicle (PBS with 0.1% (w/v) BSA). 
Proteins were then extracted after washing with PBS (section 2.5.6).
2.5.6- Cell lysis
Modified RIPA buffer was used to extract proteins from adherent cells.
Briefly, fresh ice-cold RIPA buffer containing protease inhibitors was added to cells 
washed with PBS and plates were left on ice for 15 minutes. After this incubation, 
cells were scraped and cell suspension transferred into an ice-cold eppendorf was 
centrifuged at 13,000g for 15 minutes at 4°C. Resulting supernatant was transferred 
into another clean ice-cold eppendorf and proteins were aliquoted and stored at - 
20°C.
2.5.7- Membrane preparation
Membrane proteins were extracted from cells for performing the GTPyS-binding 
assay.
After overnight staiwation in serum-free medium, cells were washed with PBS, 
scraped in 20mM Hepes, ImM EDTA, 50mM NaCl (pH 7.5) and homogenised with 
a pastette,
A first centrifugation at l,000g for 5 min was performed to remove cell debris and 
the supernatant was further centrifuged at 40,000g for 1 hour at 4°C. Pellet was
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resuspended in ice-cold 50mM Hepes, 2mM EDTA, lOOmM NaCl, ImM MgCE and 
aliquots were stored at -80°C.
2.5.8- Protein assay quantification
Protein concentration was measured using the dye-binding assay of Bradford. 
Bradford reagent (Biorad) was diluted five fold in H2O (1 part Bradford reagent:4 
parts H2O) and diluted reagent was filtered through a 0.2pM filtration unit.
A standard curve was prepared using a serial dilution series (31.25ng/pl to 250ng/pl) 
of a bovine serum albumine sample.
In a 96-well plate, 200pl of diluted reagent was added in duplicates to each protein 
standard and each protein sample (usually diluted 1/10 in H2O). Absorption was 
measured after 10 minutes at a wavelength of 595nm using a spectrophotometer.
2.5.9- Western Blot
2.5.9.1- Polyacrylamide gel electrophoresis
Proteins were analysed using dissociating, discontinuous SDS-PAGE. 
Electrophoresis was carried out in mini separating precast 10% (w/v) Tris-HCl gels 
containing a 10% (w/v) resolving gel and a 4% (w/v) stacking gel in BIO-RAD Mini 
Protean III gel apparatus. 0.75mm thick mini gels with 10 and 15 wells were used. 
Protein samples were mixed with 3X SDS-PAGE loading buffer or 5X SDS-PAGE 
loading buffer, boiled for 5 minutes at 100°C and subjected to electrophoresis in IX 
SDS-PAGE running buffer at 70mA with maximum voltage for 1 hours to 3 hours, 
depending on the protein samples to be separated. 6pg of kaleidoscope prestained 
protein standards (BIO-RAD) were subjected to electrophoresis as protein size 
markers.
2.5.9.2- Western blotting
Proteins resolved by SDS-PAGE were transferred onto polyvinylidene difluoride 
(PVDF) membrane for western analysis.
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Polyacrylamide gels and filter paper were equilibrated in western blot transfer buffer 
(20mM Tris, 150mM glycine, 20% (v/v) methanol) for 15 minutes. PVDF membrane 
was wetted in methanol and also equilibrated in transfer buffer for 15min. The 
blotting apparatus was then sandwiched together and placed in a tank of cold transfer 
buffer with a block of frozen transfer buffer to facilitate keeping the unit cool. lOOv 
were passed through for 1 hour 30 minutes and membranes were used immediately 
for western analysis
2.5,9.3- Immimodetection
Proteins resolved by SDS-PAGE and transferred onto PVDF membranes were 
analysed by immunodetection. PVDF membranes were rinsed in IX TBS then 
blocked in blocking buffer (IX  TBS/0.1% (v/v) tween 20/5% (w/v) skimmed milk 
powder) at room temperature for 1 hour. The blocking solution was discarded and 
the membranes were washed 5 times for 5 minutes in IX TBS/0.1% (v/v) tween 20 
at room temperature. The primary antibody was diluted to the optimum concentration 
(either recommended by manufacturer or previously determined experimentally, see 
Table 2.7) in 5 or 10ml of IX TBS/0.1% (v/v) tween 20/1% (w/v) skimmed milk 
powder per 8.6x6.8cm^ membrane. Diluted antibody was added to the membrane and 
incubated at room temperature for 1 hour or overnight at 4°C. The membranes were 
washed again in IX  TBS/0.1 (v/v) tween 20. The secondary HRP-conjugated 
antibody was optimally diluted (Table 2.6) in 10ml of IX TBS/0.1% (v/v) tween 
20/1% (w/v) skimmed milk powder per 8.6x6.8cm^ membrane. The diluted 
secondary antibody was added and incubated at room temperature for 1 hour. The IX  
TBS/0.1 (v/v) tween 20 washes at room temperature were repeated as before. 
Detection reagents from the ECL™ Plus western analysis system (GE Healthcare, 
formerly Amersham Biosciences) were used according to the manufacturer’s 
protocol to detect the signal produced by the antigen-antibody-antibody interactions. 
Detection reagents A and B were equilibrated at room temperature and mixed (50pi 
of reagent B with 2ml of reagent A) so that the final volume was 0.03 5ml/cm^ of 
membrane. The membranes were covered with the detection solution for 5 minutes at 
room temperature and after removal of excess solution they were sealed in cling film 
wrap and exposed to autoradiographic film for 10 seconds to 1 hour.
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Supersignal west femto maximum sensitivity substrate (Pierce Biotechnology) was 
tried as an alternative to the ECL™ Plus western analysis system. Working solution 
(0.1ml per cm^ of membrane) of substrate for detecting HRP on immunoblots was 
prepared by mixing equal parts of the stable peroxide solution and the 
luminol/enhancer solution. Membranes were covered with the detection solution for 
5 minutes at room temperature, drained, sealed in cling film wrap and exposed to 
autoradiographic film for the appropriate time.
Antibody Dilution Incubation
Rabbit anti-actin 1:1000 Overnight, 4°C
Mouse phospho- 1:2000 Overnight, 4°C
SAPK/JNK
Actin HRP-linked 1:1000 1 hour, room temperature
Anti-FLAG HRP-linked 1:5000 1 hour, room temperature
Anti-mouse HRP-linked 1:1000 1 hour, room temperature
Anti-rabbit HRP-linked 1:2000 1 hour, room temperature
Table 2.7. Dilutions and conditions o f use o f antibodies for western blottings 
2.5.9.4- Autoradiogi^aphy
Membranes from western analyses were sealed in cling film wrap and exposed to X- 
ray film in cassettes containing intensifying screens. PVDF membranes were 
incubated from 10 seconds to 30 minutes at room temperature. The autoradiographic 
film was developed using an automatic developer (Hyperprocessor, Amersham Life 
science).
2.5.10- Enzyme-linked immunosorbent assay (ELISA)
A Phospho-SAPK/JNK (Thrl83/Tyrl85) Sandwich ELISA Kit (Cell Signalling 
Technologies) was used for measuring INK activation in protein samples.
In this assay, microwells have been coated with a SAPK/INK Mouse antibody. After 
incubation with cell lysates (extracted with the cell lysis buffer provided with the 
kit), the coated antibody captures both non phospho- and phospho-SAPK/FNK 
proteins. Following extensive washing, a phospho-SAPK/FNK antibody is added to 
detect the captured phospho-SAPK/FNK protein. HRP-linked anti-rabbit antibody is 
then used to recognise the bound detection antibody and an HRP substrate.
9 1
tetramethylbenzidine (TMB), is added to develop colour. The magnitude of optical 
density for this developed colour is proportional to the quantity of phospho- 
SAPK/FNK protein.
For this assay, 20pg protein was used in duplicate and the first incubation of the 
sample in coated microwells was performed overnight at 4°C. The assay was 
performed according to the manufacturer’s protocol and consists of a series of 
incubations and extensive washings with the appropriate provided buffers. The 
optical density of the developed colour was measured at 450nm (using a 
spectrophotometer) within 5 minutes after the addition of STOP solution.
2.5.11- Immunoprécipitation
Immunoprécipitation was used for isolating proteins that complex with KIAA1189 
and therefore potentially interact with it. The N-terminal FLAG tag cloned in fusion 
with KIAA1189 allowed affinity purification and immunoprécipitation of the 
complex using a highly specific antibody.
FLAG M2 immunoprécipitation was performed using a dedicated kit (Sigma- 
Aldrich) following the manufacturer’s protocol. Briefly, FLAG-KIAAll89- 
overexpressing cells were rinsed with PBS and lysed. After centrifugation, the 
supernatant consisting of proteins was transferred to a chilled tube and stored at - 
80°C if not used straight away.
Anti-FLAG M2 agarose affinity gel (40pi per reaction) was thoroughly resuspended 
and the resin was washed twice with 0.5ml wash buffer. In order to remove any 
traces of unbound ANTI-FLAG antibody from the resin suspension, the resin was 
washed once with 0.5 ml elution buffer before to be washed again three times with 
0.5ml wash buffer.
Cell lysate was added to the resin and final volume was brought up to 1ml with lysis 
buffer. For the positive control, 200ng of a FLAG-tagged bacterial alkaline 
phosphatase (FLAG-BAP) control protein (provided) was added to the resin; for the 
negative control I ml of lysis buffer with no protein was added to the washed resin. 
Samples were agitated using a circular rotor overnight at 4°C.
The resin was briefly centrifuged and then washed three times with 0.5ml of wash 
buffer carefully removing all the supernatant each time.
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Elution was performed under native conditions by a competition with a 3X FLAG 
peptide (provided). 100pi of elution buffer containing 150ng/pl 3X FLAG peptide 
were added to the resin in each test tube. Samples and controls were incubated with 
gentle shaking for 30 minutes at 4°C. The resin was then centrifuged and 
supernatants containing protein complexes were transferred to fresh test tubes. 
Subsequent detection of proteins was performed by loading samples on an SDS- 
PAGE gel and immunoblotting with specific antibodies (anti-FLAG M2 antibody for 
the positive control).
2.5.12- Immunofluorescence
Indirect immunofluorescence was used to investigate endogenous or exogenous 
protein expression in different cell types.
Prior to the experiment, 13mm diameter coverslips were placed in 12- or 6-well 
plates and coated with poly-D-lysine by adding diluted poly-D-lysine for 10 min, 
washing with water, then air drying. Cells were grown on these coverslips as usual.
On the day of the experiment, cells were brought to room temperature, washed with 
PBS and fixed with 4% (w/v) paraformaldehyde for 10 minutes at room temperature. 
After three 5 minutes washes with PBS, cells were permeabilised for 5 minutes with 
0.5% (v/v) Triton X-100 in PBS and washed again with PBS
Non-specific adsorption of the antibodies to the coverslip was prevented by first 
covering the coverslips with blocking buffer (0.1% (v/v) Triton X-100 in PBS with 
1% (w/v) BSA) for 1 hour at room temperature.
After three 5 minutes washes with PBS, 10-50pl of primary antibody (diluted in 
blocking buffer) was applied on each coverslip and incubated for 1 hour at room 
temperature or overnight at 4°C. For double immunofluorescence procedures, cells 
were incubated simultaneously with two separate primary antibodies (in this case, the 
antibodies must be monospecific and raised in different species). The concentration 
of antibody to be used depends on the affinity of the antibody and the abundance of 
the antigen. Concentrations and incubation conditions of all the antibodies used are 
listed in table 2.8.
Coverslips were washed three times 5 minutes with PBS before being incubated with 
secondary antibodies conjugated to a fluorochrome, depending on the donor species 
of the primary antibody. Cross-adsorbed and affinity-purified secondary antibodies
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were used to minimise background, cross reactivity (in double immunofluorescence 
protocols) and non-specific reactivity from the secondary antibodies. Again, 
secondary antibodies were diluted in blocking buffer to the appropriate concentration 
and coverslips were incubated with diluted antibodies for 1 hour at room 
temperature.
In some cases, coverslips (washed three times 5 minutes with PBS) were incubated 
with 166nM Alexa Fluor® 488 phalloidin (in PBS) for 20 minutes at room 
temperature to label F-actin.
Finally, 4',6-dlamidino-2-phenylindole (DAPI) was used for staining cell nuclei; 
after further washings, coverslips were covered with a 300nM DAPI solution and 
incubated for 5 minutes at room temperature.
Coverslips were washed extensively with PBS, rinsed once with water and each 
coverslip was inverted onto a slide containing lOpl of mounting media (Vectashield, 
Vector Labs).
The edges of each coverslip were sealed with regular transparent nail polish and 
allowed to dry for 5 minutes to provide semi-permanent preparations.
Observation was done using a Nikon microscope equipped with filters for DAPI and 
for emission at 488 and 596nm.
Antibody________________Dilution_________________ Incubation_____________
Mouse monoclonal anti- 1:2000 1 hour, room temperature
FLAG M2
Rabbit polyclonal anti- Add 200pl 50/50 1 hour, room temperature
(pan)-actin Gly/H20 MilliQ and use
1:200
Rabbit polyclonal anti- 2pg/ml 1 hour, room temperature
(pan)-cadherin
Rabbit polyclonal to 1:1000 Overnight, 4°C
MAP2
Rabbit polyclonal to 1:300 Overnight, 4°C
GAP43
Polyclonal anti-rabbit 1:200 1 hour, room temperature
IgGs conjugated with 
Alexa Fluor® 488
Polyclonal anti-mouse 1:400 1 hour, room temperature
IgGs conjugated with
Alexa Fluor® 596__________________________________________________________
Table 2.8. Dilutions and conditions o f usage o f antibodies for immunofluorescence
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2.5.13- Neurite outgrowth assay
A potential role of KIAA1189 in neurite extension was investigated using PC12 cells 
overexpressing KIAA1189 and undergoing NGF-induced differentiation.
Prior to the experiment, 13mm diameter coverslips were placed in 12-well plates and 
coated with collagen (rat tail collagen I, Upstate) by covering the surface of the 
coverslips with lOpg/cm^ of collagen I diluted in PBS and incubating for 30 minutes 
at room temperature.
PC 12 cells were grown on these coverslips as usual and co-transfected with either the 
FLAG-KIAAl 189 construct or the empty pcDNA3.1 -FLAG expression vector 
together with GFP (pcDNA3.1/NT-GFP, Invitrogen) using Lipofectamine® 2000 
reagent (section 2.5.4.2). The molar ratio of FLAG-KIAAl 189 or FLAG alone to 
GFP construct was 4:1. One day after transfection, the medium was replaced for cell 
differentiation medium. Six days after differentiation, cells were fixed with 4% (w/v) 
paraformaldehyde and permeabilised with 0.5% triton X-100, followed by nuclear 
counterstaining with DAPI (section 2.5.12). GFP epifluorescence was used as a 
marker for cell morphology. Cell images were captured using a confocal microscope.
Because manual examination of cell morphology is quite a subjective method for 
measuring neurite outgrowth, a neurite outgrowth quantification assay kit 
(Chemicon) was used for semi-quantitatively evaluating neurite extension in 
differentiated KIAA1189-overexpressing PC12 cells in comparison with 
differentiated PC 12 cells transfected with the empty pcDNA3.1-FLAG vector.
Prior to initiation of neurite outgrowth assay, membranes on underside of chambers 
were coated with collagen I by adding each insert into a well of a 24-well plate 
containing 500pi of lOpg/ml collagen I and incubating for 2 hours at 37°C. In the 
meantime, PC 12 cells were removed from culture flasks using trypsin, a cell viability 
assay was performed using trypan blue and the cells were resuspended in non- 
differentiating medium at 0.5x10^ cells/ml. Subsequently, each membrane was 
removed from collagen I coating solution, placed into a well of a 24-well plate 
containing 500pl non-differentiation medium and a cell suspension volume of lOOpl 
was added on top of membrane (upper chamber).
One day after plating, PC 12 cells were transfected with either the FLAG-KIAAl 189 
construct or the empty pcDNA3.1-FLAG expression vector using Lipofectamine®
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2000 reagent (reaction detailed in chapter 2.5.4.2 was scaled down to the surface of 
the membrane).
One day after transfection, differentiation was initiated by adding 100ng/|,il NGF to 
the medium and neurites were allowed to extend to the lower chamber for 1 to 7 days 
at 37°C.
2.5.14- GTPyS binding
The GTPyS binding protocol detailed below was adapted from (Im et a l 2000) and 
required optimisation to obtain reproducible results.
25pg of membranes from native SK-N-SH cells or EDG2 DNA stably transfected 
SK-N-SH cells were incubated in 1.0ml of GTP-binding buffer (50mM Hepes, 
lOOmM NaCl, lOmM MgClz, pH 7.5) containing 25pg saponin, lOpM GDP, 0.1 nM 
[y-^^S]GTP (specific activity> 1 OOOCi/mmol) and O.lnm-lOpM LPA for 30 minutes 
at 30°C.
Bound GTPyS was separated from unbound using a cell harvester (Brandel Research 
and Development Laboratories) and GF/B filters were washed three times with 
20mM Tris, 120mM NaCl, 25mM MgCE. Filters were immersed in 5ml scintillation 
solution (Ecoscint A, National Diagnostics) and radioactivity was counted by liquid 
scintillation spectrometry.
For data analysis, background filter counts, i.e. residual radioactivity bound to the 
filter in the absence of membrane, were subtracted from each sample count and the 
data were normalised to the maximal binding displayed by SK-N-SH cells when 
stimulated with the highest dose of LPA.
Dose-response curves were plotted and analysed by non-linear regression analysis 
with a sigmoidal dose-response curve fitting (GraphPad Prism).
Percentage of increase in binding above basal was calculated to give a measure of 
efficacy (E^ax).
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2.6- In situ hybridisation
Radioactive semi-quantitative in situ hybridisation was used to assess differential 
expression of candidate genes in brain sections from PCP-treated rats compared to 
vehicle-treated controls.
2.6.1- Probe design
45-mer oligonucleotide probes of unique sequence were designed and aligned against 
the whole genome to check gene specificity. HPLC-pure oligonucleotides were 
synthesised by Sigma-Genosys.
The probe sequences are listed in table 2.9.
Probe_________ Sequence__________________________________________________
E SI -  2as GACAAGGAGGTTCTTTATTTAACAGCAGGTAGGTAGGTTGATAAT
Edg2 -  3 as GACACAAGCCACACCCTGCCTTTCCTCCTCCCC AGAATGCCACTC
Q9ULN1 -  2as TCAGTTGTCTTCCTGGTTTGACTGCTAGGCTGTTGGCCATTCTCA
Table 2.9. Sequences o f  probes usedfor in situ hybridisation
2.6.2- Oligonucleotide labelling
The probes were 3’end-labelled with a-[^^S]dATP (specific activity 1250Ci 
(46.2TBq)/mmol)) using Terminal Transferase enzyme (Roche). In a sterile 
eppendorf, the following solutions were mixed together: 2pi DEPC water, 0.9X TdT 
tailing buffer (Boehringer Ingelheim), 0.6pl CoC12, 0.6pmol oligonucleotide, 2.5pi 
[a-[^^S]dATP] and 2pi TdT enzyme. The reaction mixture was incubated in a water 
bath for 1 hour at 37°C. The reaction was inhibited by the addition of 60pi DEPC- 
treated water. Labelled oligonucleotides were purified by using QIAquick™ 
Nucleotide Removal kit (Qiagen) according to the manufacturer’s protocol. 2pi of 
final eluate containing the labelled probe was analysed by liquid scintillation. Probes 
with an activity of between 100,000 and 300,000 DPM/pl were considered to be 
successfully labelled. Subsequently 20mM DTT was added to the probe, which was 
then stored at -20°C until required.
Oligonucleotides that were successfully labelled were hybridised against test sections 
as outlined in section 2.6.4 to check for specificity and determine the level of
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background binding of the probe. This also enabled us to evaluate the time needed to 
get a measurable signal, strong enough to quantify gene expression and to compare 
PCP-treated rats and controls.
2.6.3- Slide preparation and fixation (Sandie MacGregor)
Collection and preparation of coronal sections was performed by Sandie MacGregor. 
Briefly, 10pm coronal sections were cut on a cryostat at -20°C (Leica) and collected 
onto poly-L-lysine-coated slides. Sections were obtained from the following bregma 
levels according to Paxinos (Paxinos 1998). 3.20mm (medial frontal cortex); 1.60mm 
(nucleus accumbens / striatum); -1.40mm (anterior thalamus); -2.30mm (midline 
thalamus); -4.80mm (hippocampus). Sections were air dried at room temperature, 
and once dry, they were fixed in freshly prepared, ice-cold, 4% (w/v) 
paraformadehyde in phosphate-buffered saline (PBS) for 5 min. After rinsing in PBS 
for 5min, the sections were dehydrated by consecutive 5 min immersions in 70 % 
(v/v), 95% (v/v) and 100% ethanol.
For investigating region-specific gene expression changes between PCP-treated rats 
and controls, one set of sections representing the five layers of the PFC and 
corresponding to 16 PCP-treated animals and 16 control animals was used per gene.
2.6.4- Hybridisation and controls
In situ hybridisation was performed according to the methodology of Wisden and 
Moms (2002). Briefly, sections were removed from the fridge and allowed to air dry 
for about 30 minutes. Hybridisation mixture was prepared for experimental sections 
by adding 4pi labelled probe and 16pl IM DTT to 200pl hybridisation buffer (Ix  
SSC, 25ml deionised formamide, 1.25mmol sodium phosphate, 50pmol sodium 
pyrophosphate, 5mg polyadenylic acid, 5g dextran sulphate) per experimental slide. 
For control sections, a 4 fold excess of cold oligonucleotide {i.e. 16pl unlabelled 
probe) was added to the hybridisation mixture. Slides were placed in petri dishes 
with tissue soaked in 4X SSC to prevent the sections diying out, and 200pl of well- 
mixed hybridisation mixture was applied to each slide. The slides were then covered 
with parafilm for allowing spreading the mixture so that it covers all the sections and
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potential air bubbles were eliminated by gently pressing parafilm. Petri dishes were 
sealed with parafilm and placed in the incubator at 42°C overnight.
2.6.5- Washings
Parafilm coverslips were removed in Ix SSC at room temperature and slides were 
transferred into Ix SSC prewarmed at 60°C and incubated with gentle agitation for 
about 30 minutes. Sections were then transferred through a series of washes, 
IX  SSC, O.IX SSC, 70% ethanol and 95% ethanol at room temperature for 
approximately 20 seconds each, agitating slightly. Sections were allowed to dry for 
about 30 minutes and slides were placed in X-ray cassettes and exposed to Biomax™ 
MR film (Kodak) for between 1-6 weeks.
2.6.6- Film development and image analysis
Films were developed after an appropriate time using an automatic developer 
(Hyperprocessor, Amersham Life science).The films were analysed using computer- 
based densitometry (MCID 5). Brain regions identified were anatomically defined as 
outlined in a rat brain atlas (Praxinos and Watson, 1998). Bilateral relative optical 
density measurements were taken in discrete brain sections from duplicate sections 
from each animal (n=16 per treatment group). The results were analysed using 
individual t-tests for each brain region to assess the differential expression of the 
genes after PCP treatment. Statistical significance was defined as p < 0.05.
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CHAPTERS: IDENTIFICATION, SELECTION 
AND VALIDATION 
OF DIFFERENTIALLY EXPRESSED GENES
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3.1- Introduction
A global transcriptome screen to identify differentially expressed novel psychosis- 
related genes was performed in our laboratory utilising a phencyclidine (PCP) model 
of schizophrenia and rat oligonucleotide GeneChips® (rat genome U34 set) from 
Affymetrix (data provided by Catherine Winchester). In summary, rats (n=6 per 
group) were treated chronically with PCP or vehicle according to the regime 
described in Cochran et a l  (2003). The PFC was dissected and total RNA extracted 
using the RNeasy Miniprep Kit (Qiagen). Biotin-fluorescein labelled cDNA was 
synthesised according to the Affymetrix protocol and hybridised to RG- 
U34 A, B and C GeneChips®. Pre-processing (background correction, normalisation, 
combination of probe set data into a single expression measurement and log2 
transformation) of the GeneChip® data was performed using RMA (Robust Multi- 
Array Average Expression Measure, Bioconductor) and Significance Analysis of 
Microarrays (SAM) was used to perform a high-level statistical analysis of the 
normalised GeneChip® data to identify differentially expressed probe sets. After 
stringent normalisation and rigorous statistical analyses, 118 differentially expressed 
probe sets were identified from the RGU34A GeneChip® data and 209 differentially 
expressed probe sets were identified from the RGU34B and C GeneChip® data. The 
microarray study allowed genes and also expressed sequence tags (ESTs) that have 
the potential to represent novel and uncharacterised genes to be screened.
The initial aim of this project was to identify genes from the differentially expressed 
probe sets representing ESTs from the RG-U34B and RG-U34C GeneChip® data. A 
thorough DNA sequence homology screen strategy was used for identifying genes 
and ESTs from the Affymetrix probe set IDs. Data mining tools were used to 
determine their potential functional significance with relation to schizophrenia. On 
this basis, a small number of candidate genes were selected for confirmation by real­
time PCR and in situ hybridisation.
1 0 1
3.2- Bioinformatics: homology screening to identify genes and ESTs
Lack of transcriptome information necessitated a DNA sequence homology screen in 
order to identify genes from 209 differentially expressed probe sets from the RG- 
U34B and RG-U34C GeneChip® data, representing ESTs. A comprehensive and 
thorough manual DNA sequence homology screen (against rat, mouse and human 
databases) was undertaken to identify a homologous gene for each differentially 
expressed rat probe set. Although this process was quite subjective, putative 
identified genes were ranked by decreasing confidence depending mostly on the 
degree of sequence identity of each probe set with different databases. 
Figures 3.1, A-C show representative examples of homology screens of three 
differentially expressed probe sets giving confident, uncertain and unsuccessful 
conversion into rat genes, respectively.
This rigorous analysis initially enabled the confident identification of 66 genes from 
the 209 differentially expressed EST probe sets (Appendix B) while extreme caution 
was preferred for the remaining majority of the ESTs (68% of the differentially 
expressed probe sets), considered as anonymous pieces of transcribed sequence.
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c.
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Figure 3.1, A-C. Examples o f homology screens allowing confident, uncertain and 
unsuccessfid conversion into rat genes (respectively)
In each case the consensus sequence retrieved from NetAffx™ website was aligned 
at ENSEMBL against rat, mouse and human cDNA and/or genomic databases. 
Figures give the results of these alignments in terms of length and percentage of 
sequence identity and show screenshots of ENSEMBL “contig views” showing the 
regions of the chromosomes around the BLAST hits.
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In A, the consensus sequence was found to align well with rat, mouse and cDNA 
databases, identifying orthologues of the same rat gene, Edg2, across species.
In B, alignment of the consensus sequence with rat cDNA was insufficient to identify 
any rat gene, whereas good alignment with the rat genomic sequence favoured the 
identification of a gene called D ynclhl. However, this hypothesis was not confirmed 
by BLAST against mouse and human cDNA or genomic databases (neither mouse 
Slc2a3 nor any of the potentially identified human genes is an orthologue of 
D ynclhl), casting doubt on the hypothesis that D ynclhl was the rat gene detected by 
this probe set
In C, alignments of the consensus sequence against rat, mouse and human cDNA 
databases were all insufficient to identify any gene. The consensus sequence aligned 
reasonably with anti sense rat and mouse genomic sequence located around potential 
transcripts; however, the genes identified in both species were not respective 
orthologues suggesting that the alignments were not genuine.
The homology screen was repeated as the databases are regularly updated and 
especially after the completion of the first draft of the rat genome sequence in 
February 2004. The most recent analysis identified 119 genes from the 209 
differentially expressed probe sets thereby revealing additional genes that had 
remained anonymous in the initial analysis.
In summary, bioinformatics analysis of 209 differentially expressed probe sets 
resulted in the identification of 119 rat genes, rat genomic loci, human orthologous 
genes and their genomic loci (Appendix B).
3.3- Data mining for selecting candidate genes
Data mining analysis of the human genes, orthologues of the 119 differentially 
expressed rat genes was performed using open-access tools (Genecards®, Harvester) 
to retrieve genomic, transcriptomic and functional information potentially relevant 
for assessing the interest of investigating the genes in relation with schizophrenia. 
This information is shown in Appendix B.
The initial 66 differentially expressed genes were classified into different categories 
thereby providing a “snapshot” of the function of the genes and of the biological 
processes affected in the PCP model of schizophrenia (table 3.1).
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Function Number of genes
Transcription regulators 9
Signalling molecules 9
Cytoskeletal architecture 4
Receptors 4
Metabolism 4
Electron transport 3
Protein transport 2
RNA-binding 4
Mitochondrial 2
Anti sense to a known gene 3
Unrelated function 22
Table 3.1. Initial functional classification of 66 identified ti^anscripts
All retrieved information was also analysed in the context of schizophrenia to map 
the genes with well-supported regions linked to schizophrenia and investigate their 
functional relevance with schizophrenia itself and neuropsychopathology in general. 
Published gene expression (including microarray studies on human post-mortem 
tissue) data and previous association with schizophrenia were considered as well as 
fold changes of the differentially expressed ESTs in the microarray on the rat PCP 
model. Interestingly, it is worth mentioning here that 8/66 genes {Fhnl, Sec6S, Rac2, 
Ppplr9b, Pik4ch, HistlhAj, Q8wyq3, NM_016274 and ClOorp) were found to have 
human orthologues that are located at well-supported chromosomal regions linked to 
schizophrenia (Appendix B).
All this information together with the subjective appreciation of their suitability as 
drug targets, were used as criteria for selecting a small number of candidate genes to 
validate and characterise.
Two genes and one EST were selected as candidates for further validation and 
characterisation. Edg2, a G-protein coupled receptor that had been linked with 
schizophrenic-like behaviour (Harrison et a l, 2003) was selected as well as Tm.4sfI2 
(tetraspanin 12), a membrane protein potentially important in oligodendrocytes 
signalling. Interestingly, both of these genes presented relatively high fold changes 
(> 20%) compared to most significantly differentially expressed probe sets from this 
study, whose fold changes were less than ± 20%.
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Following the same criteria and partly because it displayed the highest fold change 
among the RG-U34B and RG-U34C differentially expressed probe sets, one EST 
(rc_AI072720_at), which may or may not represent a genuine transcript, known or 
predicted gene, was selected for further validation and characterisation.
3.3.1-Er/^2: data mining and reasons for selection
Edg2 was selected based on several factors, including its fold change in the rat 
microarray (>20% increase in the rat prefrontal cortex after chronic PCP treatment), 
the fact that it was a G-protein coupled receptor and therefore an obvious potential 
drug target and evidence showing that Edg2 knock-out mice displayed 
schizophrenic-like behaviour (Harrison et a l  2003).
Edg2 (endothelial differentiation receptor 2), which is also called LPAl 
(lysophosphatidic acid receptor 1), is a G-protein coupled receptor for 
lysophosphatidic acid (Hecht et a l  1996; An et a l  1997), a lipid growth factor which 
causes various cellular events, including modulation of cell growth, differentiation, 
proliferation and migration as well as apoptotic and cytoskeletal effects (Handford et 
a l 2001; Yoshida and Ueda 2001). Edg2 is widely expressed in human tissues with 
highest abundance in the brain (An et a l  1997) where its expression was shown to be 
temporally and spatially restricted, both during development and in the adult (Hecht 
et a l 1996). In particular, its embryonic expression profile suggests a potential role 
for Edg2 in neurogenesis or neuroblast migration during development which is 
supported by in vitro studies showing Edg2-mediated morphological changes in 
neuroblasts (Contos et a l  2000a; Fukushima et a l  2000). Moreover, since Edg2 
expression reemerges in myelinating glia of the postnatal nervous system and follows 
the pattern of myelination in the early postnatal brain (Allard et al. 1998; Handford et 
a l  2001), it has been suggested to play a role in the control of myelination, a role 
which implicates this receptor in several psychiatric disorders (such as 
schizophrenia) suggested to have a developmental origin. In this context, Edg2 
knock-out mice were generated by two different groups who interestingly reported 
different phenotypes. Whereas Contos et a l  (2000a) showed that these mice had 
deficits in suckling behaviour resulting in high neonatal lethality, Harrison e/ al 
(2003) did indeed show thdiiEdg2 receptor-deficient mice displayed a schizophrenic­
like phenotype with deficits in prepulse inhibition, widespread changes in the levels
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and turnover of the neurotransmitter 5-HT and alterations in levels of amino acids. 
Moreover, the targeted deletion of Edg2 in the mice generated by Harrison et a l  
(2003) has since been shown to produce a number of changes in neurotransmitters 
(tyrosine, aspartate, glutamate, GAB A) that have been associated with a 
schizophrenic-like pathology (Roberts e ta l  2005).
In conclusion, the data generated by Edg2 knock-out studies therefore provided 
further evidence that Edg2 may be an interesting candidate (and maybe a potential 
drug target) to investigate in relation with schizophrenia.
3.3.2- Tm4sfl2: data mining and reasons for selection
Interest in Tm4sfl2, tetraspanin 12, mainly arose from its potential function and 
from its cellular localisation at the plasma membrane, which made it a potential 
target for designing new drugs. Moreover, tetraspanin 12 had shown an increased 
expression of 20% in the rat prefrontal cortex after chronic PCP treatment, which 
was a notably high fold change by comparison with all the fold changes of 
differentially-expressed genes in this microarray. Like all members of the tetraspanin 
superfamily, tetraspanin 12 protein has four transmembrane domains delimiting two 
extracellular loops (Serru et a l  2000). However, contrary to others, it appears to be 
specifically expressed in the central nervous system where its mRNA is detectable 
shortly after birth and increases in level until the period of active myelination 
(Birling et a l 1999). Moreover, there is evidence of its specific expression in cells of 
the oligodendrocyte lineage which suggests that tetraspanin 12 may play a role in 
signalling in oligodendrocytes in the early stages of their terminal differentiation into 
myelin-forming glia (Bronstein 2000).
Tetraspanin 12 function and its altered expression in the chronic PCP model may 
therefore be related to white matter changes and evidence of altered myelination in 
schizophrenia (Davis et a l  2003; Kubicki et a l  2005; Mclnnes and Lauriat 2006). 
On this basis and because very little else was known about its function, it was 
selected as a candidate gene to validate and characterise in relation with 
schizophrenia.
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3.3.3“ EST AI072720: data mining and reasons for selection
The last candidate selected was the EST AI072720, which had shown the highest 
fold change of all differentially expressed RGU34B and C probe sets. Indeed, this 
EST had shown a 46% increase in expression in the rat prefrontal cortex after 
chronic PCP treatment, which was considered as a very large fold change since most 
changes were less than 20%. Moreover, although homology screening of the 
rc_AI072720_at probe set against genomic and cDNA databases had not allowed the 
definite identification of its homologous gene, the bioinformatics analyses had 
provided intriguing evidence that the EST AI072720 may correspond to a novel gene 
which was predicted to have a carboxy-terminal ezrin-radixin-moesin (ERM) 
domain. Since this domain is assumed to bind F-actin and in the light of the critical 
role of actin in cellular architecture, neuronal morphogenesis and synaptic plasticity 
(Luo 2002), such a gene may be related to the cytoskeletal alterations found in 
schizophrenia which have been proposed to represent the molecular origin of 
alterations in synaptic connectivity in this disorder (Harrison 1999; Benitez-Ring et 
a l  2004; Rapoport et al. 2005). Hence this gene could potentially represent a novel 
therapeutic target in schizophrenia (Benitez-Ring et a l  2004).
The EST AI072720 was thus selected on the basis of fold change, novelty and its 
potential function.
The data mining evidence used to select these 3 genes is summarised in table 3.2.
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Gene GeneChip % change
Edg2
(lysophosphatidic acid
G-protein-coupled
receptor)
71 28%
(RGU34C chip)
May play a role in modulating cell 
mobility.
Knock-out mice show neurochemical 
and prepulse inhibition (PPI) deficits. 
Attractive drug target ?
Tm4sfl2
(transmembrane 4 
superfamily member 
tetraspan net-2)
71 20%
(RGU34C chip)
Expression restricted to the CNS. 
May play a role in signalling in 
oligodendrocytes and may also 
function in stabilising myelin sheath.
EST AI072720 71 46%
(RGU34C chip)
Homologous gene not definitively 
identified.
Highest fold change from RG-U34B 
and RG-U34C differentially expressed 
probe sets.
Putative protein may contain an ezrin, 
radixin, moesin domain.
Potentially involved in cytoskeletal 
architecture.
Table 3.2. Summary table o f fold changes and information relevant to schizophrenia 
o f the 3 selected candidate genes: Edg2, Tm4sfl2 andEST AI072720
3.4- Confirmation of differential expression of the candidate genes
Despite rigorous statistical analysis, microarray data cannot be exempt from false 
positives, and independent confirmation of the differential expression of candidate 
genes is essential before proceeding to undertake more elaborate characterisation 
experiments on them.
Quantitative real-time PCR (qRT-PCR) (section 2.4.5) and semi-quantitative in situ 
hybridisation (section 2.6), two methods that are commonly used for quantifying 
RNA, were used to this end.
For each gene, rat and human qRT-PCRs were performed, respectively in a set of 
cDNA samples prepared from the prefrontal cortex of rats that had been 
independently chronically treated with PCP and in cDNA samples prepared from 
post-mortem tissue (dorso-lateral prefrontal cortex) from schizophrenic patients and
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controls (section 2.2.1). Results were analysed by ANCOVA using respective 
appropriate housekeeping genes as covariates (Bond el al. 2002).
In situ hybridisation was performed on brain sections from PCP-treated and vehicle- 
treated (controls) animals. Results were analysed using individual t-tests for each 
brain region to assess the differential expression of the genes after chronic PCP 
treatment.
3.4.1- Edg2
Using qRT-PCR, Edg2 was found to show statistically significant differential 
expression after chronic PCP treatment in the rat prefrontal cortex. The qRT-PCR 
assays were repeated and the results were confirmed (1®‘ time p=0.044, +19.3%, not 
shown ; 2"  ^ time p=0.033, +29.7%, figure 3.2). Moreover, increased expression of 
Edg2 after chronic PCP treatment was consistent with the microarray data.
Edg2 qRT-PCR 
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Figure 3.2. Regression lines for rat Edg2 qRT-PCR
qRT-PCR was performed to evaluate Edg2 expression changes in the rat prefrontal 
cortex after chronic PCP treatment by comparison with a vehicle (saline solution) 
(n=6). This graph represents the repeat of this experiment which was performed 
twice. Y-axis is the logarithm of the fluorescence intensity representing the 
expression of Edg2 and X-axis is the logarithm of the fluorescence intensity for beta- 
2-microglobulin (B2m), the internal control gene that was used for normalisation. For 
each gene, the graph plots four points taken from the linear amplification phase of 
the PCR. The data were analysed by ANCOVA, which revealed 29.7% increase in 
Edg2 expression after chronic PCP treatment (p=0.033). Dotted lines illustrate 
elevated In Edg2 signal intensities in PCP-treated rats for a particular In B2m signal.
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A human EDG2 qRT-PCR assay was designed based on the rat Affymetrix target 
sequence to address the issue of isoform-specific differential expression and to 
specifically detect the isoform homologous to the rat Edg2 transcript differentially 
expressed the rat microarray.
However no differential expression of human EDG2 was detected in the entire data 
set (n=9, p=0.262, figure 3.3) or in the individual patient collections (Harvard, Brain- 
Net or UCLA; not shown).
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Figure 3.3. Regression lines for human EDG2 qRT-PCR
qRT-PCR was performed to evaluate EDG2 expression changes in human post­
mortem dorso-lateral prefrontal cortex from schizophrenic patients compared to 
controls (n=9). Y-axis is the logarithm of the fluorescence intensity representing the 
expression of EDG2 and X-axis is the logarithm of the fluorescence intensity for 
glyceraldehyde-2-phosphate dehydrogenase {GAPDH), the internal control gene that 
was used for normalisation. For each gene, the graph plots four points taken from the 
linear amplification phase of the PCR. The data were analysed by ANCOVA, which 
did not reveal any significant change in EDG2 expression in schizophrenic patients
( p = 0 .262).
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In situ hybridisation was employed to investigate the regional expression profile of 
Edg2 mRNA in the rat brain and its potential alteration in response to chronic PCP 
administration (figure 3.4).
Edg2 mRNA was expressed in several brain regions that have been implicated in 
schizophrenic pathology, especially the prefrontal cortex (A), the thalamus and the 
hippocampus (B). Edg2 mRNA expression was highest within white matter tracts 
throughout the brain. The hippocampus displayed the highest mRNA levels within 
grey matter, with lower and homogeneous cortical and sub cortical expression of 
Edg2 mRNA detected.
28 regions of the rat brain were analysed for differential expression of Edg2 
expression : prelimbic cortex (PrL), infralimbic cortex (iL), ventral orbital cortex 
(vO), lateral orbital cortex (10), primary and secondary motor cortices (M l and M2), 
anterior cingulate cortex (acg), granular (rsg) and agranular (rsa) retrosplenial 
cortices, dentate gyrus granule cell layer (DGgcl), pyramidal cell layers of the CAl 
(CAlpcl), CA2 (CA2pcl) and CA3 (C A3 pci) region of the hippocampus, primary 
auditory cortex (Aul), lateral entorhinal cortex (Lent), corpus callosum (cc), genu of 
corpsu callosum (gcc), forceps minor (fmi) and forceps major (fmj) corpus callosum, 
anterior commisure (ac), intrabulbar part of the anterior commisure (aci), external 
(ec) and internal (ic) capsules, cingulum (eg), stria medullaris of the thalamus (sm), 
mammillothalamic tract (mt), fornix (f) and fimbria of hippocampus (fi).
113
* acî /
B
 ^ C A v  , * ■ .^ •
hypotha
Figure ZA. Representative sections illustrating the regional distribution o f Edg2 
mRNA in selected regions o f the rat brain (panels A and B) and control section 
(panel C)
Coronal sections used for Edg2 in situ hybridisation experiments were obtained from 
the following bregma levels according to Paxinos (1998): A. 3.20mm (prefrontal 
cortex), B. -2.30mm (midline thalamus) (Paxinos 1998). Sections were hybridised 
with  ^ S-labelled oligonucleotide probes specific for Edg2 (in presence of an excess 
of unlabelled probe in panel C), exposed to film for 17 days and digitally scanned. 
Dark areas mark the presence of mRNA.
PrL: prelimbic cortex; iL: infralimbic cortex; fmi: forceps minor corpus callosum; 
aci: intrabulbar part of the anterior commisure: cc: corpus callosum; ec: external 
capsule; fr. fimbria of hippocampus; hipp: hippocampus; thal: thalamus; hypothal: 
hypothalamus.
The uniform, non-specific signal shown in panel C) provides confirmation of the 
specificity of the probes used for Edg2 in situ hybridisation studies.
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In situ hybridisation did not show any significant effect of PCP treatment on Edg2 
expression in prefrontal cortical areas unlike the differential expression detected by 
the microarray and by qRT-PCR (figure 3.5) Moreover, there were no significant 
effects of PCP treatment on Edg2 expression in all the regions of the white matter 
analysed (figure 3.5).
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Figure 3.5. Bar graphs for rat Edg2 in situ hybridisation
Results shown are mean ± standard error of the mean (s.e.m.)
n=6 animals for vehicle and PCP-treated rats
A. prelimbic cortex; B. infralimbic cortex; C. corpus callosum
Edg2 mRNA showed a heterogeneous expression profile throughout the rat brain. 
High levels of Edg2 were detected in the white matter consistent with published 
literature (Hecht et al. 1996; Allard et al. 1998; Handford et al. 2001). However, 
Edg2 appears to also be expressed in the cortex as well as in the thalamus and 
hippocampus, key regions implicated in schizophrenic pathology.
No significant changes in Edg2 expression were found in either the prefrontal cortex 
or in the white matter following chronic PCP treatment.
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3.4.2- Tm4sfl2
Differential expression of Tm4sfl2 was not observed in the prefrontal cortex of rats 
treated chronically with PCP when tested by qRT-PCR (figure 3.6).
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Figure 3.6. Regression lines for rat Tm4sfl2 qRT-PCR
qRT-PCR was performed to evaluate Tm4sfl2 expression changes in the rat 
prefrontal cortex after chronic PCP treatment by comparison with a vehicle (saline 
solution) (n=6). This graph represents the first of two experiments. Y-axis is the 
logarithm of the fluorescence intensity representing the expression of Tm4sfl2 and 
X-axis is the logarithm of the fluorescence intensity for beta-2-microglobulin (B2m), 
the internal control gene that was used for normalisation. For each gene, the graph 
plots four points taken from the linear amplification phase of the PCR The data were 
analysed by ANCOVA, which did not reveal any significant change in Tm4sfl2 
expression after chronic PCP treatment (p=0.303). Dotted lines illustrate unchanged 
In Tm4sfl2 signal intensities in PCP-treated rats for a particular In B2m signal.
qRT-PCR was also performed on human TM4SF12 using post-mortem dorso-lateral 
prefrontal cortex from schizophrenic patients and controls but no differential 
expression was observed, analogous to the rat prefrontal cortex (figure 3.7).
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Figure 3.7. Regression lines fo r  human TM4SF12 qRT-PCR
qRT-PCR was performed to evaluate 1M4SF12 expression changes in human post­
mortem dorso-lateral prefrontal cortex from schizophrenic patients compared to 
controls (n=9). Y-axis is the logarithm of the fluorescence intensity representing the 
expression of TM4SF12 and X-axis is the logarithm of the fluorescence intensity for 
glyceraldehyde-3-phosphate dehydrogenase {GAPDH), the internal control gene that 
was used for normalisation. For each gene, the graph plots four points taken from the 
linear amplification phase of the PCR. The data were analysed by ANCOVA, which 
did not reveal any significant change in TM4SF12 expression in schizophrenic 
patients (p=0.449).
All qRT-PCR results were therefore consistent suggesting that Tm4sfl2 differential 
expression in the chronic PCP model (revealed in the microarray) was not genuine or 
was too small to be reliably independently confirmed by other techniques. 
Consequently, in situ hybridisation, which is a semi-quantitative method less 
powerful than qRT-PCR for identifying gene expression changes, was not performed 
on this gene.
3.4.3- EST AI072720
Using qRT-PCR, the EST AI072720 was confirmed as differentially expressed in the 
rat prefrontal cortex after chronic PCP treatment. The rat qRT-PCR assay was 
performed on an independent set of rat prefrontal cortex samples and showed a 
significant upregulation (p<0.05, +16.5%) of the EST AI072720 after chronic PCP 
treatment (figure 3.8) which was consistent with the microarray data.
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Figure 3.8. Regression Unes fo r  rat EST A1072720 qRT-PCR
qRT-PCR was performed to evaluate EST AI072720 expression changes in the rat 
prefrontal cortex after chronic PCP treatment by comparison with a vehicle (saline 
solution) (n=6). This graph represents the repeat of this experiment which was 
performed twice. Y-axis is the logarithm of the fluorescence intensity representing 
the expression of the EST AI072720 and X-axis is the logarithm of the fluorescence 
intensity for beta-2-microglobulin (B2m), the internal control gene that was used for 
normalisation. For each gene, the graph plots four points taken from the linear 
amplification phase of the PCR. The data were analysed by ANCOVA, which 
revealed 16.5% increase in the expression of the EST AI072720 after chronic PCP 
treatment (p=0.04). Dotted lines illustrate elevated \n E S T AI072720 signal 
intensities in PCP-treated rats for a particular In B2m signal.
A human qRT-PCR assay was designed based on the rat Affymetrix target sequence 
to detect the human orthologous region of rat EST AI072720 which was found to 
correspond to the 3’ untranslated region (3’UTR) of a predicted gene called KJAJ189 
(section 5.2).
No differential expression of KIAAI189 expression was observed in human post­
mortem DLPFC from schizophrenic patients, neither in the entire set of patients and 
controls (n=9, p=0.888, figure 3.9) nor in the individual collections of patients 
(Harvard, Brain-Net or UCLA, data not shown).
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Figure 3.9. Regression Unes for human EST AI072720 qRT-PCR
qRT-PCR was performed to evaluate EST AI072720 expression changes in human 
post-mortem dorso-lateral prefrontal cortex from schizophrenic patients compared to 
controls (n=9). Y-axis is the logarithm of the fluorescence intensity representing the 
expression of the EST AI072720 and X-axis is the logarithm of the fluorescence 
intensity for glyceraldehyde-3-phosphate dehydrogenase {GAPDH), the internal 
control gene that was used for normalisation. For each gene, the graph plots four 
points taken from the linear amplification phase of the PCR The data were analysed 
by ANCOVA, which did not reveal any significant change in EST AI07270 
expression in schizophrenic patients (p=0.888).
In situ hybridisation was employed to investigate the regional expression profile of 
EST AI072720 mRNA in the rat brain and its potential alteration in response to 
chronic PCP administration (figure 3.10).
This EST was found to be highly expressed within all major white matter tracts. 
Within cortical and subcortical areas, it was expressed at a much lower level and had 
a homogeneous distribution. Expression was observed within all cortical areas, the 
striatum, thalamus, hypothalamus and hippocampus, with the prefrontal cortex 
appearing to display the lowest level.
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Figure 3.10. Representative sections illustrating the regional distribution o f EST 
AI072720 mRNA in selected regions of the rat brain (panels A and B) and control 
section (panel C)
Coronal sections used for EST AI072720 in situ hybridisation experiments were 
obtained from the following bregma levels according to Paxinos (1998): A) 3.20mm 
(prefrontal cortex), B) -2.30mm (midline thalamus) (Paxinos 1998). Sections were 
hybridised with  ^ S-labelled oligonucelotide probes specific for the EST AI072720 
(in presence of an excess of unlabelled probe in panel C), exposed to film for 
1 month and digitally scanned. Black areas mark the presence of mRNA.
PrL: prelimbic cortex; iL: infralimbic cortex; fmi: forceps minor corpus callosum; 
aci: intrabulbar part of the anterior commisure: cc: corpus callosum; fi: fimbria of 
hippocampus; hipp: hippocampus; thal: thalamus; hypothal : hypothalamus.
The uniform, non-specific signal shown in panel C) provides confirmation of the 
specificity of the probes used for EST AI072720 in situ hybridisation studies.
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16 regions of the rat brain were analysed for differential expression of EST 
AI072721 expression: corpus callosum (cc), genu of corpus callosum (gcc), forceps 
minor (fmi) and forceps major (fmj) corpus callosum, anterior commisure (ac), 
intrabulbar part of the anterior commisure (aci), external capsule (ec), cingulum (eg), 
stria medullaris of the thalamus (sm), fimbria of hippocampus (fi), anterior cingulate 
cortex (acg), granular (rsg) and agranular (rsa) retrosplenial cortex, pyramidal cell 
layers of the CAl (CAlpcl), CA2 (CA2pcl) and CA3 (CA3pcl) region of the 
hippocampus.
No significant change was found in the expression levels of EST AI072720 in any of 
the regions after chronic PCP treatment. However, there was a trend towards 
increased expression of the EST AI072720 in the CA3 pyramidal cell layer of the 
hippocampus after chronic PCP treatment (figure 3.11).
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Figure 3.11. Bar graphs for rat EST AI072720 in situ hybridisation
Results shown are mean ± standard error of the mean (s.e.m.) 
n=6 animals for vehicle and PCP-treated rats 
A. CA3 layer of the hippocampus; B. corpus callosum.
121
3.5- Discussion
The aim of the work described in this chapter was to select a few candidates from the 
genes identified in the rat microarray and to confirm their differential expression 
after chronic PCP treatment by two independent techniques, qRT-PCR and semi- 
quantitative in situ hybridisation.
3.5.1-Identification of differentialiy-expressed genes (DNA homology 
screening)
Thorough bioinformatic analyses of the 209 differentially expressed probe sets from 
the RG-U34B and RG-U34C GeneChip® microarray data of prefrontal cortex 
isolated from rats treated chronically with PCP were conducted to identify 
differentially expressed genes: from the ESTs, only 66 homologous genes were 
identified whilst 143 therefore remained ESTs. By comparison, 104 out of the 118 
probe sets differentially expressed in the RG-U34® GeneChip data were converted 
into genes using the same process (Catherine Winchester) which reflects the 
complexity of interpretating data on ESTs rather than from characterised full-length 
sequences of better sequence quality.
Failure to identify genes for such a large proportion of the probe sets may be due to 
the paucity of available annotation of the rat transcriptome (especially on 
untranslated regions) and to differences in the annotation level of databases of 
different species (rat, mouse and human) which often resulted in poor or 
contradictory alignments (including strand orientation issues). Moreover, even 
though ESTs are a precious tool for genome annotation, the overall quality of any 
individual sequence within all collections of ESTs remains one of the major 
problems which affects homology screening with genomic sequences and therefore 
complicates gene identification (Rudd 2003). Assigning ESTs to genes based on 
DNA sequence homology screens is subjective. In this thesis the conversion was 
rigorous and cautious, with cut off points of above 90% sequence identity for the rat 
alignments and less demanding requirements for mouse (about 80%) and human 
(about 70%) alignments according to the distance separating these species from the 
rat on the phylogenetic tree. This was to ensure confidence in the genes identified. It 
is therefore possible that more ESTs could have been converted if less rigorous
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decisions were made. Instead, a number of alignments were considered as 
insufficiently good for confidently establishing the corresponding EST and 
transcript. Moreover, ESTs could have been assigned to gene families, even if the 
corresponding gene was not identified.
However, even if it can be assumed that a number of unassigned ESTs are therefore 
likely to correspond to genuine transcripts, not all of them do and there are reasons to 
explain the origin of these non-coding ESTs. First, contamination of EST sequence 
collections by genomic DNA or cDNA from other species (“xenocontaminants”) 
appear to be an almost unavoidable problem since they are still hardly detectable 
despite improvements in the quality control of EST sequences that are being 
deposited in databases (Jongeneel 2000). EST databases may also contain “mosaic 
ESTs" arising from multiple ligations during cDNA library construction or structural 
or regulatory RNAs that should not have been cloned hence sequenced (for example, 
internal priming on intronic A-rich sequences in nuclear hnRNA is quite common) 
(Rudd 2003).
In theory, EST databases should not include microRNA (miRNA), which do not 
have a poly(A)tail and therefore should have been lost during cloning (assuming that 
oligo-dTs were used to prime first strand synthesis). However, since miRNA are 
usually expressed as part of longer transcripts and do not necessarily reside in 
introns, they may be represented in EST databases as chimeric transcripts encoding 
both a microRNA precursor and a region of an adjacent mRNA (Smalheiser 2003). 
Moreover, EST analysis has been shown to be very useful for identifying new plant 
miRNAs (Zhang et a l 2005b) suggesting that EST databases actually include a 
number of miRNAs. Some ESTs which were not translated into genes may therefore 
represent miRNAs which may play a crucial role in the regulation of gene expression 
by chronic PCP treatment.
Finally, extensive bioinformatics analyses would be necessary to examine each of the 
unassigned ESTs in detail and to determine to what it corresponds. Such studies may 
be particularly interesting as they may have the power to identify not only novel 
genes but also novel miRNAs which have recently emerged as potent regulators of 
gene expression during development (Bartel 2004; Klein et a l  2005).
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3.5,2- Selection of candidate genes (data mining)
Data mining was performed on the 66 differentially expressed genes in order to 
assess their potential relevance to schizophrenia and to select a few candidates to 
validate. A number of criteria were used to this aim, including previous linkage 
and/or association with schizophrenia and known or putative gene/protein function. 
Fold changes of probe sets in the microarray were also noted; however since 
detection of gene expression changes using brain tissue can be affected by many 
factors, fold changes may not necessarily reflect biological significance (Mimics and 
Pevsner 2004). Thus, it is worth mentioning that the modest magnitude of expression 
changes found in this microarray (the large majority of fold changes were below 20% 
increased or decreased expression) was expected partly because of the potential 
phenotypic diversity of the samples and of the limited regulation of transcription in 
the mature brain (Mimics and Pevsner 2004). Fold changes were therefore not 
strictly considered a criterion for this selection, which mostly remained a subjective 
and arbitrary process. Two genes {Tm4sfl2 and Edg2) and one EST (AI072720) were 
selected but others may have been very interesting as well.
Among these genes is filamin A, an X-linked gene which links actin cytoskeleton to 
various transmembrane proteins and receptors (including dopamine receptors; Lin et 
a l 2001) and serves as a scaffold for a wide range of cytoplasmic signalling proteins 
(Robertson 2004). Filamin plays a critical role in a particular stage of neuronal 
migration and was shown to be disrupted in several disorders of neocortical 
development (LoTurco and Bai 2006) which may be consistent with the 
neurodevelopmental hypothesis of schizophrenia.
Another gene whose implication with schizophrenia could be related with this 
hypothesis is the ephrin type~A receptor 2 precursor {Epha2\ a receptor expressed in 
projecting neurons and their target fields, and involved in axonal pathfmding (Orioli 
and Klein 1997).
Mu~protocadherin isoform 3 {Mucdhl) may also have been an interesting candidate 
as this cell-surface adhesion molecule is involved in the development and 
maintenance of neural circuitry and therefore may have underlined abnormalities in 
synaptic connectivity and plasticity shown in schizophrenia. However, since a few 
studies on different members of this family failed to confirm their role in the
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susceptibility to schizophrenia or other psychiatric disorders (Bray et a l 2002; Kirov 
et a l  2003; Giouzeli et a l 2004; Durand et a l  2006), this gene was not selected. 
Myocyte-specific enhancer factor 2C (Mef2c) is one of the genes which displayed a 
notably high fold change in the microarray, with a decrease in expression of 34% in 
the rat prefrontal cortex after chronic PCP treatment. This transcription factor 
notably implicated in activity-dependent neurogenesis (Okamoto et a l 2002) has 
been suggested to mediate infrastructure changes associated with bipolar disorder 
(Ogden et a l  2004) in a mechanism which may implicate another gene identified in 
our microarray, the proenkephalin A precursor {Penk) (Ogden et a l  2004). Since 
schizophrenia and bipolar disorder are known to have common basic neurobiological 
processes (Maier et a l 2006), both of these genes may have been selected for further 
validation and investigation in the context of schizophrenia.
Other genes whose function may be related to schizophrenia pathophysiology 
include:
SlcJalO, a member of the solute carrier family which may play a role in the 
modulation of glutamatergic transmission through mobilisation of D-serine at the 
glutamatergic synapse (Nakauchi et a l 2000) and therefore may directly be related to 
NMDA receptor function in schizophrenia,
Fbnl (fibrillin 7), a gene whose locus, chromosome 15ql5, is linked with 
schizophrenia and whose mutations cause Marfan syndrome, a connective tissue 
disorder which segregates with schizophrenia (Kalsi et a l  1994),
Pik4cb (phosphatidylinositol 4-kinase beta polypeptide), a gene located in 
chromosome lq21.3, one of the strongest loci linked with schizophrenia and 
involved in various signalling pathways potentially altered in schizophrenia 
(Stopkova et a l 2004). Interestingly, along with other members of its family, 
PIK4CA, the gene encoding the other polypeptide of the kinase, is also located in a 
key schizophrenia locus (22q ll) and has been investigated in schizophrenia (Saito et 
a l 2003),
HistlhAj (histone 7, H4j), a hi stone gene located in one of the strongest 
schizophrenia loci as well (chromosome 6p22.1) whose modification may contribute 
to the pathogenesis of prefrontal dysfunction in schizophrenia, especially through 
méthylation at gene promoters (Akbarian et at. 2005),
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Vamp5 {vesicle-associated membrane protein 5), a presynaptic terminal 
protein which may be involved in synaptic plasticity (Halim et al. 2003) and
Myelin-basic protein {Mbp), which encodes the major and specific 
constituent of myelin and is the only gene from all identified differentially-expressed 
genes which had already been studied in schizophrenia. Altered expression oiM bp  in 
the rat prefrontal cortex after chronic PCP treatment directly relates to impaired 
myelination in schizophrenia (Hakak et al. 2001; Pongrac et al. 2002; Davis et al. 
2003; Lehrmann et al. 2003; Tkachev et al. 2003), which is probably the most 
consistent finding among gene expression studies of post-mortem brain tissue from 
subjects with schizophrenia (Davis et al. 2003; Kubicki et al. 2005; Mcinnes and 
Lauriat 2006).
3.5.3- Validation of candidate genes -  qRT-PCR
As microarray studies are known to be error-prone (Chuaqui et al. 2002), validating 
their results was considered a prerequisite before undertaking any further 
characterisation experiments on selected candidate genes. In order to provide not 
only a technical but also a biologically meaningful confirmation of these results, an 
independent set of cDNA samples from rats treated chronically with PCP or vehicle 
were used for qRT-PCR.
Using qRT-PCR, two of the three selected candidates, Edg2 and the EST AI072720, 
were confirmed to be differentially expressed in the rat prefrontal cortex after 
chronic PCP treatment using the independent set of samples. Interestingly, both 
genes showed increased expression after chronic PCP treatment which was 
consistent with the microarray. qRT-PCR fold changes were smaller than the 
microarray ones which may be unexpected since qRT-PCR is usually more sensitive 
than microarray detection (Yuen et al. 2002b; Czechowski et al. 2004; Dallas et al. 
2005). However, since fold changes are related to many parameters (including probe 
length and properties, absolute abundance of transcript, data standardisation) it 
would be inappropriate to directly compare microarray and qRT-PCR fold changes. 
In addition, consistency in the direction of the change was considered as further 
support of the potential implication of these genes in schizophrenia.
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Differential expression of EDG2 and the EST AI072720 was not confirmed by qRT- 
PCR in human post-mortem dorso-lateral prefrontal cortex from schizophrenic 
patients and therefore did not provide further support of the potential involvement of 
these genes in schizophrenia. Nevertheless, the number of issues that are inherent to 
both the methodology and the design of this study strongly suggested that these 
results should be considered as a lack of evidence rather than negative results. Thus, 
despite the good validity of the rat chronic PCP model (section 1.1.4.4), this study 
was compounded by the difficulty in confirming small expression changes detected 
in microarrays and by the complexity of any gene expression analysis of brain tissue. 
In addition, potential isoform differences between species cannot be excluded, and 
the correspondence between gene expression changes in a particular brain region of a 
particular animal model of a disease and gene expression changes in the homologous 
brain region of actual people diagnosed with this disease is likely not to be direct. 
Moreover, schizophrenia, like all psychiatric disorders, is far from being uniform and 
the clinical heterogeneity between patients (Lewis and Levitt 2002) is likely to 
reflect differences in pathophysiology and in gene expression patterns. This 
heterogeneity further adds to differences in genetic background and natural gene 
expression profiles across populations (both within and across the examined groups) 
which may also mask gene expression changes between different collections of 
people (Mimics and Pevsner 2004). Finally, failure to translate gene expression 
changes found in the rat prefrontal cortex after chronic PCP treatment into gene 
expression changes in human port-mortem dorso-lateral prefrontal cortex from 
schizophrenic patients may be explained by the problem of modelling such a 
complex disease as schizophrenia in an animal and the homology between the 
examined brain regions. Thus, the rat chronic PCP model has been shown to mimic 
many pathophysiological features of schizophrenia but has particularly good validity 
towards the cognitive deficits of schizophrenia (section 1.1.4.4). However, no 
information was available as to the cognitive impairments exhibited by the 
schizophrenic patients used for the qRT-PCR analysis, so that the rat chronic PCP 
model may show gene expression changes potentially relevant to schizophrenia but 
not shown by this specific collection of schizophrenic patients. Moreover, it is very 
difficult when working across species to ascertain exact homology between brain 
regions. In particular, the prefrontal cortex has been found to show enormous 
variation across species in terms of anatomical criteria such as cytoarchitectonies and
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connectivity (Dailey et al. 2004). In the way the rat prefrontal cortex was dissected 
both for the microarray study and the qRT-PCR analyses, it included the prelimbic 
cortex, the infralimbic cortex and parts of the ventral orbital and motor (M2) cortices. 
Because direct comparison with the human brain on purely anatomical grounds is not 
straightforward (Kolb 1984), trying to find the exact homologues of these regions in 
the human brain would have been impossible, especially since the availability of 
post-mortem material from schizophrenic patients was also very limiting. Human 
qRT-PCR analyses were therefore performed on post-mortem Brodmann area 10 
from schizophrenic patients and controls. Strictly speaking, this region, known as the 
frontal pole or rostral frontal cortex, represents the anterior prefrontal cortex of the 
human brain and may be one of its least well understood regions (Ramnani and 
Owen 2004). However, this region is commonly referred to as part of the dorso­
lateral prefrontal cortex, which usually includes a combination of regions, namely 
Brodmann areas 9, 10, 44, 45 and 46 and has been used in many studies on 
schizophrenia (Kawasaki et al. 2000; Vogeley et al. 2003; Katsel et al. 2005). 
Moreover, the human dorso-lateral prefrontal cortex as a whole has been suggested 
to represent the functional homolog of the rat prelimbic cortex (Wilson et al. 2004), 
i.e. a portion of our dissected rat brain samples. Our rat and human samples were 
therefore grossly functionally homologous but were also likely to present substantial 
differences in cellular phenotypes and connectivity pattern (Uylings and van Eden 
1990; Gabbott et al. 1997), which may also explain the fact that gene expression 
changes found in the rat chronic PCP model were not confirmed in schizophrenic 
patients.
Very interestingly, evidence supporting the hypothesis that these issues may explain 
the failure to confirm differential expression of EDG2 in human post-mortem dorso­
lateral prefrontal cortex was provided by gene expression data available in the 
BioExpress® Central Nervous System (CNS) Suite (GeneLogic, USA) (obtained 
through Mitsubishi Pharma Corporation, Japan). In addition to revealing that EDG2 
expression was significantly higher in the CNS than in other tissues, this information 
from Affymetrix GeneChip® microarray studies showed indeed that EDG2 mRNA 
expression was significantly increased in schizophrenic patients (n=24) compared to 
controls (n=40) in the entorhinal cortex (Brodmann area 36) and in the anterior 
prefrontal cortex (Brodmann area 10), the latter being the same region as the one our 
human post-mortem samples came from. These data therefore provided evidence that
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EDG2 may be involved in schizophrenia, representing a concrete example of the 
potential importance of the previously discussed issues and thereby further favouring 
an extreme cautiousness in the analysis of gene expression data particularly those 
obtained using post-mortem tissue.
Contrary to the two other candidates, tetraspanin 12 was not confirmed to be 
differentially expressed, neither in the rat prefrontal cortex after chronic PCP 
treatment (in an independent set of samples or in the microarray samples) nor in 
human post-mortem dorso-lateral prefrontal cortex from schizophrenic patients. 
Failure to confirm differential expression of this gene may not be unexpected though 
since its 20% increased expression after chronic PCP treatment (notably lower than 
the 46% increased expression of the EST AI072720 in the same conditions) was 
considered a very low fold change in the microarray field, difficult to confirm by 
qRT-PCR (Dallas et a l 2005). Thus, these results were consistent with evidence 
showing a trend towards poorer correlation of microarray and qRT-PCR results for 
genes exhibiting fold changes less than 1.5 {le. <±50% expression) compared to 
those with fold changes greater than 1.5 (re. >±50% expression) (Dallas et a l  
2005). It has even been shown that validation is not consistently achieved for genes 
showing fold changes less than 4 {le. ±300% expression) (Rajeevan et a l  2001) 
which, in the context of the success in confirming confirming expression changes of 
other genes, especially Edg2 (which showed 28% increase in expression in the 
microarray), rather suggested that our qRT-PCR methodology and practise had a 
very high potential. Thus, failure to confirm the differential upregulation of 
tetraspanin 12 after chronic PCP treatment, by comparison with Edg2, suggested that 
its differential expression may not be genuine. qRT-PCR analysis of tetraspanin 12 
expression in human post-mortem brain tissue from schizophrenic patients did not 
refute this hypothesis since it also failed to confirm any expression changes, and 
thereby provide evidence that this gene may be involved in schizophrenia. Therefore, 
although its function may have fitted very well with current hypotheses on 
schizophrenia, tetraspanin 12 was suggested to represent a false-positive which had 
been identified in the rat microarray along with differentially expressed genes, and it 
was therefore decided not to pursue any more work on this gene.
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3.5.4- Validation of candidate genes -  in situ hybridisation
The purpose of using in situ hybridisation as part of the validation of the candidate 
genes was two-fold. First, it was used to determine the expression pattern of the 
candidates within the brain thereby providing potential insight into their function. 
Second, as an independent anatomical verification strategy, it was used in a semi- 
quantitative manner to confirm expression changes of candidate genes in the rat 
prefrontal cortex and evaluate potential changes in other brain areas outside the 
prefrontal cortex.
Surprisingly, Edg2 and the EST AI072720 were found to exhibit very similar 
expression patterns throughout the brain, with highest expression within all white 
matter tracts and low expression levels within cortical areas. However, within grey 
matter, both mRNAs were expressed in several brain regions that have been 
implicated in schizophrenic pathology, including the prefrontal cortex and the 
thalamus and hippocampus, which probably displayed the highest mRNA levels 
within grey matter for both genes.
Such a similarity between expression patterns of the two examined genes may cause 
concern and raise the issue of the specificity of the probes. However every probe was 
tested and checked for specificity prior to hybridisation to the proper experimental 
slides (section 2.6). Therefore the similarity (but not exact identity) between the 
expression patterns of Edg2 and the EST AI072720 appeared to be coincidental and 
both genes were genuinely highly expressed within the white matter by comparison 
with cortical areas. In addition, the hybridisation signal with each probe was 
completely absent when an excess of the same unlabelled probe was added, 
suggesting specificity of hybridisation.
The white matter, which plays a major role in connecting different brain regions 
together, is comprised of axonal projections of neurons located in various cortical 
areas as well as glial cells such as myelin-forming oligodendrocytes or astrocytes. 
Since the in situ hybridisation method did not pennit cellular localisation of mRNA 
expression, the precise expression of either gene within this highly complex tissue 
could not be determined: whether the mRNA was expressed in glial
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(oligodendrocytes or astrocytes) or neuronal cells (axonal RNA translation has been 
shown to occur both in mature and developmental axons; for review see Piper and 
Holt 2004). For this purpose, it may have been essential to achieve cellular resolution 
by coating the slides in photographic emulsion (Wisden and Morris 2002). An a 
priori similar expression pattern (such as that of Edg2 and EST AI072720 under our 
conditions) may therefore reflect very different cellular expression and does not 
necessarily mean that both genes have similar or related functions. Moreover, in the 
context of schizophrenia, it may be that it is the expression of one gene within a 
particular region which is relevant to the psychopathology whereas it is another 
region for another gene. This study did not give enough information to provide any 
insight into the role of either gene.
Nevertheless, the expression pattern of Edg2 was consistent with published literature 
showing prominent expression of Edg2 mRNA and Edg2 protein within white matter 
tracts and specifically in oligodendrocytes both in human and rat adult brains (Allard 
et a l  1998; Allard et a l 1999; Handford et a l 2001; Cervera et a l  2002). Such an 
expression pattern in the adult brain as well as colocalisation with myelin basic 
protein {Mbp) strongly suggested that Edg2 was involved in myelination and/or 
myelin maintenance during postnatal life (Allard et a l 1998; Handford et a l  2001; 
Cervera et a l  2002). However, even though its expression levels were much lower, 
Edg2 was also expressed in cortical areas where it has been hypothesised to mediate 
the LPA-induced regulation of NMDA-receptor function (Lu et a l 1999; Yoshida 
and Ueda 2001). In particular, qRT-PCR analysis of Edg2 expression in laser- 
microdissected prelimbic cortex provided confirmation that Edg2 was expressed in 
this subpart of the prefrontal cortex which plays a major role in working memory 
(Antonio Ferra and Catherine Winchester).
Interestingly, both areas of expression and both functions may be related to 
schizophrenia. Therefore examining anatomical differences in Edg2 expression after 
chronic PCP treatment turned out to be a useful strategy for elaborating a hypothesis 
about the potential role of Edg2 in schizophrenia pathophysiology. However, failure 
to confirm the differential upregulation oîEdg2 expression in any cortical area and to 
show changes in expression in other regions of the brain did not provide any 
infonuation of its role.
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Nevertheless, at the same time as this analysis was performed, Edg2 expression was 
also analysed by in situ hybridisation on tissue taken from animals that had been 
used previously (Egerton et a l  2005) to investigate the effects of chronic PCP 
administration on behaviour in the attentional set-shifting task (ASST), a task 
developed (Birrell and Brown 2000) for assessing the ability to shift perceptual 
attention forms in the rat as the equivalent to one of the core aspects of executive 
dysfunction in schizophrenia (Egerton et a l 2005). Again, there were no main effects 
of chronic PCP treatment on Edg2 expression using this paradigm but interestingly, 
behavioural testing produced a significant increase in the expression levels of Edg2 
(F(i,20) = 4.98, p = 0.037) in the infralimbic and prelimbic cortices and this effect was 
inhibited by chronic PCP treatment (F(i,20) = 6.08, p = 0.023) in the infralimbic 
cortex (figure 3.12). No significant effects of drug treatment or behavioural testing 
were observed in all the white matter regions analysed. Because the attentional set- 
shifting task has been shown to be mediated by prefrontal cortical activity, the 
increased expression of Edg2 in the prelimbic and infralimbic cortices suggested that 
neuronal EAg2 expression was involved in cognitive-related activity. Although we 
did not confirm the differential upregulation of Edg2 in the rat prefrontal cortex after 
chronic PCP treatment, this additional information provided evidence suggesting that 
neuronal Edg2 may be more important for schizophrenia-related cognitive tasks than 
white matter Edg2.
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Figure 3.12. Bar graphs for rat Edg2 in situ hybridisation (data from Alice Egerton) 
Results shown are mean ± standard error of the mean (s.e.m.)
n=6 animals for each of the 4 groups: vehicle-no behaviour, PCP-no behaviour, 
vehi cl e-behaviour and PCP-behaviour (“no behaviour” or “behaviour” meaning 
animals that were not behaviourally tested or had completed the attentional set- 
shifting task respectively).
A. prelimbic cortex, B. infralimbic cortex.
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Further support of the potential involvement of neuronal Edg2 in psychiatric 
disorders and particularly schizophrenia was provided by evidence showing that 
Edg2 knock-out mice displayed a region-specific disruption of markers of 
interneuronal function and interneuron-mediated brain rhythms. Thus, the loss of 
neuronal Edg2 induced a similar network disruption to that observed acutely with 
NMDA receptor antagonism suggesting that neuronal Edg2 may play an important 
role in schizophrenia pathophysiology (Cunningham et at. 2006).
In summary, although in situ hybridisation did not confirm the differential expression 
of both Edg2 and the EST AI072720 after chronic PCP treatment, it allowed the 
determination of the expression pattern of both genes throughout the rat brain. 
Failure to validate the gene expression changes found in the microarray within 
cortical areas may be explained by the limited sensitivity of this technique. Indeed, 
although both X-ray film images and autoradiographic signals have been shown to be 
robust and equally applicable to semi-quantitative studies (Morris 1997; Simpson 
and M onis 2000), in situ hybridisation remains more a qualitative than a semi- 
quantitative method which may not be suitable or powerful enough for detecting low 
expression changes such as the ones detected in the chronic PCP model. Moreover, 
both Edg2 and the EST AI072720 exhibited veiy low expression levels within 
cortical areas and especially the prefrontal cortex which made obtaining significant 
results even more difficult. Increasing the n number may have been necessary for 
improving the power of the study and increasing the chance of obtaining significant 
results.
In conclusion, the work presented in this chapter has allowed the identification and 
the validation of two candidates, Edg2 and the EST AI072720, whose cortical 
expression and upregulation after chronic PCP treatment will be further characterised 
in relation with schizophrenia.
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CHAPTER 4: CHARACTERISATION OF EDG2 
AS A DRUG TARGET FOR SCHIZOPHRENIA
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4.1- Introduction
Further pathway analysis of the microarray data was performed to elaborate a 
hypothesis about the potential role of Edg2 in schizophrenia. The initial analysis of 
the RG-U34A, B and C GeneChip® data reflecting differentially expressed genes in 
the rat prefrontal cortex after chronic PCP treatment was correlated with the analysis 
of a microarray investigating gene expression changes in the post-mortem dorso­
lateral prefrontal cortex (DLPFC) of schizophrenic patients compared to controls 
(Hiromitsu Ozeki). This approach allowed the identification of a set of genes 
including Ptk2b, N ckl and Mapk9 but also Gabl, Gab2, Map4k4, Map3k7 and 
MapKSipl, whose concomitant changes in expression were likely to reflect potential 
interactions within a pathway leading from Ptk2b (a non-receptor tyrosine kinase 
also referred to as proline-rich tyrosine kinase 2 or Pyk2) to Mapk9 activation (the 
“Pyk/Nck” pathway, pending British Patent application reference 0610574.6) and 
potentially compromised in PCP-treated rats and in human schizophrenic patients. 
Moreover, activation of Ptk2b by LPA, probably via stimulation of Edg2 receptors, 
suggested that this G-protein coupled receptor for LPA, differentially expressed in 
the rat PFC after chronic PCP treatment and in post-mortem DLPFC of 
schizophrenic patients, may couple to the “Pyk/Nck” pathway leading to Mapk9 
activation.
Figure 4.1 shows the potential functional relationship between all these genes. 
Further information on their expression changes in the rat and human microarrays 
can be found in Appendix C.
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Figure 4.1. Schematic representation o f the fiinctional relationship between Edg2 
and “Pyk/Nck ” pathway proteins
The “Pyk/Nck” pathway downstream from NMDA receptors was suggested to be 
located downstream from Edg2 receptors so that stimulation of these receptors may 
increase downstream signal transduction. This pathway is structurally organised as a 
Mapk signalling cascade whereby the mitogen-activated protein kinase Mapk9 
(Jnk2) is activated by the dual specificity mitogen-activated protein kinase kinases 
Map3k7/Map4k4 which are themselves activated by mitogen-activated protein 
kinase kinase kinases downstream from the protein tyrosine kinase Ptk2B. Gab 1/2 
and Nckl are scaffold proteins that bring upstream and downstream kinases in close 
proximity ensuring an effective and specific signal transduction.
The hypothesis that the “Pyk/Nck” pathway may be implicated in schizophrenia 
pathophysiology (pending British Patent application reference 0610574.6) was 
elaborated based on literature showing that Ca^^ influx through post-synaptic NMDA 
receptors not only activates CamK but also stimulates neuronal gene expression via 
signalling pathways such as the MAPK signalling cascades (Haddad 2005).
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Moreover, although coupling of NMDA receptors to the Erk family of Mapks is 
much more documented, activation of NMDA receptors has been shown to lead to 
the activation of the Ink family of MAP kinases (Ko et a l  1998; Centeno et a l 2006; 
Centeno et a l 2007) so that NMDA receptor hypofunction may induce a decrease in 
Ink (Mapks, 9 and 10) activation as was observed in the rat chronic PCP model and 
in schizophrenic patients (figure 4.1). Consistent with this hypothesis, analysis of 
differentially expressed Mapk-related proteins revealed that most of them, including 
the MAP kinase kinase kinases (Mapkkks) Map3k9 (M lkl) and Map3k7 (Takl) and 
the upstream Map4k4 (Nck-interacting kinase) protein as well as interacting or 
scaffolding proteins such as MapkSipl (Jipl), Nckl and Gab 1/2 were involved in the 
Ink (Mapks, 9 and 10) rather than the Erk signalling pathway (Johnson; Davis 2000; 
Johnson and Lapadat 2002; Vlahopoulos and Zoumpourlis 2004). This suggested that 
the Jnk pathway was compromised in the chronic PCP model and in schizophrenia, 
opposite to data showing a role for Erk but not Jnk proteins in NMDA receptor 
signalling and schizophrenia (Kyosseva et a l  2001). However major methodological 
differences (including PCP treatment regime) between these two studies and 
interactions between the Mapk signalling cascades (Shen et a l  2003; Waetzig and 
Herdegen 2005) suggested that these cascades were not mutually exclusive but were 
either together or individually differentially affected in schizophrenia, e.g. in 
different brain regions (Kyosseva et a l 2001).
Activation of the Jnk signalling cascade downstream of NMDA receptors has been 
shown to be mediated by Ptk2b (Pyk2) (also called cell-adhesion kinase |3 (CaKp) or 
focal adhesion kinase 2 (Fak2)). Ptk2b, which is activated in response to a number of 
extracellular stimuli that increase Ca^^ such as NMDA receptor activation (Girault et 
a l 1999) was found to feed into and activate Mapk pathways (Lev et a l 1995; Dikic 
et a l 1996; Della Rocca et a l  1997) and more precisely to couple with the Jnk 
pathway to trigger Jnk phosphorylation (Tokiwa et a l 1996; Yu et a l 1996; Bîaukat 
et al. 1999). Interestingly, Ptk2b was also suggested to be involved in the regulation 
of NMDA receptor activity as part of a cascade upstream of the NMDA receptors in 
which its activation by PKC may induce Src activation and potentiate NMDA 
receptor function by boosting the influx of Ca^”^ through the receptor and setting in 
motion the downstream cascade (Girault et a l 1999; Huang et a l  2001; Salter and 
Kalia 2004; Aller and Morris 2005). Downregulation of Ptk2b expression in the rat
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chronic PCP model and in schizophrenia was therefore consistent with the 
antagonism properties of PCP at the NMDA receptor and with the NMDA receptor 
hypofunction hypothesis of schizophrenia (Jentsch and Roth 1999; Olney et a l  
1999).
Evidence suggesting that the LPA receptor Edg2 may couple to this Ptk2b-activated 
signalling cascade came from studies showing that Ptk2b can be activated by 
G protein-coupled receptor (GPCR) agonists including LPA (Dikic et a l  1996; 
Seufferlein et a l 1996; Andreev et a l 2001; Wu et a l  2002) and lead to Mapk 
activation (Kranenburg et a l 1999; Kranenburg and Moolenaar 2001). The effects of 
LPA mediated by Ptk2b include cell migration (Park et a l  2006) and neuiite 
retraction and cell rounding (Kranenburg et a l 1999; Sayas et a l 2006), suggesting 
that Mapk activation may mediate the Gi/o protein-mediated proliferative effects as 
well as the G12/13 protein- and Rho-mediated morphological changes induced by 
LPA. Interestingly, coupling of LPA receptors to Gq proteins has been shown to 
initiate the cascade described previously whereby PKC-dependent activation of 
Ptk2b and Src can potentiate NMDA receptor currents (Tabuchi et a l  1997; Lu et a l 
1999; Huang et a l  2001; Salter and Kalia 2004).
Coupling of Edg2 to different types of G proteins may therefore, via Ptk2b 
activation, both regulate NMDA receptor activity and induce Mapk activation. In 
addition, stimulation of all Gi, Gq and Gs-coupled receptors can lead to 
phosphoiylation of Jnk, suggesting that G protein signals may be integrated at the 
level of Mapk, resulting in differential effects on Erk, Jnk and p38 Mapks (Chan et 
a l  2005).
Further analysis of the microarray results was therefore consistent with the literature, 
converging in the hypothesis that the Ptk2b signalling cascade downstream of both 
NMDA and Edg2 receptors was compromised in the rat chronic PCP model and in 
schizophrenic patients (figure 4.1). This pathway was termed the “Pyk/Nck” pathway 
since Nckl, an adaptor protein which was also found to be differentially expressed 
after chronic PCP treatment, had been shown to regulate the activation of Jnk 
through interaction with several proteins including the p21-GTPase activated kinase 
Pakl (Mizuno et a l 2002; Poitras et a l  2003).
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The upregulation of EDG2 expression after chronic PCP treatment and in 
schizophrenic patients was suggested to represent a compensatory mechanism aiming 
at restoring NMDA receptor function by coupling to the same signalling cascade, the 
“Pyk/Nck” pathway. Interestingly, this hypothesis was consistent with the obsei'ved 
schizophreniform behaviour and with the schizophrenia-related neurochemical 
changes exhibited by Edg2 knock-out mice (Harrison et al. 2003; Roberts et al. 
2005).
Overall, Edg2 stimulation may therefore represent an additional route for regulating 
NMDA-mediated signal transduction events eventually leading to changes in 
neuronal gene transcription and synaptic plasticity (Thomas and Huganir 2004).
In order to test the hypothesis that modulating Edg2 activity may restore NMDA 
receptor function in schizophrenia, the EDG2 human cDNA was cloned into an 
expression vector and an £DG2-overexpressing stable cell line was generated. The 
ability of EDG2 overexpression to restore activity of the “Pyk/Nck” pathway was 
investigated in viti^o by looking at gene expression changes within the cascade as 
well as measuring phosphorylation of Mapk9 (its final output), MapkS and MapklO. 
As EDG2 was emerging as a potentially attractive drug target, a [^^S]-GTPyS binding 
assay was developed using the £DG2-overexpressing stable cell line to allow 
screening of potential EDG2 agonists in vitro.
4.2- EDG2 construct genei^ation and development of a stable 
transformed cell line
To characterise functionally the role of EDG2 in relation to the “Pyk/Nck” pathway 
and schizophrenia, in vitro studies were undertaken and as a first step EDG2 was 
cloned into pMSFl, an expression vector based on pcDNA3.1 -FLAG® whose N- 
terminal signal sequence helps the anchoring of the cloned gene into the membrane 
(Mitsubishi Pharma Corporation).
A human full-length EDG2 cDNA clone was purchased as a plasmid (pBluescriptR) 
in E. coli and its identity was verified by DNA sequencing as being identical to
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Genbank mRNA sequence NM_001401 (or NM_057159), i.e. the differentially 
expressed isoform of EDG2 identified by the microarray analysis of human DLPFC 
of schizophrenic patients (Hiromitsu Ozeki). Primers containing 5’- and 3’-end 
restriction enzyme recognition sites (for EcoRV and Xhol respectively) were 
designed to allow in frame cloning 0ÎEDG2  cDNA into pMSFl expression vector 
and were used to amplify EDG2 from its original pBluescriptR vector.
The PCR-amplifled product of the expected length and the pMSFl vector were 
digested by EcoRV  and Xhol and the approximately l.lkb  EDG2 cDNA was cloned 
into the expression vector.
TOP 10 bacterial cells were transformed with pMSFl-LZ)G2 construct (section 2.5.1) 
and the cells were checked for the presence of the expression construct. Plasmid 
DNA was extracted from twenty-four colonies and digested with EcoRV  and Xbal to 
screen the plasmids for the EDG2 insert. One of the plasmids was shown to contain 
the EDG2 insert. Sequencing of plasmid DNA across the vector/insert junction 
confirmed the correct in frame insertion of the EDG2 cDNA within the pMSFl 
vector while sequencing of the entire EDG2 cDNA insert confirmed its identity as 
identical to Genbank mRNA sequence NM_001401.
In order to overexpress EDG2 in vitro, human SK-N-SH cells were transfected with 
the pMSFl-LDG2 expression construct and empty pMSFl vector (negative control 
for subsequent functional studies) (section 2.5.4.1). Cell lysate was extracted after 
48h (section 2.5.6) and proteins were quantified using the Bradford dye-binding 
assay (section 2.5.8).
FLAG® western blotting on cell lysate from pMSFl-EDG2 transfected cells was 
used first to check the overexpression of the FLAG®-EDG2 fusion protein. Both the 
methodology and the FLAG® antibody were shown to be effective by using a 
positive control consisting of another FLAG® fusion protein of known size but they 
failed to confirm the overexpression of the FLAG®-EDG2 fusion protein from 
pMSFl-£DG2 (figure 4.2). However, subsequent thorough examination of the 
pMSF 1 sequence revealed the presence of only 7 out of the 8 amino acids (Asp-Tyr- 
Lys-Asp-Asp-Asp-Asp-Lys) representing the FLAG® epitope which may be 
insufficient to allow specific binding of the FLAG® antibody to this epitope and may 
therefore prevent the detection of the fusion protein. This possibility may also 
explain the non-detected overexpression of the empty pMSFl expression vector,
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although it is more likely that the FLAG® epitope had not been translated because it 
was not in fusion with another protein.
41kDa
36kDa
Figure 4.1. FLAG western blotting on pMSFl-EDG2-transfected SK-N-SLL cell 
lysate
Lanes 1 and 2 represent SK-N-SH cells transfected with pMSFl-£Z)G2 construct 
(translating into a ~41kDa protein) and the empty pMSFl vector respectively. Lane 3 
is a no protein negative control and lane 4 is a positive control consisting of a cell 
lysate from pcDNA3.1-FLAG®-AGK7 transfected SK-N-SH cells (MW~36kDa). A 
FLAG® M2 antibody was used at a 1/5000 dilution (section 2.5.9).
As a consequence, western blotting using EDG2 antibodies was performed on 
pMSFl-EDG2 transfected SK-N-SH cells to confirm the overexpression of EDG2 in 
vitro. However none of the EDG2 antibodies utilised detected EDG2 (endogenous or 
overexpressed FLAG®-EDG2) in the pMSFl-EDG2 or pMSFl transfected cells. 
Many conditions were tried to optimise use of the EDG2 antibodies (transfection, 
cell lysis, antibody as well as western blotting visualisation substrate).
Experimental condition Experimental details
Transfection reagents and 
conditions
Lipofectamine 2000 (Invitrogen) was tried in addition 
to Mirrus TransIT-LT\. For each of these transfection 
reagents, different amounts of DNA and different ratios 
DNA/reagent were tried.
Cell lysis buffers Four different buffers were tried, including two 
different RIPA buffers (among them one following 
Upstate’s recipe), a buffer prepared following Cell 
Signalling’s recipe and one following a recipe used in a 
paper on EDG2 (Fukushima et a l  1998).
EDG2 antibodies 5 EDG2 antibodies were tried, from Abeam, Upstate, 
Abgent, Exalpha Biologicals and Sigma.
FLAG® antibody A FLAG® antibody was tried on cell lysates obtained 
with different buffers and following various 
transfection conditions.
Visualisation substrates Pierce SuperSignal West Femto Maximum Sensitivity 
Substrate was used in addition to ECL Plus detection 
System (Amersham).
Table 4.1. Summary o f different conditions tried to optimise western blotting o f  
EDG2 protein
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The transfection efficiency issue was ruled out by performing qRT-PCR on cDNA 
synthesised from mRNA extracted from pMSF 1-EDG2-transfected SK-N-SH cells. 
Three different ratios of DNA/transfection reagent were tried (from Ipg DNA for 2pi 
reagent up to Ipg DNA for 6pi reagent. Figure 4.3 shows the amplification plot of 
this qRT-PCR.
NTC
Figure 4.3. Amplification plot from ABISD S 7000 Real-Time PCR machine
X-axis is the PCR cycle number, Y-axis is the neperian logarithm (In) of the 
fluorescence. Curves shifted to the left, showing more fluorescent product at lower 
cycle number reflect more PCR product. Each curve represents one sample amplified 
in duplicate. The ‘A ’ group of curves represents SK-N-SH cells transfected with 
pMSFl-EDG2 construct using different ratios of DNA to transfection reagent and the 
‘B’ group represents controls, including SK-N-SH cells transfected with pMSFl and 
untransfected SK-N-SH cells. Therefore qRT-PCR amplification of EDG2 at later 
cycle numbers in pMSF 1-transfected and untransfected SK-N-SH cells (‘B ’ group of 
cells) reflects endogenous EDG2 expression in these cells while EDG2 
overexpression was confirmed by earlier qRT-PCR amplification of EDG2 in 
pMSFl-£DG2 transfected cells (‘A’ group of cells). NTC (non-template control) 
represents the amplification plot of the qRT-PCR reaction performed using H2O but 
no cDNA, so that no or very late amplification indicates absence of contamination
pM SFl-ÆDG2 transfected SK-N-SH cells were found to show a greater amount of 
EDG2 transcript, represented by earlier detection of the EDG2 amplicon (Figure 4.3, 
‘A’ curves), than non-transfected SK-N-SH cells (Figure 4.3, ‘B’ curves). Moreover, 
the three different ratios used for the transfection induced slight variations in 
amplification of EDG2, which allowed us to select the best ratio to use for 
subsequent studies. Ipg DNA to 6pl reagent was thus determined to be the ratio that 
induced the higher EDG2 expression (cells transfected using this ratio were found to 
express EDG2 approximately 1.75x10^ times more than wild-type SK-N-SH cells).
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In addition, the qRT-PCR showed that wild-type SK-N-SH cells express endogenous 
EDG2.
This experiment therefore confirmed the overexpression of EDG2 mRNA after 
transfection of SK-N-SH cells with pMSFl-£DG2. It was therefore assumed that the 
pM SFl-ÆDG2 transfected cells did indeed overexpress the EDG2 protein.
However, although preliminary functional studies were undertaken using these 
transiently ÆDG2-overexpressing cells, the inherent variability in their levels of 
expression of EDG2 due to the unavoidable unevenness in the transfection efficiency 
encouraged the development of an £DG2-overexpressing stable cell line. Creation of 
such a cell line was also motivated by promising preliminary functional results 
obtained using transient EZ)G2-overexpressing cells (section 4.3) and by promising 
in vivo data obtained concomitantly in the lab by Alice Egerton, Susan Cochran and 
Lee Reid (section 4.7.2). These latter results, providing further evidence that EDG2 
may potentially represent a promising drug target for schizophrenia, reinforced the 
need for an £Z)G2-overexpressing cell line of constant phenotype, essential for 
further functional studies and for screening purposes
An Æ77G2-overexpressing stable cell line was thus developed by treating transiently 
£DG2-overexpressing SK-N-SH cells with Img/ml gentamycin (G418) and isolating 
surviving £DG2-overexpressing clones. After several rounds of selection, 15 clones 
were obtained and the levels of EDG2 mRNA expression were checked using qRT- 
PCR. On the PCR amplification plot (data not shown), 7 clones were found to exhibit 
higher EDG2 expression levels than wild-type SK-N-SH cells while 8 clones did not 
show any increase in EDG2 expression. EDG2 expression levels were normalised to 
those of an internal control, GAPDH, in order to remove any potential variability due 
to different amounts of starting cDNA, and 3 clones were eventually found to show 
higher EDG2 expression levels than wild-type cells (Figure 4.4).
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Figure 4.4. Bar graph bar showing EDG2 expression levels
Bars represent EDG2 expression levels in stable clones 4, 7 and 12 and wild-type 
SK-N-SH cells (WT) and SK-N-SH cells transiently overexpressing EDG2 (tr- 
EDG2). n=2 for each condition. Data from qRT-PCR are expressed as mean ± 
standard error of the mean (s.e.m).
Of these 3 clones, clone 7 displayed the highest EDG2 expression, which was about 
7 times less than SK-N-SH cells transiently overexpressing EDG2 but almost 
25,000 times more than wild-type SK-N-SH cells. This clone was therefore 
confirmed to overexpress EDG2 receptors.
4.3- Preliminary functional studies using transiently EDG2- 
overexpressing cells
4.3.1- JNK-P western blotting
Preliminary studies were performed using SK-N-SH cells transiently overexpressing 
EDG2 to investigate the potential activation of the “Pyk/Nck” signalling cascade 
following LPA treatment. Phosphorylation (hence activation) of the final output of 
this pathway, MAPK9 (JNK2), was assessed by western blotting using a phospho- 
JNK antibody. This antibody recognises more than one JNK isoforms. On western 
blots it detects two bands of -46 and 54 kDa corresponding approximately to
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MAPKS (JNKl) and MAPK9 (JNK2) respectively, which allowed the analysis of the 
cellular response induced by LPA treatment in terms of pathway activation.
Cell lysate from SK-N-SH cells transfected with pMSFl-EDG2 and treated prior to 
lysis with IpM LPA were thus analysed for JNK phosphorylation. 40pg protein was 
subjected to electrophoresis in a 10% (w/v) SDS-PA gel and transferred by western 
blotting to PVDF membrane. Immunodetection was performed with the JNK-P 
antibody and after visualisation, membranes were wet with methanol, stripped and 
reblotted with an actin antibody to confirm even loading of proteins (figure 4.5,B). 
Visual examination of the JNK-P blots (Figure 4.5) suggested that EDG2 
overexpression (lanes 4 and 9 respectively compared to lanes 3 and 8) as well as 
LPA stimulation (lanes 6 to 9 compared to lanes 1 to 4) induced an increase in the 
phosphorylation levels of both JNK46kDa and JNK;4kDa.
B -------------------------
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Figure 4.5. Western blot showing JNK-P activation after EDG2 overexpression in 
SK-N-SH cells. A. JNK blot; B. actin blot.
Lane 5 is a positive control consisting of UV-treated SK-N-SH cells (UV is known to 
strongly activate JNK). Lanes 1 to 4 show JNK-P expression in cells treated under 
the same conditions as in lanes 6 to 9 except that cell lysates run in lanes 6 to 9 were 
from cells treated with IpM LPA for 30 minutes whereas cells run in lanes 1 to 4 
were treated with vehicle (PBS + 0.1% BSA). Lanes 1 and 6 represent wild-type SK- 
N-SH cells treated with vehicle, lanes 2 and 7 represent SK-N-SH cells treated with 
the transfection reagent only, lanes 3 and 8 represent SK-N-SH cells transfected with 
the empty pMSFl vector and lanes 4 and 9 represent pMSFl-£DG2 transfected SK- 
N-SH cells.
These autoradiographs are representative of these experiments that were repeated 4 
times (section 2.5.9). The strongest bands represent JNK-P activation (by UV 
stimulation in lane 5 and in pMSFl-£DG2 transfected cells in lane 9).
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JNK-P46kDa and JNK-P54kDa as well as actin expression levels were quantified with 
densitometry. JNK-P levels normalised to actin were analysed by ANOVA 
(Figure 4.6)
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Figure 4.6. Bar graphs showing JNK-P46kDa (A) and JNK-Ps4kDa (B) levels after LPA 
treatment
Samples (n=4 replicates) represent SK-N-SH cells treated with a vehicle, SK-N-SH 
cells treated with the transfection reagent, pMSFl-transfected cells and pM SFl- 
£DG2-transfected cells. Data are expressed as mean ± standard error of the mean 
(s.e.m). Data were analysed by ANOVA using LPA treatment (IpM  LPA for 
30 minutes) and transfection status (cells treated with PBS as vehicle, pMSFl- 
transfected cells or pMSF 1-EDG2-translated cells) as the factors (n=4). Transfection 
status was found to have a significant effect on both JNK-P46kOa (F(i3)=10.55, 
p<0.001) and JNK-P54koa (F( 1,3)= 11.362, p<0 .0 0 1 ). Significant interactions were 
further explored by simple main effects analysis (multiple comparisons were 
adjusted using Bonferroni’s procedure). * signifies p<0.05 compared with vehicle in 
each treatment group; t  signifies p<0.05 for comparisons between group treatments 
as shown on graph (Bonferroni-adjusted pairwise comparisons).
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Analyses of JNK-P levels confirmed the visual observations of the blots (example 
shown in Figure 4.5), suggesting that both JNK46koa (figure 4.6.A) and JNK54kOa 
(figure 4.6.B) were activated by EDG2 overexpression. Overall, activation of JNK 
proteins of both molecular weights by LPA stimulation did show a similar pattern 
and statistical analyses also proved to yield consistent results. Thus, for both groups 
of JNK proteins, ANOVA analyses revealed a very large effect of the transfection 
status (including EDG2 overexpression) on JNK phosphorylation overall (p 
values <0.001 for JNK-?46kDa and JNK-P54kDa). Conversely, LPA treatment did not 
have a significant effect on JNK activation overall (p=0.086 for JNK-P46kDa and 
p=0 .105 for JNK-P54kDa) but in £DG2-overexpressing cells only (as revealed by post- 
hoc pairwise analyses; p=0.036 for JNK-P46koa and p=0.016 for JNK-?54kDa). No 
interaction was found between transfection status and LPA treatment for either or 
both groups of JNK proteins.
Consistent with these overall analyses, post-hoc pairwise analyses revealed that 
EDG2 overexpression induced a significant increase in the phosphorylation of 
JNK46kDa and JNK54kOa when compared individually to non-transfected cells treated 
with a vehicle or with the transfection reagent or with cells transfected with the 
empty pMSFl expression vector. The only comparison which did not reach 
significance was the one examining JNK phosphoiylation in pMSFl-EDG2 
transfected cells compared to pMSFl-transfected cells in absence of LPA treatment 
(p==0.076 for JNK-P46kDa and p=0.067 for JNK-P$4kDa) Conversely, p values in the 
0.001 range or < 0.001 were found for all individual comparisons of JNK-P46kDa and 
JNK-?54kDa levels between LPA-treated ÆDG2-overexpressing cells and LPA-treated 
non-transfected cells suggesting that LPA-stimulation of overexpressed EDG2 
receptors resulted in a major increase in JNK46kDa and JNK54koa phosphorylation.
The observed slight increase in JNK phosphorylation in pMSFl-transfected cells 
compared to the two groups of non-transfected cells was not statistically significant 
and was not affected by LPA treatment which was consistent with the hypothesis that 
JNK activation in these conditions was due to DNA transfection-related stress rather 
than coupling of LPA to any receptor. These results further confirmed that significant 
increased phosphoiylation of JNK proteins in £DG2-overexpressing cells was 
mediated by EDG2 receptors stimulated with LPA.
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4.3.2- JNK-P ELISA
In order to confirm the results obtained by analysing JNK activation by western blot 
on £DG2-overexpressing cells, a JNK-P ELISA (Enzyme Linked Immunosorbent 
Assay) assay was used as a semi-quantitative method of measuring JNK 
phosphorylation. Similar to the antibody used for the western blots, this assay did not 
have the power to discriminate between JNK isoforms and equally detected MAPKS 
(JNKl), MAPK9 (JNK2) and MAPK 10 (JNK3). Despite this fact, the ELISA 
analysis of JNK/MAPK activity should be more reliable and accurate than western 
blot analysis.
Cell lysates from SK-N-SH cells transfected with pMSFl-£DG2 and treated prior to 
lysis with vehicle (PBS + 0.1% BSA) or IpM LPA were thus analysed for JNK 
phosphorylation using Pathscan Phospho-SAPK/JNK (Thrl83/Tyrl85) Sandwich 
ELISA Kit (Cell Signalling). The assay was performed following the manufacturer’s 
protocol using ISpg total protein. Figure 4.7 shows bar graphs representing 
absorbance at 450nm as a measure of the amount of phosphorylated SAPK/JNK 
proteins.
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F igure 4.7. Bar graph showing JNK-P levels after LPA treatment
Samples (n=3) represent SK-N-SH cells treated with a vehicle, SK-N-SH cells 
treated with the transfection reagent, pMSFl-transfected cells and pMSFl-£DG2- 
transfected cells. Data are expressed as mean ± standard error of the mean (s.e.m). 
Data were analysed by ANOVA using LPA treatment (IpM  for 30 minutes) and 
transfection status as factors, revealing a significant effect of transfection status 
(F(i,2)= 15.799, p<0.001). Further potential interactions were investigated by simple 
main effect analysis (multiple comparisons were adjusted using Bonferroni’s 
procedure). * signifies p<0.05 compared with vehicle in each treatment group; t  
signifies p<0.05 for comparisons between group treatments as shown on graph 
(Bonferroni-adjusted pairwise comparisons).
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Visual observation of JNK-P levels measured using the JNK-P ELISA assay 
appeared consistent with previous western blot analyses performed under the same 
conditions, with LPA inducing a general increase in JNK-P phosphorylation and 
EDG2 overexpression further increasing its activation particularly in LPA-treated 
cells. The most apparent difference lay in the substantial (versus hardly detectable by 
western blot) endogenous levels of JNK phosphorylation detected by the JNK-P 
ELISA assay in non-transfected cells.
ANOVA analysis of JNK-P levels revealed a significant effect of transfection status 
(including ÆDG2 overexpression) on JNK phosphorylation (p<0.001) but no effect of 
LPA treatment (p=0.568), which was consistent with western blot analyses. There 
was a significant interaction between transfection status and LPA treatment 
(p=0.023) suggesting that both factors were not completely independent.
Consistently with western blot analysis, simple main effects analyses revealed that 
LPA treatment induced a significant increase in JNK phosphorylation in EDG2- 
overexpressing cells (p-0.012) but not in any other group of non-transfected cells.
A significant effect of treatment with the transfection reagent and transfection with 
pMSFl compared with treatment with a vehicle was found in absence of LPA 
treatment while EDG2 overexpression did not induce further significant increase in 
JNK-P activation in these cells. Activation of INK by transfection-related and 
especially by DNA transfection (pMSFl transfection) may not be surprising since 
JNK is known to be preferentially and strongly activated by environmental stresses. 
The limited availability of LPA in the medium may explain that EDG2 
overexpression itself did not induce a significant activation of JNK while this 
activation was completely revealed in LPA-treated cells by the stimulation of 
overexpressed EDG2 receptors with their endogenous ligand (p<0.001 comparing 
FZ)G2-overexpressing cells and pMSFl-overexpressing cells).
In conclusion, these results showed that EDG2 overexpression and stimulation of 
EDG2 receptors by LPA induced a significant increase in JNK-P activation, which 
confirmed the ANOVA analyses of western blot experiments performed under the 
same conditions (section 4.3.1). Although these results were not restricted to any 
specific MAPK, they provided evidence that LPA stimulation of EDG2 receptors 
resulted in the final activation of MAPK proteins including MAPK9 which was
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consistent with the hypothesis that EDG2 may provide an amenable route to 
modulate the activity of the “Pyk/Nck” pathway.
Striking similarity but improved sensitivity of these results also provided evidence 
that JlNfC-P ELISA could be favourably used instead of western blots to measure 
JTSIK-P activation.
4.4- Investigation of JNK-P activation in a stable transformed 
jEDG^-overexpressing cell line
Preliminary evidence showing activation of MAPK9 (among other MAP kinases) 
after transient transfection of EDG2 receptors was consistent with the hypothesis 
suggesting that EDG2 stimulation may provide a way to restore activity of the 
“Pyk/Nck” pathway.
In this context, stable EDG2-overexpressing cells may be used as a tool for screening 
EDG2 ligand compounds. In order to validate the use of these cells in functional 
studies, the phospho-SAPK/JNK ELISA assay (section 4.3.2) was used to semi- 
quantitatively measure MAPK8/9/10 phosphorylation as an indication of the final 
output of the “Pyk/Nck” pathway in these cells.
Cell lysate from £DG2-overexpressing clones 4, 7 and 12 (section 4.2) and wild-type 
SK-N-SH cells were treated prior to lysis with IpM LPA or vehicle and analysed for 
INK phosphorylation. As for transient EDG2-overexpressing cells, 15gg total protein 
was used and the Pathscan Phospho-SAPK/JNK (Thrl83/Tyrl85) Sandwich ELISA 
assay (Cell Signalling) was performed following the manufacturer’s protocol. Figure 
4.8 shows bar graphs representing absorbance at 450nm.
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Figure 4.8. Bar graph showing JNK-P levels in stable EDG2-overexpressing clones 
after LPA treatment
Samples (n=3) represent wild-type SK-N-SH cells and £DG2-overexpressing clones 
4, 7 and 12 treated with a vehicle or with LPA. Data are expressed as mean ± 
standard error of the mean (s.e.m). Data were analysed by ANOVA using LPA 
treatment and cell type as factors, revealing a significant effect of cell type 
(F(i,3)=1 56.37, p<0.001). Further potential interactions were investigated by simple 
main effect analysis (multiple comparisons were adjusted using Bonferroni’s 
procedure). * signifies p<0.001 compared untransfected SK-N-SH under the same 
treatment (vehicle or LPA); t  signifies p<0.05 between vehicle- and LPA-treated 
cells as shown on graph (Bonferroni-adjusted pairwise comparisons).
Visual examination of the graph revealed an increased phosphorylation of JNK 
proteins in each of the 3 clones compared with wild-type SK-N-SH cells, clone 7 
displaying highest JNK phosphorylation. Interestingly, levels of JNK-P activation in 
the 3 clones (clone 7 > clone 12 > clone 4) were consistent with EDG2 expression 
levels in these clones as measured by qRT-PCR (figure 4.4).
ANOVA analysis of JNK-P levels revealed similar results for £DG2-overexpressing 
clones 4, 7 and 12. In each of these clones considered individually, EDG2 
overexpression significantly increased JNK phosphorylation independently of LPA 
treatment. Conversely, LPA treatment did not affect overall JNK activation in any of 
the clones, but it induced a small but significant decrease in JNK phosphorylation in 
£DG2-overexpressing clones 4 and 12. This result was inconsistent with previous 
data showing an increase in JNK phosphorylation in LPA-treated versus vehicle- 
treated cells transiently overexpressing EDG2 (section 4.3.2). However, the LPA- 
induced decreased JNK phosphorylation was not significant for clone 7, which 
displayed highest EDG2 expression levels (section 4.2). Moreover, JNK
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phosphorylation levels shown by this clone after LPA treatment were still massively 
higher than those of wild-type SK-N-SH cells (p<0.001).
In conclusion, these results confirmed that stable EDG2 overexpression induced the 
activation of (a) signalling pathway(s) leading to JNK phosphorylation. Among three 
stable EDG2-overexpressing clones, clone 7 displayed the highest JNK activation 
corresponding with the highest EDG2 expression (section 4.2) therefore it was 
considered as the most promising for functional investigation of the “Pyk/Nck” 
pathway and for potential screening purposes.
4.5- qRT-PCR analysis of other components of the “Pyk/Nck” 
pathway
qRT-PCR was chosen as a method to perform a preliminary investigation of the 
potential activation of the “Pyk/Nck” pathway upstream of MAPK after EDG2 
overexpression. Potential gene expression changes of several components of this 
cascade including NCKl, PAKl (NCKl-interacting protein), PTK2B and MAPK9 
itself (Figure 4.1), were thus evaluated using stable £Z)G2-overexpressing clones. 
Although the methodology (qRT-PCR) and the design (absence of LPA treatment) of 
this experiment strongly limited its power and the probability to show any significant 
results, it was intended that these data may provide an insight into the activation of 
the “Pyk/Nck” pathway and the interactions between its different components.
In order to minimise the potential effect of other factors and ensure consistency 
between the groups, expression levels of “Pyk/Nck” pathway genes in EDG2- 
overexpressing clones 4, 7 and 12 were compared with their expression levels in 
three clones (clones 3, 10 and 13) which, although resistant to 0418, displayed 
EDG2 expression levels comparable to those of wild-type SK-N-SH cells. 
Glyceraldehyde-S-phosphate dehydrogenase (GAPDH), which exhibited unchanged 
expression in ADG2-overexpressing clones, was used as a covariate in the ANCOVA 
analysis of potential changes in NCKl, PAKl, PTK2B and MAPK9 expression 
induced by EDG2 overexpression.
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Expression levels of PAKl, PTK2B and MAPK9 were unchanged in EDG2- 
overexpressing clones compared to controls (data not shown) which may not be 
surprising since increased activity of these proteins (which are all kinases) occurs 
through and thereby may be reflected by increased phosphorylation and not by 
changes in mRNA expression. Thus, unchanged expression of MAPK9 was expected 
since this kinase had been shown to be phosphorylated -hence activated- in EDG2- 
overexpressing clones (section 4.4) under the same conditions.
Conversely, there was some evidence that EDG2 overexpression induced a decrease 
in NCKl expression (figure 4.9) which would confirm a link between EDG2 
receptors and the “Pyk/Nck” signalling cascade.
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Figure 4.9. Regression lines fo r  NCKl qRT-PCR o f EDG2-overexpressing clones
qRT-PCR was performed to evaluate NCKl expression changes in EDG2- 
overexpressing clones 4, 7 and 12 by comparison with clones 3, 10 and 13 
(exhibiting expression levels of EDG2 equivalent to those of wild-type SK-N-SH 
cells) (section 2.4.5). Y-axis is the logarithm of the fluorescence intensity 
representing the expression of NCKl and X-axis is the logarithm of the fluorescence 
intensity for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), the internal 
control gene that was used for normalisation. For each of these genes, this graph 
plots three points taken from the linear amplification phase of the PCR. The data 
were not analysed by ANCOVA since the analysis assumes a constant relationship 
between target gene and covariate in both treatment groups {i.e. the lines should be 
parallel).
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In conclusion, this study provided further evidence that EDG2 overexpression 
affected the activity of the “Pyk/Nck” pathway consistently with the hypothesis that 
modulating EDG2 activity may constitute a way to alter the activity of this cascade. 
However, since like most signalling cascades, the “Pyk/Nck” pathway is a series of 
kinases, better characterisation of its activity and regulation may be achieved by 
looking at phosphorylation of its different components in EDG2-overexpressing 
clones and in response to LPA.
4.6- [^^S]-GTPyS binding assay on stable transformed EDG2- 
overexpressing cells
In order to allow screening of EDG2 ligand compounds in vitro, a f  ^ S]~GTPyS 
binding assay monitoring guanine nucleotide exchange at G-proteins upon agonist 
stimulation was developed using stable EDG2-overexpressing cells. Since the 
specificity of this assay was inherently limited by the specificity of LPA towards 
EDG2 receptors as compared to other GPCRs, it was essential to investigate the 
endogenous expression of other LPA receptors, namely EDG4, EDG7 and GRP23, in 
the cells that were being used in the assay. qRT-PCR was used as a sensitive method 
of assessing mRNA expression of these receptors in SK-N-SH cells, thereby 
enabling the specificity of [^^S]-GTPyS binding assay towards the exogenous and 
endogenous EDG2 receptors to be predicted. Using this technique, EDG2- 
overexpressing SK-N-SH cells did not show any expression of EDG4 and EDG7 and 
displayed very low endogenous GFR23 expression (data not shown) suggesting that 
a LPA-induced [^^S]-GTPyS binding assay using these cells would be quite specific 
for EDG2 receptors.
The development of a [^^S]-GTPyS binding assay using £DG2-overexpressing cells 
required optimisation of the cellular membrane preparation and of the [^^S]~GTPyS 
binding assay and many attempts were necessary to obtain an assay giving consistent 
and reproducible results. Finally, the [^^S]-GTPyS binding assay was perforaied 
using a protocol adapted from Im et a l  (2000) and a series of experiments were 
performed to obtain an LPA dose-response curve for each “type” of cells, i.e. wild
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type SK-N-SH cells and £DG2-overexpressing clones 4, 7 and 12. As in most 
papers on LPA receptors including EDG2, final concentrations of LPA ranged from 
0.1 nM to lOpM LPA. Figure 4.9 shows LPA dose-response curves for SK-N-SH 
cells and £DG2-overexpressing clones 4, 7 and 12. Analysis of these curves by non­
linear regression analysis with a sigmoidal dose-response curve fitting allowed the 
pECsoof LPA (logio concentration of LPA required to give 50% of its own maximal 
stimulation) to be calculated in each type of cell as a measure of potency 
(Table 4.2).
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Figure 4.10. LPA-induced [^^S]-GTPyS binding
Dose-response curves represent LPA-induced [^^S]-GTPyS binding mediated by 
endogenous EDG2 receptors in SK-N-SH cells (■) and by endogenous and 
exogenous EDG2 receptors in clones 4 (▼), 7 (♦) and 12 (#) (n=2 for each cell type). 
[^^S]-GTPyS binding was performed following a protocol adapted from Im et al. 
(2000) using 25pg of total protein per reaction tube and final concentrations of 
0.1 nM, InM, lOnM, lOOnM, IpM and lOpM LPA. As assessed by comparison with 
the total amount of [^^S]-GTPyS introduced per reaction (data not shown), the 
radioactivity counts (in dpm: disintegrations per minute) obtained after filtration 
revealed that more than 10% of radioactivity was retained, making these results very 
reliable. Background [^^S]-GTPyS binding was subtracted from the data which were 
normalised to the maximal binding displayed by SK-N-SH cells when stimulated 
with the highest dose of LPA. Data representing the mean [^^S]-GTPyS binding 
obtained (in dpm.) ± standard error of the mean (s.e.m.) were plotted and analysed by 
non-linear regression analysis with a sigmoidal dose-response curve fitting 
(GraphPad Prism) to allow the pECso (potency) values of LPA to be calculated in 
individual clones (Table 4.2).
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Basal ± S.E.
dpm
pECso ^  S.E.
concentration
EC5o± S.E. 
concentration (nM)
SK-N-SH 9107 ±459 -7.115 ±0.095 77 ±30
Clone 4 8291 ±650 -6.723 ±0.176 190 ± 113
Clone 7 17620± 1643 -7.914 ±0.245 12 ± 8
Clone 12 8463 ±316 -7.446 ±0.133 36 ± 17
Table 4,2. Basal constitutive activity and LPA-induced f^^S]~GTPyS binding 
following stable transfections
Levels of basal activity in membranes prepared from SK-N-SH cells and in 
£Z)G2-overexpressing clones 4, 7 and 12 are presented as dpm (disintegrations per 
minute) bound. Potency values of LPA calculated from [^^S]-GTPyS binding dose- 
response curves are given as pECso values. n=2 for each cell type.
Although all cells exhibited substantial basal [^^S]-GTPyS binding, a LPA dose- 
dependent increase in [^^S]-GTPyS binding in both wild type SK-N-SH cells and 
clones 4, 7 and 12 (Figure 4.10) was evident, confirming that these cells were 
responsive to some extent to LPA.
Basal [^^S]-GTPyS binding (table 4.2) displayed by wild-type SK-N-SH cells in 
absence of LPA and probably mediated by constitutively active GPCRs as well as 
activation of endogenous EDG2 and GPR23 receptors by potential residual LPA 
present in the assay buffer, was consistent with the literature (Yoshida and Ueda
1999), but it was more surprising that clones 4 and 12 exhibited equivalent basal 
[^^S]-GTPyS binding levels since these cells had been shown to overexpress the LPA 
receptor EDG2. Although the hypothesis that increased EDG2 mRNA expression 
may be translated into functional receptors in these cells is supported, these results 
suggested that exogenous EDG2 receptors expressed by clones 4 and 12 did not 
show constitutive activity.
Conversely, clone 7 was shown to exhibit higher basal [^^S]-GTPyS binding than 
other cells suggesting that this clone expressed exogenous EDG2 receptors (Figure 
4.10) that displayed an important constitutive activity.
The LPA-induced increase in [^^S]-GTPyS binding above basal was higher in wild- 
type SK-N-SH cells and EDG2-overexpressing clone 7 than in other EDG2- 
overexpressing clones, clone 12 appearing to be the least sensitive to LPA. 
Interestingly, the better sensitivity of clone 7 in this assay compared to other clones 
was consistent with previous results showing that this clone displayed the highest
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EDG2 expression levels (section 4.2) and mediated the highest increase in JNK 
phosphorylation (section 4.4). Moreover, clone 7 was determined to yield the lowest 
pECso value of LPA (about 6 times less than that of wild-type SK-N-SH cells), 
further confirming the superiority of this clone for screening purposes (Table 4.2).
In conclusion, [^^S]-GTPyS binding assay using EDG2-overexpressing clone 7 was 
found to be a sensitive and reproducible approach that may be used for screening 
potential EDG2 receptor agonists.
4.7- Discussion
The aim of the work described in this chapter was 1) to characterise in vitro the 
potential role of EDG2 in relation to schizophrenia by investigating the hypothesis 
that stimulation of this G protein-coupled receptor may constitute a way to restore 
the activity of the “Pyk/Nck” pathway downstream from NMDA receptors and 2) to 
develop an assay which may be used for screening potential EDG2 ligand 
compounds.
4.7.1- Transient overexpression of EDG2 in SK-N-SH cells and functional 
characterisation of the activity of the “Pyk/Nck” pathway in these 
cells
In order to test the hypothesis that EDG2 stimulation may constitute an alternative 
route to activating the “Pyk/Nck” pathway and thereby restore NMDA receptor 
function in schizophrenia, the EDG2 human cDNA was cloned into an expression 
vector to allow overexpression of the receptor in vitro. pMSFl, an expression vector 
derived from pcDNA3.1 -FLAG® whose N-terminal signal sequence helps anchoring 
the cloned gene into the membrane (Mitsubishi Pharma Corporation) was chosen to 
ensure targeting of exogenous EDG2 receptors to the plasma membrane and thereby 
their correct functioning as G protein-coupled receptors.
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Human neuroblastoma SK-N-SH cells whose ability to proliferate and to 
differentiate makes an excellent system for in vitro studies (Shastry et a l 2001) were 
transfected with pMSFl-EDG2 expression construct. Cells transfected with the 
empty pMSFl vector were used as a negative control in subsequent functional 
experiments investigating the role of EDG2 in relation with the “Pyk/Nck” pathway.
Failure to confirm overexpression of the FLAG®-EDG2 fusion protein using 
immunodetection of pMSFl FLAG® epitope may be explained by the presence of 
only 7 out of the 8 amino acids (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys) of the FLAG® 
sequence which may be insufficient to allow specific binding of the FLAG® 
antibody. However, although the FLAG® antibody used (Sigma-Aldrich) was 
correctly detecting the 8-amino acids FLAG® epitope in similar experimental 
conditions (section 5.6.2), no other antibody was tried to detect pMSFl FLAG® 
epitope, making it impossible to exclude that this specific FLAG® antibody may be 
the issue. Nevertheless, western blotting using EDG2 antibodies was attempted as an 
alternative strategy but despite sustained efforts to optimise the methodology, 
including the use of five different antibodies (section 4.2, table 4.1), this technique 
again failed to confirm the overexpression of EDG2.
Finally, overexpression o ïE D G l mRNA was confirmed using qRT-PCR on pM SFl- 
£DG2-transfected SK-N-SH cells. Interestingly, SK-N-SH cells were shown to 
express endogenous EDG2 receptors suggesting that they may mediate some effects 
of LPA in these cells (Ashagbley et a l  1996). Although this evidence did not rule out 
any subsequent potential translation issues, it was indeed unlikely that the EDG2 
overexpression detected at the level of the mRNA may not result in significant 
overexpression of the protein.
Although transiently jEDG2-overexpressing cells necessarily exhibited a great 
variability in their levels of expression of EDG2 because of the inevitable 
unevenness of the transfection efficiency, they were used to investigate initially the 
effects of EDG2 overexpression on the activity of the “Pyk/Nck” pathway and to 
validate the methodology used for potential subsequent functional studies using other 
cells or other conditions.
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Phosphorylation (hence activation) of the final output of the “Pyk/Nck” pathway, 
MAPK9 (JNK2), was investigated first as it was thought to reflect the activity of the 
signalling cascade. However, immunoblotting analysis using a phosphorylation- 
specific antibody was complicated by the fact that the sites of phosphorylation 
present in MAPK9 are actually common to all JNK isoforms (MAPK8, MAPK9 and 
MAPK 10, or JNK l, JNK2 and JNK3 respectively) which all resolve in SDS-PA gels 
as either 46 or 54 kDa proteins. Thus, specifically determining which JNK isoform 
was potentially activated in EDG2-overexpressing cells was not possible.
Despite this, a dual phosphorylation (Thrl83/Tyrl85) specific JNK antibody was 
used to investigate the activation of the “Pyk/Nck” pathway in £DG2-overexpressing 
cells both in absence of LPA and after LPA treatment. As expected, the antibody 
detected two bands of -46  and 54 kDa that corresponded each to a mixture of 
proteins, the upper band being mostly MAPK9 (JNK2) and the lower band being 
mostly MAPK8 (JNKl) (Mizuno et a l  2002).
Visual examination and ANOVA analysis of the blots measured by densitometry 
revealed that JNK46koa and JNKs4kDa followed the same activation pattern in EDG2- 
overexpressing cells and after LPA stimulation.
Thus, EDG2 overexpression had a major effect in increasing JNK activation overall, 
however, the increased JNK activation observed in £DG2-overexpressing cells 
compared with cells transfected with the empty pMSFl vector was only significant 
(pairwise) when the cells were stimulated with LPA suggesting that LPA binding to 
the overexpressed EDG2 receptors was required to induce JNK activation. 
Consistently, the effect of LPA treatment on JNK activation was not significant 
overall but in ÆDG2-overexpressing cells only.
These results provided evidence that LPA-stimulation of EDG2 receptors resulted in 
the similar and concomitant activation of both JNK46kDa and JNK54kDa proteins 
suggesting that EDG2 receptors over expressed in SK-N-SH cells coupled to one or 
several path way (s) leading to the activation of several MAPKs including MAPK 8 
(JNK l) and MAPK9 (JNK2). These results therefore confirmed the hypothesis that 
EDG2 overexpression and its stimulation with LPA affects the activity of the final 
output of the “Pyk/Nck” pathway.
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However, the precise detemiination of which of these MAPKs were activated 
following LPA stimulation of EDG2 receptors may be very important functionally. 
JNK proteins have been shown to display differing affinities and specificities for 
target transcription factors so that they may induce the activation of distinct 
pathways and cellular responses (Bozyczko-Coyne et a l  2002). However, even 
though antibodies exist which make it feasible to resolve activation of JNK family 
subgroups by immune-complex and/or immuno-depletion kinase assays, these assays 
are not straightforward. Thus, as an attempt to specifically investigate the activation 
of MAPK9 in EZ)G2-overexpressing cells, a JNK activation assay was developed 
coupling immunoprécipitation with a phospho-specific JNK (JNK-P) antibody 
(detecting the active form of JNK) with immunodetection (western blotting) using a 
JNK2 antibody. As expected, this assay specifically detected phosphoiylated 
MAPK9 (JNK2) proteins of approximately 54 kDa but it proved quantitatively non- 
reproducible, which was unacceptable since the purpose of this assay was to 
investigate semi-quantitatively the activation of MAPK9 in EDG2-overexpressing 
cells.
Another technique for profiling the MAPK pathway downstream of EDG2 receptors 
would have been to study the activation of signal transduction by quantitatively 
measuring transcription activation but this method, which would have necessitated 
further cloning experiments to set up reporters vectors, would have investigated 
downstream events and therefore would not have addressed the hypothesis of the 
“Pyk/Nck” pathway and MAPK9 being downstream of EDG2 receptors.
In order to provide confirmation of the JNK-P western blot results, a JNK-P ELISA 
assay was used as a semi-quantitatively more reliable method for measuring JNK 
phosphorylation. Use of this assay was also encouraged by results showing similar 
activation of both JNK46kDa and JNK54kDa rather than specific activation of a specific 
JNK isoform in LPA-stimulated EDG2-overexpressing cells. Thus, this assay, which 
did not have the power to discriminate between JNK isoforms, appeared an easier, 
quicker and more reliable way of assessing MAPK activity in £DG2-overexpressing 
cells.
Very interestingly, statistical analysis of JNK-P ELISA data proved exactly identical 
to the analysis of western blot data, showing that EDG2 overexpression in SK-N-SH
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cells induced an overall increase in JNK phosphorylation which, however, was only 
statistically significant after LPA treatment when comparing ÆDG2-overexpressing 
cells to cells transfected with the empty pMSFl vector. Moreover, still consistent 
with western blotting results, LPA treatment significantly increased JNK 
phosphorylation in FZ>G2-overexpressing cells only, suggesting that LPA stimulation 
of exogenous EDG2 receptors is coupled to a signalling pathway leading to JNK 
activation.
The only apparent difference between JNK-P western blots and ELISA results was in 
the endogenous levels of JNK phosphorylation measured by the ELISA assay in non­
transfected SK-N-SH cells compared with western blotting. This difference may be 
explained by the better sensitivity of the ELISA technique compared to western blot 
analysis, especially since less total protein was used for the ELISA (15gg) than for 
western blotting (40pg).
In conclusion, these results provided evidence that LPA-stimulation of EDG2 
receptors induced the activation of the final output of the “Pyk/Nck” signalling 
pathway, MAPK9, probably along with other MAPK. Whether the signal induced by 
LPA stimulation was actually transduced via the “Pyk/Nck” pathway may be 
determined by looking at the activation of other proteins within the hypothesised 
cascade (section 4.5). The similar activation pattern of JNK46kDa and JNK54koa 
induced by LPA in EDG2-overexpressing SK-N-SH cells suggested that EDG2 
receptors stimulated by their endogenous ligand probably coupled to multiple 
signalling pathways leading to various responses in terms of transcription activation. 
This hypothesis was consistent with evidence showing that LPA can mediate several 
intracellular transduction pathways via activation of different G proteins (Moolenaar 
et a l 1997; Yoshida and Ueda 1999; Yoshida and Ueda 2001).
However, this did not rule out the possibility that EDG2 receptors may potentially 
possess agonists or may be stimulated by synthetic ligands mediating the activation 
of selected transduction pathways hence potentially specific MAPK. Such a 
mechanism, shown for lysophosphatidylcholine (LPC) and sphingosine 1-phosphate 
(SIP) lipid receptors may indeed be envisaged for LPA EDG2 receptors, which are 
phylogenetically very close to LPC and SIP receptors (Uhlenbrock et a l 2002; Lin 
and Ye 2003).
161
These preliminary functional studies performed using transient EDG2- 
overexpressing cells therefore provided promising evidence suggesting that EDG2 
stimulation by LPA may mediate the activation of a signalling pathway leading to 
MAPK activation. However, LPA-induced activation of MAPK has been shown to 
be highly dependent on the cell phenotype with different protein-tyrosine kinases 
(including Ptk2b) mediating signal transduction (Buist et a l 1998) suggesting that it 
would be very premature to translate directly these results to any hypothesis in vivo. 
Moreover, the massive overexpression of exogenous EDG2 receptors (approximately 
1.75x10^ times more than wild-type SK-N-SH cells) in these cells may affect the 
pharmacology of EDG2 receptors (Kenakin 2003) so that these results may not 
reflect the physiology of endogenous neuronal EDG2 receptors in vivo. These issues 
are discussed in more detail in section 4.7.5.
4.7.2-Development of a stable transformed E'Z)G2-overexpressing cell 
line and functional characterisation of the activity of the “Pyk/Nck” 
pathway in these cells
Promising functional results showing activation of MAPK9 after LPA stimulation of 
EDG2 receptors in transiently £DG2-overexpressing cells (section 4.3) encouraged 
the generation of a stable transformed cell line for further functional studies on the 
“Pyk/Nck” pathway and potentially to develop an assay for screening EDG2 ligand 
compounds. Having a constant phenotype is indeed essential to obtain reliable and 
reproducible results from in viti'o functional studies and screening assays, for which a 
large number of clonal cells is usually needed (Eglen 2005).
Creation of a stable cell line overexpressing EDG2 receptors was also stimulated by 
promising in vivo data obtained concomitantly in the lab showing that acute Edg2 
activation restores schizophreniform sensorimotor gating deficits in prepulse 
inhibition (PPI) (Alice Egerton) and reverses PCP-induced deficits in prefrontal 
cortex metabolic hypofunction (Susan Cochran and Allan McVie). These results 
suggesting that Edg2 agonists may have an antipsychotic activity provided further 
evidence that EDG2 may potentially represent a promising drug target against 
schizophrenia and reinforced the need for an EZ)G2-overexpressing cell line of 
constant phenotype that may be used in a potential screening assay.
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An EDG2-overexpressing stable cell line was thus developed from transiently 
£DG2-overexpressing SK-N-SH cells. After a thorough selection process, 15 clones 
were obtained and three of them were found to show significantly higher EDG2 
mRNA expression levels than wild-type SK-N-SH cells. One clone in particular, 
clone 7, exhibited the largest EDG2 expression, which was lower than that of 
transiently EDG2-overexpressing cells.
In order to provide further confirmation of previous results showing coupling of the 
EDG2 receptors to MAPK, these cells were used in the JNK-P ELISA assay, a more 
effective and sensitive method to semi-quantitatively detect JNK activation (section 
4.3.2). Stable EDG2 overexpression induced JNK activation which was consistent 
with previous results using transiently ADG2-overexpressing cells. Moreover, 
maximal JNK activation was observed in £DG2-overexpressing clone 7 which 
interestingly corresponded to the highest expression levels of EDG2 mRNA in this 
clone compared to clones 4 and 12 (section 4.2). However, LPA treatment, which 
increased JNK activation in transient EDG2-overexpressing cells, showed the 
opposite effect in stable EDG2-overexpressing clones, significantly decreasing JNK 
phosphorylation in clones 4 and 12 (section 4.4). LPA-induced decrease in JNK 
activation was not significant in clone 7, which may have suggested that this clone 
was superior to other clones in terms of specificity of transduced signalling 
pathways. However, although this possibility could not be excluded, the apparent 
decrease in JNK activation induced by LPA in this clone similar to other clones 
rather suggested that all three clones were undergoing the same mechanism when 
stimulated by LPA.
Thus, stable overexpression of EDG2 in these cells in the absence of LPA may 
induce conformational changes in the GPCRs, favouring a constitutively active state 
in which the receptors may be able to initiate a biochemical response in the absence 
of LPA, as opposed to a state in which they are activated by their ligand, LPA. 
Ligand independent signalling has been reported for many GPCRs (Seifert and 
Wenzel-Seifert 2002) including receptors phylogenetically close to EDG2 (Kostenis 
2004) such as the EDG SIP receptors (Lee et al. 1996; Niedernberg et al. 2003) and 
the non-EDG cannabinoid and melanocortin receptors (Nie and Lewis 2001; Holst 
and Schwartz 2003) and is specifically a very common feature displayed by
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transformed cell lines (Seifert and Wenzel-Seifert 2002). Following this hypothesis, 
LPA stimulation of constitutively active EDG2 receptors may induce a change in the 
conformation of the receptors towards a ligand-activated state (Gether and Kobilka
1998). However, this LPA-induced effect may be progressive and dose-dependent so 
that it may be necessary to extend the duration of LPA treatment or delay before 
investigation in order to reveal the maximal activation of LPA-induced downstream 
signalling pathways. Thus, the duration of LPA treatment or the time-point used to 
look at LPA-induced JNK activation in these stable transformed cells may not be 
long enough to enable most of the receptors to switch conformation and become 
activated by LPA, so that the genuine effect of LPA in mediating activation of the 
MAPK signalling pathway may be masked under these conditions. Moreover, since 
the JNK-P ELISA assay cannot differentiate between JNKs, it may be that 
constitutively active receptors and LPA-activated EDG2 receptors actually couple to 
different JNK pathways, a mechanism which may be masked in the ELISA assay 
quantifying the whole phosphorylated JNK proteins. Such a phenomenon has indeed 
been shown for other receptors including dopamine D2 and opioid receptors 
(Kenakin 2003).
Although it may not be as likely, another possibility which may explain the decrease 
in JNK activation induced by LPA treatment in stable £DG2-overexpressing cells 
may be the desensitisation of these receptors (Ferguson et al. 1996; Conway et a l
1999). LPA-induced internalisation of EDG2 receptors resulting in decreased 
responsiveness to their ligand has indeed been shown to participate in the regulation 
of the activity of EDG2 (Avendano-Vazquez et a l  2005) and EDGl (Liu et a l  1999) 
receptors and may explain the limited activation of JNK observed in stable EDG2- 
overexpressing cells after LPA treatment.
Again, in order to address these issues, it may be very interesting to investigate the 
activation of specific JNK pathways in stable £DG2-overexpressing cells in the 
absence and in presence of LPA.
Although levels of JNK activation were decreased in LPA-treated cells compared to 
cells treated with a vehicle, they were still massively higher in LPA-stimulated 
EDG2-overexpressing clones, especially clone 7, than those displayed by wild-type 
SK-N-SH cells, suggesting that stable exogenous EDG2 receptors mediated the 
activation of (a) signalling pathway(s) leading to MAPK phosphorylation. Of three
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stable £DG2-overexpressing clones, clone 7 appeared the most promising to 
functionally investigate the “Pyk/Nck” pathway and to be used in potential screening 
purposes.
In order to investigate whether stimulation of EDG2 receptors leading to MAPK 
phosphorylation was mediated by the “Pyk/Nck” pathway, and thereby test the 
hypothesis that EDG2 stimulation may provide another route to activating this 
pathway, potential gene expression changes of several components of this cascade, 
including NCKl, PAKl (Nek 1-interacting protein), PTK2B and MAPK9, were 
evaluated using the stable EDG2-overexpressing clones. Because like most 
signalling cascades, the “Pyk/Nck” pathway is a series of kinases whose subsequent 
phosphorylation or dephosphorylation allows quick transduction of the signal, the 
methodology (qRT-PCR) as well as the design (absence of LPA treatment) of this 
study may not be ideal to investigate the activity of the “Pyk/Nck” pathway but may 
nevertheless provide an insight on the genes/proteins that may be regulated by EDG2 
signalling.
Most of the kinases examined including PTK2B, MAPK9, and PAKl did not exhibit 
any change in expression in £Z)G2-overexpressing cells compared with wild-type 
SK-N-SH cells (section 4.5) which was consistent with the hypothesis that activation 
of these proteins occurs by phosphorylation rather than regulation of gene 
expression. Thus, unchanged expression of MAPK9 in stable EDG2-overexpressing 
cells was consistent with LNK-P ELISA results showing an increased MAPK 
phosphorylation in these cells by comparison with wild-type SK-N-SH cells (section 
4.4). Nevertheless, one of the genes examined, NCKl, an adaptor protein shown to 
regulate INK activation (Mizuno et a l  2002; Poitras et a l 2003), showed decreased 
expression in stable EDG2-overexpressing cells suggesting that EDG2 receptors did 
mediate MAPK activation via the “Pyk/Nck” signalling cascade. Interestingly, this 
result was consistent with data showing a massive increase in MAPK activation in 
the prefrontal cortex of N ckl knock-out mice (Nicola Veitch).
In conclusion, these results provided further evidence that EDG2 receptors mediate 
the activation of the “Pyk/Nck” pathway leading to MAPK activation so that 
stimulation of these receptors may represent a therapeutic strategy to counterbalance 
PCP-induced deficits within this pathway and thereby its behavioural coirelates.
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4.7.3“ p^S]-GTPyS binding assay on EDG2 clones
In order to allow screening of potential EDG2 agonists in vitro, a [^^S]-GTPyS 
binding assay was developed using stable EDG2-overexpressing cells (section 4.6). 
This assay, which monitors guanine nucleotide exchange at G-proteins upon agonist 
stimulation, was preferred to radioisotopic labelling of LPA because of its power to 
differentiate between agonists and antagonists and to determine their 
pharmacological parameters (Eglen 2005). Since this assay was specific to all LPA- 
stimulated GPCRs rather than to EDG2 receptors, EDG2-overexpressing SK-N-SH 
cells were assayed for expression of other LPA receptors including EDG4, and 
EDG7 and GPR23 using qRT-PCR. Lack of expression of EDG4 and EDG7 and 
very low endogenous levels of GPR23 in these cells confirmed that a LPA- 
stimulated [^^S]-GTPyS binding assay using these cells would be quite specific to 
EDG2 receptors.
Wild-type SK-N-SH cells and £Z)G2-overexpressing clones exhibited basal f  ^ S]- 
GTPyS binding but LPA treatment dose-dependently increased [^^S]-GTPyS binding 
in all cells confirming that they were responsive to LPA. The highest basal f  ^ S]- 
GTPyS binding levels displayed by £DG2-overexpressing clone 7 compared to 
clones 4 and 12 and wild-type SK-N-SH cells suggested that the exogenous EDG2 
receptors expressed in this clone possessed an important constitutive activity which 
was consistent with the highest JNK activation exhibited by this clone in absence of 
LPA (section 4.4). In this way, further extrapolation of JNK activation data to [^^S]- 
GTPyS binding may suggest that clones 4 and 12 would display lower basal [^^S]- 
GTPyS binding, but still higher than wild-type SK-N-SH cells. Conversely, the 
similarity between the f^S]-GTPyS binding levels displayed by all these cells 
indicated that the exogenous EDG2 receptors expressed by clones 4 and 12 did not 
show constitutive activity. Indeed, it would be very unlikely that increased EDG2 
mRNA expression (section 4.2) would only be translated into protein in clone 7 but 
not clones 4 and 12 especially since they were shown to display increased JNK 
activation compared to wild-type SK-N-SH cells (section 4.4). Therefore the levels 
of EDG2 expression in clones 4 and 12 may be below the threshold required to show 
elevated basal p^S]-GTPyS binding.
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LPA dose-dependently increased f^S]-GTPyS binding in FZ)G2-overexpressing 
clones as well as wild-type SK-N-SH cells, clone 12 being the least sensitive to LPA. 
While clone 4 appeared intermediately sensitive to LPA, EDG2-overexpressing 
clone 7 and wild-type SK-N-SH cells seemed about equivalently responsive to LPA, 
showing apparently parallel [^^S]-GTPyS binding dose-response curves (section 4.6, 
figure 4.10). However, the potency of LPA (effective concentration 50%: EC50) in 
these cells revealed that M)G2-overexpressing clone 7 was actually more sensitive to 
LPA than wild-type SK-N-SH cells (table 4.2). Stable EDG2 overexpression in 
clone 7 did induce shifting of the concentration of LPA giving 50% of maximal 
[^^S]-GTPyS binding (EC50) by a factor of 6 compared to wild-type SK-N-SH cells 
which reflected a major improvement in the sensitivity of the assay in detecting 
agonist-induced [^^S]-GTPyS binding. Interestingly, these results using SK-N-SH 
cells were consistent in terms of dose-response curve with [^^S]-GTPyS binding 
results on EDG2 receptors performed using other cell lines (McAllister et a l  2000), 
Moreover, the EC50 of LPA using clone 7 (12nM) was comparable with those found 
both in a similar assay used for characterising binding of novel potential agonists to 
the EDG2, EDG4 and EDG7 receptors (EC50 of LPA: 17nM) (Santos et a l  2004) 
and in a serum response element-driven luciferase expression reporter gene assay 
(EC50 of LPA: lOnM) (An et a l 1998). Thus, clone 7 appeared superior to other 
EDG2-overexpressing clones and to wild-type SK-N-SH cells in the characterisation 
of EDG2 agonist binding.
Nevertheless, the high levels of basal f  ^ S]-GTPyS binding displayed by this clone 
and to a less extent by other clones and wild-type SK-N-SH cells may be pointed out 
as a caveat of this experiment since it may prevent the proper detection of LPA- 
induced [^^S]-GTPyS binding. Thus, even if non-specific binding was not assessed 
either in similar studies on other EDG receptors such as EDG l (Parrill et a l 2000) 
and EDG7 (Im et a l  2000), use of unlabelled or “cold” GTPyS to ensure blockade of 
all potential non-specific sites before introduction of [^^S]-GTPyS may have been 
advantageous in this assay. Moreover, since binding of [^^S]-GTPyS to G-protein 
subunits in vitro has been shown to be highly dependent on the concentration of 
added GDP (Harrison and Traynor 2003), increasing the concentration of GDP in the 
assay buffer may also be advantageous to reduce basal f^S]-GTPyS binding but
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since GDP competes f  ^ S]-GTPyS for binding, it would probably reduce the rate and 
the magnitude of LPA-induced f  ^ S]-GTPyS binding as well and thereby may not 
improve the sensitivity of the assay. Moreover, the concentration (lOpM) of GDP 
used in this study was similar to that used for the characterisation of novel Edg2 
agonists in vitro using other cells (Santos et a l  2004) suggesting that this 
concentration was suitable for screening purposes.
Finally, in order to overcome the issue of basal f  ^ S]-GTPyS binding, it may have 
been advantageous to assess the expression of LPA receptors in several cell lines 
before using SK-N-SH cells. Different cell lines have indeed been found to show 
different basal and LPA-induced [^^S]-GTPyS binding responses (McAllister et a l
2000) probably depending on their endogenous expression of LPA EDG2, EDG4, 
EDG7 and GPR23 receptors. Since LPA, the simplest of all glycerophospholipids, is 
found in 2-20pM concentrations in mammalian serum (Moolenaar 1995), any 
expressed LPA receptors may mediate the effects of LPA in cell-based assays which 
may complicate the interpretation of GPCR selectivity studies (McAllister et a l
2000). To overcome this issue, use of pertussis toxin-insensitive EDG2 receptor- 
G ial fusion protein has been proposed as an approach to monitor EDG2 receptor- 
mediated (particularly Gi-mediated) responses in vitro (McAllister et a l  2000). 
Moreover, this technique not only improves sensitivity of the assay but, similar to 
methods involving immunoprécipitation or immobilisation of the G-[^^S]-GTPyS 
complexes after the assay prior to measuring the degree of radioactivity (Harrison 
and Traynor 2003; Eglen 2005), it enables the measurement of [^^S]-GTPyS binding 
to specific G-subunit families.
All these techniques may be successfully applied to the EDG2 [^^S]-GTPyS binding 
assay and may improve its sensitivity. Nevertheless, since the [^^S]-GTPyS binding 
assay using clone 7 was found to be as sensitive as the assay used by Santos et a l to 
characterise potential novel EDG2 agonists (Santos et a l 2004), this assay appeared 
sensitive enough to use as a screening assay and therefore suitable for this purpose.
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4.7.4“ Interpretation of EDG2 functional studies in relation with the 
“Pyk/Nck” pathway hypothesis
Evidence from in vitro functional studies (JNK-P ELISA and qRT-PCR) using stable 
jEDG2-overexpressing cells provided strong evidence that LPA stimulation of stably 
overexpressed EDG2 receptors mediated the activation of a signalling pathway 
leading to MAPK9/MAPK10 in SK-N-SH cells. Differential expression of NCKl in 
these EDG2~overexpressing cells suggested that EDG2-stimulated increase in 
MAPK phosphorylation was mediated by the “Pyk/Nck” pathway.
Moreover, correlation between JNK-P ELISA and f  ^ S]-GTPyS binding results using 
stable EDG2-overexpressing cells suggested that EDG2-overexpressing clone 7 was 
superior to other transformed clones in mediating activation of the “Pyk/Nck” 
pathway. This clone, which may be suitable for use in f  ^ S]-GTPyS binding assay to 
screen potential EDG2 agonists, may also be advantageously used in further 
functional studies that may address the specificity of the MAPK pathway activated 
downstream of EDG2 receptors in SK-N-SH cells in response to stimulation by LPA 
and/or by potential EDG2 agonists. Such studies may include the investigation of 
potential changes in the activation, through phosphorylation, of “Pyk/Nck” pathway 
proteins, using western blots or ELISAs, and the examination of EDG2 downstream 
“Pyk/Nck” signalling using EDG2-overexpressing cells transfected with dominant 
negative constructs of specific “Pyk/Nck” genes.
As for most functional studies and screening assays for G-protein coupled receptors, 
a recombinant cell line overexpressing EDG2 receptors was used to investigate the 
activation of signalling pathways mediated by these receptors following stimulation 
with their endogenous ligand, LPA. SK-N-SH neuroblastoma cells were selected to 
develop this recombinant cell line because these human cells commonly used in 
neurobiology could potentially be differentiated into cells of neuronal-like phenotype 
(Shastry et a l 2001). Nevertheless, however suitable these cells appeared for our 
studies, their background (similar to that of any cells) necessarily limited our results 
to their phenotype (Kenakin 2003). GPCR pharmacology has indeed been shown to 
be very specific to the cell type which influences the formation of GPCR oligomers 
and affects the action of allosteric ligands (Eglen 2005). Moreover, the level and 
pharmacology of GPCR is determined by the cell-specific nature and expression of
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GPCR-interacting proteins (GIPs) (Eglen 2005). Thus, both the relative potency of 
compounds and G-protein selectivity is very specific to the cell type used (Kenakin 
2003). With regards to LPA for example, LPA-stimulated activation of MAPK has 
been shown to be mediated by different pathways and interacting proteins in COS-7, 
PC12 cells and fibroblasts (Buist et a l 1998). In SK-N-MC cells neuroepithelioma 
cells, which are phenotypically very similar to SK-N-SH cells, LPA-induced MAPK 
activation was not confirmed (Buist et a l  1998). However since the kinase assay 
used in this study only detected p42 MAPK activity these results do not contradict 
evidence showing LPA-induced activation of JNK MAPK in SK-N-SH cells 
(sections 4.7.2 and 4.7.3).
Moreover, although recombinant cell lines are a very valuable tool in drug discovery, 
they do not reproduce the physiological conditions and signal transduction from 
receptor to G-protein using such cells may not be as efficient and selective as when 
all signalling components have endogenous expression levels (Kurkinen et a l  1997). 
Each G-protein has indeed a distinct affinity for the receptor so that changes in 
receptor density due to massive overexpression of GPCRs may induce differences in 
the quality (composition of signals) as well as the quantity of response to agonists 
(Kenakin 2003).
Early models of GPCR function comprising two receptor states (active and inactive) 
are therefore widely obsolete especially since incoming signals from a ligand do not 
produce a uniform output signal from the receptor but can produce a signal 
distributed to various pathways (Kenakin 2003). Thus, it is likely that, as has been 
shown for many receptors, EDG2 receptors may be stimulated by different agonists 
activating specific cellular pathways, a phenomenon referred to as stimulus 
trafficking (Kenakin 1995). Moreover, studies have also indicated that the receptor 
active state mediating constitutive activity differs from the state created by agonist 
binding which may explain the decrease in JNK-P activation observed in stable 
EOG2-overexpressing cells in response to LPA (section 4.4).
These data therefore further reinforce the need and the interest of investigating LPA- 
and agonist-induced activation of EDG2 receptors and their downstream signalling 
pathways. In particular, it may be advantageous to characterise the stimulation of 
EDG2 by the LPA derivatives used in vivo as EDG2 agonists (Santos et a l 2004) in 
terms of [^^S]-GTPyS binding and mediated signalling pathways.
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Beyond these considerations, these in vitro results provided evidence that EDG2 
stimulation may constitute a novel route leading from activation of the “Pyk/Nck” 
signalling cascade down to MAPK activation. How the activation of this pathway 
and of its final output JNK, relates to schizophrenia remains a very difficult question 
because of the complexity of the JNK signalling pathway and of the potential 
diversity of its functions depending on environmental factors and different cell types 
(Davis 2000; Johnson and Lapadat 2002; Vlahopoulos and Zoumpourlis 2004; 
Waetzig and Herdegen 2004). Nevertheless, recent evidence of the physiological 
functions of JNK in the development of the brain and the integrity of the 
cytoskeleton appear particularly interesting since they may relate NMDA 
downstream signalling events with the neurodevelopmental hypotheses of 
schizophrenia (Lewis and Levitt 2002), while the roles of JNK in synaptic plasticity 
may be consistent with the hypothesis of altered synaptic plasticity and connectivity 
in schizophrenia (Stephan et al. 2006). Consistent with literature suggesting a role 
for EDG2 in myelination (Contos et al. 2000b; Handford et al. 2001), coupling of 
this receptor to the “Pyk/Nck” signalling cascade may therefore provide an example 
connecting a differentially expressed receptor with several hypotheses including the 
emerging neurodevelopmental hypothesis of schizophrenia (Rapoport et al. 2005).
In the light of the deficits in the activity of this pathway downstream of NMDA 
receptor signalling, modulating EDG2 activity may therefore represent a novel 
strategy to counterbalance PCP-induced deficits in the rat chronic PCP model and 
NMDA receptor hypofunction in schizophrenic patients. Interestingly, further 
support to this hypothesis was obtained in vivo, with evidence showing that acute 
Edg2 activation using a novel Edg2 agonist developed by MPC restores 
schizophreniform sensorimotor gating deficits in prepulse inhibition (PPI) in mice 
(Alice Egerton) and reverses PCP-induced prefrontal cortex metabolic hypofunction 
(Susan Cochran and Allan McVie). These results suggested that EDG2 agonists may 
have an antipsychotic activity, strongly reinforcing the interest in EDG2 as a 
potential promising drug target for schizophrenia.
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CHAPTER 5: FROM THE EST AI072720 TO 
AN UNCHARACTERISED GENE POTENTIALLY 
IMPLICATED IN SCHIZOPHRENIA
1 7 2
5.1“ Introduction
The aim of this work was to confirm the EST AI07270 as a genuine rat transcript and 
to further characterise it in relation with schizophrenia. Transcript analysis methods 
(RACE and RT-PCR) were used for identifying the rat gene and confirming its 
differential expression in the chronic PCP model of schizophrenia. To investigate its 
function, a variety of cellular biology techniques were used, including cloning, 
overexpression and immunofluorescence to look at sub cellular localisation and to 
examine cell morphology in vitro and immunoprécipitation for identifying 
interacting proteins. The effect of KIAA1189 (approved name of human orthologue) 
overexpression on neurite outgrowth of PC 12 cells was also examined. Genotyping 
of single nucleotide polymorphisms (SNPs) was finally used in order to explore any 
potential genetic association of this gene with schizophrenia in a Caucasian 
population of schizophrenic patients and controls.
5,2-In silico analyses towards the identification of a gene for the 
EST AI072720
5.2.1“ DNA sequence homology screening
Initial DNA sequence homology screening analyses (section 2.3.2, November- 
December 2003) showed that the human orthologous region of rat EST AJ072720 
did indeed correspond to the 3’ untranslated region (3’UTR) of a then predicted and 
now approved gene cdXlQé KIAAl 189 (71% identity over 140bp of the Affymetrix rat 
probe set target sequence and human cDNA sequence). No homologous mouse or rat 
gene was found at Ensembl but interestingly the Affymetrix rat probe set target 
sequence showed strong sequence identity (99.5% over 386bp) with a rat genomic 
sequence (Chr.3 39717303-39717688) located 2063bp downstream of the last exon 
of a predicted rat gene now called RGD1308367, orthologous to the human 
KJAA1189 gene.
This suggested that the EST AI072720 may belong to a part of the rat orthologue of 
human KIAA1189 which had not been cloned or predicted yet. We hypothesised that
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despite this EST sequence being 2kb downstream of RGD1308367, it may represent 
a splice variant or an alternative exon of this gene or belong to its 3’ untranslated 
region (3’UTR) (figure 5.1).
Alternatively, the EST AI072720 could represent a novel rat gene, not cloned or 
predicted.
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Figure 5.1. Locations o f EST AI072720 and RGDl308367 (KIAA1189 orthologue) 
within the rat genomic sequence
Blue boxes represent exons 1, 2 and 3 of predicted rat R G D l308367 gene, red box 
represents the EST and white regions represent intronic or intergenic genomic DNA. 
The pale blue box shows the location of EST AI072720 in relation with exon 3 of 
RGD1308367. R G D l308367 is the current and approved symbol of the rat gene 
named ""similar to KIAA1189'' which is the rat orthologue of human K1AA1189 
(approved gene name).
5.2.2- Sequence information retrieval and clustering of EST
Clustering and assembling ESTs is a valuable and effective method to reconstruct 
transcripts and discover new genes or new variants of genes.
In order to correlate and associate the EST AI072720 with other potential 
overlapping or neighbouring ESTs, the EST AI072720 was mined from different 
databases, including GenBank (nucleotide database including dbEST for information 
on ESTs), Unigene (gene-oriented clusters of transcript sequences), Uni STS 
(markers and mapping data) and Geo Profiles (expression and molecular abundance 
profiles) databases (all at NCBI).
A description of the source of the EST was found in the GenBank/dbEST annotation 
for AI072720: the EST AI072720 (Rn#S 13892600, mRNA reference gi 13398914) 
was identified as a clone in a subtracted cDNA library prepared from an adult rat
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individually-tagged normalised whole-eye (minus the lens) library (Bonaldo et a l  
1996)
At Unigene, the EST AI072720 was found to belong to a cluster of 4 ESTs (Unigene 
cluster Rn,20243) mapped to rat chromosome 3 (UniSTS entry ; chr.3 RH134705). 
Interestingly, the 3 other ESTs of this cluster were identified as clones in libraries 
derived from brain tissue only:
- BF568003 (Rn#S14101815, 5’ read) was cloned from dbEST3768, a subtracted 
library derived from a mixture of the following tissues: thalamus, cerebellum, 
hypothalamus, medulla, pons, midbrain, cerebral cortex, corpus striatum and 
hippocampus,
- CB734608 (Rn#S 15097956, 5’ read) was cloned from dbEST12821, a Wistar rat 
hypothalamus and pituitary gland library,
- CB781779 (Rn#S15141528, 3’ read) was cloned from dbEST12817, a rat 
hypothalamus library.
No Geo Profile reporting the identification of the EST AI072720 from microarray 
studies was found.
ClustalW at EBI-EMBL showed a very good alignment and a high similarity 
between the four Rn.20243 cluster ESTs sequences (including EST AI072720). A 
consensus overlapping sequence (common between all 4 sequences) of about 320bp 
was identified and the EST AI072720 (Rn#S 13892600) was found to exhibit 86.2% 
sequence identity over 807bp with the EST Rn#S14101815. Among the 4 sequences, 
Rn#S14101815 was found to be the longest extending at the 5’ and 3’ ends. The 
alignments did not show 100% sequence identity between the ESTs, probably 
because of sequencing errors. However the alignment of 4 EST sequences added 
weight to the hypothesis that the EST AI072720 was a genuine rat transcript.
5.2.3“ Gene prediction
Many gene prediction programs based on different methods and algorithms of gene 
prediction were used to identify a gene for the EST AI072720.
In order to maximise the chance both to confirm that the EST AI072720 belonged to 
RGD1308367, the rat orthologue of KIAA1189 gene, or to predict a novel gene in 
which the EST AI072720 was contained, these programs were run on a 7282bp-long
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sequence corresponding to the EST AI072720 sequence extended with 5’ genomic 
sequence (Chr.3 39717251-39724532, minus strand orientation).
Among the programs run, Genscan, HMMGene, EUI and GI (within GeneComber) 
predicted the three exons of the upstream RGD1308367 gene but did not predict 
anything in the region of the EST AI072720. Figure 5.2 shows the Genscan output as 
an example.
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Figure 5.2. Genscan graphical output for rat chromosome 3 39717251-39724532 
(minus strand)
The scale bar represents genomic distance in kb. The blue blocks represent the 3 
predicted exons upstream of EST AI072720.
In contrast, GRAIL, GenelD, the Integrated system for exon finding (MZEF + SPC), 
the ORNL Genome Analysis Pipeline and NIX all predicted four exons within the 
7.3Kb sequence.
GRAIL and The Integrated system for exon finding predicted, in addition to the three 
exons of RGD1308367, an exon of 135bp from 6754 to 6889 (with regards to the 
entry sequence, 39717643 to 39717778 with regards to rat genomic sequence). 
Interestingly, this putative fourth exon was found to align exactly with 41 bp at the 5’ 
end of the EST AI072720 sequence (Asymetrix consensus sequence) and its 
sequence was shown to be part of the sequence of the EST Rn#S14101815, i.e. the 
longest of the 4 members of rat cluster Rn.20243.
GenelD predicted many several possible fourth exons whose sequence also 
overlapped with the AI072720 sequence.
In the context of the ORNL Genome Analysis Pipeline, GrailEXP also predicted a 
fourth exon starting in position 6662 (rat chromosome 3 39717870) that again
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overlapped with the EST AI072720 sequence. Moreover, post-processing analysis of 
this transcript by the ORNL Analysis Pipeline predicted a putative protein that may 
contain a Pfam C-terminal Ezrin/Radixin/Moesin (ERM) domain in the third exon, 
consistent with predictions on both ml RGD1308367 and human KIAA1189 genes at 
Ensembl.
Finally, NIX was used as a tool for running additional programs on the 7.3kb entry 
sequence. Grail, Genscan, HMMGene and MZEF gave the same results as when they 
had been run separately. Among the other programs NIX includes, GeneMark very 
interestingly identified a “region of interest” from 6659 to 6913 of the entry sequence 
(rat chr.3 39717619 to 39717873) and predicted a “protein-coding exon” from 6729 
to 6816 (rat chr.3 39717716 to 39717803), i.e. about 30bp upstream from the EST 
AI072720.
In conclusion, some gene prediction programs did predict the presence of a piece of 
transcript from the genomic sequence located around the EST AI072720 but some 
others did not. Although this evidence was not sufficient to draw any definite 
conclusion, it suggested that the EST was likely to be part of an uncloned and 
uncharacterised region of R G D l308367.
Brain-specific expression of the ESTs of the AI072720 cluster together with 
confirmation of the differential expression of EST AI072720 after chronic PCP 
treatment (section 3.4.3) provided evidence of a potential role of this gene in brain 
processes in general and potentially in prefrontal cortex dysfunction in 
schizophrenia.
5.3- From EST AI072720 to RGD1308367 {‘^ similar to KIAA1189 
protein^’) gene: RACE PGR, RT-PCR
RACE (Rapid Amplification of cDNA ends) PCR was used to investigate the 
expression of the EST AI072720 in the rat brain as part of a larger transcript and in 
particular as part of the upstream predicted RG D l308367 gene.
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Prior to performing the 5’ RACE PCR, the expression of EST AI072720 was 
confirmed in the rat brain cDNA library (Clontech) that was to be used for the 
RACE PCR using both qRT-PCR forward and reverse primers (Figure 5.3) was 
performed and a discrete band of the expected molecular weight was obtained (data 
not shown).
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Figure 5.3. Positions o f qRT-PCR primers with respect to AI072720 and 
RGDI308367
This figure shows the respective positions of the forward and reverse qRT-PCR 
primers which were used to amplify EST AI072720.
5’ RACE PCR was performed on rat brain cDNA using an adaptor specific primer 
and a primer specific to EST AI072720 that was based on the qRT-PCR reverse 
primer. Figure 5.4 shows the cDNA template and the position of the primers used in 
the 5’RACE PCR
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Figure 5.4. cDNA template and primers used in the 5 'RACE PCR with respect to 
AI072720 and RG Dl308367
Marathon-Ready cDNAs (Clontech), whose structure is depicted above in the context 
of the amplification of RGD1308367, is essentially a library of uncloned ds cDNA 
that allows the amplification of specific cDNAs using different sets of primers. 
Within the adaptor-ligated ds cDNA template, marathon cDNA adapters are 
represented in white while the primer used for synthesising the cDNA is shown in 
yellow. In order to amplify the sequence located upstream of EST AI072720, a 
reverse EST-specific primer was used in combination with a forward adaptor- 
specific primer (Clontech) whose sequence was based on the cDNA adaptor ligated.
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5 RACE PCR resulted in the amplification of a 3.4kb product as well as a lower 
molecular weight smear (Figure 5.5, lane 1).
The control reactions gave expected results;
- the GAPDH 5’ RACE positive control (lane 2) generated a product of about Ikb 
(expected product is 1.09kb long according to Clontech) together with an unexpected 
product of 700bp and a smear of products,
- PCR using the RACE EST-specific primer and the forward primer used in qRT- 
PCR (positive control, lane 3) generated a product shorter than lOObp (expected size 
of amplicon; 80bp),
- negative controls without any cDNA (lanes 4, 5 and 6) did not show any amplified 
product.
bp
Figure 5.5. 5 'RACE PCR
Analysis of 1/10 (v/v) of each PCR in a 1.2% (w/v) agarose gel stained with Gel star 
nucleic acid. The molecular weight marker was 0.1 pg lkb+ DNA ladder (Invitrogen). 
The first three reactions were performed on Clontech rat brain cDNA template using 
the following primers; 1) Clontech Adapter Primer (AP) and gene-specific reverse 
primer, 2) Adapter Primer (AP) and a GAPDH 5’ RACE control primer (positive 
control), 3) EST-specific primer for RACE and the forward primer used in qRT-PCR 
(positive control). The last three reactions were performed without any template 
using the following primers; 4) the Adaptor Primer (AP) alone (negative control), 5) 
the EST-specific primer for RACE alone (negative control) and 6) same primers 
as 1).
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The length of the obtained 3.4kb RACE amplicon was analysed in the context of our 
bioinformatics analyses.
Indeed, at the time when these analyses were first performed, rat R G B1308367 gene 
was mapped to Chr.3, 39719751 to 39724482 and was predicted to have 3 exons 
spanning from 39719751 to 39720268, 39723562 to 39723654 and 39724239 to 
39724482 respectively (which gives a predicted cDNA of 852bp). The EST 
AI072720 sequence aligned with rat genomic sequence on Chr.3, 39717303 to 
39717688, i.e. 2063bp downstream from RGD l308367 last predicted exon. 
Therefore, amplification of a ~3kb (862bp + 2063bp = 2915bp) transcript from the 
EST sequence was consistent with AI072720 being part of exon 3 and most likely of 
a long 3’UTR sequence. If EST AI072720 was an alternative exon or splice variant 
of R G D l308367, the 5’ RACE PCR would have given a much shorter amplicon 
since intervening intronic sequence would not have been amplified by the RACE 
PCR
Reamplification of the RACE product using nested primers (figure 5.6) gave a ~3kb- 
long product (data not shown), consistent with the expected predicted size. 
Sequencing of this nested EST AI072720/RGD1308367 PCR product was not 
performed due to the very low yield of the 3kb amplicon. However, successful 
amplification of a product of the expected length from the RACE product template 
using gene-specific nested primers provided further evidence that the EST was part 
OÏRGD1308367.
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Figure 5.6. Position ofprimers used to reamplify the RACE product
In order to reamplify the 5’ RACE PCR product, a reverse EST-specific nested 
primer was designed and used together with forward adapter nested primer 
(Clontech). The 3 exons of RGD1308367 are numbered as 1, 2 and 3. Within the 
adaptor-ligated ds cDNA template, marathon cDNA adapters are represented in 
white while the primer used for synthesising the cDNA is shown in yellow.
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Since we had not been able to get the RACE product sequenced, a series of PCRs 
were performed to confirm that EST AI072720 was part of R G D l308367 3’UTR 
sequence. Rat brain cDNA was used as a template for amplifying 1) the full-length 
R G D l308367 transcript with its 3’UTR, 2) concatenated RG D l308367 second and 
third exons with 3’UTR and 3) RG D l308367 third exon with 3’UTR only. Three 
different combinations of primers were used to amplify these regions (Figure 5.7).
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Figure 5.7. Position o f primers usedfor the different PCRs on rat brain cDNA
To confirm that EST AI072750 was part of RG D l308367, the reverse primer used 
for qRT-PCR on EST AI072720 was used in different PCRs on rat brain cDNA in 
combination with forward primers respectively located within each of the 3 exons of 
R G D l308367. The position of each of these primers is shown on this figure. 
According to the hypothesis that EST AI072720 was part of R G D l308367 3’UTR, 
the expected sizes of amplicons were 3098bp, 2894bp and 2820bp for PCRs 
performed using the qRT-PCR reverse primer and forward primers located within 
R G D l308367 first, second and third exon respectively.
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Figure 5.8. PCRs on rat brain cDNA
Analysis of 4% (v/v) of each PCR product in a 1.2% (w/v) agarose gel stained with 
Gel star nucleic acid. The molecular weight marker was 0.1 pg lkb+ DNA ladder 
(Invitrogen). Lanes 1, 3 and 5 show PCR products amplified from rat brain cDNA 
using the qRT-PCR reverse primer and a forward primer within the first, second or 
third exon of R G D l308367, respectively. Bands of approximately 3 .Ikb (lane 2), 
2.9kb (lane 4) and 2.8kb (lane 6) were obtained, consistent with the predicted sizes. 
Lanes 2, 4 and 6 represent the same reactions, respectively, but performed without 
any template (negative controls).
PCR with qRT-PCR reverse primer and forward primer within the first exon of 
R G D l308367 was repeated in order to sequence the 3 .Ikb full-length R G D l308367 
transcript with its 3’UTR (Figure 5.9).
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Figure S.9. PCR product amplified with qRT-PCR reverse primer and forward  
primer within the first exon o f RG D l308367
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Sequencing of this PCR product confirmed that EST AI272720 was part of 
R G D l308367 3’UTR. The sequence 5’ of the EST exactly corresponded to the 
genomic sequence between exon 3 of R G D l308367 and the EST (shaded blue in 
Figure 5.9) and continued into exon 3, exon 2 and exon 1 with no intronic DNA 
included.
5.4- Validation oî RGD1308367 gene: qRT-PCR (rat/human), in situ 
hybridisation
Confirmation of EST AI072720 as part of a rat transcript RGD1308367 led us to 
hypothesize R G D l308367 might also be differentially regulated in the prefrontal 
cortex after chronic PCP treatment. This was investigated by qRT-PCR and semi- 
quantitative in situ hybridisation.
A rat qRT-PCR assay was designed within RGD1308367 coding sequence to 
investigate RGD1308367 expression in the rat prefrontal cortex after chronic PCP 
treatment (section 2.4.5). The assay was performed on an independent set of rat 
prefrontal cortex samples (not previously used for the microarray study). qRT-PCR 
showed significant upregulation of RGD1308367 after chronic PCP treatment 
(p=0.031, +45.8%) which was consistent with the microarray data and with previous 
results showing differential expression of EST AI072720 in the rat prefrontal cortex 
after chronic PCP treatment (section 3.4.3).
This result was therefore consistent with the EST AI072720 being part of 
RGD1308367 transcript and that its differential expression after PCP treatment (as 
found in the microarray) could actually be reflecting 7^(77)730^567 expression.
183
RGD1308367 qRT-PCR
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Figure 5.10. Regression lines fo r  rat R G D l308567 qRT-PCR
qRT-PCR was performed to evaluate RGD1308367 expression changes in the rat 
prefrontal cortex after chronic PCP treatment by comparison with a vehicle (saline 
solution) (n=6). Y-axis is the logarithm of the fluorescence intensity representing the 
expression of RG B1308367 and X-axis is the logarithm of the fluorescence intensity 
for beta-2-microglobulin (B2m), the internal control gene that was used for 
normalisation. For each gene, the graph plots four points taken from the linear 
amplification phase of the PCR The data were analysed by ANCOVA, which 
revealed 45.8% increase in RGD1308367 expression after chronic PCP treatment 
(p=0.031). Dotted lines show an example of increased RG D l308367 signal for a 
particular .62/w signal.
A human qRT-PCR assay from the coding region was purchased for detecting the 
expression of KIAA1189 (RGD1308367 human orthologue) in human post-mortem 
dorso-lateral prefrontal cortex (DLPFC) from schizophrenic patients. Differential 
expression was confirmed in a subset of the samples (n=5) corresponding to two 
populations of schizophrenic patients, namely the ones collected by Harvard and 
Brain-Net brain bank organisations (Figure 5.11). KIAA1189 expression was found 
to be significantly upregulated in schizophrenic patients compared to controls 
(p=0.001, +14%) which was consistent with RGD1308367 upregulation in the rat 
prefrontal cortex after chronic PCP treatment.
Interestingly, KIAA1189 differential expression in schizophrenic patients was 
therefore confirmed using this assay designed within KIAA1189 coding sequence 
whereas it had not been shown using a different qRT-PCR assay detecting K1AA1189 
3’UTR (section 3.4.3).
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Figure 5.11. Regression lines for human K1AA1189 qRT-PCR
qRT-PCR was performed to evaluate K1AA1189 expression changes in human post­
mortem dorso-lateral prefrontal cortex from schizophrenic patients compared to 
controls (n=9 in total, n=5 when considering schizophrenic patients from the Brain- 
Net and Harvard collections only). Y-axis is the logarithm of the fluorescence 
intensity representing the expression of K1AA1189 and X-axis is the logarithm of the 
fluorescence intensity for glyceraldehyde-3-phosphate dehydrogenase {GAPDH), the 
internal control gene that was used for normalisation. For each gene, the graph plots 
four points taken from the linear amplification phase of the PCR. The data were 
analysed by ANCOVA, which revealed 14% increase in KIAA1189 expression in 
schizophrenic patients from the Brain-Net and Harvard collections (n=5, p=0.001). 
Dotted lines show an example of increased KIAAJ189 signal for a particular GAPDH 
signal.
In situ hybridisation was performed on RGDI308367 using probes designed within 
the coding sequence of the gene. Two sets of films were developed in order to 
measure the higher white matter expression and lower prefrontal cortex expression 
after different exposure times.
Figure 5.12 shows the regional distribution of RGDl308367 mRNA in the rat brain. 
This gene was found to be highly expressed within all major white matter tracts. 
Within cortical and subcortical areas, it was expressed at a much lower level and had 
a homogeneous distribution. Expression was observed within all cortical areas, the 
striatum, thalamus, hypothalamus and hippocampus, with the prefrontal cortex 
appearing to display the lowest level.
This discrete expression pattern looked consistently identical to the expression 
pattern of EST AI072720 (section 3.4.3).
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Figure Representative sections illustrating the regional distribution of
R G D l508367 mRNA in selected regions of the rat brain (panels A and B) and 
control section (panel C)
Coronal sections used for ROD!308367 in situ hybridisation were obtained from the 
following bregma levels according to Paxinos (1998); A) 3.20mm (prefrontal 
cortex), B) -2.30mm (midline thalamus) (Paxinos 1998). Sections were hybridised 
with  ^ S-labelled oligonucleotide probes specific for ROD1308367 (in presence of an 
excess of unlabelled probe in panel C), exposed to film for two different periods of 
time (one for reading white matter and one for detecting prefrontal cortex 
expression) and digitally scanned. Black areas mark the presence of mRNA.
PrL: prelimbic cortex; iL: infralimbic cortex; fmi: forceps minor corpus callosum; 
aci: intrabulbar part of the anterior commisure: cc: corpus callosum; fi: fimbria of 
hippocampus; hipp: hippocampus; thal: thalamus; hypothal: hypothalamus.
The uniform, non-specific signal shown in panel C) provides confirmation of the 
specificity of the probes used ïox ROD1308367 in situ hybridisation studies.
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28 regions of the rat brain were analysed for differential expression of RGD1308367 
expression : prelimbic cortex (PrL), infralimbic cortex (iL), ventral orbital cortex 
(vO), lateral orbital cortex (10), primary and secondary motor cortices (M l and M2), 
anterior cingulate cortex (acg), granular (rsg) and agranular (rsa) retrosplenial 
cortices, dentate gyrus granule cell layer (DGgcl), pyramidal cell layers of the CA l 
(CA lpcl), CA2 (CA2pcl) and CA3 (CA3pcl) region of the hippocampus, primary 
auditory cortex (Aul), lateral entorhinal cortex (Lent), corpus callosum (cc), genu of 
corpus callosum (gcc), forceps minor (fmi) and forceps major (fmj) corpus callosum, 
anterior commisure (ac), intrabulbar part of the anterior commisure (aci), external 
(ec) and internal (ic) capsules, cingulum (eg), stria medullaris of the thalamus (sm), 
mammillothalamic tract (mt), fornix (f) and fimbria of hippocampus (fi).
In two white matter regions, the fornix (f) and the forceps minor of the corpus 
callosum (fmi. Figure 5.12A), chronic PCP administration significantly decreased 
R G D l308367 expression (p=0.006 for the forceps minor corpus callous, p=0.008 for 
the fornix), suggesting that treatment with PCP can indeed modulate the expression 
0 Î  R G D l308367 mRNA.
Although it was not significant, there was a trend for increased expression of 
RGD1308367 in the anterior cingulate cortex (p=0.067) and a trend for a decreased 
expression in the primary motor cortex (p=0.065).
These results differed from those of EST AI072720 in situ hybridisation (section 
3.4.3), where no significant change was found in the expression levels of EST 
AI072720 in any region.
In conclusion, these results show the confirmation of RGD1308367 differential 
upregulation in the rat prefrontal cortex after chronic PCP treatment (qRT-PCR 
results) and provide evidence of a regulation of its expression in white matter regions 
as well {in situ hybridisation data). Interestingly, qRT-PCR analysis of K1AA1189 
{RGD1308367 human orthologue) expression in the dorso-lateral prefrontal cortex 
(DLPFC) of schizophrenic patients provided the first confirmation of the 
concomitant differential expression of a rat gene and of its human orthologue in the 
rat prefrontal cortex after chronic PCP treatment and in the analogous human brain 
region (DLPFC) of schizophrenic patients.
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5.5- / / I  silico characterisation of KIAA1189 gene and KIAA1189 
protein
As a first step towards the characterisation of RGDl308367IK1AA1189, 
bioinformatics tools were used to do more data mining on both rat and human genes 
and proteins. GeneCards and Harvester were used to retrieve all available 
information about the genes, their expression and protein function.
Human K1AA1189 gene (name approved by HUGO Gene Nomenclature Committee 
in February 2004) was found to map to chromosome 2q24.1. Interestingly, 
chromosome 2q, from 2 q ll to 2q37, has been linked with schizophrenia in five 
independent genome scans (Levinson et a l  1998; Williams et a l  1999; Mowry et a l  
2000; DeLisi et a l  2002a; DeLisi et a l  2002b; Wijsman et a l  2003) and it was the 
only region of the genome that reached genome-wide significance in a meta-analysis 
(Lewis et a l  2003). Moreover, the 2q locus has recently been associated with visual 
working memory in a linkage study looking at cognitive trait components of 
schizophrenia (Paunio et a l  2004).
Figure 5.13 represents K1AA1189 gene expression in human tissues according to 
GeneNote (twelve normal human tissues hybridised to Affymetrix GeneChips HG- 
U95A-E) and table 5.1 shows the normalised expression distribution of K1AA1189 
for tissue type according to Uni Gene (Source @ Stanford University at Harvester).
1000 GeneNote -  expression arrays 2 probeeete; 1 unique binary pattern
BMR SPL TMS BRN SPC HRT MSL LVR PNC PST KDN LNG
Figure 5.13. KIAA1189 expression in human tissues
(BMR; bone marrow, SPL: spleen, TMS: thymus, BRN : brain, SPC: spinal cord, 
HRT: heart, MSL: skeletal muscle, LVR: liver, PNC: pancreas, PST: prostate, KDN: 
kidney, LNG: lung)
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Tissue1 .........................  .  . .
Normalized 
Expression (%)
Cluster Clones : 
Tissue clones
|Brain: 70.33 41:319574
jLymph Node: 19.26 4:113869
mixed: 5.23 3:314320
other: 5.17 4:423795
Table 5.1. K1AA1189 normalised expression in different tissues (UniGene)
Both sources gave consistent information suggesting that KIAA1189 is 
predominantly expressed in the brain and in the spinal cord in comparison with other 
tissues of the body.
At many websites including Harvester (Smart analysis) and Ensembl (InterPro 
domain), both RGD1308367 and KIAA1I89 putative proteins were predicted to have 
a carboxy-terminal Ezrin-Radixin-Moesin (ERM) domain. This domain, typically 
present in ERM proteins in conjunction with an N-terminal membrane-binding 
domain, is known to bind actin which suggested that KIAA1189 may have a role in 
cytoskeletal architecture.
Finally, TrEMBL was found to predict two proteins (corresponding to two 
alternative transcripts) for KIAA1189: a 284 amino acid (32783kDa) protein, 
Q8TAM6 (Refseq NP_001009959.1) and a 300 amino acid (34584 Da) Q9ULN1 
protein (Refseq NP_065762.1). Both proteins were predicted to have a moesin 
domain (Interpro IPR008954).
These preliminary in silico analyses of K1AA1189 therefore provided evidence that 
this gene is very highly expressed in the brain and that its locus (2q) has been 
strongly linked with schizophrenia. Moreover, a putative role of KIAA1189 in 
cytoskeletal architecture (as suggested from its C-terminal ERM domain) may be 
consistent with cell morphology abnormalities observed in schizophrenia.
Therefore, RGD1308367/KIAAl 189 appeared a very intriguing novel gene for which 
to investigate in relation with schizophrenia.
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5.6- KIAAl 189 cDNA cloning and overexpression
Molecular biology studies in vitro including cDNA cloning, expression and 
functional analyses were undertaken in order to functionally characterise 
RGDl308367/KIAAl 189 in relation with schizophrenia.
5.6.1- Generation of pcDNA3.1-FLAG®-KIAA1189 expression construct
In the absence of commercially available RGD 1308367 or KIAA l 189 antibodies, a 
mammalian expression construct containing a FLAG® tag, pcDNA3.1 -FLAG®, was 
used as a vector to sub-clone the full-length human KIAAl 189 transcript, so that 
FLAG®-KIAA1189 could be detected by N-terminal FLAG® immunoreactivity.
A full-length human KIAA1189 cDNA clone was purchased as a plasmid 
(pBluescriptR) in E. Coli and its identity was verified by sequencing as being 
identical to Genbank mRNA sequence BC026345 i.e. KIAAl 189 longest mRNA 
sequence (data not shown). Primers containing 5’- and 3’-end restriction enzyme 
recognition sites (for Kpnl and Xhol respectively) were designed for allowing in 
frame cloning of KIAAl 189 cDNA into the pcDNA3.1 -FLAG® expression vector 
and were used to amplify KIAAl 189 from its original pBluescriptR vector.
A PCR product of 0.9kb (the expected length) and pcDNA3.1 -FLAG® vector were 
digested with Kpnl m à X h o I  and ligated (section 2.4.9).
TOPIO bacterial cells were transformed with pcDNA3.1-FLAG®-KIAA1189 ligation 
reactions (section 2.5.1) and the cells were checked for the presence of the 
expression construct. Plasmid DNA was extracted from twenty-four colonies (section 
2.4.1.1) and digested with Spel to discriminate the plasmids containing KIAAl 189 
insert from the ones without. Thirteen pcDNA3.1 -FLAG® plasmids were shown to 
contain KIAA1189 the cDNA insert. The construct was sequenced across the 
vector/insert junction which confirmed that the correct reading frame had been 
maintained.
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5.6.2- Expression of pcDNA3.1-FLAG®-KIAA1189
In order to investigate the expression of KIAAl 189 in vitro, rat C6 glioma cells were 
transfected with pcDNA3.1-FLAG®-KIAAl 189 (section 2.5.4.1). Cell lysate was 
extracted after 24h and 48h (section 2.5.6) and proteins were quantified using the 
Bradford dye-binding assay (section 2.5.8).
Western blotting was used to assay FLAG®-KIAA1189 overexpression in transfected 
cells. Samples containing Ipg of protein were subjected to electrophoresis in a 10% 
(w/v) SDS-PA gel and transferred by blotting to PVDF membranes (section 2.5.9.2). 
The blots were analysed with 1/5000 dilution of an HRP-conjugated FLAG® 
antibody. A FLAG®-tagged protein of approximately 32kDa was immunodetected 
(Figure 5.14, lanes 2 and 3) consistent with KIAAl 189’s expected molecular weight 
(~32kDa), suggesting that KIAAl 189 had been translated as a FLAG® fusion protein 
in these cells. Expression of this FLAG®-KIAA1189 protein was higher at 24h (lane 
2) than at 48h (lane 3) after transfection, making 24h a better time point for looking 
at KIAAl 189 overexpression using C6 cells.
~36kDa -32  kDa
Figure 5.14. Western blotting showing FLAG®-KIAAl 189 overexpression in rat C6 
glioma cells
Lanes 1 and 2 are negative controls consisting of cell lysate from untransfected C6 
cells (lane 1) and cells transfected with the empty pcDNA3.1 -FLAG® expression 
vector (lane 2). Lanes 3 and 4 contain lysate from FLAG®-KIAA1189-transfected 
cells, lysate having been extracted at 24h and 48h (respectively). Lane 5 is a positive 
control consisting of cell lysate from C6 cells transfected with a control pcDNA3.1- 
FLAG®-NCK1 construct. The FLAG® antibody immunodetected a FLAG® 
immunoreactive FLAG®-NCK1 protein of ~36kDa (expected molecular weight).
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5.7- Immunocytochemical analyses of KIAAl 189 subcellular 
localisation in C6 cells
FLAG® immunofluorescence on pcDNA3.1-FLAG®-KIAA1189 transfected cells 
was used to investigate the cellular localisation of KIAA l 189 protein and to 
investigate its potential colocalisation with actin, predicted from the presence of a 
carboxy-terminal ezrin-radixin-moesin (ERM) domain.
Rat C6 glioma cells were transfected with pcDNA3.1-FLAG®-KIAA1189 expression 
construct (section 2.5.4.1) and processed for immunofluorescence (section 2.5.12). 
After fixation, permeabilisation and blocking of non-specific adsorption of the 
antibodies, the cells were incubated with 1/2000 dilution of mouse monoclonal anti- 
FLAG® M2 antibody followed by a 1/400 dilution of polyclonal anti-mouse IgGs 
conjugated with Alexa Fluor® 596 (both incubations were 1 hour at room 
temperature). Fluorescently labelled (Alexa Fluor® 488-conjugated) phalloidin, a 
toxin from the deadly Amanita phalloides mushroom which specifically binds 
filamenteous actin, was used for labelling F-actin and 4',6-diamidino-2-phenylindole 
(DAPI) was utilised for staining cell nuclei (section 2.5.12).
Figure 5.15 shows confocal microscopy images of C6 glioma cells transfected with 
pcDNA3.1 -FLAG®-KIAA 1189 and processed for FLAG® immunofluorescence and 
phalloidin staining.
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Figure 5.15. Confocal immunofluorescence images o f rat C6 glioma cells expressing 
the FLACp-KlAAl 189 fusion protein
Rat C6 glioma cells transfected with FLAG®-KIAA1189 were processed for FLAG® 
immunofluorescence and phalloidin staining. Panel A shows FLAG® labelling in red 
as immunodetected by the FLAG® M2 antibody conjugated with Alexa Fluor® 596. 
Panel B represents F-actin staining in green as detected by Alexa Fluor® 488- 
conjugated phalloidin. Panel C is the merged image of panels A and B, where the 
yellow-orange represents merging of the red FLAG® immunofluorescence and the 
green phalloidin staining. Scale bar represents 50pm.
FLAG®-KIAA1189 was found to be expressed either in the plasma membrane or 
very close to it and its expression was higher in all neuronal processes than around 
the cell body (Figure 5.15).
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Colocalisation of FLAG -KIAAl 189 with actin was not confirmed throughout the 
cells but was confirmed in the plasma membrane and in some neuronal-like 
processes.
5.8- Identification of potential KIAAl 189 interacting proteins by 
immunoprécipitation
Immunoprécipitation was used in order to assess possible binding of KIAA l 189 with 
actin and identify other potential KIAA l 189-interacting proteins, thereby 
deciphering the putative function of KIAA l 189 protein through in vW'o studies.
In the absence of any commercially-available antibody, highly specific FLAG® 
immunoreactivity was used to precipitate FLAG®-KIAA1189 fusion protein together 
with the proteins that may complex with it. This experiment was carried out using rat 
C6 glioma cells transfected with pcDNA3.1-FLAG®-KIAA1189 (section 2.5.4.1) 
and the cells were lysed 24h after transfection (section 2.5.6). Purification of a 
control fusion FLAG®-Bacterial Alkaline Phosphatase (FLAG®-BAP) protein 
(Sigma-Aldrich) was performed alongside experimental samples.
Isolated and purified proteins were subjected to electrophoresis in a 10% (w/v) SDS- 
PA gel and transferred by blotting to PVDF membranes (section 2.5.9). The blots 
were first analysed with 1/5000 dilution of an HRP-conjugated FLAG® antibody.
As expected, FLAG®-tagged proteins of ~32kDa and ~50kDa were detected 
corresponding to the FLAG®-KIAA1189 and FLAG®-BAP fusion proteins 
respectively, which validated the immunoprécipitation protocol.
The same samples were then again subjected to electrophoresis, transferred to PVDF 
membrane and analysed with a 1/1000 dilution of a rabbit anti-(pan)-actin antibody 
followed by 1/2000 dilution of an anti-rabbit HRP-linked antibody, A ~42kDa 
protein corresponding to actin was detected in the positive control sample consisting 
of a non-immunoprecipitated cell lysate. However actin was not detected in the 
immunoprecipitated sample from pcDNA3.1-FLAG®-KIAAl 189 transfected cells 
suggesting it was not part of the FLAG®-immunoprecipitated complex.
The experiment was repeated several times and gave the same results.
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Because of this failure to detect actin within the FLAG®-immunoprecipitated 
complex (from C6 cells transfected with pcDNA3.1-FLAG®-KIAA1189), Coomassie 
blue staining was performed on SDS-PA electrophoresed samples to detect and 
visualise all immunoprecipitated proteins. Very surprisingly, only a single band was 
visible after several hours of staining, whose molecular weight was consistent with 
the -32kDa molecular weight of the FLAG®-KIAA1189 fusion protein, suggesting 
that no other proteins had been immunoprecipitated.
To confirm this hypothesis, both the band excised from the SDS-PA gel and the 
whole FLAG®-immunoprecipitated sample were analysed by mass spectrometry. 
Apart from a very common keratin contamination (due to human manipulation), the 
only peptides that were identified by this method were derived from KIAA l 189 
protein and mouse monoclonal IgGs (resulting from insufficient purification of the 
FLAG® antibody during the immunoprécipitation protocol).
These preliminary experiments did not confirm interaction of KIAA l 189 with actin 
and did not identify any other potential interacting partners of this protein.
5.9-Immunocytochemical analyses of KIAAl 189 subcellular 
localisation in PC12 cells
Failure to confidently confirm KIAA l 189 interaction with actin or uncover any of 
KIAA l 189 potential functions using C6 glioma cells led to the use of a more 
neuronal-like cell type, rat PC 12 cells, for similar overexpression studies.
Figure 5.16 shows confocal microscopy images of differentiated PC12 cells 
transfected with pcDNA3.1 -FLAG®-KIAA1189 and processed for FLAG® 
immunofluorescence and phalloidin staining.
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Figure 5.16. Confocal immimoflorescence images o f rat differentiated PC 12 cells 
expressing the FLAG®-KIAAl 189 fusion protein
Rat differentiated PC 12 cells transfected with FLAG®-KIAA1189 were processed for 
FLAG® immunofluorescence and phalloidin staining. Panel A shows FLAG® 
labelling in red as immunodetected by the FLAG® M2 antibody conjugated with 
Alexa Fluor® 596. Panel B represents F-actin staining in green as detected by Alexa 
Fluor® 488-conjugated phalloidin. Scale bar represents 20pm.
In differentiated PC 12 cells, FLAG®-KIAA1189 was found to be predominantly 
expressed in neurites (with a very high expression in some but not all tips of 
potentially extending neurites) and in the plasma membrane and exhibited very weak 
expression within the cell body. By comparison, the expression pattern of actin was 
more homogeneous, with lower expression within the processes but higher 
expression all over the cell body, which is consistent with the essential role of actin 
in cytoskeletal architecture.
As shown in figure 5.17 (merged FLAG® and phalloidin fluorescence), FLAG®- 
KIAAl 189 did colocalise with actin in some but not all neuronal-like processes and 
in the plasma membrane which was consistent with the observations made using C6 
cells. FLAG®-KIAA1189 also colocalised with actin at the end of some neurite tips 
(figure 5.17).
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Figure 5.17. Confocal immunofluorescence images of rat differentiated PC12 cells 
expressing the FLAC^-KIAAl 189fiisionprotein
Rat differentiated PC 12 cells transfected with FLAG®-KIAA1189 were processed for 
FLAG® immunofluorescence and phalloidin staining. These images represent 
merged images of the red (Alexa Fluor® 596) FLAG® immunolabelling and the green 
(Alexa Fluor® 488) F-actin staining, the areas where both stainings coincide showing 
up in yellow-orange. Panel B (scale bar; 10pm) shows a detail of the whole 
differentiated PC 12 cell represented in panel A (scale bar; 20pm).
All together, this suggested that KIAAl 1889 may play a role in relation to peripheral 
actin at the membrane and in neurites which may be consistent with a structural role 
at the membrane and/or a role in actin-based cell migration events such as neurite 
extension.
5.10- Neurite outgrowth assay
A potential role for KIAAl 189 in neurite outgrowth was investigated in vitro using 
PC 12 cells overexpressing KIAAl 189 and undergoing NGF-induced differentiation. 
This cell line of neuroepithelial origin has been widely used and characterised as an 
in vitro model of neurite extension (Kiryushko et a l 2004).
A neurite outgrowth quantification kit was used for semi-quantitatively evaluating 
the effect of KIAAl 189 overexpression on neurite extension (section 2.5.13) while 
cotransfection of pcDNA3.1-FLAG®-KIAA1189 and GFP was performed to 
examine the effect of KIAAl 189 overexpression on cell morphology (including
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neurite length). In both cases, neurite outgrowth in KIAAl 189-overexpressing cells 
was investigated in comparison with cells that had been transfected with the empty 
pcDNA3.1-FLAG® expression vector.
Quantification of neurite outgrowth was performed at different times (1, 2, 3, 5 and 7 
days) after the initiation of PC12 differentiation in order to investigate the effects of 
KIAAl 189 overexpression on the time course of neurite outgrowth. The experiment 
was repeated and gave a similar pattern of time course for pcDNA3.1-FLAG®- 
KIAAl 189 and pcDNA3.1-FLAG®-transfected cells (figure 5.18).
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Figure 5.18. Time course of neurite outgrowth o f differentiating PC 12 cells
To examine the effects of KIAAl 189 on neurite outgrowth, PC 12 cells were plated 
onto a microporous membrane, transfected with FLAG®-KIAA1189 or the empty 
pcDNA3.1-FLAG® expression vector and PCI2 differentiation was initiated by the 
addition of NGF to the cell culture medium. Neurites were extracted at 1, 2, 3, 5 and 
7 days after transfection and quantitatively analysed by optical density (O.D.) at 
540nm.
The graphs show time courses of PC 12 cells neurite outgrowth quantified as such, 
the experiment was performed twice (panels A and B).
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Over time, pcDNA3.1-FLAG®-KIAAl 189-transfected cells were found to extend 
less and/or fewer neurites than pcDNA3.1-FLAG®-transfected cells suggesting that 
KIAAl 189 overexpression inhibits or prevents neurite outgrowth.
In order to confirm this result, PC12 cells were cotransfected with pcDNA3.1- 
FLAG®-KIAA1189 or pcDNA3.1-FLAG® together with GFP and analysed for cell 
morphology changes using GFP immunofluorescence. FLAG®-KIAA1189 
overexpression did not produce any morphological abnormalities but although no 
statistical analysis was performed, KIAAl 189-overexpressing cells appeared to 
exhibit shorter neurites than FLAG®-overexpressing cells (figure 5.19), which is 
consistent with previous results using the neurite outgrowth kit quantification.
Figure 5.19. Immunofluorescence images of rat differentiated PCI2 cells transfected 
with the empty FLACj expression vector (A) or FLAG^-KIAA I I 89 fusion protein (B) 
together with GFP
GFP epifluorescence (green colour on these images) was used to investigate the cell 
morphology of rat differentiated PC 12 cells cotransfected with the empty pcDNA3.1- 
FLAG® expression vector (A) or FLAG®-KIAA1189 fusion protein (B) together 
with GFP. Scale bar is 10pm
These experiments using differentiating PC 12 cells provided evidence of a role of 
KIAAl 189 in neurite outgrowth or inhibition of neurite outgrowth. Such a function 
is consistent with high KIAAl 189 expression within neurite tips in PC12 cells 
(section 5.9) and may be related to a potential interaction between KIAAl 189 and F- 
actin.
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5.11- KIAA1189 SNP analysis
SKP genotyping was performed in order to investigate any genetic association of 
KIAA l 189 with schizophrenia.
Average allele frequencies were used for choosing the more informative SlSlPs to 
examine, and three allelic discrimination assays were purchased that are listed in the 
dbEST database (NCBI) under the IDs rs l867846 (Applied Biosystems ID 
c_11635778_10), rsl30282B8 (Applied Biosystems ID c_3254608 30) and 
rsl2613898 (Applied Biosystems ID c 31158365 10).
SNP genotyping was performed (section 2.4.8) on a set of 600 samples from 
schizophrenic patients and controls (300 patients, 300 controls) obtained from 
Professor H.M.Gurling (Academic Department of Psychiatry, University College 
London Medical School, UK).
Out of the three assays, rsl2613898 was proven to give non-interpretable results with 
all first 95 samples appearing heterozygotes for this SNP and therefore it was not 
performed on the remainder of the samples.
Genotyping results for r s l867846 and rsl3028288 are shown in table 5.2 and the 
output of the statistical analysis is shown in table 5.3.
SNP Samples Homozygote 1/1
Genotype 
Heterozygote 1/2 Homoz>fgote 2/2
rsl 867846 Controls 11 88 201
Scliizoplirenics 8 92 197
rsl3028288 Controls 221 70 3
Scliizoplirenics 237 65 2
Table 5.2. rsl867846and rsl3028288 SNPs analysis in the London samples
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AUcle
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A nnitage’s 
trend test
rsl867846 n l l= l l  (10.08) «11=8 (9.82) Risk allele 2nl2=88 (89.83) 
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«12=92(88.36)
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ratio
(200.08)
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F=-0.04115
p=0.478197
(Pearson)
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10
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1chi2=0.46
«=0.49827
Odds ratio=1.0 
45
chi2=0.00
«=0.94570
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(Llr) (Llr) 12]<->[1] [22]<->[12] [22]<->[ll] [ll+I2]<->[22] common odds ratiop=0.700868
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p=0.562614 
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1.067
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Odds ratio=1.0 
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Odds ralio=0,9 
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C.I.=[0.738-
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chi2=0.00
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1.517]
chi2=0.13
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chi2=0.03
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«=0.94570
«=0.94598 (P) «=0.71938 «=0.52891 «=0.86215
rsl3028288
1111=221
(222.91)
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(238.92) Risk allele 2
n 12=70 (66.18) 
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C.I.=[0.609-
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chi2=0.70
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Odds ratio= 
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C.I.=[0.590-
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chi2=0.54
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Odds ratio=0.6 
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56
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chi2=0.65
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Odds ratio=0.8 
49
chi2=0.74
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p=0.294613
(Llr)
p=0.237724
(Llr) Risk aUcle 1
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60
Odds ratio= 
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09
Odds ratio=1.5 
57
Odds ratio=l.l 
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chi2=0.70
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chi2=0.13
C.I.=[0.266-
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chi2=0,27
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]chl2=0.24
chi2=0.74
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Table S,3,Hardy~Weinberg equilibrium and association analysis fo r  rsl867846 and 
r s l3028288 SNPs
Further information on statistical analysis of r s l867846 and rs l3028288 SNP 
genotyping can be found in Appendix D.
Statistical analysis of genotyping data for rsl 867846 and rsl3028288 confirmed that 
the distribution of the genotypes did not significantly deviate from the Hardy- 
Weinberg equilibrium, but this distribution was not significantly different between 
schizophrenic patients and controls. Therefore no association was found between any 
SNP of KIAAII89  and schizophrenia in this population.
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5.12- Discussion
The aim of the work described in this chapter was to confirm the EST AI07270 as a 
genuine rat transcript and to characterise it in relation with schizophrenia.
5.12.1- From the EST AI072720 to rat RGD1308367
When this work was initiated (in October 2003), the EST AI072720 was hardly 
annotated at any database and did not map to any rat gene. However, good sequence 
identity between the EST and the 3’UTR of human KIAA1189 gene and with a rat 
genomic sequence downstream from the rat orthologue of KIAAl 189, suggested that 
this EST may correspond to a rat transcript that had not been cloned or predicted yet. 
Better prediction and annotation of the human gene (than the rat gene) was not 
surprising since the first draft assembly of the human genome had already been 
announced (Lander et a l 2001; Venter et a l 2001) whereas the Rat Genome 
Sequencing Project was only under way.
Homology of the EST AI072720 sequence with a rat genomic sequence located 
downstream from a predicted gene was consistent with the fact that, like most ESTs, 
the EST AI072720 was 3’-derived and therefore likely to belong to an untranslated 
region lacking protein coding information. Although it would have been premature at 
this stage to m le out the possibility that the EST AI072720 was artefactual (such as 
being an unspliced cDNA, heterogeneous nuclear RNA or genomic DNA containing 
intragenic or intergenic sequences) (Wolfsberg and Landsman 1997), clustering of 
the EST AI072720 with three other ESTs provided evidence that the EST AI07270 
did belong to a genuine transcript. Moreover, evidence showing that each of the four 
clustered ESTs had been generated from cDNA clones derived from brain (or eye) 
tissue suggested that this rat transcript may be, if not brain specific, at least 
predominantly expressed in the brain.
Interestingly, Unigene cluster Rn.20243 now includes 3 rat mRNA sequences 
(BC086596.1, NM_001008311.2 and DQ119821.1) and 32 ESTs (in total) which are 
all derived from cDNA libraries prepared from either specific brain regions or a
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mixture of different brain regions, which confirms this hypothesis. This cluster is 
now identified as “RGD1308367: similar to KIAA l 189 protein” which is consistent 
with our findings and with the current NetAffx annotation of rc_AI07270_at probe 
set as “similar to KIAA l 189 protein (predicted)” .
Numerous gene prediction programs were used to analyse a large piece of genomic 
sequence containing the EST AI072720, however, only a few of them (including 
GRAIL, GenelD and MZEF) predicted that the EST was part of a putative yet 
unpredicted exon. Interestingly, these programs were the ones which integrate 
multiple types of information including splice signal sensors, compositional 
properties of coding and non-coding DNA in order to predict entire gene structures 
(sets of spliceable exons) in genomic sequences (Burge and Karlin 1997). No other 
program suggested that the EST was part of the 3’ untranslated region of the 
upstream RGD1308367 gene. However, failure to determine the full extent of the 
transcript with its 3’ extremity was not surprising since these gene prediction 
algorithms, although very accurate in identifying coding nucleotides, are still not 
reliable in grouping exons into transcripts (Burge and Karlin 1998; Claverie 1998). 
Moreover, prediction of a gene from this EST similarity search may have been 
affected by the presence of interspersed repeats (SINES, LINES, MAR etc ; Smit 
1996) in the genomic sequence and the identification of exons or genes may have 
benefited from adequately filtering of these repeats to maintain the signal/noise ratio 
to an acceptable level (Claverie 1997). For these reasons, experimental work was 
required to determine the full extent of the transcript (5’ and 3’ ends of the gene) and 
of its alternative splice variants (Claverie 1997; Wu et a l 2004), particularly since 
the rat is one of the mammalian species whose sequence will not receive labour- 
intensive annotation efforts such as the ones devoted to human. However, another 
alternative approach that we may have used for identifying rat genes is the method 
described by Wu et a l  (2004), who performed RT-PCR and direct sequencing based 
on dual-genome de novo predictions from TWINS CAN, a program which predicts 
which regions of a genome are transcribed into pre-messenger RNA, how they are 
spliced, and which portions of the spliced transcript are translated into protein (Korf 
et a l 2001; Flicek et a l 2003). This method, which was found to be cost-effective in 
confirming complete open reading frames and gene structures which were partially 
missed by the April 2003 Ensembl annotation of the rat genome, may well have been
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effective in identifying the full-length transcript to which the EST AI072750 
belonged.
5’ RACE (rapid amplification of cDNA ends) PCR was performed to extend the EST 
sequence in the 5’ direction and amplify the transcript to which this EST belonged. 
Amplification of the upstream sequence from the EST AI072720 produced a product 
of 3kb, suggesting that AI072720 was indeed the 3’ end of R G D l308367. Aware of 
the technical difficulties of performing 5’ RACE (Bashiardes and Lovett 2001), the 
experiment was repeated and again a 3kb RACE product was obtained. 
Unfortunately the yield of the amplicon was too low for sequencing. Therefore the 
hypothesis was further tested by predicting spliced products, which were amplified 
by PCR. These PCRs were performed using a proofreading enzyme (Kod Hot Start 
polymerase) designed for amplifying long targets with very high specificity and 
procès si vity and the longest predicted PCR product containing the 3 predicted exons 
of RGD l 3 08367 and EST AI072720 was sequenced.
These experiments enabled confirmation 1) that the EST AI072720 was part of 
R G D l308367 3’UTR and 2) that R G D l308367 included the three predicted exons. 
Failure to obtain the sequence of the 5’ RACE product did not allow us to determine 
the full-length sequence of the transcript at the 5’ end. Therefore RGD1308367 full- 
length transcript (with its untranslated regions) may be longer than the 3kb product 
sequenced.
5.12.2- Validation of RGD1308367 and KIAA1189 differential expression
Differential expression of R G D l308367 in the rat prefrontal cortex (PFC) after PCP 
treatment was confirmed by qRT-PCR: RGD1308367 expression was significantly 
upregulated in the PCP model which is consistent with the microarray data from the 
chronic PCP model. In human post-mortem dorso-lateral prefrontal cortex (DLPFC), 
expression of KIAAl 189 {RGDl308367 human orthologue) was significantly 
upregulated in a subset of our samples (n=5) corresponding to two populations of 
schizophrenic patients, namely the ones collected by Harvard and Brain-Net brain 
bank organisations. The direction of change was again consistent with that of the rat 
chronic PCP model of schizophrenia.
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Differential expression of KIAAl 189 in some schizophrenic patients but not others 
may not be unexpected since the “schizophrenia” phenotype actually reflects a 
spectrum of disorders more than a single pathology and gathers together individuals 
with very different symptomatology. Moreover, independently of the potential 
correlation between the phenotype of these patients and their gene expression 
pattern, schizophrenia is also an etiologically complex disease whose mode of 
transmission is only compatible with a multigenic model in which no single gene can 
be assumed to contribute to schizophrenia in every affected individual or in any 
population (Gottesman and Shields 1967; McGue and Gottesman 1989; Owen et al. 
2005a). Gene expression changes are therefore likely to be different between 
individuals so that they may not be detected when examining a set of clinically 
heterogeneous patients as one single group. In this present case, the difference in the 
origin of patients (Harvard, Brain-Net and UCLA brain banks) within the whole set 
of samples did add further heterogeneity to the set. Whereas there was not any 
obvious difference between patient characteristics (such as age, gender and post­
mortem delay) or processing of samples across brain banks, lack of information 
about the criteria used by each organisation for diagnosing schizophrenia (and even 
the subjectivity of establishing this diagnosis) did not rule out the potential existence 
of major clinical differences between all the patients.
Differential expression of rat R G D l308367 had previously been shown by qRT-PCR 
using an assay designed against the 3’UTR (EST AI072720, section 3.4.3). However, 
differential expression of the human gene, KIAA1189, was only shown when an 
assay in its coding region was used (section 5.4) but not when an assay in the 3’UTR 
was used (section 3.4.3). Indeed, although both human qRT-PCRs assays were 
examining the same gene, it is possible that RGD1308367 may have alternative 
splice variants which may be specifically or differently detected by different qRT- 
PCR assays. Moreover, since probe sensitivity is a sequence-inherent characteristic, 
amplification efficiencies may be different between experiments which may lead to 
different results.
In situ hybridisation did not confirm differential upregulation of R G D l308367 in the 
rat prefrontal cortex after chronic PCP treatment but revealed its significant 
decreased expression in two white matter regions, the fornix and the forceps minor of
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the corpus callosum. Whereas the RGD1308367 expression pattern looked 
consistently identical to the expression pattern of EST AI072720 (section 3.4,3), 
statistical analysis of the data yielded inconsistent results since no significant change 
had been found in the expression levels of EST AI072720 in any region of the rat 
brain after PCP treatment.
Apart from the issue of the inherent limited sensitivity of in situ hybridisation to 
detect low expression changes (section 3.5.4), these inconsistent results are likely to 
be due to differences between experiments, including the levels of cutting of the 
brains between the sets of sections used for the two studies. For example, the 
sections used for EST AI072720 were more posterior at the level of the thalamus 
than those used for RGD1308367, which reduced the size of the fornix for the 
analysis and prevented uniform detection of EST AI072720 expression within this 
region, making the two experiments impossible to compare. Moreover, another 
possibility in this context may be the expression of R G D l308367 being slightly 
variable throughout the brain in a rostro-caudal manner, probably, in relation with 
variable density of neurons in these regions (Dombrowski et a l 2001), so that its 
differential expression in the rat chronic PCP model may appear at very specific 
levels only (as shown for other genes, Susan Cochran, unpublished observations). 
Since qRT-PCR and in situ hybridisation probes were designed to detect very close 
regions of the sequence, the issue of them detecting different splice variants, which 
may have explained both the failure to confirm the qRT-PCR results in the prefrontal 
cortex using in situ hybridisation and the differential expression shown in white 
matter regions using this technique, could be excluded. Differential downregulation 
of RGD1308367 in some parts of the fornix and the forceps minor callosum after 
PCP treatment may therefore represent a genuine result which is worth analysing in 
relation with schizophrenia.
The fornix and the corpus callosum are key white-matter stmctures in the 
mammalian brain which ensure proper connectivity between brain structures and 
cerebral hemispheres respectively. Changes in gene expression, hence functional 
impairment, within such regions may therefore be consistent with the current 
hypothesis that schizophrenia is a disorder of cortical connectivity (Friston and Frith 
1995; Friston 1998; Stephan a/. 2006).
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The fornix is a bundle of axons which connects the hippocampus and the thalamus 
and has been shown to be involved in aspects of working memory (verbal and spatial 
working memory (Gaffan 1994; Calabrese et a l  1995; McMackin et al, 1995; Parker 
and Gaffan 1997) that are impaired in schizophrenic patients (Constantinidis and 
Wang 2004; Peuskens e ta l  2005). Moreover, fimbria-fornix lesionned rats present a 
working memory impairment that is attenuated by treatment with the antipsychotic 
clozapine, which may reflect some of the cognitive performance improvements 
observed after clozapine treatment in people with malfunctions of the hippocampus 
such as seen in schizophrenia (Addy et a l 2005).
Although no alterations of the fornix have been reported to date in schizophrenia, 
both its function and the regions it connects (the thalamus and the hippocampus ; 
Andreasen 1997; Gothelf et a l  2000; Harrison and Weinberger 2005) have been 
implicated in schizophrenia. Consistently, decreased expression of RGD1308367 
mRNA in the rat fornix after PCP treatment may therefore be related to some aspects 
of working memory known to be impaired in schizophrenia.
The corpus callosum is the largest white matter structure in the mammalian brain. Its 
contralateral axon projections allow connectivity and communication between the 
left and right cerebral hemispheres and play an important role in the proper 
functioning of the prefrontal cortex (Carr and Sesack 1998). Hence, in view of the 
essential implication of the prefrontal cortex in schizophrenia pathophysiology, it 
may not be unexpected to observe decreases in white matter density in the corpus 
callosum, as was reported by Hushoff Pol ei al. (2004). Besides, these changes were 
interestingly found to correlate to grey matter density changes and to illness severity 
(Hulshoff Pol et a l 2004) suggesting they are central to schizophrenia 
pathophysiology. Therefore, we propose that decreased expression of RGD1308367 
within the corpus callosum after PCP treatment may be related both to prefrontal 
activity and to aberrant connectivity in schizophrenia.
In summary, RGD1308367 in situ hybridisation revealed gene expression changes in 
white matter regions which may be particularly relevant to deficits in working 
memory and connectivity disturbances found in schizophrenia. A major caveat of 
this experiment is that the protocol used for this study did not have the power to 
determine the cellular localization of RGD1308367 mRNA and therefore in which 
cell type the gene was expressed. Gene expression changes within white matter
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regions may indeed relate to expression of RGD1308367 within glial cells such as 
myelin-forming oligodendrocytes or within axonal projections of cortical (such as 
PFC) neurons suggesting that synthesis of RGD l 3 083 67 would occur in axons rather 
than in the cell body. In terms of function, both possibilities may be relevant to 
schizophrenia as altered myelination and abnormal refining of synaptic connectivity 
are the two developmental processes which have been proposed to be disturbed in 
schizophrenia leading to altered connectivity and dysfunction of the prefrontal cortex 
and triggering the emergence of symptoms and deficits during periadolescence or 
early adulthood (Woo and Crowell 2005). Interestingly, the hypothesis suggesting 
that RGDJ308367 may be translated locally in axons may be consistent not only with 
schizophrenia but also with the hypothesis that RGD1308367 may have an ERM- 
related function as axonal protein synthesis has been shown to be involved in growth 
cone dynamics and axonal guidance (Zhang et a l 2001; Piper and Holt 2004).
Failure to detect or confirm significant alterations in RGD1308367 expression after 
PCP treatment in cortical regions such as the prefrontal cortex is likely to be due to 
its very low expression levels within these regions combined with the limited 
sensitivity of this technique. In this context, more sophisticated techniques such as 
qRT-PCR on laser-microdissected tissue may be needed to detect significant changes 
in particular cortical regions. Such a study, performed using microdissected rat 
prelimbic cortex (Antonio Ferra and Catherine Winchester), failed to identify any 
significant changes in R G D l308367 expression in this region after PCP treatment, 
suggesting that the increased expression of RGD1308367 detected in the microarray 
did reflect a change in its expression in another part (infralimbic or ventral-orbital 
cortex) of the grossly dissected prefrontal cortex used in the microarray. However, 
this experiment confirmed that RGD1308367 is expressed in the prelimbic cortex 
suggesting that it is definitely expressed by cortical neurons where it may have 
another role (potentially related to schizophrenia) than in the white matter.
Finally, since we failed to confirm the differential expression o îR G D l308367 in the 
prefrontal cortex after PCP treatment but showed expression changes within close 
white matter regions (the corpus callosum in particular), one could argue that the 
expression changes identified in the microarray did actually reflect expression 
changes within white matter tracts that would have been consistently dissected 
together with the prefrontal cortex. However, it is unlikely in that case that the same 
amount of white matter may be present in all samples, making possible the
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identification of genes regulated in these regions. Conversely, the more likely 
differing amounts of white matter that may be due to inaccurate dissections would 
have affected the whole data set either by preventing the identification of 
differentially expressed genes because of heterogeneity or by “contaminating” the 
results with a number of myelin-related genes. This was not the case since this study 
did allow the identification of a reasonable number of differentially expressed genes, 
among which there were only very few myelin-related genes (Catherine Winchester), 
which refutes the hypothesis that the changes detected may reflect expression 
changes within white matter tracts rather than prefrontal cortical areas.
5.12.3- Genetic and genomic characterisation of KIAAl 189
Mapping of human KIAA1189 gene to chromosome 2q24.1 is very unlikely to be 
irrelevant to schizophrenia since it is very close to the only region (chromosome 
2pl2-q22.1) which reached genome-wide significance in a meta-analysis including 
20 individual genome scans (Lewis et a l 2003). Loci spanning from 2 q l l  to 2q37 
have been linked with schizophrenia in five independent genome scans (Levinson et 
a l  1998; Williams et a l 1999; Mowry et a l  2000; DeLisi et a l  2002a; DeLisi et a l 
2002b) (Wijsman et a l 2003) and chromosome 2q36 has recently been associated 
with visual working memory in a linkage study looking at cognitive trait components 
of schizophrenia (Paunio et a l 2004).
All these data suggest that chromosome 2q (including 2q24.1) is not just one of the 
many loci identified across the genome but rather one of the most well supported loci 
linked with schizophrenia. Mapping of KIAAl 189 within this region therefore 
provides strong genetic evidence suggesting that this gene may account for some 
susceptibility to schizophrenia and supports the hypothesis of KIAAl 189 being an 
interesting candidate gene to investigate in relation to this disease.
Failure to detect any significant association hQtwQQn KIAAl 189 and schizophrenia in 
a population of 600 schizophrenic patients and controls (n=300) did not provide any 
additional evidence of a potential role of KIAA l 189 in schizophrenia. However, this 
study was quite preliminary in terms of design and more sophisticated analysis may 
be necessary for increasing the likelihood of identifying a significant genetic 
association. In particular, since schizophrenia displays considerable heterogeneity of
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symptoms which may reflect several different disease processes (Owen et a l  2005a), 
it may be very beneficial to refine the phenotype used for this study by defining sub­
groups of patients based on intermediate endophenotypic measures (Leboyer et a l  
1998; Gottesman and Gould 2003). Indeed, such endophenotypes, which occur 
across the schizophrenia spectrum in schizophrenia patients, may be more amenable 
to quantitative genetic analyses and some of them may even be conceptualised as 
being impaired because of a single genetic abnormality (Braff and Light 2005). Drug 
responsiveness may also be a parameter that could be used for defining sub-groups of 
patients and increase the likelihood to get a significant association by minimising 
sample heterogeneity. Increasing sample size may also be needed as schizophrenia is 
a complex disorder whose genetic component is likely to involve a few or several 
genes which may contribute to the susceptibility for schizophrenia, so that larger 
samples may be required to reliably detect significant associations of single genes 
with schizophrenia. Moreover, independently of the sample size and of the 
phenotype used, another way to increase the power of this study may be to examine 
haplotypes instead of considering each SNP separately. Usage of haplotypes has 
indeed been shown to increase the power of genetic association studies by reducing 
the dimension of statistical tests for association (Clark 2004; de Bakker et a l  2005). 
Therefore to maximise the power of the analysis, association studies should ideally 
be designed to take into account all these different parameters. However, this is quite 
a recent concept and failure to detect or to replicate significant genetic associations in 
complex diseases using designs similar to that used here has long been very common 
in the literature. Thus, it would be very premature to draw any conclusions from this 
study and, on that assumption, to refute the hypothesis that KIAAl 189 may have a 
role in schizophrenia.
5.12.4- In silico analyses of KIAA1189 expression and function
KIAAl 189 tissue expression profile was obtained from different sources, including 
GeneNote (Shmueli et a l  2003) and Unigene (Pontius 2003) which consist 
respectively of a database of gene expression in twelve normal adult human tissues 
based on in-house DNA array experiments using Affymetrix GeneChip HG-U95A-E, 
and of a reconstruction of gene expression profiles from unbiased cDNA library data 
based on the frequency of occurrence of an EST in Unigene EST clusters.
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Information about KIAA l 189 expression (RT-PCR and ELIS A data) was also 
obtained from the Kazusa DNA Research Institute which has made fundamental 
information on the structure and function of genes available to the public. Very 
interestingly, all three databases consistently showed that K1AA1189 is highly 
expressed in the brain (including both white and grey matter regions) and in the 
spinal cord in comparison with other tissues of the body, which was consistent with 
the hypothesis KIAAl 189 may have a role in schizophrenia pathophysiology.
In addition, further support for the potential involvement of KIAA l 189 in 
schizophrenia was provided by data showing that AI207881, one of the many human 
ESTs which have been attributed to KIAA l 189, was first identified as expressed in 
the frontal lobe of a schizophrenic patient (Mieg e ta l  2005).
Finally, R G D l308367 and KIAA l 189 putative proteins were investigated for the 
presence of typical domains which may give an insight into the potential role of the 
rat or the human protein. Both amino acid sequences were found to have limited 
similarity with the ERM (ezrin-radixin-moesin) proteins, which typically contain an 
N-terminal FERM (4.1, ezrin, radixin, moesin) domain which is known to bind 
membrane proteins followed by a long helical coiled-coil region and a C-terminal 
filamenteous (F)-actin binding site (Bretscher et a l 2002; Ramesh 2004). ERM 
proteins are ubiquitously expressed proteins which cross-link membrane proteins to 
the cortical cytoskeleton and are involved in the regulation of the actin cytoskeleton 
(Ramesh 2004). RGD1308367 and KIAA l 189 both lack the N-terminal FERM 
domain but show a weak similarity along the a-helical central region and shared 18 
almost identical amino acids with ERM proteins in their F-actin binding site 
(Bretscher et a l 2002; Ramesh 2004). KIAA l 189 may therefore be considered as a 
distant member of the ERM family of proteins which may bind F-actin but not 
membrane proteins. Thus, limited similarity with ERM proteins was not enough 
evidence to provide an insight into KIAA l 189 function, which may or may not be 
related to that of ERM proteins. However, since the activity of ERM proteins has 
been shown to be regulated by intramolecular associations between their N-terminal 
and C-terminal domains (Louvet-Vallee 2000), one hypothesis could be that 
KIAA l 189 may function as an endogenous regulator of ERM proteins by interacting 
though its C-terminal domain with the N-terminal domain of ERM proteins thereby 
further regulating their activity. Interestingly, such a function may be relevant to
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schizophrenia as ERM proteins, via their interaction with the actin cytoskeleton, 
regulate the development and the maintenance of growth cones, these highly 
dynamic structures which guide the developing neurites to their distant targets and 
are involved both in their elongation and branching (Goldberg and Burmeister 1989; 
Devoto 1990; Dent et al. 2003). Thus, a potential role of KIAA l 189 in the regulation 
of the function of ERM proteins hence in growth cone dynamics may be consistent 
with a number of abnormalities that have been reported in schizophrenia including 
abnormalities in synaptic and dendritic arborisation as well as reduced volume of 
neuropil (Lewis 1997; Selemon and Goldman-Rakic 1999) and altered rearrangement 
of neuronal connections (Benes 1995; Benes 1997).
However, independently of this potential role of KIAAl 189 in the regulation of 
ERM protein function, binding of KIAA l 189 to F-actin via its C-terminal ERM 
domain may still be consistent with many cytoskeletal abnormalities found in 
schizophrenia. Indeed, actin, as a major part of the cytoskeleton, has been shown to 
play a major role in the morphological development of neurons and in the structural 
changes of adult neurons (Luo 2002). In particular, actin plays a critical role in the 
formation and plasticity of dendritic spines, whose density has been shown to be 
reduced in neurons of the hippocampal formation and dorso-lateral prefrontal cortex 
in post-mortem studies of schizophrenic patients (Glantz and Lewis 2000; Kolluri et 
a l 2005; Kolomeets et a l 2005). Moreover, the integrity of the actin cytoskeleton is 
a determinant for the activity of NMD A receptors and activation of NMD A receptors 
in turn initiates changes in the actin cytoskeleton of dendritic spines that stabilise 
synaptic structure (Ackermann and Matus 2003). Thus, alterations of actin 
cytoskeleton or disruption of its dynamics during development or in response to 
learning and experience may also be consistent with the NMD A receptor 
hypofunction in schizophrenia (Coyle e ta l  2003).
5.12.5- Functional characterisation of KIAAl 189 in vitro
Unfortunately, although the FLAG® epitope has been shown to facilitate superior 
detection and purification of recombinant fusion proteins when using highly specific 
and sensitive anti-FLAG® antibodies, we failed to confirm the direct interaction 
between KIAA l 189 and actin by FLAG® immunoprécipitation in C6 cells
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transfected with the FLAG®"KIAA1189 construct. Because the FLAG® epitope was 
expressed at the N- rather than at the C-terminus of KIAA l 189 (where the protein 
harbours its ERM-like actin-binding site), it is unlikely that its presence affected the 
function of the protein. However, failure to detect any of its interacting partners may 
not be unsurprising if KIAA l 189 is an ERM protein since the self-associating 
activity of these proteins has been shown to interfere with their association with other 
binding partners thereby preventing their identification using this technique (Vaheri 
et a l 1997; Bretscher e ta l  2002). Similarly, following on the hypothesis (see above) 
that the C-terminal domain of KIAA l 189 may bind the N-terminal domain of ERM 
proteins, KIAA l 189 could be suggested to form a regulatory complex with ERM 
proteins in which the FLAG® epitope would be masked. Yet another hypothesis is 
that coimmunoprecipitation of the protein and its partners failed because the 
overexpressed KIAA l 189 proteins were not functional. Indeed, although a FLAG®- 
KIAA1189 fusion protein of about the right size had been shown to be translated 
from the transfected construct using rat C6 cells, we cannot exclude that this protein 
may have small structural defects, may have undergone misfolding or may need to be 
activated to become functional. Indeed, the KIAA l 189 amino acid sequence suggests 
many potential phosphorylation sites including protein kinase C, cAMP-dependent 
protein kinase and serine/threonine/tyrosine phosphorylation sites. In particular, 
KIAA l 189 was predicted to have a threonine phosphoiylation site at its C-terminus 
which may correspond to a specific residue of ERM proteins (Simons et a l  1998) 
which was shown to contribute to their activation by unmasking of their F-actin 
binding site, independently of their N-terminal ERM site. Therefore phosphorylation 
of this particular site and/or others is likely to be necessary to activate the protein and 
reveal its potential actin-binding function. Finally, independently of all proposed 
hypotheses, it may be also be that the cell line used was not suitable for examining 
KIAA l 189 function. Indeed, rat C6 glioma cells were used as a model of glial cells 
but we did not have any direct evidence that KIAAl 189 is expressed in glial rather 
than neuronal cells (see discussion about in situ hybridisation results). Therefore it 
may well be that KIAA l 189 was not functional in these cells. Further experiments 
would have been needed using different cell lines as well as different potential 
activators of this protein in order to identify its potential interacting partners.
A nice way to refine the hypothesis would have been to examine the subcellular 
localisation of endogenous RGD 1308367 protein in the rat brain and to investigate
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potential protein expression changes in the rat chronic PCP model. Unfortunately, 
commercial antibodies were not available for RGD 1308367 or KIAA l 189 (due to 
time constraints we were unable to generate our own) so that we decided to 
investigate KIAA l 189 function in vitro by overexpressing in mammalian cells. Since 
failure to identify any potential KIAA l 189 interacting partners by 
coimmunoprecipitation using C6 cells may be explained by many issues, we decided 
to investigate KIAA l 188 function not only in these cells but also in more neuronal- 
like cells. Rat C6 glioma cells, which were originally cloned from a chemically 
induced rat brain tumour and classified as an undifferentiated astrocytic cell type 
(Benda et a l  1968), were thus used to investigate KIAA l 189 function in glial-like 
cells while the rat PC 12 cell line, established from a transplantable rat adrenal 
pheochromocytoma and which responds reversibly to nerve growth factor (NGF) by 
induction of a neuronal phenotype (Greene and Tischler 1976) was used as an in 
vitro model for the study of the role of KIAA l 189 in neuronal-like cells. Again, 
KIAA l 189 was expressed as a fusion protein with an N-terminal FLAG® to allow 
immunocytochemistry studies through FLAG® immunoreactivity.
In C6 glioma cells, KIAA l 189 was found to be predominantly expressed within the 
plasma membrane (or very close to it) and within neuronal-like processes, showing 
an expression pattern which at first appeared very similar to that of actin. However, 
thorough investigation of colocalisation of KIAAl 189 with actin revealed that the 
proteins only colocalised at very few sites, not providing enough evidence to confirm 
KIAA l 189 interaction with actin. KIAA l 189-transfected cells did not present any 
striking phenotypic difference compared with C6 cells expressing the empty FLAG® 
expression vector which did not allow us to draw any hypothesis on KIAA l 189 
function in these cells.
Keeping in mind that there may be an activation issue, KIAA l 189 was 
overexpressed in rat PC 12 cells to study its function in neuronal-like cells as opposed 
to glial-like C6 cells. In differentiated PC12 cells, KIAA l 189 was found to be 
predominantly expressed in neurites and in the plasma membrane which was 
consistent with the expression of ERM proteins at the cytoplasmic surface of plasma 
membranes (Sato et a l  1991). KIAA l 189 expression pattern did not overlap exactly 
with that of actin suggesting that it did not bind actin throughout out the cell body as 
a structural element of the cellular cytoskeleton. However, KIAA l 189 was found to
214
colocalise with actin in some processes and especially at the end of some neurite tips 
as well as in the plasma membrane around the cell body.
Colocalisation of KIAAl 189 and actin in the plasma membrane suggested that 
KIAA l 189 may bind actin at cell membrane-actin adhesion sites. Although 
KIAAl 189 was not predicted to bind membrane proteins, this expression pattern was 
therefore consistent with that of ERM proteins at cell-surface structures (Ramesh 
2004). High expression of KIAA l 189 in neuronal processes and at the end of neurite 
tips suggested that KIAA l 189 may have a role in the architecture and in the 
extension of neurites, which was consistent with its partial colocalisation with actin 
at some of these sites which are critical in neurite outgrowth. These studies therefore 
provided evidence suggesting that KIAA l 189 may be related to ERM proteins which 
are known to provide a link between membrane proteins and the cytoskeleton and to 
regulate growth cone motility in neurons by interacting with F-actin (Ramesh 2004). 
In the context of our in situ hybridisation results, predominant expression of 
KIAA l 189 within neuronal processes may be consistent with the hypothesis 
according to which R G D l308367 mRNA expression within white matter tracts did 
actually reflect its presence within the axons of cortical neurons, where local protein 
synthesis would have occurred. Such an axonal translation, which is much more 
flexible and efficient than axoplasmic transport, has been suggested to provide a 
rapid supply of proteins at the synapse thereby playing an essential role in 
modulating synaptic plasticity and long-term potentiation (Piper and Holt 2004). 
Alterations in axonal translation of critical proteins may thus be consistent with the 
hypothesis of schizophrenia being a “disorder of the synapse” (Owen et a l  2005b) 
by providing an explanation and a molecular substrate to the altered plasticity 
(altered response to guidance clues and long-term potentiation) in schizophrenia 
(Stephan et al. 2006). Such abnormalities have besides already been suggested in 
neuronal-based diseases such as spinal muscular atrophy (Jablonka et a l 2004) and 
Fragile X syndrome (Antar and Bassell 2003).
Both the KIAA l 189 expression pattern and its partial colocalisation with actin in 
differentiated PC 12 cells suggested that this protein may have a role in neurite 
extension.
Semi-quantitative measurement of neurite outgrowth using PC 12 cells showed that 
KIAA l 189 overexpression prior to differentiation prevented the extension of neurites
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by comparison with PC 12 cells transfected with the empty expression vector. This 
finding was confirmed by looking at cell morphology in comparing GFP 
epifluorescence of FLAG®-KIAA1189/GFP and FLAG®/GFP co-transfected PC 12 
cells; KIAA l 189 overexpression was associated with shorter neurites. Although 
further experiments would be needed to exclude the possibility that the observed 
reduced neurite length shown by FLAG®-KIAA11889 transfected cells may reflect 
neurite retraction during cell death rather than genuine alterations in neurite 
extension due to FLAG®-KIAA1189 overexpression, no obvious signs of apoptotic 
cell death (nuclear condensation and fragmentation) were observed in these cells. 
This strongly suggested that KIAAl 189 did alter normal processes of neurite 
outgrowth in neuronal-like cells, as it indeed has been shown for mutant DISCI 
protein (Ozeki et a l 2003). Interestingly, these results were also consistent with the 
upregulation of RGD 13 083 67 expression in the rat prefrontal cortex after PCP, in the 
sense that increased expression could be linked with impaired synapse formation.
This role of KIAA l 189 appeared reminiscent of the ability of other ERM proteins to 
affect cell morphology (Martin et a l 1997; Litman et a l 2000). Moreover, it was 
consistent with the hypothesis that the C-termini of ERM proteins may be involved 
in the organisation of the cytoskeleton at particular cortical sites and may modulate 
membrane protrusive activity at those sites (Henry et a l  1995).
All together, these results suggested that KIAA l 189 may somehow interact (directly 
or indirectly) with actin thereby affecting the tightly-regulated cytoskeletal 
dynamics, which are essential for neurons to extend their processes and steer them to 
their potential synaptic partners (Luo 2000). As it is the interplay between 
cytoskeletal elements (especially microtubules and actin) (Jan and Jan 2003) which 
governs growth cone motility and neurite outgrowth, many different mechanisms 
could be proposed by which KIAA l 189 may disrupt or dysregulate actin dynamics 
leading to alterations in neuronal cell morphology. However, in terms of temporality, 
the suggestion that FLAG®-KIAA1189-overexpressing cells presented shorter rather 
than fewer neurites provided evidence indicating that KIAA l 189 may be involved in 
the process of neurite extension rather than in the initial steps of neurite induction 
(formation of protusions) and sprouting.
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5.12.6- A potential role for KIAA1189 in schizophrenia
Alterations in neurite outgrowth are consistent with the neurodevelopmental 
hypothesis of schizophrenia, which suggests that schizophrenia results from a 
disturbance in a maturational or developmental brain process (Weinberger 1987; 
Harrison 1999; Andreasen 2000; Lewis and Levitt 2002; Sawa and Snyder 2002). 
Recent studies have provided reliable evidence in favour of this hypothesis and 
converge on suggesting that cytoskeletal abnormalities (such as alterations of 
neuronal size and synaptic and dendritic organisation) actually reflect subtle 
alterations in schizophrenic cerebral cortical development which may become 
apparent at critical periods of the development such as the onset of puberty, and may 
explain at least a proportion of the defective synaptic plasticity and connectivity 
observed in schizophrenia. These alterations, which are likely to concern the basic 
steps of brain histogenesis (cell production, migration, neurite outgrowth and 
formation of the synaptic circuitry) may be, at least in part, associated with actin 
dynamics (Kamiya et a l 2005).
By affecting neurite extension via some disruption or dysregulation of cytoskeletal 
dynamics, probably at a critical time during brain development, KIAA l 189 may thus 
play a critical role in the development of the cerebral cortex so that subtle alterations 
in its expression may lead to abnormalities in neuronal connectivity which may 
contribute to schizophrenia pathogenesis (Sawa and Snyder 2002).
However, with regards to the chronic PCP model, a slightly different hypothesis has 
to be proposed since changes in RGD 1308367 expression in this model were induced 
by chronic administration of PCP to adult (~3 month-old) rats in which all brain 
regions, even the prefrontal cortex (the latest brain region to achieve maturation) 
were likely to be mature already. Therefore a potential contribution of RGD 1308367 
to alterations in the development of the cerebral cortex cannot explain the phenotypic 
range of metabolic, neurochemical and behavioural changes observed in PCP-treated 
rats (Morris et a l 2005). Rather, KIAA l 189 may play a role in the plasticity of the 
brain in response to learning and experience so that its altered expression may 
contribute to abnormal pruning of synapses during adolescence and early childhood 
and to impaired neurotransmission in adults, both of which have been proposed in 
schizophrenia (Harrison 1999; Rapoport et a l 2005; Stephan et a l 2006). In 
particular, KIAA l 189 may be involved in the chemical and structural modifications
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of dendritic spines which are known to be essential for synaptic plasticity (Hering 
and Sheng 2001; Yuste and Bonhoeffer 2001) and whose development and stability 
is highly dependent on the actin cytoskeleton (Fischer et a l  1998; Luo 2002). This 
hypothesis would therefore be consistent with the number of alterations in dendritic 
spines which have been shown in the dorso-lateral prefrontal cortex of schizophrenic 
patients (Carr et a l  1999; Flores et a l 2005; Hill et a l  2006).
Moreover, this proposition may also explain the ability of PCP to induce a psychosis 
in adult humans which closely resembles schizophrenia and is representative of not 
only the negative and positive symptoms of the disease but also the cognitive deficits 
(Adler et a l 1999). At the molecular level, this effect of PCP may be related to its 
NMDA antagonism properties since NMDA receptor activity, which has been shown 
to be highly interdependent on the actin cytoskeleton, is essential for long-term 
potentiation and synaptic plasticity (Carlisle and Kennedy 2005).
We suggest as a general hypothesis that KIAA l 189 may affect the assembly and/or 
disassembly of actin filaments in extending neurites during development by 
interacting with actin-binding proteins or by direct interaction with actin, or be 
involved in the rapid reorganisation of the actin cytoskeleton necessary for neurite 
outgrowth. As actin turnover in the growth cone has been shown to be tightly 
regulated as the brain matures, its dysregulation at critical developmental stages is 
likely to induce important abnormalities in neuronal cytoarchitecture. In adults, 
KIAA l 189 is likely to play a role in synaptic plasticity by mediating dendritic spine 
changes in response to experience and learning.
Whether KIAA l 189 directly interacts or not with actin (and how) will have to be 
determined to elaborate a more precise hypothesis on KIAA l 189 functional role in 
neuronal architecture and neurite outgrowth. In vitro studies may be performed first 
to determine if KIAA l 189 binds to filaments or monomers of actin, whether it 
bundles F-actin and investigate the effects of the protein on actin polymerisation.
While this study was close to completion, KIAAl 189, under the name of “Ermin”, 
was reported in the literature and characterised as a myelinating oligodendrocyte- 
specific protein (Brockschnieder et a l 2006). Ermin (another name of KIAA l 189) 
had been identified as exclusively expressed in oligodendrocytes in a microarray 
comparing cDNAs from wild-type and dysmyelinated mice. An antibody was raised
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to examine the endogenous expression of the protein in the brain and in cell cultures. 
Consistently with our in situ hybridisation results, they found that Ermin is expressed 
along white matter tracts and claim that it is not expressed by astrocytes or neurons. 
However, these data are not shown in their article which may cast some doubt on the 
clarity of their findings and may leave room for our hypothesis of neuronal 
expression of KIAA l 189. Consistent with this, a multiple tissue northern blot shows 
low but genuine expression of Ermin in cortical areas, suggesting that this protein 
may have a role there. To examine this hypothesis further, qRT-PCR was performed 
on laser-capture microdissected prelimbic cortex, where the level of RGD1308367 
(rat orthologue of KIAAl 189) was high enough to quantify easily (Antonio Ferra and 
Catherine Winchester). Although this dissected part of the prefrontal cortex did 
necessarily represent a heterogeneous population of neuronal and glial cells, it 
appeared unlikely that this expression of RGD1308367 in a region of the cortex 
where the ratio of glia/neurons is around 0.9 (which theoretically means that there 
are a few more neurons than glial cells in this region, (Dombrowski et a l  2001), only 
reflected glial expression. Consistently with our hypothesis, these data therefore 
further suggested th.2it RGD1308367 was genuinely expressed in neurons.
As soon as in August 2005, another paper was also published that described the 
identification of a novel oligodendrogial protain, called juxtanodin (Zhang et a l 
2005a), but the relevance of this gene to this work was not fully realised until its 
completion. Juxtanodin, which had been identified during a process of screening cell- 
type-specific CNS genes, appears indeed very similar to RGD1308367 in terms of 
sequence and very similar to Ermin in terms of functions. In their study, Zhang et a l 
(2005) showed that at the cellular level juxtanodin colocalises with 2’,3’-cyclic 
nucleotide-3’-phosphodiesterase (CNPase), a cytoskeletal-related oligodendroglial 
protein, and that in the myelin sheath its expression delineates the juxtanode, at the 
Ranvier node/paranode junction (Zhang et a l 2005a). However, the authors also 
describe expression of juxtanodin. With regards to its role, juxtanodin was found to
promote arborisation of cultured oligodendroglia cells and increase transport to the 
process arbors of oligodendrocyte precursors. Therefore the authors suggest that 
juxtanodin is a cytoskeleton-related oligodendroglial protein that may be involved in 
CNS myelination and/or specialisation at the node of Ranvier (Zhang et a l 2005a).
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At present and after performing a number of alignments between RGD 1308367 and 
juxtanodin mRNA, it appears that these different names are in fact likely to relate to 
the same gene and therefore to Ermin as well, which was shown to be likely to 
represent the same gene as RGD13098367. The identity of Ermin and Juxtanodin 
were checked and the GeneBank accession numbers and GenelDs reported in the 
different papers were confirmed to correspond to that of rat RGD 13 083 67 and 
human KIAA l 189 mRNAs and proteins. However, Brockschnieder et al. (2006) 
cloned the open reading frame of Ermin from mouse brain by PCR and Zhang et a l  
(2005) cloned fragments of a rat library cDNA clone, while we cloned a commercial 
Image Clone of human KIAA l 189 cDNA. The sequences were confirmed to match 
database sequences and were therefore likely to correspond to genuine orthologues. 
However, we cannot ascertain that they are in fact genuine orthologues and that both 
the cDNA probes and the antibody Brockschnieder et al. (2006) designed against the 
mRNA and the protein were specific to this transcript and did not detect any other 
potential (although not predicted) splice variant of this gene or even any very similar 
transcript.
Nevertheless, evidence showing that Ermin is a marker of myelinating 
oligodendroglia and plays a role in cytoskeletal rearrangements during myelination 
(Brockschnieder et a l 2006), as well as evidence showing that juxtanodin might be 
involved in CNS myelination and might play a role in oligodendrocyte motility, 
differentiation or myelin-axon signalling, may be consistent with published literature 
showing oligodendrocyte dysfunction and altered myelination in schizophrenia 
(Hakak et a l 2001; Pongrac et a l  2002; Davis et a l  2003; Lehrmann et a l  2003; 
Tkachev et a l 2003). Interestingly, such a hypothesis would make the in situ results 
showing decreased expression of RGD 1308367 in white matter regions after PCP 
treatment relevant to oligodendrocyte dysfunction and altered myelination in 
schizophrenia.
Therefore the results presented here are completely compatible with those of 
Brockschnieder et al. (2006) and Zhang et al. (2005) and suggest that 
Ermin/Juxtanodin/KIAAl 189 is likely to have dual functions in oligodendrocytes 
and neurons, both of which may be related to schizophrenia.
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In summary, the work described in this chapter provides several lines of evidence 
which suggest that KIAA l 189 may be involved in schizophrenia susceptibility and 
pathophysiology: 1) KIAA l 189 maps to a key schizophrenia locus (genetic 
evidence), 2) KIAA l 189 expression is predominant in the brain by comparison with 
other tissues and its expression was altered both in the rat prefrontal cortex after PCP 
treatment and in human post-mortem dorso-lateral prefrontal cortex of schizophrenic 
patients (genomic evidence) and 3) KIAA l 189 may interact with actin at the plasma 
membrane and may play a critical role in neurite extension and synaptic plasticity in 
the brain which is consistent with schizophrenia pathophysiology and hypotheses 
(functional evidence).
KIAA l 189 therefore appears as a completely novel and intriguing candidate gene for 
schizophrenia.
2 2 1
CHAPTER 6: SUMMARY 
AND FINAL DISCUSSION
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The overall aim of this work was to identify and characterise novel genes that may be 
associated with schizophrenia and may be particularly relevant to the development of 
novel antipsychotic drug treatments for the negative and cognitive symptoms of 
schizophrenia.
The rat chronic phencyclidine (PCP) model developed in YRING was used to this 
aim as it provides a very valuable model of the schizophrenia syndrome, displaying a 
pattern of metabolic, neurochemical and behavioural deficits that closely mirror that 
observed in schizophrenic patients. In addition, the ability of this model to very 
reliably model the cognitive deficits observed in schizophrenia is particularly 
relevant to the development of antipsychotic compounds since improving atypical 
activity is probably the major challenge (together with improving drug safety and 
reducing the number of side effects of antipsychotics) the pharmaceutical industry 
has to face at present.
Microarray analysis of gene expression in the prefrontal cortex of the rat chronic 
PCP model of schizophrenia was utilised as a cutting-edge technology of assessing 
the transcriptome profile in this given brain tissue as a reflection of gene expression 
in a key brain region involved in schizophrenia. Thus, this study may compare to the 
number of microarray analyses of gene expression profiles that have recently been 
successfully applied to the study of central nervous system (CNS) diseases, in 
particular schizophrenia (Mimics et a l 2006). However, beyond the issue of using an 
animal model of a disease and potentially comparing data obtained using this 
approach with results obtained using post-mortem brain tissue from affected 
individuals, there is such a discrepancy between experimental designs across studies 
that it would be unreasonable to compare the data obtained in our study and the 
genes identified as differentially expressed in our conditions with other 
schizophrenia microarray results. Thus, in addition to the differences in the studied 
cohorts or tissue samples, usage of different microarray platforms and varying 
statistical analysis of microarray data are two of the factors whose influence on the 
outcome of microarrays has largely been studied and is likely to explain a significant 
proportion of the divergent profiles of gene expression yielded by different 
microarray studies (Tan et a l 2003; Hollingshead et al. 2005). The lists of 
differentially expressed genes across platforms show indeed relatively little overlap, 
as do the fold changes of potential differentially expressed genes concomitantly 
identified in different studies (Yuen et a l 2002a). Nevertheless, rather than
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suggesting that microarray experiments are useless, these findings, in particular the 
confirmation of the potential involvement in schizophrenia of a few genes identified 
in these but not other microarray experiments, suggest that microarray analyses 
conducted to date may provide incomplete data and will therefore benefit from 
further evolution of microarray analysis tools and improvements in platform 
sensitivity (Mimics et a l  2006).
In this context and although validation of small gene expression changes may be 
challenging (section 3.5.3), data verification by independent methods appears a 
critical step that has to remain a major part of transcriptome profiling experiments 
(Mimmack et a l 2004). As it was practically confirmed in this work (with Tm4sfl2, 
section 3.4.2), usage of such independent methods of assessing gene expression may 
indeed be particularly very valuable in identifying false positives (type I errors) 
necessarily present among all identified differentially expressed genes, while false 
negatives (type II errors) should not be considered a definite proof of unaltered gene 
expression.
6.1- A few novel candidate genes for schizophrenia
Micro array analysis of gene expression in the prefrontal cortex of rats chronically 
treated with PCP revealed the differential expression of a number of ESTs whose 
potential to represent novel and uncharacterised genes or transcripts was exploited by 
a thorough manual bioinfonnatics analysis process. Thus, individual homology 
screening of the 209 identified ESTs against genomic and cDNA databases across 
species (rat, mouse, human) revealed 66 cDNAs, a proportion which further 
supported the value of our strategy to genuinely identify differentially expressed 
uncharacterised genes and suggested that the list of identified genes was unlikely to 
be exhaustive.
Nevertheless, as genuine as the differential expression of these genes may be, 
whether it reflects causative or adaptational changes to schizophrenia cannot be 
determined straightforwardly. Different classes of transcriptome changes can indeed 
be expected with regards to the mechanism of altered gene expression in complex 
brain disorders and they are not easy to separate. Thus, even if the use of a rat animal
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model of the disease allows the exclusion of the possibility that gene expression 
changes may be related to an additional treatment (which could be the case in human 
schizophrenic patients), these changes may still represent primary or secondary 
changes, that is, they may either reflect the core causative basis whereby chronic 
PCP treatment triggers schizophrenia-like symptoms, or, they may reflect potential 
adaptations developed by rats following their enduring schizophrenia-like symptoms 
induced by chronic PCP treatment. Obtaining conclusive information on causality 
between gene expression and behavioural phenotype is very challenging and cannot 
be obtained using a single approach, however this issue may not matter much in 
terms of drug development in this context since all the genes which are differentially 
expressed in the chronic PCP model are likely to converge in “disease-affected 
molecular hubs” (Mimics et a l 2006) that may represent correlates of the 
behavioural features of this model. Analysing gene expression changes in the brain 
of schizophrenic patients would be a very different situation, since expression 
changes may then also arise from a number of genetic susceptibilities and 
environmental insults that may be much more specific to individuals or subsets of 
individuals and therefore would not constitute promising drug targets for most 
patients with schizophrenia.
The potential significance of the 66 identified differentially expressed genes with 
relation to schizophrenia was assessed by doing some data mining on each of these 
genes. Although this process was conducted very thoroughly using a few criteria, the 
idea was really to get an overall picture of each gene in terms of function (known or 
predicted) and potential association with schizophrenia, in order to be able to make 
an informed decision on the potential value of each gene to constitute the basis of 
novel hypotheses of schizophrenia pathophysiology and/or to potentially represent 
promising dmg targets for the treatment of schizophrenia. Thus, the rationale for the 
selection of Edg2, Tm4sfl2 and the EST AI072720 was very different, each of these 
candidates being typically taken up at different stages of characterisation and 
association with schizophrenia: Edg2, a G-protein coupled receptor with high affinity 
for lysophosphatidic acid (LPA), had indeed already been linked with schizophrenic­
like behaviour (Harrison et al, 2003) while Tm4sfl2 {tetraspanin 12) had been 
suggested to be involved in potentially schizophrenia-relevant oligodendrocytes 
signalling, and the EST AI072720 may or may not correspond to a genuine rat
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transcript predicted to possess an ezrin-radixin-moesin (ERM) domain that may be 
functionally relevant to schizophrenia. Consistent with the divergence of findings 
across microarray studies of schizophrenia, none of these genes had been previously 
identified in gene expression profiling of brain tissue either from any animal model 
of schizophrenia or from post-mortem tissue from schizophrenic patients. Only Edg2 
had been previously detected in other contexts since it was shown to be differentially 
expressed in the temporal cortex from patients with major depressive disorder (Aston 
et a l  2005) and in the nucleus accumbens of corticotropin releasing factor (CRF) 
overexpressing mice (Peeters et a l 2004). Interestingly, differential expression of 
EDG2 as a myelination-related gene in major depressive disorder was suggested to 
be part of potential common oligodendroghal abnormalities between this disorder 
and schizophrenia and bipolar disorder (Aston et a l 2005). In addition, although it 
was not a microarray experiment, evidence has been published showing differential 
expression of LPA acyltransferase, le . the enzyme that catalyses the conversion of 
lysophosphatidic acid (LPA) to phosphatidic acid (PA), in the mouse striatum and 
frontal cortex in response to clozapine and haloperidol treatment, suggesting that 
LPA metabolism as part of the cell lipid metabolism pathways may be of importance 
in the mechanisms of antipsychotic drug action and in the pathophysiology of 
psychiatric disorders (Thomas et a l  2003).
As there is no consensus concerning microarray data analysis and because of the 
number of factors that affect and complicate brain disease microarray results, 
independent validation of the differential expression of the 3 selected candidates was 
undertaken as a critical prerequisite to further characterisation of these genes.
Success in confirming the differential expression of Edg2 and EST AI072720 by 
qRT-PCR in the rat chronic PCP model despite the low fold changes they exhibited 
provided evidence not only of the sensitivity of the technique but of the reliability of 
the chronic PCP model to exhibit consistent gene expression patterns. Hence, failure 
to confirm the differential expression of Tm4sfl2 in the rat chronic PCP model using 
this technique provided further evidence of the necessity to validate microarray 
results. In the context of this work, because confirmation of microarray changes was 
strictly considered a prerequisite for further characterisation, Tm4sfl2 was not 
investigated further. Nevertheless, confirmation of such low fold changes is so 
difficult (section 3.5.3) that Tm4sfl2, whose function may be relevant to
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schizophrenia, may well not be a false positive in the microarray but a genuinely 
differentially expressed gene whose differential expression, by coincidence, was not 
confirmed in the rat chronic PCP model and in post-mortem tissue from 
schizophrenic patients. Conversely, Edg2 and EST AI072720 were taken forward for 
further genetic, genomic and in vitro functional characterisation studies
6.2- EDG2, a promising drug target for schizophrenia?
EDG2 (also referred to as LPA l) is a G-protein-coupled receptor for 
lysophosphatidic acid (LPA), predominantly expressed in the brain, where its 
temporal expression and its expression pattern in the adult were suggested to reflect a 
potential role in neurodevelopment and/or in the control of myelination, both 
functions potentially relevant to the aetiology of several psychiatric disorders 
including schizophrenia (section 1.1.5). Consistent with this hypothesis, Edg2 knock­
out mice were shown to exhibit deficits in prepulse inhibition (PPI) and 
neurochemical changes that have been associated with a schizophrenic-like 
pathology (Harrison et a l 2003; Roberts et a l 2005). However, whether this 
potential role of Edg2 in schizophrenia was related to its expression in the white 
matter remains to be confirmed. Evidence of the role of Edg2 in interneuronal 
function and interneuron-mediated brain rhythms (Cunningham et a l  2006) may 
indeed provide another hypothesis whereby alterations in neuronal expression of 
Edg2 in the cortex may contribute to the loss, or reduction in function, of 
interneurons underlying the network dysfunction seen in schizophrenia 
(section 1.1.4).
qRT-PCR data showing increased Edg2 expression in the prefrontal cortex of rats 
chronically treated with PCP and in post-mortem dorso-lateral prefrontal cortex of 
schizophrenic patients were consistent with this hypothesis, suggesting that the role 
of Edg2 in cortical regions was indeed critical in schizophrenia, and interestingly, 
was somehow related to altered NMDA receptor transmission. Further support to this 
hypothesis was provided by in situ hybridisation data showing an increased 
expression of Edg2 in the prelimbic and infralimbic cortices of rats having 
undergone a behavioural task of executive function (section 3.5.4), suggesting that
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neuronal Edg2 was more important for schizophrenia-related cognitive tasks than 
white matter Edg2.
Further pathway analysis of gene expression data obtained from the microarray 
performed in the rat chronic PCP model and from a microarray investigating gene 
expression in the post-mortem dorso-lateral prefrontal cortex of schizophrenic 
patients (Hiromitsu Ozeki) allowed the development of a hypothesis about the 
mechanism whereby Edg2 may contribute to schizophrenia pathophysiology and 
how this may be related to NMDA receptor function. Thus, Edg2 was suggested to 
couple to a common signalling cascade with NMDA receptors, leading from Ptk2b 
(Pyk2) to the MAP kinase Mapk9 (Jnk2) and held together by adaptor proteins such 
as Nckl -hence the proposed “Pyk/Nck” pathway. Importantly, potential 
neurotoxicity of the NMDA receptor antagonist PCP has to be excluded as the 
mechanism inducing decreased activity within this cascade since the dose treatment 
regime used in the chronic PCP model (Cochran et a l 2003) was specially developed 
to ensure that neuronal loss could not account for the neurochemical and behavioural 
deficits of the model. Conversely, further support for the involvement of this cascade 
in schizophrenia may interestingly be provided by a number of interactions, 
suggested in the literature, between members of the “Pyk/Nck” pathway and other 
pathways or mechanisms potentially implicated in schizophrenia. These include in 
particular the role of Mapk9 in the activation of gene transcription (Ham et a l 2000) 
and the role of the Nckl-interacting protein Pakl in synaptic structure, in the 
regulation of glutamate receptor levels and potentially in the modulation of gene 
transcription and synaptic plasticity through indirect interaction with the 
calcium/calmodulin-dependent protein kinase IV (CamKIV) (Kang e ta l  2001).
The hypothesis that restoring activity within the “Pyk/Nck” cascade may constitute a 
route to counterbalance PCP-induced deficits in the rat chronic PCP model and 
NMDA receptor hypofunction in schizophrenic patients was confirmed in vitro using 
a stable cell line overexpressing ADG2 receptors: in these cells, EDG2 activation was 
shown to induce gene expression changes within the proposed “Pyk/Nck” cascade. In 
addition, despite the limited specificity of available antibodies against MAP kinases, 
consistent evidence was obtained from western blots and ELISA experiments which 
strongly suggested that EDG2 activation in these cells induced increased 
phosphorylation -hence activation- of Jnk2, the final output of the “Pyk/Nck” 
pathway. Nevertheless, further studies would be necessary to maintain this
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assumption, including use of EDG2 agonist compounds and more specific 
investigation of the activation of the “Pyk/Nck” pathway, both in vitro (using 
different cell lines as well as primary neurons) and in vivo. Moreover, although this 
evidence suggested that Edg2 activation may provide a way to counterbalance 
potential deficits within the “Pyk/Nck” pathway, use of EDG2 agonist compounds in 
NMDA receptor hypofunction-related contexts would be necessary to assess the 
differential up- and downregulation of the “Pyk/Nck” pathway signalling activity in 
vitro and in vivo after induction of NMDA receptor hypofunction by PCP and after 
stimulation of EDG2 receptors by specific agonists. In particular, such evidence 
would establish the pharmacological proof of concept that is required to further 
support the development of EDG2 agonists as compounds acting at the “Pyk/Nck” 
cascade and thereby as promising compounds for the treatment of schizophrenia.
Despite this lack of irrefutable evidence that Edg2 stimulation may counterbalance 
NMDA receptor hypofunction in schizophrenia, literature supporting the 
involvement of Edg2 in schizophrenia stimulated the use of EDG2 agonists, 
developed in other respects (Santos et a l  2004), in the chronic PCP model of 
schizophrenia and the investigation of critical deficits particularly relevant to some 
aspects of schizophrenia lacking effective therapeutics. In vivo experiments using 
EDG2 agonists were thus undertaken in the laboratory (Susan Cochran, Alice 
Egerton, Allan Me Vie) and in vivo evidence of the potential of EDG2 compounds in 
the treatment of schizophrenia was in fact obtained prior to any conclusive in vitro 
evidence, with data showing EDG2 agonist-induced reversal of PCP-induced 
sensorimotor gating deficits in prepulse inhibition (PPI) (Alice Egerton) and deficits 
in prefrontal cortex metabolic hypofunction (Susan Cochran and Allan McVie). The 
latter results may appear particularly promising since this ability of EDG2 
compounds may demonstrate an improved efficacy of these compounds compared to 
clozapine, one of the best atypical antipsychotic drugs, commonly used as a 
reference in pharmacological studies attempting at developing better treatments for 
schizophrenia, and which does not have the ability to reverse the critical deficits in 
prefrontal cortex metabolic hypofunction induced by chronic PCP treatment 
(Cochran ry/. 2003).
Whether this activity of EDG2 agonists occurs through the activation of the 
“Pyk/Nck” pathway still needs to be determined. However, concomitant evidence of
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the ability of EDG2 stimulation to trigger the activation of the NMDA receptor- 
downstream “Pyk/Nck” cascade in vitro and to reverse critical deficits in the chronic 
PCP model of schizophrenia in vivo provided further support to the hypothesis that 
this cascade may represent a core molecular basis of the chronic PCP model which 
may reflect of a critically dysfunctional pathway in schizophrenia in humans.
In vitro and in vivo evidence providing further evidence that EDG2 may potentially 
represent a promising drug target for schizophrenia stimulated the development of a 
an assay to be used for screening potential BDG2 agonists. The [^^S]-GTPyS binding 
assay optimised for use with the stable transformed EDG2-overexpressing cell line 
was thus confirmed to reliably detect dose-dependent activation of EDG2 receptors 
(and potential GPR23 receptors expressed in these cells) by LPA. Although use of 
specific EDG2 agonists and antagonists would be necessary to definitely conclude on 
its specificity and sensitivity, the ability of this [^^S]-GTPyS binding assay, shown 
for LPA, to allow the calculation of exact pharmacological parameters, supported its 
use and its potential value in screening the agonist properties of potential EDG2 
compounds.
Generation of the hypothesis that EDG2 receptors were coupled to a cascade 
dysfunctional in the chronic PCP model and in schizophrenic patients so that their 
activation may constitute a way to counterbalance deficits critical to schizophrenia 
pathophysiology, was first driven by concomitant evidence both obtained through 
YRJNG microarray results {Edg2 and EDG2 both showing increased expression in 
the prefrontal cortex of rats chronically treated with PCP and in post-mortem dorso­
lateral prefrontal cortex of schizophrenic patients respectively) and from the 
literature about Edg2, showing that Edg2 knock-out mice displayed behavioural 
deficits and neurochemical changes similar to those observed in schizophrenia. In 
other terms, the chronic PCP model and Edg2 knock-out mice, whih both show 
schizophrenia-like behaviour, showed opposite directions in Edg2 expression 
changes. These concomitant but opposite changes provided therefore strong support 
of the involvement of this gene in schizophrenia pathophysiology, but also suggested 
that in one of these animals, the changes in expression were likely to reflect a 
compensatory mechanism whereas in the other they may be causative. Interestingly, 
the observed changes in the expression of Edg2 in the chronic PCP model were
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proposed to be related to expression changes of a number of genes with which Edg2 
may interact as part of a signalling cascade located downstream of NMDA receptors. 
The work presented in this thesis together with additional data obtained in the lab 
provided strong evidence in support to this hypothesis.
Nevertheless, the core foundations of this hypothesis of Edg2 overexpression being a 
compensatory mechanism attempting to restore activity within the “Pyk/Nck” 
pathway may well be doubted since this theory does not take into account the 
expression of Edg2 in glial cells, which is so predominant that it was long thought to 
be its exclusive cellular localisation. Thus, although the levels of expression do not 
necessarily reflect biological significance, it may be suggested that it is this loss of 
glial Edg2 that is responsible of the schizophrenia-like phenotype of Edg2 knock-out 
mice, rather their lack of low neuronal Edg2 expression. In the light of the potential 
role of Edg2 in myelination, this hypothesis may be consistent with the concept that 
schizophrenia may be primarily a disorder of neurodevelopment, in which 
dysmyelination may account for critical alterations in brain and cortical connectivity 
in schizophrenia.
Following on this theory, hypotheses may have to be proposed to explain the changes 
in Edg2 expression observed in the rat chronic PCP model and those of EDG2 in 
schizophrenic patients, assuming that these changes were genuine and relevant to 
schizophrenia. Depending on whether these detected changes reflected increased 
glial or neuronal expression of Edg2, several hypotheses may be proposed (including 
the hypothesis that increased neuronal Edg2 activation may induce a retraction of 
neurites thereby altering synaptic architecture and connectivity). However, how these 
changes may result from PCP-induced NMDA receptor hypofunction may be 
difficult to explain.
Conversely, evidence showing that NMDA receptor antagonism and loss of Edg2 
function induced a range of similar deficits, including not only behavioural 
impairments and neurochemical changes but also comparable alterations in 
entorhinal gamma oscillations (which constitute markers of interneuronal function 
and interneuron-mediated brain rhythms and are associated with cognitive function) 
(Cunningham et a l  2006), recently provided further support to the hypothesis that
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increased neuronal expression of Edg2 in the prefrontal cortex constituted indeed an 
attempt at restoring NMDA receptor hypofunction in PCP-treated rats and in 
schizophrenic patients.
In conclusion, these results provided very strong evidence that stimulation of EDG2 
receptors may represent a very promising approach for the treatment of 
schizophrenia and may lead to the development of compounds of improved efficacy 
towards the negative symptoms and the cognitive deficits that currently lack effective 
therapeutics. Moreover, the “Pyk/Nck” pathway identified in this work may well 
represent a core mechanism of schizophrenia since it may provide a link not only 
between NMDA receptor hypofunction and EDG2 but also with a number of 
mechanisms underlying alterations in synaptic structure, glutamate receptor levels 
and synaptic plasticity-associated gene transcription in schizophrenia. Interestingly, 
further investigation of the activation of the “Pyk/Nck” pathway and of the 
mechanisms whereby EDG2 agonists exert their effect may benefit from the 
availability of such compounds, developed in the context of other diseases. Overall, 
EDG2 receptors have indeed emerged as a promising therapeutic target for several 
diseases including dysmyelinating disorders (Beer et a l  2000) but also, beyond 
neurobiology, for a range of cancers, particularly colorectal cancers for which EDG2 
was proposed to represent a very potential chemopreventive target (Shida et a l 
2004).
6.3- KIAA1189, a novel gene for schizophrenia?
Following on the same innovative strategy of attempting to identify novel 
schizophrenia-associated genes and first reflected by the use of the partially EST- 
based Affymetrix RG-U34 GeneChips, the EST AI072720 was selected as a 
candidate gene for which to investigate and characterise in relation with 
schizophrenia. Initial support for the genuine expression of this EST in the rat brain 
and its potential relevance to schizophrenia (provided by qRT-PCR confirmation of 
the differential expression of the EST AI072720 in the prefrontal cortex of the 
chronic PCP model of schizophrenia) did indeed stimulate further analysis of this
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EST, potential identification of a transcript that it may be related to and 
characterisation of this transcript in relation with schizophrenia. Molecular biology 
techniques were used for this aim and 5’ Rapid Amplification of cDNA Ends 
(5’RACE) PCR provided confirmation that the EST AI072720 was genuinely 
expressed as part of a rat predicted gene called RGD1308367, which had been 
suggested by the bioinformatics analysis of its surrounding genomic sequence 
(section 5.2). Interestingly, although "'similar to KIAA1189 proteirE {i.e. the 
description of rat RGD1308367 gene) was mostly uncharacterised, the putative 
protein was predicted to have a C-terminal ezrin-radixin-moesin (ERM) actin- 
binding domain suggestive of a potential role in cytoskeletal architecture which 
further reinforced the interest in studying this gene in relation with schizophrenia.
Importantly, identification of RGD1308367 as a rat transcript, yet uncharacterised 
but predicted, for EST AI072720 paved the way for further characterisation studies 
not only of the rat gene but also of its human orthologue, KIAA1189. In particular, 
this allowed the investigation of KIAA1189 expression in post-mortem tissue from 
schizophrenic patients and genotyping of single nucleotide polymorphisms (SNPs) 
within KIAA1189 in blood samples from schizophrenic patients, of which both 
sample types were available in the laboratory. Very interestingly, using qRT-PCR, 
K1AA1189 expression was shown to be differentially increased in post-mortem 
dorso-lateral prefrontal cortex samples from the Harvard and Brain-Net collections 
of schizophrenic patients, consistent with the increased expression of R G D l308367 
confirmed by qRT-PCR in the prefrontal cortex of rats treated with PCP according to 
the chronic PCP model treatment regime (Cochran et al. 2003). Moreover, although 
genotyping of three SNPs within the human KIAAI189 gene did not provide 
evidence of genetic association between KIAA1189 and schizophrenia in a case- 
control population of 600 schizophrenic patients and controls, this probably did not 
constitute sufficient data to draw any conclusion since it is likely that the design of 
this experiment was not sophisticated enough to yield any positive finding. As 
discussed in section 5.12.3, insufficient SNP density, localisation of the SNPs 
examined in different haplotype blocks and heterogeneity on the collection of 
populations are among all the issues that may explain the negative results. Compared 
to the most recent association studies performed in schizophrenia, such as that of 
Gurling et al. (2006) investigating the effect of a genetic susceptibility on an
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endophenotype in carefully selected populations of schizophrenic patients (Gurling et 
a l 2006), the design of this SNP association study may appear too simplistic, 
suggesting that further experiments including more complex designs and analyses 
may be needed to yield positive findings and to further explore this aspect of the 
characterisation OÏKIAA1189 in schizophrenia.
Finally, the genomic localisation of KIAA1189 at chromosome 2q is a key 
schizophrenia locus pointed out in several linkage studies and recently associated 
with visual working memory. Thus, this evidence interestingly added to 
RGD1308367 and KIAA1189 expression results, providing further support to the 
hypothesis that KIAA1J89 may be an intriguing novel candidate gene for 
schizophrenia.
In order to provide some insight on the potential function of R G D l308367, in situ 
hybridisation was performed using probes designed within its predicted sequence, as 
close as possible to the location of the probes used in R G D l308367 qRT-PCR. 
RGD1308367 was shown to exhibit a specific expression pattern, which was, again, 
consistent with that of EST AI072720, providing evidence that the EST AI072720 
and RGD1308367 were likely to be the same transcript, the EST AI072720 being 
part of the 3’ untranslated region of RG D l308367. Very high expression of 
R G D l3083637 within all major white matter tracts and much lower expression 
within all cortical and sub-cortical areas suggested that R G D l308367 was 
predominantly expressed in glial cells. Moreover, although in situ hybridisation 
analysis of EST AI072720 and RGD1308367 expression did not provide consistent 
semi-quantitative results, RGD1308367 expression was found to be decreased in the 
fornix and the corpus callosum of rats treated with PCP according to the chronic PCP 
treatment regime by comparison with rats treated with a vehicle (saline). 
Interestingly, because these white matter structures are essential to the connectivity 
between brain structures and cerebral hemispheres (respectively), changes in gene 
expression, hence functional impairment, within such regions may be consistent with 
the hypothesis of schizophrenia being a disorder of cortical connectivity 
(section 1.1.5.1). Interestingly, concomitant to writing up this work, a paper was 
published describing the characterisation of KIAA1189, hereby called Ermin, as a 
myelinating oligodendrocyte-specific protein (Brockschnieder et a l  2006). To some
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extent, the data presented in this paper may be considered further support for the 
hypothesis that changes in glial RGD1308S67 expression may be related to 
alterations in the myelination process which is critical to proper connectivity within 
the brain.
However, although both hypotheses do not have to be exclusive, evidence showing 
increased expression of RGDI308367 and its human KIAA1189 orthologue in the 
chronic PCP model and in schizophrenia patients, respectively, was strongly 
evocative of another potential mechanism as to the involvement of 
RGD1308367/KIAA1189 in schizophrenia. Data showing R G D l308367 expression 
in laser-capture microdissected prelimbic cortex (Antonio Ferra and Catherine 
Winchester) provided further support for this hypothesis by confirming that 
R G D l308367 was not only expressed in white matter but also in a region of the brain 
densely populated with neurons.
Following on both hypotheses, KIAA1189 was overexpressed as a fusion protein 
with an N-terminal FLAG epitope not only in glial- but also in neuronal-like cells, to 
investigate its subcellular localisation. In either rat C6 glioma or differentiated PC 12 
cells, KIAA1189 overexpression did not induce any apparent phenotype and very 
similar subcellular localisation of KIAA1189 was shown in both cell lines, not 
providing any insight into the potential role. Nevertheless, its subcellular localisation 
in the plasma membrane and within neurites was consistent with the potential actin- 
binding role of the predicted C-terminal ERM domain of KIAA1189 and with 
expression of typical ERM proteins at the cytoplasmic surface of membranes (Sato et 
a l  1991). Moreover, although in situ hybridisation did not have the power to 
precisely identify the subcellular localisation of the mRNA, consistency between the 
expression of KIAA1189 in neurites and the putative expression of R G D l308367 
mRNA, suggested from in situ hybridisation data, within the axons of cortical 
neurons suggested that KIAA l 189 may be, at least partially, locally translated within 
the axons and may thus play a critical role in the regulation of synaptic plasticity 
(Piper and Holt 2004).
Although immunoprécipitation studies did not demonstrate interaction between 
KIAA l 189 and actin, maybe due to technical issues (including the possibility that the 
N-terminal FLAG® epitope may alter KIAA l 189 folding, that the protein may need 
to be activated or that the cell line used in these experiments may not be suitable),
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KIAA l 189 was shown to colocalise with actin in some processes of differentiated 
PC12 cells, at the end of some neurite tips and in the plasma membrane, suggesting 
that it may have a critical role at cell membrane-actin adhesion sites and in the 
architecture and extension of neurites.
Very interestingly, such a role of KIAA l 189 in neurite outgrowth was confirmed by 
overexpressing KIAA l 189 in non-differentiated PC 12 cells and examining neurite 
outgrowth in the course of NGF-induced differentiation, both by semi-quantitatively 
measuring neurite length and by looking at epifluorescence of a co-transfected GFP 
protein. Both methodologies gave consistent and reliable results, showing reduced 
neurite length in KIAA l 189-overexpressing cells by comparison with cells 
transfected with the empty FLAG expression vector.
That this phenotype of KIAA l 189-overexpressing cells had not been detected in 
initial experiments attempting to determine the subcellular localisation of KIAA l 189 
may not be surprising due to the essential difference between both studies in terms of 
timescale of KIAA l 189 transfection and NGF-induced differentiation. The FLAG- 
KIAA1189 fusion protein was indeed initially overexpressed in differentiated PC12 
cells while in the neurite outgrowth assay, PC12 cells were first transfected prior to 
being treated with NGF to induce the differentiation process. Therefore, it may be 
suggested that KIAA l 189 has a critical role during the process of differentiation 
rather than in differentiated cells, which may explain failure to confirm KIAA l 189 
interaction with actin and to show any phenotype in the initial studies.
Extrapolating in vitro evidence into in vivo hypotheses always requires extreme 
caution but even more when attempting to relate in vitro results (obtained using a 
particular cell type etc) to complex disease mechanisms such as those occurring in 
schizophrenia, which involve disturbances within networks rather than single cells or 
specific cell types. Nevertheless, evidence that KIAAl 189 overexpression may affect 
neurite extension, together with gene expression results showing an increased 
expression of RGDl308367/KIAAl 189 in the rat chronic PCP model and in 
schizophrenic patients, not only further confirmed that KIAA l 189 was involved in 
schizophrenia but strongly suggested that the mechanisms whereby it may play a role 
in schizophrenia were likely to be somehow related to alterations in the processes of 
the formation of cortical networks during the development of the brain. Probably by 
interacting with actin at critical times of development, KIAA l 189 probably plays a
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critical role in the basic steps of brain histogenesis (cell production, migration, 
neurite outgrowth and formation of the synaptic circuitry) so that subtle alterations in 
its expression may lead to abnormalities in neuronal connectivity contributing to 
schizophrenia pathogenesis (Sawa and Snyder 2002).
However, this hypothesis of the critical role of KIAA l 189 during development as 
potentially contributing to susceptibility to schizophrenia cannot be valid as such in 
the context of a pharmacological model such as the chronic PCP model, in which it is 
the chronic administration of PCP to adult animals that somehow induced changes in 
its (or exactly in that of its rat orthologue R G D l308367) expression. In this context, 
evidence of an axonal translation of KIAAl 189, based on in situ hybridisation results 
and in vitro subcellular localisation studies using overexpressed proteins, may 
provide the foundations of another mechanism whereby KIAA l 189 may play a role 
in relation to schizophrenia. Axonal translation has indeed been shown to play a 
critical role in providing a flexible and efficient way of modulating synaptic 
plasticity and long-term potentiation (LTP, i.e. the strengthening of synapses which 
occurs in response to learning and experience), both processes requiring synaptic 
activation of NMDA receptors. Thus, chronic administration of the NMDA receptor 
antagonist PCP necessarily affects this process, reflected at the molecular level by 
dramatic structural changes of dendritic spines associated with actin polymerisation. 
Although the extent to which spines remain plastic in the adult brain is unclear, this 
hypothesis may also be true at mature synapses where a process similar to LTP was 
shown whereby NMDA receptor activation triggers spine expansion and actin 
polymerisation (Lang et al. 2004). Thus, the expression of KIAA l 189 in neuronal­
like processes (where it may be locally translated) of mature neurons may suggest a 
role for KIAA l 189 in the actin dynamics-related structural changes of dendritic 
spines induced by decreased NMDA receptor activity. Whether the changes in 
K1AA1189 expression in the chronic PCP model actually constitute an attempt at 
counterbalancing the alteration of synaptic plasticity induced by PGP-mediated 
decreased NMDA receptor activity or reflect its contribution to further altering these 
processes remains unknown. Further experiments such as additional
immunofluorescence studies, use of actin dynamics-perturbing agents and 
histological examination of dendritic spines would be necessary to refine this 
hypothesis and provide further insight into these complex mechanisms.
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In conclusion, although all these findings may be considered preliminary since most 
of, if  not all, experiments would benefit from improved designs including increasing 
sample size etc, they provide veiy intriguing genetic, genomic and functional 
evidence suggesting that KIAA l 189 may have role in schizophrenia susceptibility 
and/or physiopathology. Probably the most important caveats of this work lay in the 
functional part of KIAA l 189 characterisation, with the fact that the techniques used 
1) did not have the power to determine the cellular localisation of R G D l308367 
protein, i.e. if R G D l308367 was expressed in neurons and/or in glial cells (and in 
which cell type etc) and to what extent; and 2) were limited, due to the unavailability 
of an antibody against RGD1308367/KIAA1189, to the functional characterisation of 
exogenous proteins, which may disturb normal cellular physiology and may not 
exactly reflect the function of endogenous proteins.
Nevertheless, although for these reasons no precise mechanism as to the role of 
KIAA l 189 in schizophrenia can be proposed on the basis of this work, we suggest as 
a general hypothesis that KIAA l 189, probably by directly or indirectly interacting 
with actin, plays a role in the extension of neurites which occurs during the 
development of the brain and to some extent underlies the formation of cortical 
networks critical for brain connectivity, and is involved in the modulation of synaptic 
plasticity in adults by mediating NMDA receptor-dependent dendritic spine changes.
In addition, expression of KIAA l 189 in oligodendrocytes, shown by 
(Brockschnieder et al. 2006), may suggest a role for KIAA l 189 in myelination.
Whatever the mechanism, all these hypotheses may be consistent with the current 
hypotheses suggesting that schizophrenia is a neurodevelopmental disorder in which 
alterations in synaptic plasticity and connectivity probably represent the core 
molecular foundations that underlie the complexity of the schizophrenia phenotype. 
Therefore, KJAA1189 may represent a very intriguing novel candidate gene for 
schizophrenia.
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6.4- Final conclusion
The data presented in this thesis represent very promising findings for schizophrenia 
which may help, in the short or longer term, in the development of novel 
antipsychotic drugs. Through the identification of two novel schizophrenia- 
associated genes using one of the best validated models of schizophrenia, the rat 
chronic PCP model, and through the combination of different approaches that is 
necessary to lay the foundations of any hypothesis about a such complex disorder, 
they provide a very valuable insight into the mechanisms potentially involved in the 
pathophysiology of schizophrenia and more particularly into the mechanisms 
underlying the critical negative and cognitive deficits which currently lack effective 
therapeutics. In this respect, evidence suggesting that EDG2 agonists may have an 
atypical antipsychotic activity makes EDG2 a particularly promising novel drug 
target for schizophrenia. In addition, although further studies are needed to refine the 
potential role of KIAA l 189 in schizophrenia, this previously completely 
uncharacterised gene appears very promising, especially since its role may allow the 
bridging of all major current hypotheses of schizophrenia.
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- APPENDICES -
Appendix A.
Screenshots of the different stages of the bioinformatics analysis process
MT':
—'fnkaui
Screen displaying probe retrieval atNetAffx™ website
MftSÆSîvïiîofcm''
Screen displaying probe set information at NetAffx™ website
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Avr--;
Probe set sequence retrieval at NetAffx™ website
From here on, the bioinformatics homology screening process is shown for one 
species only (rat), it was then repeated to align each retrieved probe set against 
mouse and human databases. The following manual analysis of these alignments is 
shown in figure 3.1 A-C, which represent examples of homology screens allowing 
good, uncertain and unsuccessful conversion into rat genes.
.-MW w '1 ###
Multi — ' E:p-  •- —ear
« 3  c
>BBS
ENSEMBL Blast entry screen: probe set sequence copied from NetAffx™ was 
entered to be aligned against rat cDNA database
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ENSEMBL Blast processing screen
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CV'*''••«Multi Si..,I* a^ CTT,
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2.' Z- ZF a,. % -^•-'r %# • M ^  • SSP • •* ••
ENSEMBL screen displaying a genome overview of alignments of entry sequence
t3<W« ■ —' » — ■
C." Rat.
■imiwn m#m« t •iiU
4 CNomowm# 3
— %::r-----
ENSEMBL screen displaying a view of the contig where the entry sequence showed 
the best alignment
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ENSEMBL screen displaying information about the gene potentially identified from 
aligning the probe sequence against rat cDNA database
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Appendix C.
Schematic representation of the functional relationship between Edg2 and “Pyk/Nck” 
pathway genes and microarray gene expression changes in the chronic PC? model of 
schizophrenia (RG-U34A, B and C GeneChip® data, Catherine Winchester) and in 
dorso-lateral prefrontal cortex from schizophrenic patients (HG-133A GeneChip® 
data, Hiromitsu Ozeki)
Glutamate LPA
NMDA
receptor
PSD-95
Edg2 * , 
receptormm mm
( MapkS
i i
M ap3k?)
The “Pyk/Nck” pathway is structurally organised as a MAPK signalling cascade 
whereby the MAP kinase Mapk9 (Jnk2) is activated by the dual specificity MAP 
kinase kinases Map3k7/Map4k4 which are themselves activated by MAP kinase 
kinase kinases downstream from the protein tyrosine kinase Ptk2B. Gab 1/2 and Nckl 
are scaffold proteins that bring upstream and downstream kinases in close proximity 
ensuring effective, specific signal transduction.
Direction of expression changes of “Pyk/Nck” genes detected by microarray analysis 
of the prefrontal cortex of rats treated with PCP according to the chronic PCP model 
treatment regime (Cochran et a l 2003) and in post-mortem dorso-lateral prefrontal 
cortex from schizophrenic patients are shown in grey boxes located beside each gene, 
orange arrows representing rat microarray changes and green arrow human 
microarray changes. Horizontal dashes signify that no significant change in 
expression was detected, either in the rat microarray (orange dash) or in the human 
microarray (green dash).
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Appendix D.
Further details on statistical analysis of SNP genotyping experiments
1. Tests for deviation from Hardv-Weinberg equilibrium
Exceptions (non-equilibrium)
- Mutation 
Gene migration 
Genetic drift
- Non-random mating 
Natural selection
2. Tests for association (adapted from Sasieni PD, 1997). 
n 11(e): Genotype 11 (expected)
n 12(e): Genotype 12 (expected) 
n22(e): Genotype 22 (expected) 
f  al : Frequency of allele 1 +/- standard deviation
F: Inbreeding coefficient
p (Pearson): Pearson's goodness-of-fit chi-square (degree of freedom = 1)
p (Llr):Log likelihood ratio chi-square (degree of freedom = 1) 
p (Exact): Exact test
The following equations correspond to risk allele 2.
Odds ratio (allele freq, difference): (Case_a2 * Contrôl a i) / (Case a l *
Control_a2)
Chi2 (allele freq. difference): (P) = Pearson's goodness-of-fit chi-square (df=l), (F) 
Fisher's exact test
Odds ratio (heterozygous): (Case_12 * Control_ll) / (Case_l 1 * Control_12)
Odds ratio (homozygous): (Case_22 * Control l 1) / (Case l 1 * Control_22)
Odds ratio (allele positivity): ((Case_12+Case_22) * Control l 1) / (Case l 1 * 
(Control_12+Control_22))
Common odds ratio: ( C a s e l  2 * Cont rol l  1/NOl + Case_22*Control_12/N12 + 
4*(Case_22*Control_l l/N02))/(Case_l l*Control_12/N01 +
Case_l 2 * Control 22/N12 +
4*(Case_22*Control_l 1 *Case_l 1 *Control_22)**0.5/N02)
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